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ABSTRACT 
Ischaemic heart disease is a major contributor to global morbidity and mortality rates. Manoeuvres 
such as ischaemic preconditioning confer cardioprotection against ischaemia/reperfusion (I/R) 
injury by activating several intracellular signalling pathways. These pathways have been defined 
solely in terms of the kinases involved, despite the realization in recent years that protein 
phosphatase activity also contributes significantly to the attributes of the propagated signal. Protein 
phosphatase 2A (PP2A) is a heteromultimeric enzyme involved in an array of phosphatase 
reactions. We hypothesized that PP2A is an important participant in the myocardial response to I/R 
by regulating intracellular signalling.  
 
This project aimed to (i) characterize PP2A during myocardial I/R; (ii) determine the importance of 
its contribution to the cellular response to I/R; and (iii) investigate its role in the signalling pathways 
mediated by PKB/Akt, GSK-3β, ERK p42/p44 and p38 MAPK. 
 
Two models were used to characterize PP2A during I/R: (i) H9c2 cells exposed to simulated 
ischaemia (SI) buffer in conjunction with hypoxia (0.5% O2) for a maximum of 2 hours, followed by 
reoxygenation in standard growth medium for up to 30 minutes; and (ii) isolated working rat hearts 
exposed to a maximum of 20 minutes global ischaemia and 10 minutes reperfusion. In both 
models samples were collected at several time points during I/R for Western blotting analysis. 
PP2A-C (the catalytic subunit) accumulated in the nucleus during early ischaemia, but later 
redistributed to the cytosol. At the end of ischaemia there was an elevation of PP2A-C relative to 
PP2A-A in the unfractionated whole cell preparation concomitant with an increase in the inhibitory 
phosphorylation of PP2A-C. 
 
The impact of PP2A activity was evaluated by either inhibiting PP2A using okadaic acid (OA, 10 
nM) or activating it by administering FTY720 (1 μM) in an isolated working rat heart model exposed 
to either 35 minutes of regional ischaemia (RI) with infarct size (IFS) as primary end-point, or 20 
minutes global ischaemia (GI) with functional recovery as end-point. The results showed that the 
pre-ischaemic administration of OA or FTY720 reduced or exacerbated IFS respectively, indicating 
that PP2A activation during I/R favours cell death. 
 
OA and FTY720 were also employed to assess the contribution of PP2A to intracellular signalling 
in an isolated working rat heart exposed to I/R. Samples were collected at several timepoints and 
analyzed using Western Blotting. Pre-ischaemic administration of OA enhanced the 
phosphorylation of PKB/Akt, ERK p42/p44 and GSK-3β at the onset of reperfusion, while FTY720 
given before ischaemia reduced the phosphorylation of GSK-3β, p38 MAPK and PKB/Akt at the 
end of ischaemia and onset of reperfusion. 
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 In summary, PP2A is part of an early nuclear-based response to ischaemia, while long-term 
ischaemia induces an increase in PP2A-C. A portion of this PP2A-C is stored in an inactive form, 
while an active portion acts as a regulator of the pro-survival signalling components PKB/Akt, GSK-
3β and ERK p42/p44 at the end of ischaemia and the onset of reperfusion. PP2A is therefore an 
important component of the myocardial response to I/R by regulating pro-survival signalling. 
 
  
Stellenbosch University  http://scholar.sun.ac.za
OPSOMMING 
Iskemiese hartsiekte is een van die belangrikste komponente wat bydra tot globale morbiditeit en 
mortaliteit. Ingrepe soos iskemiese prekondisionering aktiveer veelvoudige intrasellulêre 
seintransduksiepaaie om kardiobeskerming teen iskemie/herperfusie (I/H)-besering te ontlok. Die 
kinases betrokke in hierdie seintransduksiepaaie is reeds deeglik nagevors, terwyl die potensiële 
belang van die proteïenfosfatases in seintransduksie tot onlangs misken is. Ons hipotese was dat 
Proteïenfosfatase 2A (PP2A), wat in ‘n wye verskeidenheid fosfatase reaksies betrokke is, ‘n 
belangrike rolspeler in die miokardiale reaksie op I/H-besering is, deur deelname aan die 
regulering van intrasellulêre seintransduksie. 
 
Hierdie projek het ten doel gehad om (i) PP2A te karakteriseer tydens miokardiale I/H; (ii) die 
belang van PP2A in die sellulêre reaksie op I/H-besering te bepaal; en (iii) PP2A se rol in die 
seintransduksiepaaie, gemedieer deur PKB/Akt, GSK-3β, ERK p42/p44 en p38 MAPK, te 
evalueer. 
 
Twee modelle is aangewend om PP2A tydens I/H te karakteriseer: (i) H9c2-selle blootgestel aan ‘n 
simuleerde iskemiebuffer tesame met hipoksie (0.5% O2) vir ‘n maksimum van 2 uur gevolg deur 
heroksiginasie in standaardgroeimedium vir verskillende tydsperiodes tot ‘n maksimum van 30 
minute; en (ii) geïsoleerde, werkende rotharte blootgestel aan ‘n maksimum van 20 minute globale 
iskemie en 10 minute herperfusie. In beide modelle is monsters op verskillende tye versamel vir 
Western-kladanalise. Tydens vroeë iskemie het PP2A-C in die kern toegeneem, waarna dit met 
verloop van tyd na die sitosol herversprei het. Teen die einde van iskemie was daar ‘n toename in 
die vlakke van PP2A-C relatief tot PP2A-A in ongefraksioneerde weefselhomogenate, tesame met 
‘n toename in die inhibitoriese fosforilering van PP2A-C. 
 
Die belang van PP2A-aktiwiteit is ondersoek deur die effek te bepaal van die inhibisie of aktivering 
daarvan op infarktgrootte (IFS) en funksionele herstel in ‘n geïsoleerde werkende rothartmodel, 
blootgestel aan onderskeidelik 35 minute streeksiskemie (RI) of 20 minute globale iskemie. Pre-
iskemiese toediening van die PP2A-inhibitor okadaïensuur (OA, 10 nM), of aktiveerder FTY720 (1 
μm) het infarktgrootte respektiewelik beperk of vergroot. PP2A-aktivering tydens I/H is dus nadelig. 
 
OA en FTY720 is ook aangewend om die bydrae van PP2A tot I/H-verwante, intrasellulêre 
seintransduksie in die geïsoleerde, werkende rothart te bepaal. Monsters is op verskeie 
tydintervalle versamel en ontleed deur gebruik te maak van die Western-kladtegniek. Pre-
iskemiese toediening van OA het die fosforilering van PKB/Akt, ERK p42/p44 en GSK-3β by die 
aanvang van herperfusie bevoordeel, terwyl pre-iskemiese toediening van FTY720, die 
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fosforilering van GSK-3β, p38 MAPK en PKB/Akt aan die einde van iskemie en die begin van 
herperfusie verminder het. 
 
Ter opsomming: PP2A is deel van ‘n vroeë gelokaliseerde kerngebaseerde reaksie op iskemie, 
terwyl langdurige iskemie ‘n toename in PP2A-C relatief tot PP2A-A induseer. ‘n Deel van hierdie 
PP2A-C is onaktief, terwyl die res funksioneer in die regulering van die 
seintransduksiekomponente PKB/Akt, GSK-3β en ERK p42/p44 wat oorlewing fasiliteer met die 
aanvang van herperfusie. PP2A is dus ‘n belangrike komponent in die miokardiale reaksie op I/H 
deurdat dit tot die beheer van seintransduksiepaaie bydra. 
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CHAPTER 1 
Introduction 
 
 
  
“I praise you because I am fearfully and wonderfully 
made; your works are wonderful, I know that full well.” 
Ps. 139:14 
The Bible 
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Chapter 1 - Introduction 
The ischaemic heart 
Ischaemic heart disease 
A recent report by the World Health Organisation (WHO, Global status report on noncommunicable 
diseases 2010) highlighted a shift in the global burden of disease from more traditional 
communicable causes of morbidity and mortality to non-communicable diseases (NCDs): in 2008 
63% of deaths globally were due to NCDs. Non-communicable diseases include conditions such 
as obesity, hypertension, diabetes and cardiovascular disease – all conditions which are 
intrinsically linked to life-style. Traditionally these health issues were confined to the affluent 
nations of the world, but trends reveal that low- and middle-income countries are also increasingly 
being exposed to these diseases as life-styles shift and westernize, while populations age. In fact 
80% of deaths associated with NCDs were reported in low- and middle-income countries (WHO, 
2010). Amongst these NCDs one of the primary causes of mortality is ischaemic heart disease 
(IHD). 
 
In 1997 Murray and Lopez published a study in which they projected that ischaemic heart disease 
would remain the top cause of death from 1990 through to 2020, as well as be in the top 5 causes 
of disability adjusted life years (DALYs) in both developed and developing regions. Nine years later 
Mathers and Loncar (2006) published updated and extended projections of global morbidity and 
mortality to the year 2030. The trend however remains the same: in high-, middle- and low-income 
countries ischaemic heart disease is expected to remain one of the top 5 causes of death. 
Assessing the situation in 2010, Lozano et al. confirmed the WHO-report, as well as these 
projections: From 1990 to 2010 the number of global deaths attributable to NCDs increased by 
approximately 8 million deaths per year, an increase of 30%; largely due to increases in population 
size and age. Ischaemic heart disease caused the largest fraction of deaths in 2010 at 13.3%. 
Almost unbelievably, stroke and IHD combined contributed to a quarter of global deaths, an 
increase from a fifth 20 years ago.  
 
Ischaemic heart disease is therefore clearly a health concern of global proportions. As the world 
population increases and grows older and unhealthy life-styles persist, the impact of ischaemic 
heart disease will also increase. Since this is not a new problem, and in fact it has its genesis in the 
resource-rich nations, the question arises: What is the current approach to treating and managing 
the ischaemic heart? 
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Treating and managing the ischaemic heart 
In the real-world clinical setting there are at least three situations which are associated with 
myocardial ischaemia: (1.) heart transplantation; (2.) cardiac surgery in conjunction with 
cardiopulmonary bypass; and (3.) myocardial infarction (MI). Of these three, myocardial infarction 
has probably received the most attention from researchers, since it presents an unpredictable, 
medical emergency with potentially fatal consequences. We will therefore primarily focus on this 
setting. 
 
Myocardial ischaemia is defined as insufficient blood supply to the heart (Stedman’s Medical 
Dictionary). This has two fundamental consequences: (1.) There is an inadequate supply of oxygen 
and nutrients to meet the heart’s high metabolic demands; and (2.) Metabolic waste products 
cannot be drained away from the heart, leading to their toxic accumulation.  Sustained ischaemia is 
therefore associated with cell death (Reimer et al., 1977; Jennings & Reimer, 1983).  
 
There are several cellular mechanisms underlying the injury inflicted by ischaemia. The cessation 
of blood flow to the heart almost immediately places its energy metabolism under pressure. In the 
absence of sufficient oxygen levels oxygen-dependent mitochondrial metabolism diminishes. 
Within the first seconds of ischaemia, however there is an acute, transient increase in anaerobic 
glycolytic rate (approximately 60-90 seconds), whereafter the rate of glycolysis slows down. 
Creatine phosphate reserves are also rapidly consumed. The degree and severity of ischaemia will 
determine how long glycolysis continues (Jennings et al. (1990) reported 40-60 minutes), but after 
some time it too will finally grind to a halt whilst adenosine triphosphate (ATP) levels are spent. 
This severely compromises the cell’s ATP-dependent capacity to maintain normal trans-membrane 
ion gradients (Jennings et al., 1990; Meisenberg & Simmons, 1998; Gurbel et al., 1998; Opie, 
2004).  
 
ATP-dependent proteasomal processes of the ubiquitin-proteasome system (UPS) will also be 
inactivated, thereby reducing the cardiomyocyte’s ability to maintain protein homeostasis and 
leading to an accumulation of misfolded and damaged proteins and protein aggregates, which in 
turn will induce proteotoxic and endoplasmic reticulum (ER) stress (Churchill et al., 2010; Divald et 
al., 2010; Calise & Powell, 2013). ER stress refers to the build-up of misfolded and damaged 
proteins inside the ER and, if allowed to progress, will eventually stimulate apoptosis (Wang et al., 
2008). This ischaemia-induced loss of UPS function is however seemingly compensated for by an 
increase in autophagy inside the cell (Yan et al., 2005; Dosenko et al., 2006; Zheng et al., 2011; 
Calise & Powell, 2013). Autophagy, specifically macroautophagy, is the process by which double-
membrane vacuoles are formed around proteins, protein aggregates and even whole organelles in 
order to remove these cytosolic components through the merger of these vacuoles 
(autophagosomes) with lysosomes, thereby degrading and effectively recycling the 
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autophagosomal content (Nishida et al., 2009; Dong et al., 2010). It is clear from this definition that 
autophagy entails more than simply protein homeostasis, we will however for simplicity focus on 
autophagy in only this context. This process seems to be an adaptive response as it removes 
dysfunctional proteins, as well as compromised mitochondria and supplies substrates for energy 
metabolism which rival the oxygen efficiency of glucose (Gottlieb et al., 2009; Dong et al., 2010; 
Loos et al., 2011). Despite these beneficial effects, excess autophagy can also in itself lead to cell 
death (Valentim et al., 2006; Matsui et al., 2008; Nishida et al., 2009). Autophagy is however also 
an ATP-dependent process which will not be sustained if the ischaemic insult is prolonged and 
severe (Loos et al., 2011).   
 
In conjunction with the depletion of energy resources, there is an accumulation of metabolic waste-
products such as lactate, creatine, inorganic phosphates, hydrogen ions (H+), etc. This leads to a 
detrimental reduction in the intracellular pH, as well as an increase in the intracellular osmolarity 
(Jennings et al., 1990; Meisenberg & Simmons, 1998; Gurbel et al., 1998; Opie, 2004).  
 
The cardiomyocyte is therefore challenged on four fronts: (1.) depletion of energy necessary for 
survival; (2.) dysregulation of protein homeostasis; (3.) acidic intracellular conditions; and (4.) 
increased inward flux of fluid into the cell. These combined stressors eventually lead to cell death. 
Ischaemic tissue is however not homogenous. Jennings & Reimer (1983) distinguished between 
reversibly and irreversibly damaged cells at any one timepoint in the ischaemic heart. Also, cells 
follow different modes of cell death: autophagy (Matsui et al., 2007; Loos et al., 2011) , apoptosis 
(Fliss & Gattinger, 1996; Anversa et al., 1998)  and oncotic necrosis (Ohno et al., 1998; Freude et 
al., 2000) are potentially all three present in the ischaemic myocardium. 
 
The clinical features of myocardial infarction were described as early as 1910 (Nabel & Braunwald, 
2012). At that stage of course, treatment options were limited to bed rest and general heart ailment 
cures, such as digitalis (Herrick, 1912). As time progressed physicians became increasingly aware 
that the treatment of these patients could be optimized by a combination of effective patient 
monitoring (in the acute phase following the onset of symptoms) and the application of 
resuscitation techniques, which eventually led to the introduction of coronary care units in the 
1960s (Julian, 1987). Treatment was however still largely symptomatic and primarily aimed at 
combating life-threatening rhythmic disturbances following infarction (Julian, 1987). At this time 
there was however also a growing interest in different pharmacological and mechanical 
interventions which could be used to improve the prognosis of MI. An in-depth discussion of these 
interventions falls outside the scope of this thesis and is briefly summarized in table 1.1. For an 
excellent review concerning the state of treatment and scientific pursuit in 1981, before the 
mainstream acceptance of reperfusion strategies and cardioprotection as we know it today, see 
Rude et al. (1981). 
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Table 1.1. Summary of the treatment regimens which were either in use, or under investigation, for 
the treatment of myocardial infarction before the mainstream application of reperfusion strategies. 
Clinical aim Specific mechanism Treatment tested Reference 
To increase 
oxygen availability 
to the ischaemic 
zone. 
 To increase blood flow 
through collateral blood 
vessels. 
 To reduce coronary 
spasm. 
 To limit further 
thrombus formation. 
 To increase oxygen 
content of the blood. 
 Nitroglycerin and other 
nitrate preparations. 
 Hyaluronidase. 
 Ca2+ channel blockers. 
 Anticoagulants, eg. 
heparin. 
 Antiplatelets, eg. aspirin. 
 Steroidal anti-
inflammatory drugs. 
 Oxygen inhalation. 
 Rude et al., 
1981. 
 Kloner & 
Braunwald, 1987. 
 Ganz, 1983.  
 ISIS-2 group, 
1988. 
To reduce the 
oxygen demand of 
the ischaemic 
myocardium. 
 To reduce contractile 
activity of the heart 
muscle. 
 To reduce the afterload 
on the heart. 
 β adrenergic blockade. 
 Vasodilators. 
 Ca2+ channel blockers. 
 Rude et al., 
1981. 
 Kloner & 
Braunwald, 1987. 
 Maroko et al., 
1971. 
 Herlitz et al., 
1983. 
To optimally 
modify the 
metabolism of the 
heart. 
To enhance anaerobic 
metabolism, while reducing 
the amount of free fatty 
acids in the circulation. 
Glucose-insulin-potassium 
administration. 
 Rude et al., 
1981. 
 
To oppose the 
cellular 
derangements 
associated with 
prolonged 
ischaemia. 
 To restore intracellular 
K+ levels. 
 To minimize Ca2+ entry 
into the cardiomyocyte. 
 Glucose-insulin-
potassium 
administration. 
 Ca2+ channel blockers. 
 Brachfeld, 1973. 
 Kloner & 
Braunwald, 1987. 
To reduce 
inflammation. 
To reduce the development 
of general inflammation 
due to the ischaemic injury. 
Steroidal and non-steroidal 
anti-inflammatory drugs. 
 Rude et al., 
1981. 
 
 
It quickly became evident that one of the most important aspects of treating MI, was to keep the 
time duration between the onset of symptoms and the onset of treatment as short as possible. This 
was confirmed by basic science studies which revealed that as time progresses, ischaemic injury 
to the myocardium spreads like a wave from the subendocardium to the subepicardial myocardium 
(Reimer et al., 1977), i.e. from deeper to more superficial layers of the heart muscle. It therefore 
follows that the duration of ischaemia is one of the most important determinants of the eventual 
extent of ischaemic damage (Reimer et al., 1977; Rude et al., 1981; Jennings et al., 1983; Edoute 
et al., 1983). This realization set the scene for the modern approach to myocardial ischaemia: rapid 
reperfusion. 
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Two different strategies can be followed, depending on the availability of resources, to reperfuse 
the ischaemic heart: 
1.) Percutaneous coronary intervention (PCI): In its most basic form this technique entails the 
catherization of the occluded coronary artery with a catheter equipped with an inflatable 
balloon, which is then used to open the occluded artery. Since its first description in 1979 
(Grüntzig et al.), it has developed to an intervention allowing the placement of a stent in the 
artery as well as delivering drugs directly to the myocardium (Stefanini & Holmes, 2013). 
Where the availability of resources allows it, it has become the intervention of choice 
(Keeley et al., 2003), although the optimal treatment of acute MI is still a point of debate 
(Bogaty & Brophy, 2006). 
2.) Thrombolytic treatment: This approach predates PCI and simply entails the 
pharmacologically mediated fibrinolysis of the obstructing thrombus (De Bono, 1987; Nabel 
& Braunwald, 2012). It is ideal in resource-limited settings, although it is considered less 
effective than PCI (Ting et al., 2006).  
 
Irrespective of the reperfusion strategy followed, the most important variable that should be kept in 
mind is keeping the ischaemic time as short as possible (Bogaty & Brophy, 2006; Ting et al., 2006; 
Boden et al., 2007). According to the guidelines of the American College of Cardiology / American 
Heart Association, where PCI is possible, reperfusion must be attained within 90 minutes from the 
time that the patient first made medical contact (Ting et al., 2006; Boden et al., 2007).  
 
Although reperfusion is therefore considered as the best treatment for the ischaemic heart, its 
advent has revealed yet another challenge: reperfusion injury. 
Reperfusion injury 
Reperfusion injury refers to injury associated with reperfusion per se. The underlying causative 
mechanism is situated in the events associated with reperfusion and not the preceding sustained 
ischaemia (Piper et al., 1998). This implies that at the end of an ischaemia / reperfusion (I/R) 
episode a portion (possibly as much as 30-50%) of the final infarcted zone was viable immediately 
prior to reperfusion and died during reperfusion, due to reperfusion (Yellon & Hausenloy, 2007). 
This is a challenging concept since “reperfusion” as a phenomenon only exists because there was 
a prior ischaemic episode, and it is difficult to distinguish between damage due to ischaemia and 
damage due to reperfusion. It is therefore not surprising that for a long time the very existence of 
reperfusion injury was a matter of hot debate (Przyklenk, 1997), although the relatively recent 
discovery of interventions applied at the onset of reperfusion and capable of limiting tissue damage 
has illustrated the contribution of reperfusion injury itself to the pathology associated with 
ischaemia and reperfusion (Piper et al., 1998). Regardless of the precise definitions, it has become 
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undeniable that reperfusion is associated with a number of detrimental events within the 
cardiomyocyte: 
Calcium overload 
Calcium ion (Ca2+) dysregulation at the onset of reperfusion could lead to contracture, 
compromised function and eventual cell death. Several different mechanisms have been implicated 
in the increased influx of Ca2+ into the cardiomyocyte. On the one hand the reduction in ATP 
availability during ischaemia leads to a reduction in the activity of the Na+/K+-ATPase pumps in the 
sarcolemma, whilst the accumulation of intracellular H+ leads to a reversal in the direction of ion 
fluxes controlled by the sarcolemmal Na+/H+-exchanger. The net effect is an intracellular Na+ 
accumulation, which in turn drives the influx of Ca2+ through the Na+/Ca2+-exchanger (Gumina et 
al., 1999; Piper & García-Dorado, 1999; Inserte et al., 2002). More direct routes of Ca2+ influx have 
also been identified in the forms of the sarcolemmal L-type Ca2+-channel (Przyklenk et al., 1989) 
and the Ca2+-ATPase located in the membrane of the sarcoplasmic reticulum (SR). In the absence 
of adequate ATP levels Ca2+-ATPase cannot mediate the re-uptake of Ca2+ into the SR, while 
during reperfusion and re-energization the capacity of the SR may be too small to effectively 
remove Ca2+ from the cytosol (Piper & García-Dorado, 1999). It can also transpire that Ca2+-
ATPase becomes damaged and dysfunctional due to ischaemia (Smart et al., 1997).  
 
Irrespective of the routes followed, this catastrophic increase in intracellular Ca2+ levels may lead to 
hypercontracture (both during ischaemia and reperfusion) and is also at least partially responsible 
for the phenomenon of stunning (Piper & García-Dorado, 1999; Gross et al., 1999). Stunning refers 
to the transient reduction in the functional ability of cardiomyocytes following I/R, even though the 
involved cells are still viable and will eventually recover (Braunwald & Kloner, 1982; Bolli, 1990).  
Free radical generation 
Free radicals are highly reactive chemical species with an unpaired electron in their outer orbital 
(Park & Lucchesi, 1999). At moderate, physiological intracellular levels they have been implicated 
in regulating signalling proteins (Corcoran & Cotter, 2013). However, in large quantities they 
become toxic to cells in that they react with, and in the process damage, all types of 
macromolecules: proteins, nucleic acids, membrane lipids, etc. Such an increase in free radicals, 
specifically reactive oxygen species (ROS), has been observed during reperfusion and contributes 
to the eventual injury associated with reperfusion (Ferrari et al., 1990; Gross et al., 1999; Zweier & 
Hassan Talukder, 2006).   
 
There are several potential sources of ROS in the heart when reperfused (Park & Lucchesi, 1999), 
two of which are the xanthine oxidase system (Thompson-Gorman & Zweier, 1990) and the 
mitochondria. Mitochondria produce ROS if the supply of oxygen and electrons to the electron 
Stellenbosch University  http://scholar.sun.ac.za
- 8 - 
 
transport chain is unsynchronized causing oxygen to be incompletely reduced (Zweier & Hassan 
Talukder, 2006).  
 
Despite these observations that reperfusion elicits ROS generation, and the very probable 
detrimental effects of ROS on cardiomyocytes, their contribution to reperfusion injury is 
questionable in the light of several studies which have failed to show that ROS lowering 
interventions confer cardioprotection (Richard et al., 1988; Piper & García-Dorado, 1999; Park & 
Lucchesi, 1999). 
The mitochondrial permeability transition pore (mPTP) 
Mitochondria are of critical importance in energy metabolism, free radical generation, apoptosis 
regulation and intracellular Ca2+ homeostasis. It is therefore not surprising that the patency of the 
mitochondria has emerged as one of the most important, if not the central, mediator of reperfusion 
injury. 
 
More specifically, an increase in the permeability of the inner mitochondrial membrane (termed 
mitochondrial permeability transition) for any molecule smaller than 1.5 kDa has been implicated in 
the genesis of reperfusion-linked cell death (Halestrap et al., 2007). It is accepted that this 
transition occurs through the opening of a specific pore (Crompton & Costi, 1988) called the 
mitochondrial permeability transition pore (mPTP). The exact molecular composition of the mPTP 
is still a matter of investigation, although cyclophilin-D (CypD) is in all likelihood somehow involved 
(Baines et al., 2005; Nakagawa et al., 2005). Recently it has been proposed that the mPTP might 
form between two dimerized ATP synthase molecules due to changes in the interactions between 
these two molecules (Bernardi, 2013). Despite this uncertainty regarding the molecular structure of 
the mPTP, it can be pharmacologically modulated (Halestrap et al., 2007; Bernardi, 2013). 
 
Opening of the mPTP is precipitated by Ca2+ accumulation in the mitochondrial matrix, especially 
when this occurs in conjunction with an increase in the matrix concentrations of ROS and inorganic 
phosphates (Pi) (Crompton & Costi, 1988; Compton, 2000). Since these stimuli are also 
characteristic of the cellular milieu during reperfusion, it is not surprising that reperfusion, and not 
ischaemia, is associated with an increased tendency for the mPTP to open (Halestrap et al., 2007). 
Opening of the mPTP is detrimental for several reasons.  
 
Firstly the free movement of H+ through the mPTP obviously reduces the H+ concentration gradient 
across the inner membrane which is supposed to drive the synthesis of new ATP through oxidative 
phosphorylation. The consequence of this is not only a loss of ATP generation capability, but also 
an increase in the degradation of ATP as the ATP synthase in the inner membrane switches to an 
ATPase. Secondly, the localised depolarization accompanying the opening of a single pore will 
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induce opening of the surrounding mPTPs. Thus, opening of a single pore will lead to the opening 
of all the pores in a mitochondrion. Thirdly, while the small solutes exit the mitochondrial matrix and 
equilibrate with the extra-mitochondrial space, the larger osmotically active proteins remain trapped 
in the matrix. This leads to the development of an osmotic gradient driving the movement of water 
into the matrix causing it to swell and the outer mitochondrial membrane to eventually burst. This 
allows the release of pro-apoptotic mediators (such as cytochrome c) into the cytoplasm, thereby 
initiating apoptosis (Halestrap et al., 2007). 
 
The importance of the mPTP in reperfusion injury has been illustrated by the observation that 
maintenance of the mPTP in a closed conformation limits the development of reperfusion-linked 
myocardial damage (Hausenloy et al., 2003; Kim et al., 2006). Similarly the efficacy of several 
other cardioprotective interventions are also dependent on keeping the pore closed (Gateau-
Roesch et al. 2006; Argaud et al., 2005; Bopassa et al., 2006; Lim et al., 2007). 
Other factors contributing to reperfusion injury 
As mentioned previously, ischaemia induces an increase in glycolytic flux with an associated 
accumulation of anaerobic metabolites, such as H+ and lactate. This leads to a reduction in 
intracellular pH (acidosis). On reperfusion excess H+ are transported out of the cell via Na+/H+ 
transporters. This is however detrimental in three ways: (1.) As mentioned before, the resulting 
increase in intracellular Na+ can drive Ca2+ influx into the cell, contributing to Ca2+ overload through 
the Na+/Ca2+ exchanger; (2.) The increase in intracellular Na+ concentrations can contribute to the 
generation of an osmotic gradient across the sarcolemma favouring the inward flux of water into 
the cell (Inserte et al., 1997; Piper & García-Dorado, 1999); and (3.) The rapid normalisation of pH 
constitutes the removal of a cardioprotective agent. Transient acidosis is protective since it inhibits 
the contractile machinery of the cardiomyocyte (thereby inhibiting the development of reperfusion 
contracture – Piper & García-Dorado, 1999) and keeps the mPTP in a closed conformation (if the 
pH of the mitochondrial matrix is also reduced - Petronilli et al., 1993). In this regard, transient 
reperfusion acidosis has been associated with cardioprotection (Kitakaze et al., 1988; Hori et al., 
1991; Fujita et al., 2007; Cohen et al., 2007). 
 
Sodium ions are however not the only osmotically active species in the cells during reperfusion. As 
the interstitial space is more rapidly flushed of all accumulated ischaemia-related metabolites than 
the intracellular space, an osmotic gradient develops which leads to cell swelling and eventual 
damage being incurred by the sarcolemma (Tranum-Jensen et al., 1981; Ruiz-Meana et al., 1995; 
Piper & García-Dorado, 1999).  
 
As mentioned previously, ischaemia also influences protein homeostasis by reducing the activity of 
the UPS, with a concomitant increase in autophagy. Reperfusion has been reported to induce a 
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partial recovery in proteasomal activity (Dosenko et al., 2006; Hochrainer et al., 2012), which might 
not be beneficial, since Dosenko and colleagues (2006) reported that the administration of low 
concentrations of proteasomal inhibitors immediately before the reoxygenation of anoxic neonatal 
cardiomyocytes led to a reduction in the occurrence of apoptosis and necrosis in these cells. The 
increase in ATP levels, as well as the degree of oxidative protein damage and ER stress 
associated with reperfusion are all factors which stimulate an increase in autophagy during 
reperfusion (Hamacher-Brady et al., 2006; Matsui et al., 2008; Nishida et al., 2009). The 
implications of this increase in autophagy is uncertain, with researchers arguing for both its 
beneficial (Hamacher-Brady et al., 2006; Giricz et al., 2012) as well as deleterious effects (Matsui 
et al., 2007; Matsui et al., 2008; Nishida et al., 2009). 
 
On a more systemic level, the inflammatory response to an ischaemic episode, and its associated 
tissue injury, also contribute to cardiomyocyte damage – especially since it is only during 
reperfusion that the inflammatory effectors can actually reach the relevant tissue. Some of the 
inflammatory machinery which has been implicated in I/R are the complement system (Hill & Ward, 
1971; Yasojima et al., 1998; Buerke et al., 2006) and neutrophils (Romson et al., 1983; Kin et al, 
2006). For reviews on this see Parks & Lucchesi (1999) and Jordan et al. (1999). 
Conclusion 
Ischaemia is not simply a lack of oxygen, but also constitutes a series of perturbations due to the 
lack of nutrition and the accumulation of waste products, putting affected cardiomyocytes under 
severe stress. This stress can only be alleviated by reperfusion, which makes it the only viable 
treatment. Yet, at the same time, reperfusion itself initiates molecular events which eventually lead 
to the demise of cells already under stress, but not yet dead, due to preceding ischaemia. 
 
The aim of this literature overview is to give the reader an overall perspective of the events 
associated with both ischaemia and reperfusion; it is not aimed at contributing to the debate 
concerning the existence and / or definition of reperfusion injury. It is however clear that 
reperfusion is in itself associated with a molecular identity quite different from that of ischaemia, 
although the two are inexorably linked. For the purposes of this thesis, I will therefore approach 
ischaemia and reperfusion as two distinct conditions in the cardiomyocyte, while at the same time 
attempting to recognise both of them as different components of a single stressor namely 
ischaemia / reperfusion injury. 
Cardioprotection following ischaemia / reperfusion 
At the moment the best treatment intervention for a patient suffering MI is rapid reperfusion. There 
are however limits as to how quickly this can be achieved (see Boden et al. (2007) for a discussion 
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concerning the practicalities of timely reperfusion). At the same time, we now know that reperfusion 
itself is associated with cell death.  
 
These two observations lead to two questions: Firstly, can more be done additional to rapid 
reperfusion to treat the heart exposed to I/R? Secondly, what can be done to alleviate the 
detrimental effects of reperfusion, thereby enhancing the advantages of early reperfusion? These 
two questions lead us into the realm of cardioprotective interventions. 
Cardioprotective interventions 
In 1986 Murry and colleagues made the surprise observation that the administration of multiple (2 
or 4) short episodes of ischaemia (10 minutes), separated by 20 minutes reperfusion, did not lead 
to the expected accumulation of ischaemic effects (measured as loss of adenine nucleotides and 
cell death) in comparison to a single 10 minute ischaemic exposure (Reimer et al., 1986). These 
intriguing results lead them to test the hypothesis that the administration of short ischaemic cycles 
prior to sustained ischaemia might actually protect the heart against the ensuing ischaemic stress. 
A hypothesis which was proven correct: 4 cycles of 5 minutes ischaemia/reperfusion reduced 
infarct size by 25% after 40 minutes of coronary occlusion in dogs (Murry et al., 1986). Since this 
technique utilized brief periods of ischaemia to “prime” the myocardium to become more resistant 
against the detrimental consequences of a sustained ischaemic episode in the future, it was called 
“ischaemic preconditioning” (IPC). At that stage the discovery of IPC served to invigorate research 
on myocardial ischaemia because it revealed that the heart has the innate potential to protect itself 
against ischaemic damage. Indeed further research revealed that IPC could reduce infarct size 
(IFS) (Murry et al., 1986) and reperfusion arrhythmias (Shiki & Hearse, 1987), as well as improve 
function following I/R (Cave & Hearse, 1992). Ischaemic preconditioning is still regarded by many 
as probably the most robust, reproducible and strongest cardioprotective intervention known. 
 
Later it was found that the protection afforded by an IPC stimulus was biphasic: in the short term 
(within minutes to 2 to 3 hours) a potent cardioprotective effect was elicited which then waned 
away but was later (12 – 24 hours later) replaced by a less potent but longer lasting (in the order of 
3 to 4 days) cardioprotective effect. This second stage of protection is called delayed, or late 
preconditioning, or simply the second window of protection (SWOP) and can be ascribed to protein 
expression dependent mechanisms which are recruited by the initial short periods of ischaemia 
(Kuzuya et al., 1993; Marber et al., 1993; Bolli, 2000; Yellon & Downey, 2003). 
 
Interestingly Przyklenk and colleagues (1993) found that the application of brief cycles of 
ischaemia to the vascular bed supplied by the circumflex branch induced protection to an 
ischaemic episode in the tissue supplied by the descending coronary artery. Protection was 
therefore being “communicated” between vascular beds in the heart. This concept was later 
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extended to show that IPC of other organs or limbs can also confer resistance to the heart against 
an ensuing sustained ischaemic episode (Gho et al., 1996). This form of intervention is called 
remote ischaemic preconditioning (RIPC), and it reveals that at least a degree of the protection 
elicited by brief ischaemic episodes must be mediated by some form of systemic communication 
system – the nervous system and / or a blood borne chemical messenger (for a review concerning 
RIPC see Tapuria et al. (2008)). 
 
In 2003 the group of Vinten-Johansen (Zhao et al., 2003) described a phenomenon similar to IPC, 
but with the critical difference that short cycles of I/R were administered at the very onset of 
reperfusion.  Postconditioning (PostC), as it became known, utilized shorter and more numerous 
ischaemic cycles than IPC and also proved to be less potent and consistent in the protection that it 
evoked (Tang et al., 2006; Dow & Kloner, 2007). It however has the clinical edge on IPC, since it is 
a cardioprotective intervention which can be applied after sustained ischaemia and therefore falls 
within the exact timeframe when a patient would present for treatment following an MI. PostC also 
highlighted reperfusion as a period which could be (and should be) targeted for cardioprotection 
(Vinten-Johansen et al., 2005; Downey & Cohen, 2005). The fact that an intervention applied at 
reperfusion could elicit cardioprotection also confirmed the existence of reperfusion injury per se 
(Piper et al., 1998). Interestingly most researchers found that the very first moments of reperfusion 
is the critical timepoint to intervene to protect the heart (Kin et al., 2004; Yang et al., 2004), 
although it has been reported that interventions at a later stage could also still limit I/R injury 
(Roubille et al., 2011). 
 
These cardioprotective manoeuvres have been thoroughly investigated in the basic science setting 
and have even been shown to benefit the human heart exposed to I/R. Ischaemic preconditioning 
is in its nature limited in its potential application to the MI scenario, since it needs to be applied 
prior to ischaemia. It has however been applied with success in more controlled situations, such as 
coronary artery bypass grafting (CABG), where the onset of ischaemia can be controlled (Yellon et 
al., 1993; Teoh et al., 2002). As an intervention applied during the first moments of reperfusion, 
postconditoning has been identified as potentially clinically relevant. Already in 2005 it was proven 
to be effective in the human heart (Staat et al., 2005). Other studies soon followed which also 
confirmed its potential benefits in the human heart (Ma et al., 2006; Yang et al., 2007). The clinical 
applications of remote ischaemic preconditioning has also been explored, especially since RIPC 
allows for the non-invasive application of a preconditioning stimulus (in the form of limb 
ischaemia/reperfusion applied by a pressure cuff) to protect the heart (Schmidt et al., 2012). 
Emboldened by the successes of PostC, researchers have bypassed the limitation of having to 
apply the conditioning stimulus before ischaemia, by rather applying the conditioning stimulus 
during sustained ischaemia (Bøtker et al., 2010).  
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Mechanical intervention in already diseased coronary arteries, as required by “ischaemic 
conditioning”, is however a risky endeavour. However, these different “ischaemic conditioning” 
interventions exposed the heart’s own innate capacity to become more resistant to the detrimental 
effects of I/R – a capacity which could be exploited by more acceptable pharmacological means to 
induce cardioprotection. The question which however first needs to be answered is what is the 
mechanism(s) whereby “ischaemic conditioning” elicits cardioprotection? 
Mechanisms of cardioprotection 
A considerable body of research has already been done in the pursuit of this question and is 
reviewed in detail by Yellon & Downey (2003); Hausenloy & Yellon (2007); and Zhao & Vinten-
Johansen (2006). For the purposes of this introduction a very brief overview of what is currently 
known will be given, with the focus on specifically IPC and PostC.   
Reducing inflammation 
The original descriptions of both IPC and PostC were done in in vivo experimental models which 
revealed that these cardioprotective interventions elicit some of their protective effects by reducing 
the systemic inflammatory response to I/R. In this regard it has been reported that IPC reduces 
neutrophil accumulation during reperfusion (Bufkin et al., 1998; Wang et al., 1999). PostC has also 
been shown to reduce neutrophil accumulation in the area at risk, as well as tissue oedema in the 
ischaemic epicardium (Zhao et al., 2003; Kin et al., 2004; Mykytenko et al., 2007). Recently Xiong 
and colleagues reported (2011) that both IPC and PostC reduced serum levels of tumour necrosis 
factor-α (TNF-α) in an in vivo rat model, although the effect was more pronounced following IPC. In 
fact, PostC has even been found to reduce the release of TNF-α in a neonatal cardiomyocyte 
model (Sun et al., 2006).  
 
The observation that both IPC and PostC can be applied in the isolated heart perfused with a 
crystalloid buffer however implied that there are even more intrinsic mechanisms at work. 
Reactive oxygen species 
Both IPC and PostC have been shown to be associated with a reduction in the generation of free 
radicals during reperfusion (Halkos et al., 2004;  Zhao et al., 2003; Mykytenko et al., 2007; Quarrie 
et al., 2012). This makes sense since, as discussed before, ROS production has been implicated 
as a contributing factor to reperfusion injury. However, the association between ROS and 
cardioprotection is not that simple. Oxygen radicals have also been implicated as important 
components involved in triggering IPC-mediated protection (Baines et al., 1997; Vanden Hoek et 
al., 1998). Likewise in PostC, the administration of ROS scavengers prior to (Tsutsumi et al., 2007) 
or during (Penna et al., 2006) a PostC intervention abolished the protection elicited by PostC. 
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These findings emphasise the importance of timing and possibly also of quantity in determining the 
effects of ROS in the setting of cardioprotection. 
Protein homeostasis 
In light of the perturbations in protein homeostasis via the UPS and autophagy associated with I/R, 
it is not surprising that both these processes have been implicated in cardioprotection as well. 
Concerning proteasomal degradation there is both evidence for its inhibition and its activation to 
induce protection against I/R injury, with both the timing of modulation of UPS activity as well as 
the specific protein substrates involved determining the eventual outcome (Yu & Kem, 2010; Calise 
& Powell, 2013). It is however noteworthy that IPC activates proteasomal activity during I/R, while 
proteasomal inhibition abrogates the protective effects elicited by IPC and PostC (Dosenko et al., 
2006; Churchill et al., 2010; Divald et al., 2010). 
  
Similar to the UPS, there is also still uncertainty regarding the role of autophagy in protection. 
Some have found that its inhibition confers protection (Valentim et al., 2006), while others have 
reported that its activation induces an increased resistance against I/R injury (Yitzhaki et al., 2009; 
Loos et al., 2011; Sciaretta et al., 2012). There are some compelling explanations for the proposed 
beneficial effects of autophagy, including an increase in the generation of ATP, a reduction in the 
number of damaged mitochondria in the cell which might contribute to the initiation of cell death, a 
reduction in ER stress which in turn will limit the development of apoptosis and a reduction in the 
acidification of the cytosol due to an increase in the inward movement of H+-ions into the 
lysosomes involved with autophagy (Gottlieb RA et al., 2009; Dong et al., 2010; Loos et al., 2011; 
Giricz et al., 2012). 
Intracellular signalling pathways 
Intracellular signalling constitutes the communication pathways linking external stimuli and 
conditions to intracellular responses and adaptation. In the case of IPC, the cycle(s) of brief 
ischaemia prior to sustained ischaemia serve as the “trigger” which initiates signalling cascades 
which will communicate a message of adaptation to the cellular end-effectors; i.e. the cellular 
components which must facilitate the final cardioprotection. The way in which the “trigger” IPC 
stimulus “informs” the cardiomyocytes is by the release of autocrine and paracrine messengers, 
the most prominent of which are adenosine, bradykinin, the opioids and catecholamines. These 
molecules are released by the heart due to ischaemia and then bind to their receptors (which are 
Gi protein-coupled receptors (Gi-PCR)) in the myocardial sarcolemma.  
 
Activation of these receptors initiate several signalling pathways. How these signalling pathways 
interact is not completely known, but the following model (proposed by Yang and colleagues, 2010) 
seems to emerge: 
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Binding of adenosine, bradykinin and the opioids to their respective receptors induces the 
activation of Protein kinase C (PKC) (Goto et al., 1995; Miki et al., 1998). Protein kinase C seems 
to be of critical importance, since PKC inhibition abolishes IPC protection (Ytrehus et al., 1994). 
Through some unknown mechanism PKC then increases the affinity of the A2b adenosine receptor 
(A2bAR) for adenosine (Kuno et al., 2007). This then enhances the signalling associated with 
A2bAR, including the extracellular signal-regulated kinase p42/p44 (ERK p42/p44) and the 
phosphatidylinositol 3-kinase (PI3-kinase) – protein kinase B (PKB)/Akt pathways (Solenkova et 
al., 2006). The involvement of these pathways has been shown both during the triggering phase 
(prior to sustained ischaemia) (Tong et al., 2000; Uchiyama et al., 2004), as well as during 
reperfusion (Hausenloy et al., 2005) – in the context of which they are collectively known as the 
Reperfusion injury salvage kinase (RISK) pathway. It should also be mentioned that several 
different stimulants can activate the RISK pathway, not only the A2bARs. 
 
Active PKB/Akt stimulates the production of nitric oxide (NO) via the phosphorylation of endothelial 
nitric oxide synthase (eNOS). In turn NO can stimulate guanylyl cyclase (GC) to increase the levels 
of cyclic guanosine monophosphate (cGMP) which then activates protein kinase G (PKG). PKG 
opens the mitochondrial ATP dependent potassium channel (mKATP channel). Opening of the 
mKATP channel induces a burst of ROS production by the mitochondria (Cohen et al., 2001; 
Oldenburg et al., 2004) which then contributes to signalling, probably by activating PKC 
(Korichneva et al., 2002; Liu et al., 2008). This would then potentially lead to a positive feedback 
strengthening of these protective signalling cascades. 
 
Although the above described theory makes sense and is strengthened by experimental evidence, 
reality is not as simple: there are several signalling molecules not accounted for by this model, 
amongst them the signal transducer and activator of transcription 3 (STAT3) which has been 
shown to represent an alternative cardioprotective pathway to RISK (Lecour et al., 2005) known as 
the SAFE (Survivor Activating Factor Enhancement) pathway (Lecour, 2009). 
 
In addition, there is also the question as to the final target onto which all these signalling pathways 
signal. From the data it is the mitochondria, and specifically the mPTP, which emerges as the 
probable ultimate end-effector. As mentioned previously, opening of the mPTP during early 
reperfusion is detrimental. It has however been found that IPC maintains the pore in a closed 
conformation (Javadov et al., 2003; Hausenloy & Yellon, 2007), thereby favouring survival. 
Juhaszova and colleagues (2004) suggested that it is possibly glycogen synthase kinase 3-β 
(GSK3-β) which acts as a central nexus point between several cardioprotective pathways and in 
some, as yet unknown way, interacts with the mitochondria to stabilize the mPTP in a closed 
conformation. 
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The mechanism behind the cardioprotection elicited by PostC utilizes exactly the same role-
players, only in a new setting. Possibly the most complete model explaining PostC protection at the 
moment is described by Cohen et al., 2007. Just as is the case with the triggering stimulus of IPC, 
sustained ischaemia leads to the release of opioids, adenosine and bradykinin. These molecules 
bind to and activate their respective receptors but, in the absence of adequate levels of oxygen, 
cannot stimulate the production of the ROS which is required to activate PKC. In normal 
reperfusion, the rapid rate of pH restoration proves detrimental in that the inhibitory effects of 
acidosis on the mPTP is relieved before the mPTP can be kept closed by cardioprotective 
signalling pathways. PostC however is simply a technique to decelerate the rate of pH 
normalization, while still allowing the supply of enough oxygen for ROS-dependent signalling to 
become suitably activated to recruit the RISK pathway to keep the mPTP closed.  
 
We therefore see that these different forms of cardioprotection, IPC and PostC, recruit common 
signalling pathways to confer protection. These pathways are receptor activated and recruit 
multiple participators, the most important of which are PKC, PKB/Akt, ERK p42/p44, GSK3-β, and 
finally the mPTP in the mitochondria. This is then also the strength of IPC and PostC 
cardioprotection: it is not dependent on a single intracellular mediator, but rather recruits several 
signalling pathways and mediators in order to efficiently and robustly increase resistance to I/R 
injury. 
Cardioprotection: a clinical reality? 
It is now 27 years since the cardioprotective effects of IPC was first described. Massive gains have 
been made in understanding the way in which the heart reacts to ischaemia and reperfusion, how 
I/R injury develops and which mechanisms are naturally available to confer resistance against I/R 
injury. Several pharmacological mimetics and interventions have been put forward, tested and 
proven to also confer cardioprotection (Gerczuk & Kloner, 2012). Yet, as things stand, clinical 
translation of these cardioprotective interventions have not met expectations at all, in fact none of 
the researched and proposed cardioprotective interventions has been assimilated into standard 
clinical practice. This has left the research field in a conundrum and caused a shift in the field of 
cardioprotective research away from delineating mechanisms to application of protective 
interventions. In recent years many authors and working groups have attempted to address the 
reasons why there is a lack in the clinical translation of our basic research: see Bollli et al. (2004); 
Cohen & Downey (2011); Kloner & Longacre (2011) and Sanz-Rosa and colleagues (2012). 
 
In an attempt to determine why cardioprotection is still confined to the laboratory Bolli and 
colleagues (2004) distinguished between limitations and challenges on the clinical and pre-clinical 
levels. A complete discussion concerning all these possibilities falls outside the scope of this 
thesis. It is however interesting to note some of the possible reasons put forward on the pre-clinical 
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level. The most disturbing phenomenon characterizing the field of cardioprotection is the lack of 
consistency in terms of the efficacy of an intervention between different research labs, and also 
between different animal species tested. This could be ascribed to inappropriate animal models. It 
could also be symptomatic of interventions that are simply not robust enough to work at all times 
and in all animals. This is a reasonable assumption, since many of the interventions targeted only 
one or two of the pathways involved in cardioprotection, while IPC and PostC recruit numerous 
pathways simultaneously.   
 
In my opinion there is also merit in the argument that we simply do not yet understand enough of 
the complete signalling picture in cardioprotection. Could it be that we are missing something 
which could increase the robustness and strength of the pharmacological mimetics of IPC and 
PostC which have already been identified? As Gerd Heusch puts it in his review on the topic in 
Lancet (2013): “Clearly we must develop an improved understanding of cardioprotective signalling, 
particularly in human hearts, to progress with this approach.” 
 
Almost all of the research concerning the problem of I/R injury has focussed on the participation of 
several kinases in cardioprotective signalling. These enzymes phosphorylate other proteins and 
enzymes thereby changing the function of their respective substrates. There is however another 
side to this story... 
Signalling through protein phosphorylation 
Protein phosphorylation is an enzyme mediated process was first described in 1953 by Burnett and 
Kennedy. Since then it has become increasingly evident that protein phosphorylation is a dynamic 
process which serves to dramatically expand the functional, spatial and temporal characteristics of 
proteins beyond the dynamics of protein expression and degradation. It is in fact very conceivable 
that in the years to come phosphorylation, and other forms of protein posttranslational modification, 
will rival traditional genomic based regulation of cellular proteins in terms of complexity, as well as 
importance for the control of cellular processes (Pawson & Scott, 2005; Porter et al., 2012). This is 
illustrated by a recent study done by Olsen and colleagues (2006). They performed a 
phosphoproteomic analysis of HeLa cells exposed to endothelial growth factor (EGF) in order to 
map the phospho-proteins recruited by this signalling pathway, over time (the first 20 minutes 
following exposure), in both the cytosolic and nuclear fractions. They detected 2 244 phospho-
proteins with a total of 6 600 phosphorylated residues between them, leading them to conclude 
that most in vivo phospho-sites are still to be discovered. There are only three amino acid residues 
which have been found to be phosphorylated: serine, threonine and tyrosine (Porter et al., 2012). 
In Olsen’s experimental setup they found that of the phosphorylated sites detected 1.8% were 
tyrosine residues, 11.8% were threonine residues, while  86.4% constituted serine 
phosphorylation. 
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The level of phosphorylation of a protein is determined by the balance between the 
phosphorylation of that protein (mediated by a kinase, or kinases), as well as the 
dephosphorylation of that protein (mediated by a phosphatase, or phosphatases) (Wera & 
Hemmings, 1995; Hunter, 1995). Traditionally the kinases have received more attention than the 
phosphatases. This might be due to an earlier school of thought that the phosphatases are merely 
house-keeping enzymes, maintaining an ubiquitous degree of dephosphorylation. An approach 
which could be justified when it is taken into account that the human genome codes for 
approximately 518 kinases (90 tyrosine kinases and 428 serine/threonine kinases) and only about 
137 phosphatases (107 tyrosine phosphatases and 30 serine/threonine phosphatases) (Shi Y, 
2009). It has however come to light that the phosphatases are also, like the kinases, subject to 
stringent intracellular regulation. In fact, the limited number of phosphatase catalytic subunits in the 
genome has necessitated a degree of regulation employing more diversity and complexity than is 
the case for most kinases. (For a general overview of these regulatory mechanisms see Shi (2009) 
and Gomperts et al. (2009).) 
 
As mentioned earlier, intracellular signalling in its most basic form, is the communication of events 
outside a cell to the interior of the cell in order for the cell to respond to the extracellular 
environment. As already discussed, myocardial IPC is a typical example of this: transient 
ischaemia is communicated to the nucleus and mitochondria of a cardiomyocyte in order to elicit 
adaptations to increase the resistance of the cell to I/R damage. This transfer of information is 
mediated by several “communicator” molecules: adenosine, the adenosine receptors, PKC, PKB, 
GSK3-β, etc. Fundamentally intracellular signalling is communication via sequential protein 
phosphorylation. In reality, the signal being communicated is “coded” for in the phosphorylation 
status of the communicator molecules. This is not unlike other forms of basic communication such 
as Morse code or binary code, where the message being communicated is coded for using only 
two variations – for Morse code it is “sound” or “no sound”, for binary it is “1” or “0”, and for 
signalling it is “phosphorylated” or “unphosphorylated” (Figure 1.1). Keeping this simplified model 
of signalling in mind it becomes obvious why the balance between “phosphorylation” and 
“dephosphorylation” is important. 
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In the 1970’s work was done on trying to describe the activity of metabolic pathways on a systems 
biology level using mathematical modelling, an approach called metabolic control analysis (MCA) 
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(Kacser et al., 1995; Westerhoff, 2008). At the turn of this century this approach was applied to 
signalling cascades in an attempt to define the control of kinases and phosphatases involved in 
signal transduction (Heinrich et al., 2002; Hornberg et al., 2005). While this type of science falls 
outside the scope of this thesis, these authors came to some interesting conclusions which will be 
briefly mentioned. 
 
As is the case with models such as these, they are built on certain assumptions in order to simplify 
the situation. For signalling cascades the following assumptions were made: (1.) the signalling 
pathway is a simple, linear pathway; (2.) activating processes in the pathway entail either receptor 
activation or kinase mediated phosphorylation of participating proteins; (3.) deactivating processes 
entail receptor internalization or degradation, or phosphatase mediated dephosphorylation of 
participating proteins; and (4.) after activation the signalling pathway will eventually return to its 
pre-activation state. We will focus on three parameters which were investigated:  
1.) Signal duration, defined as the average period of time that a specific kinase is activated. 
2.) Signal amplitude refers to the concentration of the specific kinase  which is activated. 
3.) Integral signal strength is a measure of the number of downstream molecules eventually 
affected by the pathway. 
 
What these authors found was that their models predicted the kinases to have a more significant 
impact on the amplitude of a signal than the phosphatases, although phosphatase activity also 
contributed. Signal duration and integral strength were however primarily determined by the 
deactivating reactions – i.e. the phosphatases. Hornberg and colleagues (2005) went on to 
demonstrate these trends in an actual mitogen activated protein kinase (MAPK) / ERK kinase 
(MEK)-ERK signalling cascade.  
 
These models represent an approximation of reality, but their results are thought-provoking. They 
indicate that the phosphatases might be more influential in determining some of the characteristics 
of the signal being propagated than the kinases. Even if a person is sceptical concerning these 
results, it must be conceded that the phosphatases might be more important in signalling than 
initially appreciated.  
 
If this is in fact true, then the contribution of the phosphatases to cell survival signalling and 
cardioprotection must be pronounced and may therefore be a good target for the modulation of I/R 
injury treatment. 
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The protein phosphatases and myocardial ischaemia / 
reperfusion 
Targeting protein phosphatases in cardioprotection 
As mentioned previously, there are only three amino acid residues which have been found to be 
phosphorylated: serine, threonine and tyrosine. Reversal of phosphorylation is accomplished by 
three broad families of phosphatases: the protein tyrosine phosphatases (PTPs), the dual 
specificity phosphatases (DSPs) and the protein serine/threonine phosphatases (PSPs) (Gomperts 
et al., 2009). According to Gomperts et al. (2009) the DSPs can be classified as a subfamily of the 
PTPs since they contain a conserved PTP signature motif in their structure. They however have 
the ability to dephosphorylate all three residues. One of the better known subdivisions of this family 
are the MAPK phosphatases (MKPs), which specifically catalyze the dephosphorylation of both 
tyrosine and threonine residues (Bermudez, et al., 2010). 
 
In 1994 Kobryn & Mandel reported that renal tissue anoxia was associated with a reduction in 
kinase activity, which is to be expected as ATP levels decrease, while protein phosphatase activity 
(specifically the PSPs Protein phosphatase 1 (PP1) and Protein phosphatase 2A (PP2A)) 
remained relatively unchanged. These findings imply that dephosphorylation processes will be 
favoured during ischaemia. Depending on the specific substrate involved, these changes in 
phosphorylation might be important in I/R injury. It is outside the scope of this thesis to report on 
the probable involvement of all the known protein phosphatases in I/R and cardioprotection. I will 
however highlight some examples of the work that has been done to illustrate the possible 
importance of phosphatase activity in these settings. 
 
In view of all the research which has focussed on the importance of the activity of pro-survival 
kinases in cardioprotection it is perhaps not surprising that phosphatase inhibition in general 
seems to be associated with better outcomes following I/R. For example, in 1997 Xiuhua and 
colleagues found that the administration of okadaic acid, an inhibitor of PP1 and PP2A, prior to the 
hypoxia  and reoxygenation of  vascular smooth muscle cells led to an increase in cell viability, 
while the administration of a phosphatase activator (2,3-butanedione monoxide (BDM)), prior to an 
IPC protocol, alleviated the protective effects of IPC. These authors speculated that the effects 
observed were due to the interaction of these phosphatases with PKC, although they did not 
directly investigate this link. Armstrong and co-workers (1998) however refuted this speculation 
when they found that the cardioprotection elicited by the inhibition of PP1 and PP2A was not 
dependent on the activity of PKC in their model of isolated rabbit cardiomyocytes. They 
administered the phosphatase inhibitors (OA, Calyculin A and fostriecin) prior to simulated 
ischaemia, or after 75 minutes of ischaemia. Surprisingly, phosphatase inhibition was found to be 
still beneficial, even when initiated so late in ischaemia. Weinbrenner et al. (1998) made similar 
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observations. In their studies using the isolated rabbit heart, as well as isolated rabbit 
cardiomyocytes, the inhibition of PP1 and PP2A (by the administration of fostriecin) was found to 
be associated with a reduction in cell death, even when administered after the onset of ischaemia. 
Somewhat surprisingly though, they found that IPC did not exert an effect on the activity of either 
these phosphatases – thereby excluding PP1 and PP2A from the IPC-mediated mechanism of 
protection. In a separate study, Weinbrenner et al. (1998) reported similar results using inhibitors 
for the PSP protein phosphatase 2B (PP2B, also commonly known as calcineurin (CaN)). 
Interestingly they found that although the administration of the inhibitor Cyclosporine A (CsA) 10 
minutes after the onset of 30 minutes regional ischaemia conferred an infarct sparing effect, this 
protective effect was lost if the administration occurred too late in ischaemia. It is important to note 
at this point that CsA is currently predominantly utilized in cardioprotection research as a 
pharmacological inhibitor of the formation of the mPTP. It could therefore be that these results are 
due to its effects on the mitochondria rather than PP2B. That being said, the observation that 
“early” administration of the drug during ischaemia was more beneficial than “late” administration, 
could be indicative of effects on the mediators of protection and not necessarily on the end-
effector, in this case the mPTP which is expected to play a role during reperfusion only. 
Weinbrenner et al. also found that the inhibition of PP2B with FK506 administered as pre-treatment 
conferred cardioprotection. Confirming these early studies, Feng et al. (2011) reported that BK506 
pre-treatment prior to in vivo regional ischaemia limited infarct size and apoptosis, probably 
through the suppression of PP2B and apoptosis signal-regulating kinase 1 (ASK1).  
 
In both studies of Weinbrenner et al. phosphatase inhibition was applied for the whole duration of 
ischaemia. These studies therefore showed that PP1, PP2A and PP2B were possibly involved in 
the events associated with ischaemia and could be potential targets for intervention during 
ischaemia – at that stage (and still) a very exciting prospect. In 2002 Isotani and co-workers 
extended the applicability of phosphatase inhibition into the reperfusion phase: they found that the 
administration of OA within the first minutes of reperfusion protected rat kidneys exposed to 45 
minutes of in vivo renal ischaemia followed by up to 24 hours of reperfusion.  
 
Much of the earlier work was done on PSPs such as PP1, PP2A and PP2B; more recently the 
tyrosine and dual specificity phosphatases have also received attention, as will be discussed 
below. 
 
Mackay and Mochly-Rosen (2000) employed vanadate as a PTP inhibitor and found that it was 
associated with an elevation in p38 MAPK phosphorylation in isolated rat cardiomyocytes, which 
when combined with ischaemia was associated with an increase in lactate dehydrogenase (LDH) 
release, indicating cell injury. These findings implicated tyrosine phosphatase activity as an 
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important determinant of p38 activity and therefore also cell injury. However, as we’ve already 
established, in I/R timing is everything… 
 
Takada et al. (2004) found that the reperfusion administration of orthovanadate, a PTP inhibitor, 
following 30 minutes regional ischaemia exerted an infarct sparing effect at 24 hours reperfusion 
and improved function at 72 hours reperfusion in an in vivo rat model. They ascribed this protective 
effect to the activation of PKB/Akt and its downstream effectors such as GSK3-β and Bad. In 2008 
Bhuiyan et al. showed that reperfusion administration of another vanadate molecule, vanadyl 
sulphate, following 30 minutes of regional ischaemia, reduced infarct size and the degree of 
apoptosis concomitant with positive effects on cardiac function in an in vivo rat model of I/R. They 
propose that these positive effects are mainly due to vanadyl sulfate mediated phosphorylation and 
activation of PKB/Akt. Expanding on these findings, Bhuiyan & Fukinago wrote a review in 2009 
concerning the cardioprotective effects of vanadium compounds. Their group has repeatedly found 
that vanadium compounds exert cardioprotective effects in the setting of I/R and proposed that 
these protective effects are due to the inhibition of the PTPs responsible for the dephosphorylation 
of receptor tyrosine kinases, which eventually leads to an increase in the phosphorylation and 
activity of downstream PKB/Akt. Linking with this line of  investigation, Sandin et al. (2011) 
reported that 30 minutes hypoxia followed by 30 minutes reoxygenation of NIH3T3 fibroblast cells 
was associated with an increase in the oxidation of the PTPs, in the process reducing their activity. 
One of the PTPs which were specifically investigated by this group was SHP-2, an upstream 
regulator of MAPK signalling. Administration of an antioxidant also reduced the reoxygenation 
associated phosphorylation of ERK p42/p44; supposedly through an increase in the activity of 
SHP-2. This illustrates an inherent mechanism aimed at favouring pro-survival signalling following 
I/R. 
 
Comparatively little work has been done on the effects of the MKPs (a member of the DSP family) 
in the setting of I/R. Fan and co-workers (2009) addressed this void by testing the effects of the 
MKP-1 activator dexamethasone on infarct size (following ex vivo regional ischaemia) and 
functional recovery (following ex vivo global ischaemia) in a rat model. They found that 
dexamethasone administered intraperitoneally or directly to the perfusate, prior to ischaemia or 
during the onset of reperfusion, reduced infarct size and increased functional recovery. These 
beneficial effects were associated with an increased expression of MKP-1 (in the intraperitoneally 
treated group), as well as a reduction in the phosphorylation of p38 MAPK. These observations 
confirm the detrimental consequences of p38 MAPK phosphorylation during reperfusion (Omar et 
al., 2012). This study of Fan et al. serves as a reminder that phosphatase activation is not always 
detrimental - the substrate targeted determines the effects. Interestingly the study by Omar et al. 
(2012) concerning p38 MAPK activity implicated p38 MAPK as a downstream substrate of either 
PP1 and/or PP2A, illustrating the complexity of kinase and phosphatase interaction. 
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Another PSP which has recently also received more attention is protein phosphatase 2C (PP2C). 
Protein phosphatase 2C, along with pyruvate dehydrogenase phosphatase, belongs to a 
Mn2+/Mg2+-dependent  sub-family of PSPs (Gomperts et al., 2009).  In 2006 Zhang & Herman 
characterized some of the characteristics of the protein ‘apoptosis repressor with a CARD domain’ 
(ARC) in H9c2 cardiomyoblasts exposed to oxidative stress. They found that ARC exerted an anti-
apoptotic effect which is dependent on it being phosphorylated on a threonine residue. They then 
went on to identify PP2C as a possible inactivator of ARC through the dephosphorylation of this 
site. This implicates PP2C as a pro-apoptotic regulator involved in oxidative stress. 
 
PH domain leucine-rich repeat protein phosphatase (PHLPP), a member of the PP2C family, has 
also been implicated in I/R injury. Miyamoto et al. (2010) found that silencing PHLPP in neonatal 
rat ventricular myocytes led to an increased phosphorylation of PKB/Akt at specifically ser473 
following stimulation by the administration of insulin-like growth factor-1 (IGF-1) or sphingosine-1-
phosphate (S1P). This increased phosphorylation was linked to an increase in the activity of 
PKB/Akt as well as enhanced leukemia inhibitory factor (LIF) mediated cardioprotection following 
exposure to doxorubicin. This pattern was maintained in PHLPP knockout mice. Exposure of these 
animals to 30 minutes regional ischaemia and 120 minutes reperfusion was associated with a 
reduction in infarct size concomitant with an increase in the ser473 phosphorylation of PKB/Akt 
(measured at 30 minutes reperfusion). This study therefore identified PHLPP as a negative 
regulator of PKB/Akt.  
 
Not all studies have however implicated phosphatase activity, or the inhibition thereof, in 
cardioprotection. Hausenloy et al. (2002) administered the PP2B inhibitor FK506 at the onset of 
reperfusion following 35 minutes of regional ischaemia in the isolated rat heart and found that it 
exerted no effect on infarct size. Similarly Fan and colleagues (2010) reported that administration 
of the drug cantharidin to isolated rat hearts at a concentration where both PP1 and PP2A is 
inhibited, exerted no cardioprotective effects, either as a pre-treatment or during reperfusion. 
Similarly, OA administration at a PP2A-specific concentration failed to confer any protection. 
 
Despite these negative results, most studies implicate the participation of all three families of 
protein phosphatases in the events associated with myocardial ischaemia and reperfusion. As 
more research is done regarding the phosphatases, a larger and more complex signalling network 
of interconnecting kinases and phosphatases is being revealed.  
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Inducing cardioprotection requires targeting multiple molecules and 
pathways 
A study of the events and mechanisms underlying myocardial I/R injury and the attempts that have 
been made to harness these mechanisms to pharmacologically protect the heart reveal the 
following: 
1.) Ischaemia / reperfusion injury encompasses a multitude of intracellular mediators and end-
effectors.  Injury is associated with several aspects, such as mitochondrial dysfunction, 
Ca2+ dysregulation, pH perturbation, oxidative stress and metabolic adaptations. Each of 
these aspects involves numerous molecules including enzymes, membrane channels, 
chaperones, cytoskeletal proteins, contractile machinery, etc. 
2.) Such a complex series of events ultimately require a complex and intricate solution. 
Ischaemic conditioning provides that solution by recruiting multiple signalling pathways to 
signal to divergent targets such as the nucleus, the mitochondria, sarcolemmal channels 
and carriers, etc. No wonder that attempts to mimic this type of “cellular systemic” 
phenomenon by manipulating single role-players in the process have proven disappointing. 
 
In order to increase the robustness and efficacy of the cardioprotective interventions that have 
already been identified, we must search for yet more signalling regulators to manipulate alongside 
existing cardioprotective interventions in an attempt to enhance the strength and reproducibility of 
cardioprotection. In view of the work done by Heinrich et al. (2002) and Hornberg et al. (2005), as 
well as the laboratory work referred to above, the protein phosphatases might be those signalling 
regulators which may be additionally targeted in the search for robust, clinically-applicable 
cardioprotective interventions. The following studies illustrate this possibility by demonstrating that 
the phosphatases are involved in determining the characteristics of induced cardioprotection and 
can therefore be used alongside existing cardioprotective interventions to broaden the applicability 
of these interventions to situations where their efficacy is reduced. 
Protein phosphatases can modify the characteristics of 
cardioprotection 
‘Phosphatase and TENsin homologue deleted from chromosome 10’ (PTEN) is a DSP of which its 
lipid phosphatase activity has been best described. Essentially it is involved in dephosphorylating 
3-phosphoinositide, thereby maintaining it at low levels. As such it is also involved in the 
dephosphorylation of phosphatidylinositol (PI)-3,4,5- triphosphate (PIP3) to PI-4,5-diphosphate 
(PIP2), a reaction which is also involved in the activation of PKB/Akt. The activation of PKB/Akt is 
mediated by PIP3, which is synthesized by PI3-kinase (Gompers et al., 2009). PTEN is therefore 
an antagonist of PI3-kinase and associated with the inhibition of PKB/Akt. In 2005 Cai and 
Semenza investigated the possible role of PTEN in IPC. In their isolated rat heart model they found 
that during the brief reperfusion period following the IPC trigger / stimulus ischaemic exposure, 
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PTEN activity and content was downregulated in conjunction with an increase in the activity of 
PKB/Akt. This was however transient, and over time PTEN re-accumulated and antagonized 
PKB/Akt activation, thereby acting as a “timer”-switch triggering the decay of the acute protective 
effect elicited by an IPC trigger-ischaemic exposure. Inhibition of PTEN could therefore 
theoretically increase the short-term duration of protection elicited by a IPC stimulus. 
 
PTEN has also been implicated in setting the threshold of protection. Siddall et al. (2008) found 
that in a mouse model of PTEN haplo-insufficiency an IPC protocol of 4 x 5 minutes cycles I/R 
reduced IFS, while in the littermate controls this protocol was still insufficient to induce protection – 
it was only at 6 x 5 minutes I/R that IPC elicited an infarct sparing effect in this group. Interestingly 
it seemed as if this reduction in protection threshold associated with reduced PTEN activity was 
due to an elevation in the phosphorylation of thr308 in PKB/Akt. This is in contrast to Miyamoto et 
al. (2010) who found that PHLPP inhibition enhanced ser473 phosphorylation in PKB/Akt, 
associated with an infarct-sparing effect. This implies that two different phosphatases, PTEN and 
PHLPP, regulate the phosphorylation of two separate amino acid residues in PKB/Akt. Regardless 
of this, the silencing of PHLPP enhanced the cardioprotective effect of leukemia inhibitory factor 
(LIF) in cardiomyocytes exposed to the cardiotoxic agent doxorubicin, by favouring the ser473 
phosphorylation of PKB/Akt. Inhibition of both PTEN and PHLPP has therefore been shown to 
increase the strength of a co-applied cardioprotective intervention. 
 
These three studies therefore illustrate the potential for phosphatase modulation to modify and 
enhance the efficacy of cardioprotective interventions. 
Protein phosphatases in conjuction with other cardioprotective 
interventions 
The ability to optimize the protection conferred by a cardioprotective intervention is especially 
desirable in situations where baseline conditions do not favour cardioprotection, such as old age 
and obesity.  
Protecting the aged heart 
Fenton and colleagues (2005) found that ventricular PP2A activity was elevated by approximately 
48% under baseline conditions in aged compared to young rats. Following 45 minutes of regional 
ischaemia and 3 hours reperfusion this difference increased to 82%. Ischaemic preconditioning 
also failed to exert a cardioprotective effect in aged hearts. However, the inhibition of both PP1 and 
PP2A by the addition of OA during the IPC cycles restored the protective ability of IPC, although 
not to the same degree as seen in young hearts (Fenton et al., 2005). Similarly, Przyklenk et al. 
(2008) reported that old mouse hearts could not be postconditioned. In their model, the aged 
hearts also presented with an increased expression of MKP-1. Administration of sodium 
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orthovanadate, a non-specific MKP-1 inhibitor, for 45 minutes prior to sustained ischaemia and for 
the first 10 minutes of reperfusion in conjunction with a PostC protocol reduced the expression of 
MKP-1 and restored the protective ERK p42/p44 signalling and infarct sparing effects associated 
with PostC in the aged hearts – again not to the same degree as in young hearts, but significantly 
so. Both these studies show that aging is associated with an increase in cardiac phosphatase 
activity which, at least partially, reduces the cardioprotection associated with ischaemic 
conditioning.  
Protection in obesity 
In a genetic model of obesity (the leptin deficient ob/ob mouse) Bouhidel et al. (2008) found that 
PostC also failed to confer cardioprotection relative to controls. This loss of protection was 
associated with the absence of pro-survival signalling activation by PostC, as determined by the 
phosphorylation of PKB/Akt, ERK p42/p44, p70S6K1 and AMP-activated protein kinase (AMPK) 
and an increase in the levels of the phosphatases PP2A, MKP-3 and PTEN. Interestingly, at 
baseline, the ob/ob mice presented with elevated pro-survival signalling with an associated 
reduction in phosphatase levels. Postconditioning itself elevated the phosphatase levels relative to 
ob/ob control which did not receive PostC. These results are difficult to explain and it could be 
argued that a genetic model of obesity is not ideal. In principle though, this study shows that 
obesity could be associated with the dysregulation of the protein phosphatases – making them 
possible targets for pharmacological intervention in an attempt to restore the cardioprotective 
characteristics of PostC in obesity. 
 
These studies all illustrate the potential of phosphatase modulation to enhance the cardioprotection 
elicited by ischaemic conditioning. We do not propose that the protein phosphatases constitute 
new targets for cardioprotection, rather they present adjunct targets which may enhance the 
efficacy of current cardioprotection interventions. 
Summary and contextualization: Why the phosphatases need 
to be studied in the setting of ischaemia/reperfusion 
Ischaemic heart disease is a global health problem, and indeed the foremost single contributor to 
mortality – in both developed and developing countries. Myocardial ischaemia and its deleterious 
effects have been studied since the 1970’s. Clinical treatment of acute myocardial infarction by 
reperfusion of the affected zone, using either pharmacological thrombolysis or percutaneous 
coronary intervention, was also developed in that time and is still the mainstay treatment option. In 
light of the advanced reperfusion techniques that have been refined over the past three decades 
we are left with two factors that still exert negative effects on clinical outcomes: (1.) the time delay 
between the onset of ischaemia and reperfusion; and (2.) reperfusion injury. These two factors now 
drive the development of cardioprotective interventions that could be applied alongside standard 
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reperfusion protocols. The discovery of ischaemic conditioning (IPC, PostC, RIPC and SWOP) 
exposed the natural innate cardioprotective capacity of the heart. Studies to delineate the 
mechanisms behind this cardioprotective capacity have revealed a common, but intricate, 
signalling network mediating protection. Unfortunately ischaemic conditioning, and its 
pharmacological mimetics, have not been translated to clinical practice. Many reasons for this have 
been put forward, amongst them the inconsistent cardioprotective effects which have been 
reported in the laboratory. This author believes that a part of the problem is ignorance regarding 
the complete signalling networks that are recruited by cardioprotective interventions. One of the 
very important components of signalling which has largely been ignored is the role of protein 
phosphatase activity. Recently it has been postulated that the phosphatases might contribute as 
much, or more, than the kinases to the characteristics of a signalling network. Studies that have 
already been done have confirmed the potential importance of the phosphatases. 
 
In light of the importance of signalling in cardioprotection, and the fact that the role of the 
phosphatases in myocardial signalling is not as well documented as some of the kinases, we 
decided to focus our attention on the significance of phosphatase activity within some of the 
cardioprotective signalling cascades. 
 
There are however numerous protein phosphatases in the heart, potentially targeting a vast array 
of substrates. For the purpose of this study it was decided to select a single phosphatase, focusing 
on a single class of substrates. 
Selecting a phosphatase 
As already mentioned, the majority of phosphorylated residues in HeLa cells following EGF 
stimulation are serine residues (86.4%), followed by threonine (11.85) and lastly tyrosine residues 
(1.8%) (Olsen et al., 2006). This observation immediately casts the spotlight on serine and 
threonine phosphorylation, and by implication also dephosphorylation. Serine and threonine 
residues can be dephosphorylated by either DSPs or PSPs. It has however been reported that up 
to 90% of serine/threonine phosphatase activity in mammalian cells is catalysed by PP1 and PP2A 
only (Oliver & Shenolikar, 1998). The major contribution of these two PSPs to cellular 
phosphorylation becomes evident when both are inhibited. Neumann et al. characterized the 
effects of okadaic acid (1993) and cantharidin (1995), both inhibitors of PP1 and PP2A, on isolated 
guinea pig cardiomyocytes. They found that inhibition of PP1 and PP2A led to an increase in 
numerous, unidentified proteins, as visualized by a smear of phosphorylated proteins separated by 
electrophoresis in a 10% polyacrylamide gel. However Ingebritsen et al. (1983) reported that there 
was much more PP2A than PP1 present in the heart. Foulkes & Jefferson (1984) also measured 
50% more PP2A activity than PP1 in the heart. In fact, according to Shi (2009), in some tissues up 
to 1% of total protein content can be attributed to PP2A. 
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In light of its cellular abundance and significant contribution to serine/threonine phosphatase 
activity we decided to focus our study on describing the participation of PP2A in myocardial I/R 
injury and determining its importance in this situation. 
Protein phosphatase 2A: a brief introduction 
For an excellent review concerning PP2A, see Janssens & Goris (2001). PP2A is a ubiquitously 
expressed phosphatase that has been implicated in a wide variety of processes ranging from 
development, cell proliferation and cell death, cytoskeletal dynamics, regulation of the cell cycle 
and the regulation of several signalling pathways. It is the extremely complex regulatory 
mechanisms of this enzyme (discussed in Chapter 3) which allows it to be involved in numerous 
divergent cell functions. 
Cardioprotection 
As already mentioned, the inhibition of PP2A has been found to confer cardioprotective effects, 
although in most of these studies PP1 was also inhibited alongside PP2A (Xiuhua et al., 1997; 
Armstrong et al., 1998; Weinbrenner et al. 1998; Isotani et al.  2002). Other studies not yet 
mentioned include Barancik and co-workers (1999) who also reported that the inhibition of both 
PP1 and PP2A by OA administration directly prior to sustained ischaemia conferred an infarct 
sparing effect in their in vivo pig model of regional ischaemia. An earlier study by Armstrong et al. 
(1997) reported that the pre-treatment of isolated cardiomyocytes from both pigs and rabbits with 
fostriecin at PP2A-specific concentrations elicited protection similar to IPC – thereby implicating 
specifically PP2A as a possible target for cardioprotection. In agreement with this, Sariahmetoglu 
et al. (2012) reported that OA administration at a PP2A specific concentration before and after 20 
minutes of global ischaemia, in an isolated rat heart model, was associated with a significant 
improvement in functional recovery. Opposing these studies however, Fan et al. (2010) reported 
that inhibition of PP1 and PP2A using cantharidin, as well as inhibition of PP2A alone using OA, 
failed to elicit any cardioprotective effect on either IFS or functional recovery in an isolated rat heart 
model. In fact, they found that administration of these drugs prior to ischaemia was associated with 
mechanical failure during reperfusion.  
 
These divergent results as well as the use of inhibitors which might also influence PP1, necessitate 
further clarification concerning the cardioprotective potential of PP2A. 
PP2A in pathological conditions 
Protein phosphatase 2A has also been implicated in chronic pathological conditions, such as 
diabetes and cardiac hypertrophy. Interestingly, initial work showed no association between either 
PP1 or PP2A and diabetes in the heart (Foulkes & Jefferson, 1984). However, more recently 
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Rastogi and co-workers (2003) found that in hearts from streptozotocin-induced diabetic rats both 
protein serine/threonine phosphatase activity, as well as PP1 and PP2A protein content, was 
elevated. Interestingly, PP1 expression was increased first (1 week after diabetic induction), 
followed by PP2A after 4 weeks. Similarly Katare et al. (2011) found that PP2A levels were 
increased in left ventricular tissue of streptozotocin-induced diabetic rats – although in their model 
these changes were only evident after 12 weeks.  
 
An association between cardiac hypertrophy and PP2A has also been shown. In 2000 Bokník and 
colleagues found that in a cardiac hypertrophy model of chronic β-adrenergic stimulation the 
activities of both PP1 and PP2A were elevated and contributed to a reduction in  the 
phosphorylation of phospholamban (PLB). In accordance with these results, Zhang et al. (2002) 
found that the overexpression of a nuclear isoform of Ca2+/calmodulin-dependent protein kinase II 
(CaMKII) led to hypertrophy in mice which was also characterized by a reduction in PLB 
phosphorylation in association with an increase in the expression and activity of PP2A. In a reverse 
approach, Gergs et al. (2004) characterized a model of the overexpression of the catalytic subunit 
of PP2A (PP2A-C) which they found presented with cardiac hypertrophy and dilatation in 
conjunction with reduced phosphorylation of PLB, the inhibitory subunit of troponin (TnI) and 
eukaryotic elongation factor 2. In contrast to these results, Huang et al. (1999) reported that in their 
model of post-infarction remodelled hypertrophy the activity of only PP1 was increased, which was 
in association with a reduction in the phosphorylation of PLB.  Wjinker et al. (2011) reported similar 
results in human ischaemic cardiomyopathy tissue: PP1 activity was increased, while PP2A 
remained unchanged. This implies that different models of hypertrophy recruit different intracellular 
adaptations. In line with this, dilated cardiomyopathy seems to be associated with reduced 
expression of PP2A-C (Wjinker et al., 2011; Walker et al., 2013).  
 
There is therefore a trend for the involvement of PP2A as a contributor to pathological conditions in 
the heart. This might lead one to think that chronic PP2A inhibition could be a protective 
intervention. PP2A is however necessary for survival and knock-out of PP2A-C proves lethal at 
embryonic level (Götz & Schild, 2003).  Linking with this, silencing of the PP2A scaffold subunit 
(PP2A-A) in PC3-6 cells led to reduction in cell viability at day 4, with almost complete cell loss at 
day 8 (Strack et al., 2004; Van Kanegan et al. 2005).  
 
As is to be expected from an enzyme presenting such a major contribution to cellular protein 
dephosphorylation, numerous substrates for PP2A have been identified. We will briefly touch on 
some of the more important ones in the setting of the heart. 
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Calcium regulation and contraction 
Studies regarding PP2A in hypertrophy identified PLB, an important regulator of Ca2+ movement 
into the sarcoplasmic reticulum, as one of the substrates of PP2A (Bokník et al., 2000; Zhang et 
al., 2002; Gergs et al., 2004).  Protein phosphatase 2A has however also been identified as part of 
the macromolecular complex regulating the ryanodine receptor-2 (RyR2). This complex also 
contains PP1 and protein kinase A (PKA) (Marx et al., 2001). Interestingly, Terentyev and 
colleagues (2003) found that both PP1 and PP2A could induce an increase in spark-mediated Ca2+ 
release from the SR, thereby depleting its Ca2+ stores. Regulation of the sodium/calcium 
exchanger has also been linked to a macromolecular protein complex containing PP2A, as well as 
PP1, PKA and PKC (Schulze et al., 2003). The research of Dubell et al. initially (2002) showed that 
both PP1 and PP2A contributed to steady-state L-type Ca2+ channel activity, although in later work 
(2004) they specifically identified PP1 as the relevant phosphatase. However, Shi et al. (2012) 
recently showed that PP2A physically interacts with the L-type Ca2+ channel, Cav1.2, and that 
inhibition of PP2A is associated with increased flux through this channel thereby illustrating that 
PP2A contributes to the regulation of this channel.  
 
Ke and colleagues (2010) reported that p21-activated kinase-1 (Pak-1) is an upstream regulator of 
PP2A which under bradykinin stimulation activates PP2A, leading to the dephosphorylation of PLB 
as well as cardiac troponin I (TnI). Dephosphorylation of the latter leads to an increase in the Ca2+ 
sensitivity of the myofilaments. The interaction between PP2A and TnI has also been shown by 
others (Gergs et al., 2004; Deshmuk et al., 2007). It is interesting to note that this study by Ke et al. 
implicated the recruitment of PP2A into a signalling pathway which is associated with 
cardioprotection (i.e. bradykinin receptor stimulation). 
 
Taken together these studies illustrate the importance of PP2A in the regulation of Ca2+ 
homeostasis and contraction. 
Apoptosis 
For a review on the participation of PP2A in apoptosis-related signalling see Van Hoof & Goris 
(2003). Most of the work done on PP2A in this setting has been done in other tissues than the 
myocardium, although the same, or at least similar, apoptotic signalling should occur in the 
stressed myocardium. In general, PP2A has been identified as a mediator of apoptosis by 
dephosphorylating and thereby activating several pro-apoptotic mediators such as Bad (Chiang et 
al., 2001 & 2003; Ray et al., 2005) and Bax (Xin et al., 2006); as well as dephosphorylating, and in 
the process inhibiting, anti-apoptotic mediators, specifically Bcl-2 (Deng et al., 1998; Ruvolo et al., 
1999; Tamura et al., 2004; Ray et al., 2005). PP2A has also been implicated as a pro-apoptotic 
regulator of other signalling molecules involved in the regulation of apoptosis. These include the 
transcription factor FOXO (Forkhead box, class O) which is dephosphorylated by PP2A, allowing it 
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to stimulate the upregulation of pro-apoptotic Bim (Yan et al., 2008). Several studies have also 
found that PP2A induces apoptosis by dephosphorylating and inactivating the pro-survival ERK 
p42/p44. Intriguingly, p38 MAPK has been suggested as an upstream activator of PP2A in this pro-
apoptotic signalling cascade (Westermarck et al., 2001; Li et al., 2003; Grethe  & Pörn-Ares, 2006) 
which has also been identified in cardiac myocytes (Liu  & Hofmann, 2004). Although these studies 
all implicated PP2A as a pro-apoptotic mediator, Boudrea et al. (2007) reported that PP2A 
inhibition in Jurkat- and T leukemia cells promoted apoptosis within 18 hours after the onset of 
inhibition, via a mechanism that involved the permeabilization of the mitochondrial membrane. 
Protein phosphatase 2A therefore emerges as an important role-player in the regulation of 
apoptosis, both as a pro-apoptotic mediator and an anti-apoptotic regulator. Despite this 
conclusion, very little research has been done on the contribution of PP2A to apoptotic processes 
in the heart. 
Signalling 
Protein phosphatase 2A has been linked to the regulation of several signalling cascades, as 
exemplified in the p38 MAPK – PP2A – ERK p42/p44 pathway described above. For a review on 
PP2A and its involvement in signalling see Hunter (1995) and Millward et al. (1999). See Chapter 4 
for a brief overview of what is known regarding the interactions between PP2A and some of the 
pro-survival signalling pathways which have been identified in myocardial tissue thanks to studies 
done on IPC and PostC. 
 
Protein phosphatase 2A therefore presents as a highly abundant protein phosphatase which exerts 
a significant contribution to serine/threonine phosphatase activity within cells. As such it has been 
linked to Ca2+ homeostasis and the regulation of contractility within the heart and has also been 
characterized as a regulator and mediator of apoptosis. It exerts many of these effects through its 
participation in numerous signalling cascades. 
General hypothesis and aims 
Better and more complete knowledge of the contribution of the phosphatases to myocardial I/R 
injury and cardioprotection related signalling might reveal possible targets which could be 
modulated to enhance the efficacy and repeatability of existing cardioprotective interventions by 
simultaneously modulating both the phosphorylation and dephosphorylation of key signalling role-
players. 
 
This study sought to contribute to our basic knowledge and insight regarding the role and 
importance of protein phosphatase activity in the setting of myocardial ischaemia and reperfusion. 
We purposefully chose to study I/R injury in a pathology free setting and in the absence of known 
cardioprotective interventions, since our focus was to describe and explore the most basic 
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physiological condition. Knowledge gained from these baseline studies can then be applied and 
tested in more complex situations such as obesity, insulin resistance, IPC, etc. 
 
We hypothesize that PP2A is an important and central participant in the intracellular response of 
the myocardium to ischaemia and reperfusion, specifically with regards to pro-survival signalling. 
Should our hypothesis prove to be true, then PP2A is a potential target for the enhancement of 
current cardioprotective interventions. 
 
To address this hypothesis we concentrated on three aims: 
1.) To describe the expression, post-translational modification and intracellular distribution of 
PP2A as ischaemia progresses, as well as during the clinically important first moments of 
reperfusion. 
2.) To assess if PP2A makes a significant contribution to the development of I/R injury. In order 
to ascertain this we utilized pharmacological activation and inhibition of PP2A in the context 
of ischaemia and reperfusion. 
3.) To determine the participation of PP2A in pro-survival signalling we sought to determine the 
signalling-related mechanisms underlying the effects observed in Aim  2. 
 
For the description of PP2A in I/R we utilized both a cell based model of simulated 
ischaemia/reperfusion, as well as an isolated rat heart model. By comparing the results obtained 
from these two different models we hoped to generate a more clear picture of how PP2A 
participates in I/R. 
 
The rest of the aims were addressed using the isolated rat heart exposed to either 35 minutes of 
regional ischaemia, or 20 minutes of global ischaemia. This allowed us to investigate the effects of 
PP2A activity modulation in a setting which is more physiological than the cell based model. 
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CHAPTER 2 
Materials and Methods 
 
“Science works by experiments. It watches how things behave. Every 
scientific statement in the long run, however complicated it looks, really 
means something like, 'I pointed the telescope to such and such a part of the 
sky at 2:20 a.m. on January 15th and saw so-and-so,' or, 'I put some of this 
stuff in a pot and heated it to such-and-such a temperature and it did so-and-
so.' Do not think I am saying anything against science: I am only saying what 
its job is.” 
C.S. Lewis 
Mere Christianity 
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Chapter 2 - Materials and Methods 
 
In pursuit of defining the role and importance of PP2A in the setting of myocardial I/R we utilized two 
fundamentally different experimental models: (1.) A cell culture model; and (2.) an isolated rat heart 
model. Both these models have advantages and disadvantages and by utilizing both we sought to 
generate a robust picture of the events surrounding I/R. 
 
For the cell culture experiments we utilized a myoblast cell line of cardiac origin – the H9c2 cell line 
(Kimes & Brandt, 1976). The advantages of this model lie in its technical and experimental robustness: 
the cells are relatively easy to culture and maintain, they offer a relatively homogeneous cell 
population and since they are one of only a few cell lines of cardiac origin they have been used 
extensively by many cardiac researchers. This model allows for the use of cell-based techniques such 
as flow cytometry, immunofluorescence microscopy and fluorescence-based enzyme and survival 
assays. The H9c2 cell line therefore offers a standardized, widely accepted experimental model with a 
broad application. We therefore utilized the H9c2 cell model as part of our study describing PP2A in 
the context of I/R. Any cell-model however has the disadvantage that it functions within a supremely 
unphysiological environment and is therefore only an approximation of what is really happening within 
a cell, in an organ, in a whole organism. This is especially true of a cell line such as the H9c2 cells 
which differs from heart tissue in several ways, the most notable being that these cells do not beat; 
which implies reduced energy demand and intracellular Ca2+ flux compared to beating ventricular 
cells. Also, in contrast to terminally differentiated cardiomyocytes, H9c2 cells are proliferating cardiac 
progenitor cells. In 1991 Hescheler et al. investigated some of  the characteristics of this cell line, and 
although it is true that these cells do not have the same morphology as isolated heart cells, they have 
a similar surface coat composition, L-type Ca2+ current across the plasma membrane, and a G protein 
pattern similar to striated muscle cells and adult cardiac myocytes. These authors therefore concluded 
that the H9c2 cell line may be used as a cardiac cell model with regards to transmembrane signal 
transduction. 
 
The isolated rat heart model however offers more insight into phenomena and mechanisms within a 
much more physiological setting: an actual beating heart. This experimental model has also been 
extensively described and utilized by many researchers (for a review on the technique and its 
applications see Sutherland & Hearse, 2000). Although it obviously also functions within an 
unphysiological environment (a heart functioning outside the body), it has the experimental advantage 
that the researcher can simplify the system to which the heart is exposed, relative to the internal 
environment of the body. This allows for more efficient investigation of an intervention and the 
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outcomes associated with that intervention. We utilized the isolated working rat heart as the 
experimental model of choice for the majority of our investigations. 
Cell culture 
Culture and maintenance 
H9c2 cells were obtained from the European Collection of Cell Cultures (ECACC) and cultured at 
37⁰C in a 40 – 60% humidified 5% CO2 atmosphere in Dulbecco’s modified Eagle’s medium (DMEM) 
containing L-glutamine and 4.5 g/L of glucose (Lonza; BE12-604F) supplemented with 10% fetal 
bovine serum (FBS) (Highveld Biological) and 1% Penicillin-Streptomycin (10 000 units/mL, Invitrogen; 
#15140122) mixture. Cell medium was replaced every 2-3 days.  
 
On reaching a confluency of 80-100% cells were passaged in a ratio of one to between two and four. 
After removal of the DMEM growth medium, cells were washed twice with warm (room temperature) 
sterile phosphate buffered saline (PBS), whereafter they were incubated in 0.25% Trypsin-EDTA 
(containing 0.105 mM trypsin and 0.913 mM Na2•EDTA) until the cells detached from the plate 
surface (approximately 1-4 minutes). The resulting Trypsin-cell mixture was then added to a volume of 
DMEM growth medium (either equal to, or half of the volume trypsin used). This cell-suspension was 
then centrifuged at 657xg for 4 minutes. The supernatant was removed and the pellet resuspended in 
the appropriate volume of growth medium to obtain a density of 3x104 – 6x104 cells/mL. Depending on 
the type of experiment, cells were seeded in either 35x10 mm or 100x20 mm cell culture dishes (SPL 
Life Sciences) in  a volume of either 2 ml or 10 ml DMEM growth medium respectively. 
Simulated ischaemia and reperfusion 
As mentioned previously, the H9c2 cell line has been used extensively as a cardiac cell model for 
various experimental interventions, including hypoxia and simulated ischaemia (Bonavita et al., 2003; 
Agnetti et al., 2005; Lin et al., 2010). In order to expose the cells to a situation comparable to tissue 
ischaemia we incubated 80-100% confluent H9c2 cells in a modified Esumi buffer (Esumi et al., 1991) 
containing (in mM): NaCl 137, KCl 12, Cl2Mg 0.5, CaCl2•2H2O 0.9, HEPES 4, lactate 20 and 2% FBS 
at a pH of 6.4. This buffer simulates ischaemia with regards to several parameters: an elevated 
extracellular potassium concentration, low nutrition (reduced FBS and no glucose), low pH (combined 
with a low pH buffering capacity) and accumulation of toxic waste products (the presence of lactate). 
Although lactate in itself could potentially directly inhibit the glycolytic pathway (Leite et al., 2007 & 
2011) we also experimented with the addition of the glycolytic inhibitor 2-deoxy-glucose (2-DG, 20 
mM) (Fuglesteg et al., 2008) and / or the mitochondrial inhibitor sodium dithionate (SDT, 0.5 mM) 
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(Cumming et al., 1996).  In addition to these chemical interventions, incubation of the cells in Esumi-
buffer was also combined with exposure of the cells to a hypoxic atmosphere. Initial experiments were 
done in a cell incubator set at 5% CO2, 1% O2 and the balance N2. Due to technical problems we later 
replaced this system with a hypoxia incubator chamber (Stemcell technologies) in which we performed 
the brunt of our experiments. In this hypoxic chamber cells were incubated at 5% CO2, 0.5% O2 and 
the balance N2. The effects of different durations of exposure (2h, 4h, 6h and 24h) on cell survival 
were also tested. For a review on work done on simulated ischaemia (SI) and hypoxia, as well as 
ischaemic preconditioning, in different cell models, see Diaz and Wilson (2006). 
 
Simulated reperfusion simply entailed removal of the ischaemic buffer, washing the cells once with 
warm PBS where after the cells were returned to the standard 21% O2 / 5% CO2 atmosphere and 
incubated in normal DMEM growth medium.  
Detemination of cell viability and cell death 
Cell death was determined using flow cytometry based measurement of fluorophores associated with 
cell death. Two fluorophores were used which allow simultaneous distinction between necrotic and 
apoptotic cell death: (1.) Propidium Iodide (PI) binds DNA, but is not able to cross the cell membrane. 
Therefore a positive PI signal will imply that the cell membranes have become permeable, as would 
be the case during late stage apoptosis or necrosis. (2.) Annexin V (AV) binds phosphatidylserine 
which is usually only found on the intracellular side of the plasma membrane, however during early 
apoptosis the plasma membrane loses its asymmetry causing the phosphatidylserine to become 
accessable for AV binding on the extracellular side. Fluorochrome-labeled AV can therefore be used 
to identify cells undergoing apoptosis. Both PI and Alexa Fluor® 647 AV were from BioLegend. 
 
Briefly, cells were exposed to SI (as described above), as well as simulated ischaemia / reperfusion 
(SI/R) for different durations of time (as will be defined in Chapter 3). Following this cells were washed 
twice with sterile PBS, trypsinized and resuspended in binding buffer (also obtained from BioLegend) 
at a concentration of approximately 1x106 cells/mL. Of this cell suspension 100 µL (i.e. 100 000 cells) 
was assayed by the addition of 10 µL PI and 5 µL Alexa Fluor® 647 AV. Following addition of the 
fluorophores the cell suspension was incubated for 15 minutes in the dark at room temperature. 
Samples were then measured using the Becton Dickinson FACSCalibur (BD Biosciences), set to 
acquire between 5000 and 10 000 events – depending on the yield of cells on the day. The resulting 
fluorescence spectra was analyzed using WinMDI (Windows Multiple Document Interface Flow 
Cytometry Application, developed at the Scribbs Research Institute and avalaible at 
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http://facs.scripps.edu/software.html) in order to quantify the percentages of the cell population 
undergoing apoptosis and / or necrosis. 
 
For each intervention (SI and SI/R) three repetitions were done on three different days. Each repetition 
consisted of three control cell dishes, while five to six dishes were exposed to the relevant 
experimental intervention. 
Animals 
Experimental protocols relating to animal experiments were approved by the Animal Ethics committee 
of the University of Stellenbosch (Faculty of Medicine and Health Sciences). All animal experiments 
were done in accordance to the “Guide for the care and use of laboratory animals” published by the 
US National Institutes of Health (NIH application no 85-23, revised 1985).  
 
Male Wistar rats were given free access to food and water until the time of experimentation. Animals 
weighing between 200 and 350 gram, were anaesthetized by administration of an intra-abdominal 
injection of pentobarbital, at a dose of approximately 60 mg/rat. 
Isolated rat heart perfusion 
Having determined sufficient sedation (as determined by foot pinch test), hearts were rapidly excised 
and arrested in ice-cold Krebs-Henseleit solution. Hearts were then immediately mounted on the 
perfusion apparatus by cannulation of the aorta. Once the aorta was secure, hearts were retrogradely 
perfused using a Krebs-Henseleit bicarbonate buffer (KHB) containing (in mM): NaCl 119; NaHCO3 
24.9; KCl 4.74; KH2PO4 1.19; MgSO4•7H2O 0.6; Na2SO4 0.59; CaCl2•12H2O 1.25 and glucose 10. The 
perfusion buffer was continuously gassed with a 95% O2 / 5% CO2 combination in order to ensure 
adequate oxygenation of the heart, as well as to maintain the pH of the buffer at 7.4. The perfusion 
apparatus consisted of double-walled glasware, connected to a circulating waterbath, in order to 
maintain the heart’s temperature at approximately 36.5 °C. Cardiac temperature during 
experimentation was monitored using a thermal probe inserted into the coronary sinus. Functional 
parameters such as intra-aortic pressure generated and heart rate were measured by a pressure 
transducer (Viggo Spectromed) inserted into the aortic perfusion line and connected to a computerized 
system. 
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Through the course of experimentation hearts were exposed to three different modes of perfusion: 
 
1.) Retrograde perfusion (Langendorff perfusion): Hearts were retrogradely perfused with Krebs-
Henseleit buffer at a pressure of 100 cm H2O. Coronary flow (CF) was measured by timed 
collection of coronary effluent.  
 
2.) Work mode: This required cannulation of the left pulmonary vein (which was done immediately 
following aortic cannulation). During work mode retrograde perfusion was discontinued, and 
replaced by the infusion of KHB into the left atrium at a preload of 15 cm H2O. This inflow of fluid 
into the left ventricle stimulated ventricular contraction, thereby expelling buffer through the aorta 
against an afterload of 100 cm H2O. The volume of buffer pumped by the heart, i.e. the aortic 
output (AO), was then manually measured and expressed as volume flow per minute.  
  
Besides aortic output, left ventricular work performance was also used to assess cardiac function. 
Work performance was calculated using the formula described by Kannengieser et al. (1979): 
 
0.002222 (PAO – 11.25)(CO) 
Where: PAO  = aortic pressure 
  CO  = cardiac output (aortic output + coronary flow rate). 
 
3.) Induced ischaemia: We utilised two different forms of ischaemic insult during retrograde 
perfusion: (1.) Global ischaemia (GI) was applied by the total cessation of retrograde coronary 
perfusion of the heart, leaving the whole heart ischaemic. The damage conveyed by global 
ischaemia was assessed by calculating the percentage recovery in functional parameters after 30 
minutes reperfusion. Where functional recovery was the main end-point at least five hearts were 
included in the control group, while a minimum of four hearts were used in the experimental 
groups. Specific n-values will be reported at the relevant sections in the text. The advantage of 
this intervention is that the whole heart is exposed to ischaemia and therefore presents as a 
homogeneous cell population which can then be subjected to biochemical analyses, such as 
enzyme activity determination or Western blotting.  
 
In contrast to global ischaemia, (2.) regional ischaemia (RI) was induced by the occlusion of the 
left coronary descending artery. This was done by using a silk suture to ensnare the proximal part 
of the left coronary artery. The suture was then closed by using two pieces of interlocking tubing, 
leaving tissue distal to the occlusion ischaemic (referred to as the area at risk (AAR)), while the 
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surrounding heart muscle still received adequate perfusion (the viable area (VA)). Reperfusion 
was initiated by simply opening the two pieces of tubing. Damage associated with this intervention 
was primarily quantified by measuring the area of necrosis (the infarct size (IFS)) following 60 
minutes of reperfusion. This end-point is considered the “gold standard” for assessing the 
outcome of I/R injury. Function and functional recovery were also recorded. 
 
During both forms of ischaemia cardiac temperature was continuously monitored and maintained 
at 36.5 °C. 
Determination of infarct size 
As described in the previous section, regional ischaemia was one of the ischaemic models used in this 
study. This intervention allows for the determination of the effects of an I/R protocol on tissue viability 
by measuring the associated infarct size as follows:  
 
At the end of reperfusion the silk snare surrounding the left descending coronary artery (which was 
used to initiate ischaemia) was carefully re-closed and the heart retrogradely infused with 0.5% Evans 
Blue dye through the aortic cannula. This served to clearly indicate which area of the heart received 
normal perfusion throughout the regional ischaemia intervention (the viable area (VA)). The heart was 
then removed from the perfusion apparatus and frozen (-20 °C) for a period of 1 to 5 days. Following 
this, the left ventricles (from where the suture was inserted to the apex of the heart) were sliced into 
approximately 2 mm thick slices. These slices were then stained by incubating the slices in a 
phosphate buffer (pH 7.4) containing 1% w/v triphenyltetrazolium chloride (TTC) for 15 minutes, at 
room temperature. TTC reacts with active dehydrogenases in viable tissue to form a brick-red 
precipitate (Pitts et al. 2007). This staining reaction was then terminated by fixing the slices in a 10% 
v/v formaldehyde solution. Following this procedure, three different coloured-areas should be visible: a 
dark blue area indicating the viable area, a brick-red area indicating tissue exposed to ischaemia but 
still viable and a non-stained white area in which all the cell membranes were permeable to 
intracellular enzymes, such as the dehydrogenases (i.e. a necrotic area). 
 
These area’s were quantified by tracing each ventricular slice on a transparency, scanning it into a 
computer and using the UTHSCSA ImageTool program (developed at the University of Texas Health 
Science Center at San Antonio, Texas, which is available from the internet at 
http://ddsdx.uthscsa.edu/dig/itdesc.html) to quantify the relevant surface areas as described above.  
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For the determination of IFS a minimum of six animals were used as controls for each experimental 
intervention, while hearts from at least six animals were used for pharmacological intervention. In each 
of the following chapters the precise n-values will be supplied in conjunction with the relevant 
experiments. 
Western Blotting protocol 
H9c2 cells: Protein extraction 
In order to ensure a sizable protein yield cells were cultured in 100x20 mm cell culture dishes. 
Similarly to the FACS analysis previously described, for Western blotting experiments three repetitions 
of the experiments were done on three separate days, with each repetition containing three control cell 
dishes, as well as five experimental dishes. Following exposure to several simulated ischaemia and/or 
reperfusion time durations (as will be outlined in the appropriate sections), cells were trypsinized as 
described before. Following the initial centrifugation step, the supernatant was decanted and the cell 
pellet resuspended in PBS. Cells were then centrifuged again, the PBS removed and the pellet lyzed 
by the addition of a detergent-containing lysis buffer in combination with mechanical homogenization. 
The lysis buffer contained (in mM): Tris-HCl (pH 7.5) 200; EGTA 10; EDTA 100; NaCl 1000; Triton X-
100 1%; a cocktail of phosphatase inhibitors: β-glycerophosphate 1, tetrasodiumpyrophosphate 2.5, 
Na3VO4 10; and the protease inhibitors: phenylmethylsulphonylfluoride (PMSF) 100, leupeptin 10 
µg/ml and aprotonin 10 µg/ml. Mechanical homogenization was done by adding 0.5 mm diameter 
zirconium oxide beads (Next Advance, Inc.) to the cell pellet and using a Bullet Blender™ (Next 
Advance, Inc.) at a setting of 1, for 3 cycles of 1 minute each, interspersed with 5 minutes, at a 
temperature of 4ºC. Following this, the homogenate was spun down at 1000xg for 15 minutes and the 
supernatant removed from the bead-containing pellet and kept for protein determination and 
subsequent Western Blotting. 
Isolated rat heart: Collection of tissue samples 
For Western blotting analysis of tissue we used a minimum of three hearts as controls (with the 
exception of the analysis of the effects of FTY720 under baseline conditions in chapter 5, where only 
two hearts were used), while the different experimental interventions ranged between three and six 
hearts. The specific n-values will be reported at the appropriate sections in the text. As will be 
described in more detail later in the text, hearts were freeze-clamped at different timepoints in the 
perfusion protocol using liquid nitrogen cooled tongs and immediately plunged into liquid nitrogen. 
These tissue samples were then stored in liquid nitrogen for later analysis. 
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Isolated rat heart: Protein extraction 
Non-fractionated whole cell lysates 
Approximately 0.2 gram of frozen tissue samples were pulverized in a stainless steel mortar under 
liquid nitrogen cooled conditions, where after the tissue samples were immediately transferred to 700-
900 µL lysis buffer (same composition as described above for the homogenization of the H9c2 cells). 
Samples were then homogenized using a SilentCrusher M homogenizer (Heidolph Instruments) set at 
a speed of 15000 rpm for 2-3 cycles of 5 seconds each. Following this, lysates were left to stand for 
20 minutes, followed by 1000 g centrifugation for 15 minutes. The initial inclusion of a detergent (Triton 
X-100) in the lysis buffer, as well as the 20 minute incubation step led to the degradation of all the 
organel and cellular membranes, thereby yielding a cellular homogenate containing content from all 
the cellular compartments. Following centrifugation the supernatant was separated from the pellet and 
used for further experimentation. Samples were kept at 4 °C at all times.  
 
Following extraction the amount of protein was determined using the Bradford technique (Bradford; 
1976). Lysates were then appropriately diluted with lysis buffer in order to ensure that the final 
samples contained equal amounts of protein. Finally, Laemmli sample buffer was added in a ratio of 
1:2, where after the samples were boiled for 5 minutes and stored at -20 °C. 
Cell fractionation 
The cell fractionation protocol utilized (Figure 2.1) was a differential centrifugation fractionation 
protocol modified from Williams & Ford (2001) and Sakamoto et al. (2000), which has also previously 
been used in our laboratory (Marais et al., 2005). Although this protocol can only generate crude 
fractions, it was ideally suited for this study in that it served as a platform for initial and explorative 
characterization. 
As described above, frozen tissue samples were powdered under liquid nitrogen cooled conditions 
and immediately transferred to lysis buffer. Exactly the same lysis buffer was used as described 
above, except that it contained no Triton X-100. Samples were homogenized using the SilentCrusher 
M, incubated for 20 minutes on ice and centrifuged for 10 minutes at 1000xg (centrifugation 1). The 
supernatant was then separated from the pellet and again centrifuged for 60 minutes at 100 000xg.  
The supernatant following the second centrifugation contained the cytosolic fraction, while the pellet 
contained the crude membrane fraction, which was resuspended in 300 µL of lysis buffer and 
homogenised using a Teflon homogenizer. The original pellet (generated in centrifugation 1) was also 
resuspended in 250 µL lysis buffer supplemented with 1% Triton X-100 and homogenized using a 
Teflon homogenizer. This homogenate was then incubated on ice for at least 10 minutes, followed by 
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a second centrifugation at 15 000xg for 30 minutes. The supernatant generated in this spin contained 
the nuclear extract (see Figure 2.1). 
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As described above for the whole cell lysates, the protein content of each fraction was determined 
using the Bradford technique, followed by dilution of all samples to a uniform protein concentration to 
which Laemmli sample buffer was added and the samples boiled for 5 minutes and stored at -20 °C. 
Protein separation 
Proteins in the lysate samples were separated using sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). Samples were first boiled for 5 minutes, followed by brief centrifugation 
(4-5 minutes), before being loaded in a 4% stacking polyacrylamide gel and separated in a 12% 
polyacrylamide gel, using the standard Bio-RAD Mini-PROTEAN II System. Running buffer used 
contained (in mM): Tris 25; glycine 192 and sodium dodecyl sulfate (SDS) 3.5. For each SDS-PAGE 
experiment, an equal amount of protein per sample was loaded. 
Western blotting 
After SDS-PAGE separation, proteins were transferred from the polyacrylamide gel to a polyvinylidene 
fluoride (PVDF) membrane (ImmobilonTM P, Millipore) using a tank electrotransfer system. For transfer 
the membrane-gel stack was immersed in transfer buffer containing (in mM): Tris 25; glycine 192 and 
20% methanol. The quality of the transfer was regularly assessed by staining the membranes after 
transfer with the reversible protein stain Ponceau red.  
Blocking of the membrane 
Following transfer, non-specific protein binding sites on the PVDF membranes were blocked by 
incubating the membrane in 5% fat-free milk in washing buffer (Tris-buffered saline (TBS)-0.1% 
Tween 20 solution), under constant agitation, for at least one hour. 
 
Incubation with antibodies 
Between blocking and antibody incubation the membranes were thoroughly washed with three 
changes of TBS-Tween, followed by at least 4 cycles of 5 minutes each washing with larger volumes 
of TBS-Tween. This washing regime was also utilised between primary and secondary antibody 
incubation, as well as prior to visualisation. 
 
Following sufficient washing the membranes were incubated with the relevant primary antibody for at 
least 5 hours or overnight, at 4 °C, under constant agitation. Antibodies were diluted in TBS-Tween 
with the appropriate dilution factor (1:1000). Antibodies used for this study are listed in table 2.1. All 
antibodies were raised in rabbit, except nonmethylated PP2A-C which is of murine origin. 
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Table 2.1: Antibodies used for Western Blotting analyses throughout this study. 
Cell Signaling Technology 
Antibody against total protein Antibody against a post-translational modification 
PP2A-C (catalytic subunit) Nonmethylated PP2A-C 
PP2A-A (scaffolding subunit)  
PKB/Akt Phospho-PKB/Akt (Ser473) 
GSK3β  Phospho-GSK3β (Ser9) 
ERK p42/p44 Phospho-ERK p44/p42 (Thr202/Tyr204) 
p38 MAPK Phospho-p38 MAPK (Thr180/Tyr182) 
Β-Tubulin  
R & D Systems 
 Phospho-PP2A-C (Tyr307) 
 
This was again followed by a washing cycle, after which the membranes were incubated with 
appropriate horseradish peroxidase-linked secondary antibody. For most primary antibodies this was 
ECLTM anti-rabbit immunoglobulin G (from donkey), but for nonmethylated PP2A-C Subunit ECLTM 
anti-mouse immunoglobulin G, (from sheep) was used. Both secondary antibodies were obtained from 
Amersham. 
Visualisation and analysis 
Membranes were covered with ECLTM detection reagents for one minute and then immediately 
exposed to autoradiography film (Hyperfilm ECL, RPN 2103). Suitable time was allowed for adequate 
light emmision to be generated by the luminescence reaction between the detection reagents and the 
conjugated horseradish peroxidase. 
 
Densitometric analyses of the membranes were done using UN-SCAN-ITTM version 5.1, Silkscience. 
In order to take inter-membrane variability into account, and for comparison purposes, all experimental 
groups were expressed as a ratio of the average of the relevant control hearts. In the case of post-
translational modifications (i.e. phosphorylation and nonmethylation) the ratio between the modified 
form and the total was calculated using the original pixel values. The calculated ratio was then 
normalized to the average of the control ratios. All ratios and normalized data were expressed in 
arbitrary units (AU). 
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Co-immunoprecipitation 
Co-immunoprecipitation (co-IP) was employed to determine possible substrates of the catalytic 
subunit of PP2A (PP2A-C). Four hearts were included in the control group, as well as in each of the 
experimental groups. Tissue samples collected from isolated rat hearts at the end of sustained 
ischaemia as well as at the onset of reperfusion were pulverized under liquid nitrogen conditions and 
added to 850 µL of lysis buffer with a similar composition to the one used for Western Blotting but with 
two crucial differences: (1.) the concentration of the detergent (Triton X-100) was reduced from 1% to 
0.1% in order to conserve protein-protein interactions; and (2.) the serine/threonine protein 
phosphatase inhibitors β-glycerophosphate and tetrasodiumpyrophosphate were left out to avoid any 
chemical interference between PP2A and its substrates. Samples were then homogenized using the 
Silent Crusher M and incubated on ice for ~2 hours, where after they were centrifuged for 15 minutes 
at 1000xg and the supernatant collected for Bradford protein determination. Approximately 2.5 mg of 
protein was incubated with 10 µg of a goat poly-clonal antibody against PP2A-Cα/β (Santa Cruz, sc-
6110) for 3-4 hours, at 4ºC, under constant rotary agitation. A 1:1 mixture (final volume: 60 µL) of 
Protein A-Sepharose 4B (SIGMA, P9424) and Protein G-Sepharose 4B (SIGMA, P3296) was then 
added to the lysate and incubated overnight at 4ºC, under constant rotary agitation. 
 
The next morning the beads were recovered by centrifugation at 1000xg for 30 seconds. The beads 
were washed once with sterile PBS, centifuged for 30 seconds at 1000xg and the bound proteins 
eluated by boiling the beads in 40 µL SDS-Laemmli buffer. This final protein sample was then 
separated using SDS-PAGE and proteins visualized using standard Western Blotting techniques as 
described above. 
 
Although equal amounts of protein were subjected to the immunoprecipitation protocol we could not 
be sure that equal amounts of protein were loaded on to the SDS-PAGE gels. This is obviously also a 
fundamental experimental consequence: if the experimental condition led to an increase in the 
interactions between PP2A and other cellular proteins, more protein would be co-immunoprecipiated 
with PP2A-C. The final densitometry results were therefore expressed relative to the signal generated 
by the primary target of the immunoprecipitation, namely PP2A-C, and reported in Arbitrary Units 
(AU). 
Phosphatase activity assay 
Measuring the activity of PP2A in heart tissue proved to be very challenging. We initially utilized a 
method based on the generation and measurement of free phosphates in tissue homogenates. This 
serine/threonine phosphatase assay system (Promega, V2460) utilized a phosphopeptide, 
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RRA(pT)VA, which is a substrate for several of the serine/threonine protein phosphatases (PP2A, 
PP2B and PP2C). Briefly: free phosphates first had to be cleared from tissue lysates using  
Sephadex® G-25 spin columns. The phosphate free lysate was then incubated with the substrate, 
whereafter free phosphate generation was measured using a Molybdate reaction mixture which 
generates a colourimetric signal at 600-630 nm in the presence of free phosphates. In order to 
distinguish the activity of PP2A from the other phosphatases, an inhibitor of PP2A (okadaic acid (OA)), 
had to be added to a separate set of lysates. The OA-sensitive signal was then defined as PP2A 
dependent. Although this method has been used with success by others (Tikh et al., 2008), we could 
only measure PP2A in a sample of purified PP2A-C while failing to measure any differences between 
our experimental groups (hearts perfused with an inhibitor or a possible activator of PP2A, as will be 
explained in a future chapter), possibly due to a persistently high free phosphate background. 
 
We therefore switched to another, possibly more sensitive, approach based on the  protein 
phosphatase mediated generation of a fluorescent species. There are a number of compounds that 
can serve as substrates for protein phosphatases and in the process generate fluorescent products 
which can be measured as a readout of phosphatase activity. One such substrate is 6,8-difluoro-4-
methylumbelliferyl phosphate (DiFMUP) which can be hydrolyzed by phoshatases to a more 
fluorescent species: 6,8-difluoro-4-methylumbelliferone (DiFMU). DiFMUP offers a sensitive tool for 
the continuous measurement of phosphatase activity within a broad pH range. We utilized the 
EnzChek® Phosphatase Assay kit from Molecular Probes and modified the protocol according to an 
article by Wegner et al. published in Methods in Molecular Biology (2007) in which they described a 
method to measure PP2A based on the same principle. 
 
Lysates were prepared, as already described, from heart tissue (control n=2, experimental intervention 
n=4) in a lysis buffer containing the following (in mM): Tris – HCl (pH 7.5) 200, EGTA 8, EDTA 8, NaCl 
1000, PMSF 100, Triton X-100 1%; leupeptin 10 µg/ml and aprotonin 10 µg/ml. Following Bradford 
protein determination samples were immunoprecipitated using a similar protocol as already described: 
1500 µg of protein was incubated with 6 µg of anti-PP2A-Cα/β (Santa Cruz, sc-6110) as well as 75 µL 
of protein A/G bead slurry (Protein A/G PLUS-Agarose Immunoprecipitation Reagent, Santa Cruz, sc-
2003) overnight, under rotational agitation at 4ºC. Beads were recovered and washed twice with PBS 
and resuspended in 145 µL of 200 mM Tris (pH 7.5) buffer. Two duplicate sets of 35 µL each of 
sample were then added to a black 96-well plate (SPL Life Sciences). To one set 10 µL OA was 
added at a PP2A-specific concentration of 10 nM, while the other set received an equivalent volume of 
Tris buffer. This was necessary to specifically distinguish and quantify the contribution of PP2A to the 
signal generated. Additionally 5 mg/mL bovine serum albumin (BSA) was also added to the reaction 
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mixture. Finally 50 µL DiFMUP (Molecular Probes) at a working concentration of 100 µM (200 µM 
stock) was injected into each sample. Fluorescence measurements were performed on a FLUOstar 
Omega multi-mode platereader at an excitation / emission wavelength of 355 / 460 nm, approximately 
every 5 minutes after addition of the substrate for a period of 40 minutes, with additional shaking of the 
plate before each cycle. The whole reaction was allowed to proceed at room temperature. 
 
The signal measured was corrected for background signal by substracting the signal generated from 
an appropriate sample void of beads and protein. The PP2A signal was then calculated by 
substracting the signal generated in the presence of OA from the signal measured in the absence of 
OA. All values were then normalized to the average of the control group. 
 
Statistical analysis 
Results were processed using GraphPad Prism statistical software (versions 5 and 6). All results are 
presented as average ± standard error of the mean (SEM). Where only two groups were directly 
compared to each other an unpaired T-test was used to assess the difference. More than one group 
was compared using an one-way analysis of variance (ANOVA). When all groups were compared with 
each other, the Bonferroni correction was applied, but when all experimental groups were compared to 
the control alone, the Dunnett post hoc test was utilised. P-values of less than 0.05 were considered 
significant. 
 
[(Sample – OA) – (blank – OA)] [(Sample + OA) – (blank + OA)] –  
Average of [(Control – OA) – (blank – OA)] 
Calculation of PP2A activity measurements: 
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CHAPTER 3 
Characterization of protein phosphatase 2A 
(PP2A) during myocardial ischaemia and 
reperfusion 
  
“We actually find hidden regularities within the complex variety of a system’s 
behavior.” 
-Ian Malcom 
Micheal Crichton 
Jurassic Park 
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Chapter 3  
Characterization of protein phosphatase 2A 
(PP2A) during myocardial ischaemia and 
reperfusion 
Introduction 
Protein phosphatase 2A (PP2A) is a major determinant of the largest portion of protein 
phosphorylation in mammalian cells, namely serine and threonine phosphorylation (Oliver & 
Shenolikar, 1998; Olsen et al., 2006). PP2A is a member of the protein serine/threonine 
phosphatase (PSP) superfamily and is classified as a phosphoprotein phosphatase (PPP), along 
with other phosphatases such as protein phosphatase 1, protein phosphatase 2B and the lesser 
known protein phosphatases 4, 5, 6 and 7 (Shi, 2009). Although it is a serine/threonine 
phosphatase based on the structure of its catalytic site, it would actually be more accurate to think 
of PP2A as a dual specificity phosphatase, since under certain conditions (as will be discussed 
later in this section) it demonstrates tyrosyl phosphatase activity. 
 
For a long time the phosphatases were dismissed as passive dephosphorylators of signalling 
pathways, while the kinases were considered the dynamic regulators of signalling, especially when 
taking into consideration that there are considerably fewer protein phosphatases than kinases 
coded for in the human genome (Shi, 2009). It was therefore assumed that the phosphatases were 
regulated to a minimum extent. Recent research has revealed that nothing is further from the truth. 
This section will introduce the reader to what is currently known regarding the regulation of PP2A 
in the cell. 
Molecular structure 
The key to PP2A’s ability to dephosphorylate such a large number and wide diversity of substrates, 
as it does, lies in its modular structure.  
The catalytic subunit (PP2A-C) 
The active component of PP2A is its catalytic subunit (PP2A-C), a globular protein of ~36 kDa in 
size, containing two manganese ions at its catalytic site (Xing et al., 2006) which is ubiquitously 
expressed in all tissues (Janssens &Goris, 2001). Its structure is remarkably well conserved 
between species (Janssens & Goris, 2001) indicating its importance in the molecular processes of 
life. Two isofoms of PP2A-C have been identified: α and β. The α isoform is the most abundantly 
expressed of the two (Janssens & Goris, 2001) and it seems that their functions are not redundant. 
This was shown by Götz and colleagues (1998 & 2000) who generated a PP2A-Cα knock-out 
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embryonically lethal mouse model. Their model implicated a role for PP2A-Cα during embryonic 
development, which could not be salvaged by a likely upregulation of PP2A-Cβ. One of the 
reasons for this could be the differential cellular distribution of these two isoforms in the embryonic 
cells. As recently as 2012 an alternative enzymatically inactive spliced isoform of PP2A-Cα was 
discovered (Migueleti et al.). However, the physiological importance of this isoform is unknown, 
since its generation seems to be dependent on the incubation conditions that ex vivo cells are 
exposed to.  
 
Irrespective of the isoform, PP2A-C has a very broad substrate recognition ability, which poses a 
potential threat to any phospho-serine, or -threonine residues in the cell. The task of modulating 
and regulating PP2A-C activity lies with the array of proteins that associate with it. 
The scaffold subunit (PP2A-A) 
The most important of these is the ubiquitously expressed scaffold subunit (PP2A-A). This scaffold 
is an elongated structure consisting of 15 HEAT (huntingtin-elongation-A subunit-TOR) repeats, 
each containing two anti-parallel α-helices. This structure is flexible and allows PP2A-A to bind to 
PP2A-C, as well as to other proteins. Its association with PP2A-C necessitates a pronounced 
change in its conformation which might influence both the association of other proteins with the 
phosphatase complex, as well as the phosphatase activity of PP2A-C (Xing et al., 2006). The 
dimer formed when PP2A-C and –A interact is also known as the core enzyme. Although PP2A-A 
was initially considered as only a scaffold, it has recently been implicated in contributing to the 
substrate specificity of PP2A (Zhou et al., 2003). Just like PP2A-C, there are two scaffold isoforms: 
PP2A-Aα and PP2A-Aβ. As is the case with PP2A-C, the alpha isoform is much more abundant 
than the beta isoform. Interestingly, there are differences in the binding affinities of the two 
isoforms for different binding-partners, as well as in tissue distribution. Of the two, the alpha 
subunit shows a greater affinity for most binding-partners as well as a more homogenous 
expression in all tissues (Zhou et al., 2003). 
The regulatory subunits (B subunits) 
Additionally to the scaffold, a third subunit can also associate with the C subunit, namely the 
regulatory B subunit. Simply calling it the B subunit is, however, a gross simplification. In reality the 
“regulatory subunit” refers to a vast group of proteins consisting of four unrelated families: B (also 
known as R2, or PR55), B’’ (R3 or PR72), B’ (R5, B56 or PR61) and B’’’ (PR93/PR110). Each of 
these families contain multiple isoforms: Bα – δ, B’’α – γ, B’α – ε. There are therefore 
approximately 15 regulatory subunits. Both PP2A-C isoforms bind with equal affinity to the A and B 
subunits, while PP2A-Aβ has a lower affinity for both PP2A-C and B (Zhou et al., 2003). The 
implication of this is that any of these different C, A and B isoforms can theoretically associate with 
each other to generate at least 75 different enzymatically active versions of PP2A. Unlike the C 
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and A subunits, the regulatory subunits are not expressed in all tissues, in fact they show a definite 
tissue and subcellular distribution. Therefore, it is thought that the regulatory subunit acts to 
“target” the core AC enzyme to specific intracellular locations thereby bringing it into proximity with 
its substrate(s) (Janssens & Goris, 2001; Silverstein et al., 2010; Sents et al., 2013).  
 
Addition of a regulatory subunit gives rise to the trimeric or so-called holoenzyme. Studies of the 
crystal structure of the PP2A holoenzyme has revealed that the B subunit binds to both the A and 
C subunits, although it forms a relatively weak bond with the scaffold. The addition of B subunit to 
the dimer influences the substrate specificity of the C subunit by changing the accessibility of the 
catalytic site for different substrates (Xu et al., 2006; Cho et al., 2007). In 1991 Kamibayashi and 
colleagues showed that dissociation of the B subunit leads to an increase in both the Vmax and Km-
values of PP2A, indicating that the B subunit indeed influences substrate affinity, as well as – 
perhaps unexpectedly – also the catalytic ability of PP2A. 
 
Although I shall briefly touch on some of the research concerning the dynamics of the regulatory 
subunit, it is not the purpose of this chapter to give an exhaustive account of the distribution and 
substrate-targeting patterns of the regulatory subunits. For this the reader is referred to Silverstein 
et al., 2010. 
B’’ / PR72 / R3 isoform 
The rat form of the B’’ / PR72 subunit was described in 1997 (Nagase et al.) and was detected in 
all tissues including the heart with an intracellular distribution targeted to the cytosol, microsomes 
and mitochondria. This intracellular distribution was later expanded to include the nucleus 
(Kremmer, 1997). The targeting capability of the regulatory B subunits is nicely exemplified by the 
ability of PR130 (a B’’ / PR72 isoform) to target PP2A to RyR2 in the heart (Marx et al., 2001). 
Interestingly Nagase and colleagues (1997) noted that B’’ could also be phosphorylated by PKA, 
thereby leading to an increased activity of PP2A against some, but not all, of its substrates (Usui et 
al., 1998). This illustrates the potential for the regulatory B subunits to be targeted and modified by 
cellular processes in order to modify the activity or substrate specificity of PP2A. 
B’ / PR61 / B56 / R5 isoform  
The B’/PR65 (B56) subunit shows a relatively high abundance in cardiac tissue (Kamibayashi et 
al., 1994; Tehrani et al., 1996; Gigena et al., 2005). A look at this protein reveals the complexity of 
PP2A regulation. Different isoforms are associated with different cellular locations: α, β and ε are 
primarily found in the cytoplasm; γ1 and γ3 are targeted to the nucleus; while δ can be found in 
both the cytoplasm and nucleus, depending on the cell cycle (Tehrani et al., 1996; McCright et al., 
1996; Ito et al., 2000; Gigena et al., 2005; Zhou et al., 2007). In the heart it was found that B’α 
specifically targets PP2A to the M-line and Z-disc of the sarcomere (Bhasin et al., 2007). This is a 
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dynamic arrangement since β-adrenergic stimulation led to a redistribution of B’α away from these 
structures (Yin et al., 2010). The targeting ability of the regulatory subunits is not only limited to an 
area in the cell, but also to specific substrates, an example of this is B’ containing holoenzymes 
that have been found to be involved in the PP2A-mediated dephosphorylation of  ERK p42/p44 
(Letourneux et al., 2006) and PKB/Akt (Rocher et al., 2007). In an intriguing application of 
proteomics Zhou et al. (2007) identified the binding-partners of specifically B56γ1 from heart tissue 
as proteins involved in Ca2+ handling, as well as nuclear proteins. 
 
The B’ subunit is a target of multiple forms of regulation. Most of the isoforms are phosphoproteins 
which can be phosphorylated. In this this regard PKA has been implicated in the phosphorylation of 
B’δ, thereby increasing the activity of PP2A, without favouring the dissociation of B’ from the 
holoenzyme (Ahn et al., 2007; Dodge-Kafka et al., 2010). A model of stress in cultured myocytes 
revealed that the protein levels of only B’α (and not B’γ1) is downregulated in a c-Jun NH2 -
terminal kinase (JNK)-dependent fashion.  
 
The importance of the regulatory subunits in also determining the activity of PP2A-C is illustrated in 
a study by Ito and co-workers (2000). They found that a mutation of B’γ1 in melanoma cells was 
associated with a reduction in PP2A activity aimed at paxillin, in the absence of a change in the 
affinity of the PP2A-B’γ1 holoenzyme to paxillin. 
B / PR55 / R2 
In 1994 Kamibayashi et al. succeeded in isolating and characterizing a B subunit from cardiac 
tissue, which they identified as Bβ. Later Strack and colleagues (1999) also isolated Bδ in the 
heart, as well as confirmed the presence of Bβ.  Accentuating the differences between isoforms, 
Kamibayashi et al. (1994) used an insect cell model to express and compare different 
holoenzymes and found that although Bα and Bβ targeted similar substrates, their response (in 
terms of activity) to endogenous modulators differed. 
Core enzyme versus holoenzyme 
Initially it was thought that the dimer core enzyme was not physiologically relevant and only an 
artefact of the PP2A isolation process. Kremmer and colleagues however proved this wrong and 
showed that almost a third of PP2A in the cell is actually in the core complex assembly (1997). It 
could be argued that this constitutes an intracellular pool of enzyme which can be recruited to 
rapidly generate the holoenzyme. It is however interesting that the core enzyme can recognize 
substrates which differ from the holoenzyme’s substrate selection (Kremmer et al., 1997; Reudiger 
et al., 1997). The ratio between core enzyme and holoenzyme also seems to be important, since a 
mutation in the A subunit which favours the formation of the dimeric core enzyme above the 
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trimeric holoenzyme was associated with the development of a dilated cardiomyopathy phenotype 
(Brewis et al., 2000). 
 
In conclusion, PP2A is an enzyme which recruits several functional subunits in different 
combinations, thereby modulating its cellular location, activity and substrate specificity. The effects 
of the different subunits on some of these parameters were investigated by Price and colleagues 
(2000). They reported that addition of the A subunit to PP2A-C led to a substantial reduction in the 
reaction rate and Km-values of the catalytic subunit. Recruiting a Bα subunit initiated even more 
pronounced effects: a further reduction in Km, combined with changes in kinetics and pH 
dependence.  
 
The question that now arises pertains to the mechanism by which PP2A-C manages to recruit the 
different B subunits, or otherwise stated: how does PP2A-C allow itself to be recruited by different 
B subunits? 
Regulation of the interaction between PP2A-C and the regulatory 
subunits 
The answer to this question is focussed on a single portion of the catalytic enzyme, namely the 
carboxylic tail and the posttranslational modification of three of the amino acid residues in this tail. 
Phosphorylation at Tyr307 and Thr304 
In 1992 Chen and colleagues showed that the catalytic subunit of PP2A can be phosphorylated on 
its C-terminal tail at tyrosine residue 307 thereby reducing its activity. In this original study they 
showed that a number of nonreceptor tyrosine kinases and receptor tyrosine kinases, including 
insulin and epidermal growth factor receptors, can phosphorylate PP2A-C. At the same time, Guo 
and co-workers (1993) purified and characterized a novel serine/threonine kinase with an 
autophosphorylation capacity that has the ability to phosphorylate PP2A on a threonine residue, 
thereby also inhibiting the enzyme. Possibly the most intriguing result from these studies was the 
observation that the pharmacological inhibition of PP2A-C lead to an accumulative increase in the 
level of phosphorylation (both on tyr307, as well as the threonine residue), indicating that PP2A-C 
has the ability to dephosphorylate itself. Autodephosphorylation ensures that the inactivation of 
PP2A remains transient. 
 
Additionally to its implications for enzyme activity, phosphorylation of both tyr307 and thr304 in the 
C-terminal tail has been implicated in the selection and recruitment of different B subunits. This 
could either be because the phosphorylated form of these residues might obstruct the physical 
association between the regulatory subunit and PP2A-C, or in the case of tyr307, its 
phosphorylation impedes the addition of a methyl group on leucine residue 309 (Ogris et al., 1997; 
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Cho et al., 2006; Nunbhakdi-Craig et al., 2007; Longin et al., 2007). This brings us to another 
important regulatory posttranslational modification of PP2A-C: methylation. 
Methylation of Leu309 
Leucine 309 is also located in the C-terminal tail, in fact it is the last amino acid residue of PP2A-C, 
and it has the potential to be methylated. The crystal structure of the PP2A holoenzyme (Cho et al., 
2007) revealed that the methylation status of the C-terminal tail influences its interaction with the A 
subunit, thereby modulating the availability of a binding site for the regulatory subunits. Several 
studies utilizing mutational approaches found that the methylation of leu309 is indeed a 
determining factor in the recruitment of regulatory subunits, in that some subunits are only found 
associated with the methylated form of PP2A-C, while the binding of other B subunits seem to be 
independent of methylation (Bryant et al., 1999; Schild et al., 2006; Nunbhakdi-Craig et al., 2007; 
Longin et al., 2007). This regulatory mechanism is only aimed at selecting the regulatory subunit 
and it does not influence the formation of the PP2A-AC core dimer enzyme (Schild et al., 2006; 
Longin et al., 2007). With regards to this, it is interesting to note that a larger fraction of 
holoenzyme trimers are methylated, while the dimer core enzyme seems to mostly be 
nonmethylated (Bryant et al., 1999; Longin et al., 2004). Of the regulatory subunits which have 
been studied it seems that the binding of B’’ (PR72) and B’’’ (PR93/PR110) is independent of 
methylation, while the recruitment of B is more (although not absolutely) dependent on methylation. 
Interestingly Ikehara et al. (2007) found that the methylation status of PP2A had no effect on trimer 
assembly with the B (PR55) subunit. Their observations can probably be ascribed to the fact that 
they studied a specific subunit isoform in a specific milieu which is not that sensitive to methylation. 
The dependence of B’ (B56 / PR61) on methylation seems to be uncertain (Bryant et al., 1999; Yu 
et al., 2001; Nunbhakdi-Craig et al., 2007; Longin et al., 2004). The impact of methylation on 
regulatory subunit recruitment is also summarized in Table 3.1. 
 
Unlike tyr307 phosphorylation, the methylation of PP2A-C does not seem to influence its activity 
per se, although by influencing B subunit association it will necessarily influence catalytic activity 
and substrate specificity (Bryant et al., 1999; Schild et al., 2006; Ikehara et al., 2007). 
 
As described previously, the regulatory subunit in a holoenzyme is essential in determining the 
cellular location of PP2A. It therefore follows that the methylation of PP2A is important in 
determining the cellular distribution of the enzyme. In this regard Longin and colleagues (2008) 
reported a specific cellular distribution of PP2A methylation with higher levels of nonmethylated 
PP2A in the nucleus and a higher proportion of methylated PP2A in the cytoplasm. The functional 
implications of PP2A-C methylation has recently fallen under the spotlight. It has been shown that 
adenosine A1 receptor stimulation of isolated rat hearts induces the translocation of PP2A from the 
cytosol to the particulate fraction concurrent with an increase in the level of methylation, all in a Gi-
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dependent manner (Liu & Hofmann, 2002). Similarly exposure of isolated rat cardiomyocytes to 
hydrogen peroxide (H2O2) led to an increase in PP2A-C methylation, as well as a shift in PP2A 
activity from a Triton-soluble cytosolic to the myofilament-particulate fraction. This redistribution 
was however blocked by the inhibition of methylation (Deshmukh et al., 2007). It is noteworthy that 
these authors also measured some adrenergic-stimulated translocation of B’α from the cytosol to 
the particulate fraction. This is quite possible, since B’α has been found in both these fractions 
(Gigena et al., 2005; Yin et al., 2010), however their data indicate that the whole holoenzyme 
translocates in a methylation-dependent manner – in contrast to the existing theory that the dimer 
is shuttled between regulatory subunits. Their findings are possibly related to alternative splice 
forms of the B’α isoform, or the involvement of even more intricate and as yet unknown 
mechanisms. Regardless the precise mechanisms at work, the methylation status of PP2A-C is 
important in determining the cellular distribution of the enzyme and presents a mechanism of 
rapidly translocating PP2A. 
 
Table 3.1. The influence of leu309 methylation of the PP2A-C subunit on regulatory subunit 
association. The specific isoform which was measured by each study is indicated. Three groups 
are distinguished: “Methylation dependent” absolutely requires leu309 methylation for holoenzyme 
assembly; “Nonmethylation dependent” is defined as regulatory subunits which prefer to bind to 
nonmethylated PP2A-C; and “Methylation indifferent” are subunits which seem to bind with almost 
equal ease to both the nonmethylated and methylated forms of the enzyme. 
Regulatory 
subunit 
Methylation 
dependent 
Nonmethylation 
dependent 
Methylation 
indifferent 
B  
(R2 or PR55) 
α – Schild et al. 2006 
α, β1 – Longin et al., 2007 
α – Bryant et al., 1999 
α – Nunbhakdi-Craig et al. 
α – Yu et al., 2001 
α – Lee et al., 2007 
 α – Ikehara et al., 2007 PR55 – Longin et al., 2004 
B’  
(R5, B56 or PR61) 
ε – Schild et al. 2006 
α, δ – Nunbhakdi-Craig et 
al. 
γ – Schild et al. 2006 
α, β1, δ1, ε – Longin et 
al., 2007 
 
B’’  
(R3 or PR72) PR72 – Longin et al., 2004 
β – Schild et al. 2006 
β – Nunbhakdi-Craig et al. 
(significance not reported) 
PR70, PR72 – Longin et 
al., 2007 
B’’’  
(PR93/PR110)  
Striatin, SG2NA – Yu 
et al., 2001  
 
In summary, the dynamics of regulatory subunit association with PP2A-C – with consequential 
changes in cell distribution, enzyme activity and substrate specificity – is determined to a large 
extent by tyrosine and threonine phosphorylation, as well as leucine methylation. Several tyrosine 
kinases have been implicated in the phosphorylation of tyr307, and at least one serine/threonine 
kinase has possibly been linked to thr308 phosphorylation. The level of methylation however also 
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requires rapid and dynamic regulation, accomplished by two enzymes: leucine carboxyl 
methyltransferase (LCMT-1) and protein phosphatase methylesterase (PME-1). 
Leucine carboxyl methyltransferase (LCMT-1) 
Recently Lee et al. (2007) confirmed that LCMT-1 is the mammalian enzyme responsible for 
methylating PP2A-C. They went on to confirm the importance of PP2A methylation by showing that 
silencing LCMT-1 in HeLa cells blocked the assembly of Bα into the holoenzyme which eventually 
induced apoptosis. Longin and colleagues (2008) investigated the cellular distribution pattern of 
PP2A methylation and found that LCMT-1 is located in both the nucleus and cytoplasm; in 
conjunction with a cytoplasmic distribution of methylated PP2A. Intriguingly LCMT-1 favours 
methylating the active catalytic subunit. This would constitute a mechanism by which PP2A-C is 
incorporated into a holoenzyme immediately after its activation (Stanevich et al., 2011). By 
modulating PP2A assembly, LCMT-1 has also been implicated in cell signalling. Jackson and co-
workers (2012) found that stimulating a reduction in PP2A methylation (by amongst others LCMT-1 
knockdown) led to an increase in the activity of PKB/Akt and p70/p85 S6 kinase (S6K), thereby 
implicating LCMT-1 as a negative regulator of PKB/Akt. 
Protein phosphatase methylesterase (PME-1) 
Protein phosphatase methylesterase (PME-1) was first identified in 1999 (Ogris et al.) and has 
been confirmed as the primary enzyme responsible for demethylating PP2A (Ortega et al., 2008; 
Puustinen et al., 2009). It is chiefly located in the nucleus, corresponding with the observation that 
nuclear PP2A is mostly demethylated (Longin et al., 2008). As is the case for LCMT-1, complete 
loss of PME-1 is lethal, signifying its importance (Ortega-Gutiérrez et al., 2008). 
 
Interestingly, the activity of both LCMT-1 and PME-1 is reduced in the presence of okadaic acid 
(Stanevich et al., 2011; Ogris et al., 1999). Since okadaic acid binds to the active-site pocket of 
PP2A-C (Xing et al., 2006) this suggests that LCMT-1 and PME-1 also recognize and associate 
with the actual catalytic site of PP2A-C. For PME-1 this was recently proven by crystal structure 
studies (Xing et al., 2008). Intriguingly binding of PME-1 to PP2A-C activates PME-1, and seems to 
inactivate PP2A-C (Xing et al., 2008). In this sense PME-1 ceases to function as only a catalyst of 
demethylation, but also acts as a protein exerting a direct effect on PP2A by binding to it. 
Binding partners which regulate PP2A 
PME-1: safekeeping an inactive pool of PP2A 
The original cloning of PME-1 was made possible by the fact that PME-1 was found to bind to a 
mutational inactive form of PP2A (Ogris et al., 1999). Likewise Longin and colleagues (2004) found 
PME-1 to be preferentially associated with inactive PP2A, coincidentally mostly the dimeric core 
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enzyme. These authors speculated that PME-1 might therefore be involved in the maintenance of 
an inactive intracellular pool of PP2A, possibly in the nucleus (Longin et al., 2008). Although this is 
a compelling theory, several pieces of data in the literature argue against it: 1.) Ortega-Gutiérrez et 
al. (2009) reported that loss of PME-1 was lethal, implying that demethylated PP2A must be 
important for survival. They also found that PP2A activity seemed to be negatively influenced by 
the loss of PME-1, not what you would expect if PME-1 is always linked to inactive PP2A; 2.) It has 
been reported by several researchers that some of the regulatory subunits bind easily to 
nonmethylated PP2A. This beckons the question; why would a regulatory subunit bind an inactive 
form of the enzyme?; 3.) In the original paper concerning the existence of the core enzyme in cells, 
Kremmer et al. (1997) reported that the core enzyme presented with a different substrate 
specificity than the holoenzyme. This implies that the core enzyme could be active inside the cell, 
and not merely serve as an inactive pool. 
 
No doubt, the precise mechanisms and significance behind the effects of PME-1 and the 
methylation balance of PP2A-C still awaits further elucidation. If there is however a pool of inactive 
PP2A in the cell, the next question would be how the cell will access this pool? The answer to this 
lies with another very interesting protein which can interact with, and regulate PP2A; namely 
phosphotyrosyl phosphatase activator (PTPA). 
The activator of PP2A: PTPA 
It was mentioned earlier in this text that PP2A has the ability to autodephosphorylate its inhibitory 
phosphorylation site. Although the data indicates that this is indeed the case (Chen et al., 1992), it 
is problematic since the relevant phosphorylated residue is a tyrosine residue, while PP2A is 
supposed to be a serine/threonine phosphatase. 
 
Already in 1983 it was realized that PP2A also exhibits tyrosine phosphatase activity, although this 
PTP component contributes less than its serine/threonine phosphatase activity to the total protein 
phosphatase activity of PP2A (Chernoff et al., 1983). A comparison of the PTP activity of PP2A 
with a genuine PTP revealed that PP2A is more limited in the substrates it targets, implying that it 
must have a physiological role (Agostinis et al., 1996). 
 
In 1990 it was however realized that this PTP activity of PP2A was induced, or activated, by an 
activator protein which was called phosphotyrosyl phosphatase activator (PTPA). This activator 
seems to preferentially interact with the dimeric core enzyme in order to stimulate the PTP activity 
of PP2A to such a degree that it visibly contributes to the total cellular tyrosine phosphatase activity 
(Cayla et al., 1990). This led to the relatively recent proposal that PTPA drives a shift in the 
substrate specificity of PP2A (Chao et al., 2006). Further characterization of PTPA (Van Hoof et 
al., 1994) revealed that it is present in all tissues, located in the cytosolic fraction and present in 
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concentrations in the same range as PP2A, implying that the interaction between PTPA and PP2A 
must be important. A fascinating aspect of the interaction of PTPA with PP2A is that it requires the 
presence of Mg2+ and ATP and is associated with a low degree of ATPase activity, which can be 
inhibited by OA. This immediately leads one to suppose that some kind of kinase activity is 
involved, yet there is no evidence of kinase activity being present (Cayla et al., 1990; Van Hoof et 
al., 1994; Chao et al., 2006).  
 
A decade after the first descriptions of PTPA, Fellner et al. (2003) made the observation, using 
yeast homologs of PTPA, that it is not only involved in the activation of a PTP activity in PP2A, but 
it is actually also important for the functioning of the serine/threonine phosphatase activity of PP2A. 
Deletion of the yeast PTPA homologue was associated with changes in the conformation of PP2A-
C which led to shifts in substrate specificity and a reduction in protein stability. This illustrated that 
PTPA could somehow modify the actual structure of PP2A-C, thereby influencing all aspects of 
PP2A activity. Linking with this, Longin and co-workers (2004) found that PTPA could re-activate 
the serine/threonine phosphatase activity of an inactive pool of PP2A bound to PME-1. This pool 
consisted mostly of core enzyme and although the activation process required ATP hydrolysis, it 
did not seem to be transient nor did it require continuous energy input. The affinity of PME-1 for 
active PP2A is lower than for the inactive form, also ensuring that the newly activated PP2A could 
not easily be “trapped” back in storage as an inactive enzyme. These authors therefore suggested 
that the name of PTPA be changed to “phosphatase two A phosphatase activator”. These studies 
therefore clearly implicated PTPA as a major contributor to PP2A activity, but the mechanism how 
it accomplishes this was still a mystery. 
 
Two years later in 2006, Jordans et al. classified PTPA as a peptidyl-prolyl cis/trans-isomerase and 
linked this activity of PTPA to its activation function. They proposed that PTPA targets and 
isomerizes prolyl 190 in PP2A-C, thereby altering the conformation of PP2A-C from an inactive to 
an active form. This might explain the requirement for Mg2+ and ATP, since it is plausible that 
inducing a conformation change in a whole protein could require a substantial energy input.  
 
The body of work which has been published therefore implicates PME-1 as an inhibitor of PP2A, 
while PTPA is an activator. Both target the core enzyme – PME-1 maintains it in an intracellular 
pool, while PTPA activates it. Once activated, the dimer can be rapidly methylated by LCMT-1 
ensuring that it is built into a holoenzyme. 
 
Another aspect of enzyme regulation which should always be kept in mind, is the control of the 
absolute levels of the enzyme within the cells.  
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Regulating the total amount of PP2A in the cell 
Knock-out of PP2A-C proves lethal on embryonic level (Gotz et al., 1998), indicating the 
significance of PP2A in cellular processes. Attempts to investigate PP2A-C  by overexpressing it 
has mostly failed, since there isn’t a stable model of PP2A-C overexpression. The reason for this 
seems to be that there is a strict autoregulatory mechanism at work maintaining PP2A-C levels 
within certain limits (Baharians et al., 1998). These authors found that this autoregulatory feedback 
mechanism targets the translational phase of enzyme expression, while protein turnover seems to 
be less important. This is yet another fascinating phenomenon which emphasizes the critical 
importance of PP2A-C. 
 
Despite this conclusion by Baharians et al. (1998), protein degradation seems to play a role under 
certain conditions and especially with regards to the other components of the holoenzyme. Strack 
and colleagues (2004) reported that knock-down of PP2A-A initiated cell death and was associated 
with a loss of PP2A activity, as well as a proteosomal mediated reduction in the protein levels of 
PP2A-C, B and B’. Interestingly B’’ and B’’’ (striatin) levels remained stable. The implication of their 
results is that while the dimeric core enzyme, or trimeric holoenzyme is stable, any components 
which are not assembled into either of the two are unstable and consequently degraded – a 
phenomenon which was also reported, or at least implicated, by others (Van Kanegan et al., 2005; 
Lee et al., 2007). If this is indeed the case, one could easily argue that the expression of PP2A-C is 
the central most important factor in determining core- and holoenzyme levels, since it has been 
reported to have a longer half-life than PP2A-A (16.5 hours vs 10 hours – Baharians et al., 1998; 
and Zhou et al., 2003). 
Alpha4 – targeting PP2A-C for degradation? 
Adding to the number of potential molecules that can bind to PP2A, Murata et al. reported in 1997 
that a protein called α4 has the ability to directly bind to PP2A-C. Later work confirmed that the 
ubiquitously expressed α4 binds directly to the catalytic subunit, competing with PP2A-A, PME-1, 
LCMT-1 and okadaic acid (Kloeker et al., 2003; Yang et al., 2007; Kong et al., 2009; Migueleti et 
al., 2012). The implication of this is that PP2A-C can exist in the cell as a dimer with α4, which in 
the process also reduces PP2A activity (Nanahoshi et al.; 1999).  
 
Despite α4 inhibiting PP2A-C, Kong and colleagues (2009) found that α4 is of critical importance 
for protein phosphatase stability, since deleting it was associated with a progressive reduction in 
PP2A activity in conjunction with a loss in PP2A-A. It is also noteworthy that α4 also associates 
with PP4 and PP6 following similar dynamics as with PP2A-C. This however leads to the question: 
What is the function of α4? 
 
There are three different possibilities, which are probably all true to differing degrees: 
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1.) α4 has the ability to bind both PP2A-C and another protein, Midline 1 (MID1), simultaneously. 
MID1 is an E3 ubiquitin ligase – in other words it is involved in the final step of ubiquitination of 
a protein by acting as a type of scaffold bringing an activated  ubiquitin group into the proximity 
of the substrate (Calise & Powell, 2013), thereby “tagging” the substrate protein for 
proteosomal degradation. The obvious conclusion is therefore that α4 is involved in the MID1-
mediated degradation of PP2A-C. In fact this is one of the proposed mechanisms of the 
congenital disorder Opitz syndrome, which is molecularly characterized by an increase in the 
cytosolic levels of PP2A (Trockenbacher et al., 2001). MID1 has also been shown to simply 
inhibit PP2A (Collison et al, 2012). A geometrically opposing function for α4 which involve 
MID1 has however also been proposed. 
2.) McConnel and colleagues (2010) found that although PP2A-C, bound to the α4-MID1 complex 
was ubiquitinated, this was not associated with the degradation of PP2A-C; rather it seemed to 
protect PP2A-C. They suggested a mechanism whereby PP2A-C is only mono-ubiquitinated, 
followed by the binding of an “ubiquitin-interacting motif” in α4 to the ubiquitin group, thereby 
“capping” it and preventing the addition of more ubiquitin groups. This prevention of the poly-
ubiquitination of PP2A-C might explain how α4 protects PP2A-C against degradation (Kong et 
al., 2009). 
3.) Two studies have found that α4 is also involved in targeting PP2A-C to specific locations 
(Fielhaber et al., 2009) and substrates (Prickett et al., 2007) within the cell. This identifies α4 
as a scaffold protein which simply brings PP2A into the proximity of its intended substrates. 
 
Taken together the scaffold function of α4 best describes its role in living cells. The eventual effect 
of α4 association with PP2A-C is therefore dependent on the eventual cellular / substrate target 
associated with α4 scaffolding in that specific context. α4 can therefore possibly even be 
considered as an alternative scaffold to PP2A-A. It is however intriguing that α4 association has 
been implicated with the inhibition of PP2A-C, reportedly via an allosteric mechanism (Nanahoshi 
et al.; 1999; Smetana et al., 2007). α4 is however not the only protein that can bind to, and in the 
process inhibit, PP2A-C. 
Other proteins which can bind to PP2A-C 
As mentioned in the beginning of this mini-review, the key to PP2A’s wide range of substrates and 
cellular processes it mediates, lies in its modularity; the fact that it consists of units which can be 
assembled in different combinations to generate a wide array of substrate specificities, cellular 
locations and enzyme kinetics. Besides the proteins that have already been mentioned, the 
following molecules can also bind to and – in each case inhibit – the activity  of PP2A. 
 
 In 1995 Li and colleagues isolated two potent endogenous inhibitors of PP2A from bovine 
kidney: I1PP2A and I2PP2A. These inhibitors were shown to be highly specific for PP2A, but 
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interestingly only inhibited the phosphatase activity of PP2A directed at specific substrates and 
failed to inhibit PP2A’s autodephosphorylation. A year later the same investigators determined 
the identities of these two inhibitors: I1PP2A is also known as “putative histocompatibility 
leukocyte antigens class II-associated protein I" (PHAP-I), while I2PP2A proved to be a truncated 
form of SET (Suvar3-9, enhancer of zeste, trithorax). PHAP-I has been shown to be part of a 
family of PP2A inhibitors known as the acidic nuclear phosphoprotein 32 (ANP32) family 
(Santa-Coloma, 2003). These proteins are also targets of modulation and in 2012 Irie et al. 
reported that the PP2A inhibitory function of SET could be reduced by its phosphorylation. On 
the other hand, phosphorylation of ANP32e is a prerequisite for it to interact with PP2A 
(Costanzo et al., 2006). 
 In yeast Tip41-like proteins have been found to exert some of their function by regulating 
PP2A (Fenyvuesvolgyi et al., 2005). The mammalian ortholog of Tip41 is TOR signalling 
pathway regulator-like (TIPRL), also known as TIP41. TIPRL has been shown to also bind 
PP2A-C at a site distant from the binding site of α4, a trimer can therefore be formed between 
PP2A-C, α4 and TIPRL. As is the case for α4, TIPRL exerts an allosteric inhibitory effect on 
PP2A-C (Smetana & Zanchin, 2007). 
 Simian virus 40 (SV40) small-t antigen (small-t) has the ability to bind to either PP2A-A or the 
core enzyme, in the process competing with the regulator subunit for a position in the 
holoenzyme and inhibiting the activity of PP2A in a substrate-specific manner (Yang et al., 
1991). PP2A is therefore one of the targets for simian virus 40 and polyoma virus mediated 
cellular transformation (Janssens & Goris, 2001). Small-t presents as a useful experimental 
tool for the modulation of PP2A (see for example Andrabi et al., 2007). 
Conclusion 
The regulation of PP2A activity is a vast and complex process, involving numerous regulator 
proteins. For a review concerning the dynamics of PP2A assembly, see Janssens et al. (2008). 
The reader is also referred to Sents and colleagues (2012) who suggested a model incorporating 
these various role-players in an attempt to generate a cohesive understanding of PP2A. Their 
model is built on the premise that a free active catalytic subunit would be catastrophic in a cell and 
therefore needs to be tightly controlled, as well as protected from degradation. A summary of their 
model, incorporating the information discussed here combined with some conjecture, is as follows 
(see Figure 3.1.): 
 
Newly synthesized PP2A-C is stabilized in an inactive state in complex with α4, and possibly also 
TIPRL – thereby forming a storage depot of PP2A-C. α4 is centrally placed to regulate the rate of 
PP2A-C MID1 mediated proteosomal degradation, as well as intracellular translocation of PP2A-C 
alone.  
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Activating PP2A-C for its cellular functions is a multistep process. First PP2A-A must replace α4 
(and probably also TIPRL). This resulting core enzyme could possibly participate in cellular 
processes (after activation by PTPA), or (more likely) also go into a storage depot from which core 
enzyme can rapidly be withdrawn. This dimeric store is maintained and stabilized in an inactive 
form by PME-1, which will also ensure that the dimer remains unmethylated.  
 
If the core enzyme needs to be recruited for cellular functions, it will have to be activated by PTPA 
which catalyses the necessary conformational change. As soon as the core enzyme is active it will 
become methylated by LCMT-1, in the process facilitating the addition of a regulatory subunit to 
the core enzyme. The result is the release of a holoenzyme with a specific activity, intracellular 
location and substrate specificity. 
 
Phosphorylation also influences regulatory subunit selection, so the phosphorylation of thr304 and 
tyr307 might present a way in which intracellular signalling intercepts and contributes to the 
determination of the holoenzyme assembly. The phosphorylation of tyr307 also presents an 
opportunity for tyrosine kinase mediated regulation of PP2A activity. Due to its 
autodephosphorylation, this form of inhibition is transient and allows for the short-term 
phosphorylation of substrate proteins in conjunction with tyrosine kinase mediated signalling. 
Phosphorylation of the regulatory subunits is another way in which PP2A activity can be modulated 
by signalling pathways. 
 
This is a very simple model which ignores some of the dynamics of PP2A function and regulation. 
Questions remain, such as: What is the physiological importance of core enzyme activity? What 
determines the selection of the regulatory subunit? How can such a wide variety of subunits be 
recruited by a single “on/off” switch (methylated / nonmethylated)? Some have found that the 
nonmethylated form is ideal for inactive storage, while others have found that methylation status 
has no effect on enzyme activity, so what is the link then between methylation and function? What 
determines the selection of binding to α4 versus PP2A-A? There is therefore still a lot of research 
depth left with regards to PP2A. 
Protein phosphatase 2A in the heart 
As discussed in the previous sections, PP2A has emerged as an incredibly complex enzyme. The 
body of work which has already been done in an attempt to elucidate its mysteries has however 
laid the foundation to better investigate and understand its role and contribution in general 
pathologies. One such pathology is ischaemic heart disease. Although the original work done in 
the 1990’s concerning the effects of phosphatase inhibition (Xiuhua et al., 1997; Armstrong et al., 
1997; Armstrong et al., 1998; Weinbrenner et al. 1998; Barancik et al., 1999; Isotani et al.  2002) 
showed the importance of the phosphatases in this setting, researchers simply didn’t have enough 
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information to contextualize and expand on their results. However, in light of all the new knowledge 
we have to our disposal, it is an opportune time to re-examine PP2A in the heart. One such study 
is the recently published description of PP2A in the heart by DeGrande and colleagues (2013). 
 
Applying Western Blotting these authors found that 9 regulatory subunits are expressed in human 
heart tissue: B  (PR55 α, β); B’’ (PR72); B’’’ (PR93/PR110); B’ (PR56 α, β, γ, δ, ε), implying that 
there are numerous PP2A holoenzymes at work in heart tissue. As expected, in mouse myocytes 
the regulatory subunits showed differential intracellular distribution, while PP2A-A and –C were 
spread throughout the cells.  Interestingly, they also found that there is a higher expression of 
PP2A-A and PP2A-C in the right ventricle than in the left ventricle – confirming earlier observations 
(Lüss et al., 2000). Comparison of regulatory subunit expression between animal species revealed 
a worrying difference in expression between rodents (mice and rats) and humans – these 
differences must obviously be kept in mind when interpreting experimental results. It is also 
noteworthy that they found that PP2A subunit expression changed in pathological models, but in a 
unique way for each pathology investigated (ischaemic and non-ischaemic heart failure). These 
changes in expression were more visible on protein level than transcriptional level, indicating the 
importance of regulation on other levels – such as translation and degradation. They also reported 
that heart failure per se was also associated with an increase in tyr307 phosphorylation and a 
reduction in methylation (with a concurrent reduction in LCMT-1 expression). This study therefore 
clearly confirms the importance and participation of PP2A in cardiac pathology. 
Motivation, hypothesis and aims 
We therefore know that PP2A is present in the heart; it is involved in several processes such as 
Ca2+ homeostasis, contraction, apoptosis and signalling; inhibition of PP2A has been shown to be 
cardioprotective and its expression is modulated in ischaemic and non-ischaemic heart failure. It 
should therefore be involved in the acute setting of myocardial I/R injury. Remarkably little is 
however known concerning the basic dynamics of PP2A participation in this context.  
 
This study aims to address this shortcoming by simply describing PP2A levels and 
posttranslational modification in unfractionated tissue, as well as in different cellular fractions, as 
ischaemia progresses and during the clinically relevant first moments of reperfusion.  
 
Due to the explorative nature of this study, it is difficult to predict the outcomes – our hypothesis is 
therefore very limited. In light of earlier work done in renal tissue (Kobryn and Mandel, 1994), we 
expect that PP2A will continue to function as an active phosphatase during ischaemia. The 
implication of this is that the phosphorylation level of PP2A should remain unchanged. As 
ischaemia progresses, with concomitant reduction in ATP levels, the phosphorylation of PP2A will 
also decrease. Even in the absence of a cardioprotective intervention, we expect the heart to 
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respond to I/R stress by attempting to activate its inherent cardioprotective capability. This is 
dependent on phosphorylation driven survival signalling. Therefore, reperfusion and the generation 
of ATP should be associated with a transient increase in PP2A phosphorylation.  
 
Ischaemia is associated with a relatively rapid cessation of contraction, while heart tissue still 
remains viable. PP2A might contribute to this by reducing the phosphorylation and activity of the 
sarcolemmal L-type Ca2+ channel, (Cav1.2). However, it is also conceivable that PP2A could 
contribute to Ca2+ overload and contracture later in ischaemia and during early reperfusion by 
modulating PLB, RyR2, as well as TnI.  We therefore expect to find a translocation of PP2A 
between cellular fractions; possibly towards a membrane fraction. This translocation will be 
associated with changes in the level of methylation of PP2A. Depending on the degree of damage 
incurred, reperfusion should be associated with the redistribution of PP2A back to its pre-ischaemic 
intracellular positions, although the time-frame for this is unknown. 
Material and Methods 
Rationale 
To investigate the response of PP2A to ischaemia and reperfusion we focussed our attention on 
the levels of PP2A-A and PP2A-C at different timepoints in the latter half of an ischaemic incident, 
as well as during the first moments of reperfusion. We specifically chose to investigate the latter 
half of ischaemia, since we expected to see the most pronounced effects after a relatively 
extended period of ischaemia. Our interest in early reperfusion was due to the fact that this has 
been shown to be a critical period in the genesis of I/R injury and therefore also a window of 
opportunity for clinical intervention. Since the activity and cellular location of PP2A are influenced 
by phosphorylation and methylation, these parameters were also measured. All protein and 
posttranslational modification (PTM) determinations were done using standard Western Blotting 
techniques (previously described in Chapter 2). 
 
In order to confirm our results we chose to use two different experimental models, namely cell 
culture and the isolated rat heart. Each of these models were exposed to different periods of 
ischaemia and reperfusion, as relevant for that experimental model, whereafter samples were 
collected and analysed using Western Blotting. 
Cell culture experiments 
Protocols 
For the cell culture experiments we utilized a myoblast cell line of cardiac origin: H9c2 cells. 
Ischaemia was simulated in these cells by exposing them to a combination of hypoxia (0.5% O2, 
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5% CO2 and the balance N2) and chemically simulated ischaemia (SI) in the form of a modified 
Esumi buffer (Esumi et al., 1991) containing the metabolic mitochondrial inhibitor sodium dithionate 
(SDT, 0.5 mM). We first had to determine the optimal maximum duration of SI exposure. For this 
we assessed cell viability, measured by PI and AV staining, using a Becton Dickinson FACS 
(fluorescent activated cell sorting) Calibur. This approach allowed us to determine both early and 
late apoptosis / necrosis. Exposure was considered sufficient if it elicited a significant degree of cell 
death. Following this appoach we utilized 120 minutes of SI exposure as the maximum ischaemic 
duration. 
 
See Figure 3.2 for the different protocols of SI and reperfusion which were followed. Briefly, cells 
were exposed to SI for 60 minutes, 90 minutes or 120 minutes. Following 120 minutes of SI the 
cells were reperfused. Simulated reperfusion entailed a brief rinse with PBS followed by incubation 
in normal DMEM growth medium under normoxic conditions for either 15 or 30 minutes.  
 
Western blotting was used to determine the profile of PP2A-C and –A expression, as well as 
phosphorylation and methylation of PP2A-C, following these different durations of SI or SI/R. Each 
intervention was paired with a relevant control group. The control groups were exposed to the 
PP2A-C 
PP2A-A 
Phospho  
PP2A-C 
Nonmethylated 
PP2A-C 
β-Tubulin 
(loading control) 
60 
90 
120 
30 
15 120 
120 
  
Simulated ischaemia (minutes) Reperfusion (minutes) 
B. Cells lyzed and 
analysed using 
Western blotting for: 
30 120 
A. 
120 
Cell viability 
determined 
Figure 3.2. Simulated ischaemia and reperfusion in the H9c2 cell model. 
(A) To confirm the detrimental effects of our model of simulated ischaemia (SI) and 
reperfusion, cells were exposed to either 120 minutes SI alone, or 120 minutes SI 
followed by 30 minutes reperfusion. Following these interventions cell viability was 
determined using prodium iodide (PI) and Annexin V (AV) staining. (B) After confirming 
that 120 minutes SI was sufficient to elicit cell damage and death, protein levels and 
posttranslational modification of PP2A was determined at 60, 90 and 120 minutes SI, as 
well as 15 and 30 minutes reperfusion. 
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same handling as the experimental groups, i.e. PBS washes and growth medium replacement. The 
only difference was that they received normal DMEM growth medium throughout. 
Statistics 
Each experimental intervention was repeated three times, on different days. For each repetition of 
the relevant experimental condition at least three separate culture dishes served as controls, while 
four to six culture dishes were exposed to SI or reperfusion. Flow cytometry data was originally 
collected as the percentage of the cells counted presenting with either AV or PI positive staining, or 
both. As described in Chapter 2, densitometry was applied to quantify the final Western blotting 
films, thereby expressing the Western blots in terms of pixels. For both end-points measured 
comparison of data generated on different occasions were facilitated by expressing all the data 
relative to the mean of the relevant control group and expressed in arbitrary units (AU). Since the 
control condition remained the same between experimental repetitions, we pooled all the 
normalized data into a single statistical comparison for each end-point measured.  
 
Since, for each intervention, only one experimental group was compared with its relevant control, 
data analysis was done using an unpaired T-Test. Depending on the distribution of the data, 
determined by a D’Agostino & Pearson omnibus normality test, either an unpaired T-test (for 
Gaussian distributed data), or a Mann-Whitney test (a nonparametric test) was used. A P-value of 
less than 0.05 was considered significant.  
Isolated rat heart experiments 
Protocols 
As previously described (Chapter 2), hearts were excised from male Wistar rats and quickly 
mounted on a work heart perfusion apparatus. As was the case for the cell-based experiments we 
first had to determine which duration of global ischaemia (GI) would be sufficient to elicit significant 
damage, as determined by the functional recovery of the hearts. Functional recovery is defined as 
functional performance, as determined by aortic output, cardiac output and total work 
measurements, at 30 minutes reperfusion relative to pre-ischaemic values. We found that a period 
of 20 minutes GI was adequate. Therefore, following 40 minutes of stabilisation hearts were 
exposed to 10, 15 or 20 minutes GI, or 20 minutes GI followed by either 5 or 10 minutes of 
reperfusion (see Figure 3.3). Tissue was collected at each of these timepoints and stored in liquid 
nitrogen for later analysis. 
 
As described for the cell based experiments, tissue was analysed using Western Blotting for PP2A-
C, PP2A-A, phosphorylated PP2A-C and nonmethylated PP2A-C. Beta tubulin was used as a 
control for equal loading. Since a large part of the regulation of PP2A involves the cellular 
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translocation of the enzyme, we also utilized the collected tissue to prepare crude nuclear, 
cytoplasmic and membrane fractions, as described in Chapter 2. Each of these fractions were then 
also analysed using Western blotting for the same targets as investigated in the unfractionated 
preparation. 
 
Control hearts  were perfused for a similar duration of time as the hearts exposed to global 
ischaemia. 
Statistics 
Each timepoint was investigated as a separate experiment with at least three control hearts and 
four ischaemia/reperfusion hearts. Due to technical limitations, we performed Western Blotting on 
each timepoint separately. We therefore decided to only directly compare each timepoint with its 
non-ischaemic control, and not timepoints with each other. Statistical analysis was therefore done 
using an unpaired T-test, where a P-value of less than 0.05 was considered as significant. 
B. 
20 
A. 
15 15 10 10 20 
15 15 10 
15 15 10 
20 15 15 10 
10 
20 15 15 10 5 
20 15 15 10 10 
15 
Functional recovery 
Tissue either 
fractionated into nuclear, 
nuclear, cytoplasmic 
and membrane 
fractions; or prepared as 
unfractionated lysates. 
Further analysed using 
Western Blotting 
Figure 3.3. Global ischaemia in the isolated rat heart model. 
(A.) To determine the effects of global ischaemia (GI) and reperfusion in our model, 
hearts were stabilised for 40 minutes and then exposed to 20 minutes global ischaemia at 
a temperature of 36.5°C. This was followed by a total of 30 minutes reperfusion. 
Functional recovery was then calculated as the post-ischaemic function relative to pre-
ischaemic values. 
(B.) Having confirmed that 20 minutes GI conferred significant damage, hearts were 
exposed to 10, 15 or 20 minutes GI; or 20 minutes GI followed by 5 or 10 minutes 
reperfusion. At each of these timepoints heart tissue was collected and analysed using 
Western Blotting. For each time point an unfractionated “whole cell” lysate was prepared, 
as well as fractionated (nuclear, cytoplasmic, membrane) samples. 
 
Retrograde 
     
Retrograde Retrograde Work Work Global 
ischaemia 
Time duration (minutes) 
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Results 
Cell culture experiments 
Cell viability following simulated ischaemia and reperfusion 
At the onset of this project we did not have an established SI model for the H9c2 cells in our 
laboratory. We therefore first had to setup a suitable model of SI and reperfusion (data not shown). 
We wanted a cell based model of ischaemia which could be comparable to our isolated rat heart 
ischaemic model. We therefore decided to not only expose the cells to hypoxia, but also to some of 
the other aberrations associated with ischaemia.  
 
To this end we combined hypoxia (0.5% O2) with a modified Esumi buffer containing elevated 
potassium  concentrations, no glucose, low FBS, low pH (6.4), reduced buffering capacity (HEPES 
buffer at a concentration of 4 mM versus 20 mM in a normal HEPES buffer) and lactate (as 
discusssed in Chapter 2). H9c2 cells however have a high resistance to hypoxia and ischaemia, 
possibly due to, amongst other factors, their low metabolic requirements compared to beating 
cardiomyocytes. To increase the potency of our SI, we also included 0.5 mM of sodium dithionate 
(SDT), a reversible metabolic inhibitor. We found that exposure of the H9c2 cells to this SI buffer 
for a period of 2 hours elicited a slight, yet significant degree of cell death (Figure 3.4), both in 
terms of early apoptosis (AV staining: Control: 1.00±0.14 arbitrary units (AU) vs 2h SI: 3.44±0.97 
AU; p<0.001) and late apoptosis (AV and PI positive: Control: 1.00±0.17 AU vs 2h SI: 2.48±0.35 
AU; p<0.001). There was also a significantly smaller population of viable cells (negative staining for 
either AV or PI) after 2 hours SI (Control: 1.00±0.01 AU vs 2h SI: 0.83±0.04 AU, P<0.0001). 
Similarly, 2 hours SI followed by 30 minutes reperfusion also elicited significant cell death, of 
approximately the same magnitude as SI alone, with regards to early and late apoptosis, as well as 
a reduction in the number of viable cells (Figure 3.5). 
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PP2A during late ischaemia and early reperfusion 
Having established an SI/reperfusion (SIR) intervention which was associated with a significant 
degree of cell injury and death in the H9c2 cells, we proceeded with the characterization of PP2A 
during the latter half of simulated ischaemia and early reperfusion. We focussed on the levels of 
total PP2A-C and PP2A-A, as well as tyr307 phosphorylation and leu309 methylation of PP2A-C. 
Beta-tubulin was also blotted for as a loading control.  
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60, 90 and 120 minutes of simulated ischaemia 
Following 60 minutes of exposure to simulated ischaemic conditions (Figure 3.6) there was a 
significant reduction in the levels of PP2A-A (Control: 1.00±0.05 AU vs 60 min SI: 0.84±0.03 AU; 
P<0.01) in the absence of any changes in PP2A-C levels. This reduction was also reflected by a 
shift in the ratio of PP2A-C to PP2A-A (Control: 1.00±0.03 AU vs 60 min SI: 1.16±0.05 AU; 
P<0.05), indicating that there was now more PP2A-C than PP2A-A relative to control conditions.  
 
These observations regarding the ratio of PP2A-C to – A (PP2A-C/A) can be explained as follows: 
most of PP2A inside a cell consist of either the dimer or the trimeric holoenzyme. In both these 
forms PP2A-C and –A is present in a ratio of 1:1. We would therefore expect that under normal 
conditions there should be approximately an equal number of both PP2A-C and –A molecules 
within a cell. Western Blotting does not allow for the determination of exact protein concentration in 
the tissue. We therefore do not have the data to determine the actual ratio of PP2A-C molecules 
relative to PP2A-A. We do however have an immunoreactive signal representing PP2A-C and 
PP2A-A and the response in their levels to different situations. To optimise the data we therefore 
decided to also express these signals relative to each other, similarly as is done for the expression 
of phosphorylated signal relative to its total, in order to give an indication of changes in the values 
of PP2A-C and PP2A-A relative to each other – and therefore per implication also give us 
information regarding dimer and trimer composition. Since we do not have absolute values, we can 
only express our data relative to a central reference point – which is obviously the control 
condition. This means that control has the designated value of “1”, not to be confused with an 
actual 1:1 ratio of absolute values. The PP2A-C/A ratio therefore serves as an indication whether 
there are changes in dimer or trimer assembly. The increase we see after 60 minutes SI indicates 
that there is more PP2A-C in the cell than PP2A-A, relative to pre-ischaemic control conditions. 
This implies that there must be PP2A-C which is not built into either a dimer or a trimer at 60 
minutes SI. This might be the case under control conditions as well, since we can’t measure if the 
absolute ratio is 1:1 under control conditions. However after 60 minutes there is more PP2A-C not 
associated with PP2A-A than under control conditions. 
 
Along with these changes in PP2A-A relative to PP2A-C, there was an increase in the 
nonmethylated signal (Figure 3.7) indicating a reduction in methylation of PP2A-C – both in 
absolute terms (i.e. the amount of PP2A-C nonmethylated – Control: 1.00±0.05 AU vs 60 min SI: 
1.17±0.04 AU; P<0.05) and relative to total PP2A-C (i.e. the degree of nonmethylation of the 
PP2A-C population – Control: 0.99±0.06 AU vs 60 min SI: 1.19±0.03; P<0.01).  
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Surprisingly, no differences were observed with regards to total protein levels (Figure 3.8) or 
phosphorylation and methylation (Figure 3.9) at 90 minutes of SI. This implies that the differences 
observed after 60 minutes were only transient and probably part of a relatively initial response to SI 
which includes PP2A participation.  
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Although there were no significant differences relative to control concerning the levels of PP2A-C 
and –A at 120 minutes of SI (Figure 3.10), there was a significant increase in PP2A-C relative to 
PP2A-A (Control: 1.00±0.03 AU vs 120 min SI: 1.17±0.04 AU, P<0.01). As was the case after 60 
minutes, this indicates that there must be PP2A-C in the cell not assembled into the canonical 
dimer or trimer, relative to control conditions. This shift is evidence of slight, statistically 
insignificant changes in both PP2A-A and PP2A-C. It therefore seems that the PP2A-C/A value 
serves to also magnify small changes in PP2A-C and PP2A-A levels, which might be missed 
otherwise. 
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Similarly as at 60 minutes, this shift is associated with an increase in absolute nonmethylated 
PP2A-C levels (Control: 1.00±0.05 AU vs 120 min SI: 1.18±0.06 AU; P<0.05). This increase is 
however not enough to reflect an increase in the degree of nonmethylation of PP2A-C (Figure 
3.11). 
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15 and 30 minutes of reperfusion 
Interestingly, 15 minutes of reperfusion was associated with a reduction in PP2A-A levels (Control: 
1.00±0.06 AU vs 5 min Repf: 0.84±0.04; P<0.05). The importance of this is however doubtful, 
since there is no accompanying shift in the ratio of PP2A-C to –A, implying no changes in trimer or 
dimer composition (Figure 3.12). There was also no associated change in methylation as observed 
at 60 and 120 minutes SI (Figure 3.13). There was however a reduction in the amount of 
phosphorylated PP2A-C (Control: 1.00±0.06 AU vs 15 min Repf: 0.84±0.04 AU; P<0.05). The 
importance of this is also doubtful, since there was no observed reduction in the degree of 
phosphorylation of the population of PP2A-C as a whole. 
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It seemed that by 30 minutes of reperfusion the intracellular milieu had returned to normal, as 
evidenced by the absence of any changes in PP2A levels (Figure 3.14) or posttranslational 
modification (Figure 3.15). 
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Isolated rat heart experiments 
Functional recovery following an ichaemia / reperfusion intervention 
Isolated rat hearts were allowed to stabilize on the perfusion apparatus for a period of 40 minutes 
followed by 20 minutes of GI during which time the heart received no perfusion with oxygenated 
Krebs-Henseleit buffer and was kept warm at 36.5 °C. This was followed by 30 minutes of 
reperfusion, at which time the functional ability of the hearts was assessed and expressed as a 
percentage of pre-ischaemic function. This combination of GI and reperfusion was associated with 
a significant reduction in functional performance of the hearts (Table 3.2.), indicating that 20 
minutes of ischaemia already exerted a profoundly detrimental effect and could therefore be used 
to assess PP2A in I/R injury. 
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Table 3.2. Functional recovery of isolated rat hearts exposed to 20 minutes of global ischaemia 
(GI) followed by 30 minutes of reperfusion indicating the harmful consequences of this intervention. 
n=9. 
Functional 
parameter 
Pre-
ischaemic  
Post-
ischaemic  
Percentage 
recovery 
Difference  
Aortic output 
(ml/min) 48.00±2.51 12.72±4.18 25.24±10.76 P<0.0001 
Cardiac output 
(ml/min) 64.44±2.53 24.11±4.96 37.52±9.57 P<0.0001 
Total work 
(mW) 14.44±0.47 4.38±1.34 29.18±10.51 P<0.0001 
PP2A during late ischaemia and early reperfusion 
The primary reason why we used two experimental models (cell culture and isolated heart) to 
address the same question was to explore potential differences in these models, to utilize different 
techniques and to confirm our results. We therefore utilized our model of I/R injury in the isolated 
rat heart to characterize PP2A in exactly the same way as was done using SI in the H9c2 cells. 
10, 15 and 20 minutes of global ischaemia 
Figure 3.16 shows the effect of sustained ischaemia in the isolated rat heart on the levels of PP2A-
A and –C. We made the very surprising observation that as ischaemia progressed the levels of 
both PP2A-C and –A increased so that it was significantly elevated above control at 20 minutes GI 
(PP2A-C: Control: 1.03±0.11 AU vs 20 min GI: 1.78±0.10 AU; P<0.05, PP2A-A: Control: 1.00±0.03 
AU vs  20 min GI: 1.18±0.04 AU; P<0.05). This increase was especially evident in PP2A-C, to such 
a degree that at 20 minutes GI there was a significant increase in the amount of PP2A-C relative to 
PP2A-A (PP2A-C/A:  Control: 1.02±0.07 AU vs 20 min GI: 1.62±0.15 AU; P<0.01). 
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Although there were no changes in phosphorylation and methylation relative to the cellular pool of 
PP2A-C (Figure 3.17), we observed an increase in absolute phosphorylated levels in late 
ischaemia (Control: 0.98±0.10 AU vs 20 min GI: 1.78±0.13 AU; P<0.05), as well as nonmethylation 
(Control: 1.00±0.19 AU vs 20 min GI: 2.30±0.14 AU; P<0.05). The failure of these significant 
changes to influence the relative degree of posttranslational modification of PP2A can obviously be 
ascribed to the concurrent increase in PP2A-C levels. This means that the proportion of the 
accumulated PP2A-C which is phosphorylated and not methylated remains unchanged. There is 
however an increase in the absolute cellular load of these modifications and it must therefore be of 
importance. 
Stellenbosch University  http://scholar.sun.ac.za
- 86 - 
 
 
These results were so unexpected that we sought to confirm them by increasing the n-values. As 
will be described later in this thesis, we also did similar perfusion experiments later in the project in 
conjunction with pharmacological studies. In order to better assess the changes associated with 20 
minutes GI we therefore decided to pool the normalized data from these different experiments for 
comparable timepoints (Figure 3.18). The result was a data set with a much larger n-value (10-16) 
and representing experiments spanning 4 years. This pooled data set confirmed our results: PP2A-
C was elevated at 20 minutes ischaemia (Control: 1.00±0.04 AU vs 20 min GI: 1.30±0.10 AU; 
P<0.05), which was associated with an increase in PP2A-C/A (Control: 1.00±0.03 AU vs 20 min 
GI: 1.32±0.10 AU; P<0.01). Interestingly PP2A-A did not show an increase. The absolute levels of 
PP2A-C phosphorylation was also elevated (Control: 1.00±0.04 AU vs 20 min GI: 1.40±0.10 AU; 
P<0.01), as well as the levels of nonmethylation (Control: 1.00±0.07 AU vs 20 min GI: 1.76±0.19 
AU; P<0.01). In fact, nonmethylation was also increased relative to total PP2A-C as well (Control: 
1.00±0.08 AU vs 20 min GI: 1.30±0.04 AU; P<0.01). 
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5 and 10 minutes reperfusion 
Just as surprising as our GI data, we observed an increase in total PP2A-C (Control: 1.00±0.06 AU 
vs 10 min Repf: 1.40±0.05 AU; P<0.05) and PP2A-A (Control: 1.00±0.02 AU vs 10 min Repf: 
1.22±0.08 AU; P<0.05) levels at 10 minutes reperfusion (Figure 3.19). An observation that linked 
nicely with the increases observed at 20 minutes GI, but for the fact that both proteins were 
present at control levels at 5 minutes reperfusion – an observation which is very difficult to explain.  
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Figure 3.20 shows the posttranslational modifications of PP2A-C at the onset of reperfusion in the 
original experiment. Five minutes reperfusion was associated with a robust increase in both 
phosphorylation (absolute levels: Control: 1.00±0.11 AU vs 5 min Repf: 1.52±0.09 AU; P<0.05; 
relative to PP2A-C: Control: 1.00±0.11 AU vs 5 min Repf: 1.86±0.16 AU, P<0.05) and 
nonmethylation (absolute levels: Control: 1.00±0.11 AU vs 5 min Repf: 1.67±0.11 AU; P<0.05, 
relative to PP2A-C: Control: 1.00±0.13 AU vs 5 min Repf: 2.00±0.17 AU; P<0.05). 
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The repetition of these reperfusion experiments in combination with later pharmacological studies 
however gave us the opportunity to pool our data in the same way as was done for 20 minutes GI. 
These results showed a much different picture regarding the fluctuations in total protein levels 
during the first 10 minutes of reperfusion. At 5 minutes reperfusion (Figure 3.21) there was a slight 
decrease in PP2A-A (Control: 1.00±0.02 AU vs 5 min Repf: 0.85±0.05 AU; P<0.01), with an 
associated increase in the ratio of PP2A-C to –A (Control: 1.00±0.03 AU vs 10 min Repf: 
1.13±0.06 AU; P<0.05). At 10 minutes reperfusion the pooled data showed no increase in PP2A-C 
or –A (Figure 3.22). This would indicate that following ischaemia there is a rectification in the levels 
of PP2A-C and –A back to control levels. The slight reduction in PP2A-A seen at 5 minutes 
reperfusion was possibly due to washout of cellular protein from damaged and dead cells following 
I/R. This might also explain the reduced PP2A-C and –A relative to 10 minutes reperfusion in the 
original data set (Figure 3.19). 
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Interestingly, despite the loss of differences in total protein in the combined data set, these 
posttranslational modifications are confirmed and even more evident in the larger group (Figures 
3.21 and 3.22). Five minutes reperfusion was associated with an increase in the relative degree of 
both phosphorylation (Control: 1.00±0.06 AU vs 5 min Repf: 1.74±0.12 AU; P<0.0001) and 
nonmethylation (Control: 1.00±0.08 AU vs 5 min Repf: 1.85±0.11 AU; P<0.0001), with 10 minutes 
reperfusion following exactly the same trend (relative phosphorylation: Control: 1.00±0.06 AU vs 10 
min Repf: 1.30±0.10 AU; P<0.05, and relative nonmethylation: Control: 1.00±0.05 AU vs 10 min 
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Repf: 1.21±0.07 AU; P<0.05). Our data therefore clearly illustrates a very robust pattern of 
phosphorylation and demethylation of PP2A at the onset of reperfusion. 
 
Having observed these changes in early reperfusion, raised the question as to the duration of 
these effects; will they still be evident at 30 minutes reperfusion? As shown on Figures 3.23 and 
3.24 these early reperfusion events were all absent by late reperfusion. In fact, at 30 minutes 
reperfusion there was a reduction in the ratio of PP2A-C/A (Control: 1.00±0.06 AU, and 10 min 
Repf: 0.93±0.03 AU vs 30 min Repf: 0.76±0.05 AU; P<0.05), indicating an excess PP2A-A for the 
available PP2A-C. Thirty minutes of reperfusion was also associated with a reduction in absolute 
phosphorylation of PP2A in comparison with 10 minutes reperfusion (10 min Repf: 1.00±0.12 AU 
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vs 30 min Repf; P<0.05), an effect not seen relative to total PP2A-C. It therefore seems as if all the 
measured parameters are nearing normal values again at 30 minutes reperfusion. 
 
Our results showed that sustained ischaemia and reperfusion exerted an effect on PP2A-C and 
PP2A-A levels, as well as the levels of phosphorylation and methylation of PP2A-C. Taking into 
account the fact that the regulation of PP2A is to a large degree dependent on the cellular 
localization of the enzyme, the question arose as to what is happening with regards to PP2A in 
different cellular fractions. 
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The cellular distribution and posttranslational modification of PP2A during 
ischaemia and reperfusion. 
To answer this question, tissues from control hearts and hearts exposed to different durations of 
ischaemia and reperfusion were lyzed and fractionated using differential centrifugation into three 
fractions: nuclear, cytosolic and membrane. Each fraction was then analysed using Western 
blotting for the same targets as described for the unfractionated samples. 
 
10 minutes global ischaemia 
At 10 minutes GI there was a pronounced increase in the levels of PP2A-C in the nuclear fraction 
(Control: 0.98±0.08 AU vs 10 min GI: 4.38±0.37 AU; P<0.0001), with a concomitant increase in 
PP2A-C/A (Control: 1.02±0.21 AU vs 10 min GI: 2.97±0.28 AU; P<0.001) indicating an extreme 
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accumulation of PP2A-C in the nuclear fraction in the absence of changes in PP2A-A; i.e. there 
was no accumulation of either the dimeric or trimeric forms of the enzyme (Figure 3.25).  
 
Although the absolute levels of phosphorylation (Control: 1.00±0.12 AU vs 10 min GI: 1.82±0.07 
AU; P<0.001) and nonmethylation (Control: 0.98±0.11 AU vs 10 min GI: 1.73±0.14 AU; P<0.01) 
increased in the nucleus, the elevation of PP2A-C was so great that the relative values were 
actually reduced (Phosphorylation: Control: 0.98±0.08 AU vs 10 min GI: 0.42±0.04 AU; P<0.0001; 
and nonmethylation: Control: 1.00±0.10 AU vs 10 min GI: 0.37±0.03 AU; P<0.0001). This means 
that the PP2A-C in the nucleus was not only not associated with PP2A-A, but it was also 
unphosphorylated and methylated (Figure 3.26).  
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These fluctuations in the nuclear fraction occurred in the absence of any changes in the levels of 
PP2A-C in the cytosolic and membrane fractions (Figures 3.27 – 3.30). In fact the only significant 
change was in the relative methylation of PP2A in the membrane fraction (Control: 1.00±0.07 AU 
vs 10 min GI: 1.27±0.07 AU; P<0.05).  
Stellenbosch University  http://scholar.sun.ac.za
- 97 - 
 
 
Stellenbosch University  http://scholar.sun.ac.za
- 98 - 
 
 
Stellenbosch University  http://scholar.sun.ac.za
- 99 - 
 
 
The question therefore arises where does the PP2A-C accumulating in the nucleus comes from? 
One possible explanation for why we did not see a reduction in any of the other fractions relates to 
the relative amounts of PP2A-C in the three fractions. Of the three fractions, under normal control 
conditions the nucleus contains by far the least amount of PP2A-C (pixels expressed relative to the 
amount of protein loaded onto SDS-PAGE: nucleus: 199.4±52.7 pixels/μg vs. cytosolic: 
4381.0±319.2 pixels/μg and membrane: 2710.0±472.2 pixels/μg; if expressed relative to the 
nucleus: 1.00±0.3 AU vs. cytosolic: 22.0±1.6 AU vs membrane: 13.6±2.4 AU, n=4; P<0.001). The 
implication of this is that a small reduction in the other fractions could lead to a massive increase in 
the relatively small pool present in the nucleus. Keeping this in mind, it is noteworthy that 10 
minutes GI was associated with a borderline significant reduction in PP2A-C levels in the 
membrane fraction (Figure 3.29: Control: 0.98±0.17 AU vs. 10 min GI: 0.62±0.03 AU; P=0.0647), 
thereby identifying the membrane as a possible contributor to the accumulated PP2A-C pool in the 
nucleus. 
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15 minutes global ischaemia 
 
Only 5 minutes later the large increase of PP2A-C observed in the nucleus at 10 minutes GI had 
disappeared (Figure 3.31). Phosphorylation and methylation of PP2A also show no deviation from 
control values at this time (Figure 3.32).  
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In contrast to this inactivity in the nuclear fraction there is a significant increase in the levels of 
PP2A-C in the cytosolic fraction (Control: 1.02±0.03 AU vs 15 min GI: 1.22±0.04 AU; P<0.01), 
although not enough to cause a shift in the PP2A-C/A value (Figure 3.33). This increase in PP2A-C 
in the cytosol is associated with a reduction in phosphorylation (absolute phosphorylated: Control: 
1.00±0.18 AU vs 15 min GI: 0.38±0.11 AU; P<0.05; and phosphorylated relative to total: Control: 
1.02±0.18 AU vs 15 min GI: 0.30±0.08 AU; P<0.01), implying that the PP2A-C present in the 
cytosol is predominantly active (Figure 3.34). 
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In the membrane fraction (Figure 3.35) we unexpectedly saw a significantly higher signal for β-
Tubulin in the ischaemic group than in the control group (Control: 1.00±0.11 AU vs 15 min GI: 
1.45±0.05 AU; P<0.01). The explanation for this anomaly is unknown and might simply be due to a 
miscalculation concerning protein content in the final lysates. Irrespective of the reason, it 
necessitated us to recalculate our total PP2A-A and –C data by expressing them relative to β-
Tubulin (Figure 3.36). This adjustment of the data revealed a borderline significant reduction in 
PP2A-A (Control: 1.07±0.30 AU vs 15 min GI: 0.46±0.03 AU; P=0.09) which contributed to a 
significant increase in the ratio of PP2A-C to –A (Control: 1.04±0.07 AU vs 15 min GI: 1.84±0.15 
AU; P<0.01).  
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This shift in relative total protein values was not associated with any change in posttranslational 
modification (Figure 3.37). Adjustment of the phosphorylated and nonmethylated data for β-Tubulin 
and then expressing that data relative to β-Tubulin adjusted PP2A-C values did not alter the 
relative differences between control and 15 minutes GI, since both PP2A-C and the relevant 
modification is expressed relative to the same value (β-Tubulin). 
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20 minutes global ischaemia 
Although 20 minutes GI did not influence total PP2A-C and PP2A-A in the nuclear fraction (Figure 
3.38), it was associated with a significant increase in the value of PP2A-C relative to PP2A-A 
(Control: 1.00±0.08 AU vs 20 min GI: 1.38±0.13 AU; P<0.05). This shift was associated with a 
reduction in nonmethylated signal (absolute nonmethylated: Control: 1.03±0.03 AU vs 20 min GI: 
0.60±0.07 AU; P<0.01; and relative to total PP2A-C: Control: 0.98±0.05 AU vs 20 min GI: 
0.68±0.09 AU; P<0.05), as well as an increase in the absolute phosphorylation values (Control: 
1.00±0.25 AU vs 20 min GI: 1.81±0.16 AU; P<0.05) (Figure 3.39).  
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In the cytosolic fraction, similarly to the nuclear fraction, there was an increase in the PP2A-C/A 
ratio (Control: 1.00±0.04 AU vs 20 min GI: 1.35±0.13 AU; P<0.05) in the absence of changes in 
either PP2A-C or PP2A-A alone (Figure 3.40). In contrast to the nuclear fraction though, this 
occurred in the absence of any posttranslational modifications (Figure 3.41). 
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There were no changes in the membrane fraction (Figures 3.42 and 3.43), except for a reduction in 
the nonmethylated signal (absolute nonmethylated: Control: 1.00±0.06 AU vs 20 min GI: 0.60±0.06 
AU; P<0.01; and relative to total PP2A-C: Control: 1.03±0.10 AU vs 20 min GI: 0.78±0.04 AU; 
P<0.05). 
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5 minutes reperfusion 
Contrary to expectation, not many of the parameters measured changed at this timepoint (Figures 
3.44, 3.47 and 3.48). There was an increase in the phosphorylation of PP2A-C in the nuclear 
(Figure 3.45, phosphorylation relative to PP2A-C: Control: 1.00±0.09 AU vs 5 min Repf: 1.37±0.07 
AU; P<0.05), as well as the membrane (Figure 3.49, phosphorylation relative to PP2A-C: Control: 
1.00±0.05 AU vs 5 min Repf: 1.41±0.08 AU; P<0.01) fractions. This indicates a probable reduction 
in PP2A activity in these two compartments. 
 
Interestingly, the increase in PP2A-C/A observed in the cytosolic fraction at 20 minutes GI was 
maintained at 5 minutes reperfusion (Figure 3.46, Control: 1.00±0.03 AU vs 5 min Repf: 1.12±0.02 
AU; P<0.01). 
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10 minutes reperfusion 
Even at 10 minutes reperfusion the shift in the levels of PP2A-C relative to PP2A-A was still 
evident in the cytosolic fraction (Figure 3.52; Control: 1.00±0.03 AU vs 10 min Repf: 1.17±0.05 AU; 
P<0.05), in the absence of any posttranslational modifications (Figure 3.53). The observed 
increase in phosphorylation in the nuclear fraction at 5 minutes reperfusion was however 
dissipated at 10 minutes reperfusion, indeed there were no significant alterations concerning any of 
the measured parameters in the nuclear fraction at this time (Figures 3.50 and 3.51). 
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The methylation pattern in the membrane fraction had switched around from a reduced 
nonmethylation signal at the end of ischaemia, to an increase in nonmethylation at 10 minutes 
reperfusion (Figure 3.55, Control: 1.00±0.13 AU vs 10 min Repf: 1.5±0.14 AU; P<0.05). This 
change was not associated with any changes in total protein or PP2A-C/A (Figure 3.54).  
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Discussion 
In this part of the study we endeavoured to describe the changes in PP2A levels, phosphorylation 
and methylation during the latter half of a severe ischaemic episode, as well as during the first 
moments of reperfusion. We decided to investigate the latter half of our experimental ischaemic 
exposure, since we expected to see the most outspoken response of PP2A to ischaemia within 
that time frame. Early reperfusion was of interest since it presents a clinically relevant period which 
has been associated with the genesis of reperfusion injury and as such, could be exploited as an 
opportunity for a cardioprotective intervention.  
 
We used two very different models of I/R injury in our investigation: a cell-based model, as well as 
an isolated perfused rat heart model. The rationale behind this was to establish if a common 
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pattern could be observed in both models. The dynamics of these models are very different with 
regards to energy homeostasis and cellular proliferation.  
 
The isolated heart has the ability to contract and perform work, which implies a high metabolic 
demand, while the cell model we used was a myoblast model of cardiac origin which does not 
contract or beat and therefore has a much lower metabolic demand. These differences in energy 
demand were especially evident with regards to the duration of ischaemia which was necessary to 
inflict damage: 20 minutes GI and 35 minutes RI for the isolated heart preparation versus 2 hours 
SI in the cell model.  
 
The continual proliferation of the H9c2 cells could also be a confounding factor in our project, since 
PP2A has been found to be involved in the regulation of the transition into and out of mitosis. A 
detailed discussion of the participation of PP2A in the cell cycle falls outside the scope of this 
thesis, but in brief: It has been observed as early as 1989 that the addition of OA to proliferating 
cells can lead to the premature initiation of mitosis (Picard et al., 1989), implicating PP1 and PP2A 
in the regulation of the transition into mitosis. Since then it has become clear that the transition into 
and out of mitosis is dependent on the activation of several kinases, of which cyclin-dependent 
protein kinase (Cdk1) is one of the most important (Hunt, 2013). This dependence on 
phosphorylation events, just as with intracellular signalling as dealt with in this text, implies the 
presence of phosphatase activity. Although several phosphatases are possibly involved, PP2A has 
emerged as a negative regulator of the transition into mitosis and has also been implicated in 
mediating the departure from mitosis (Jansens & Goris, 2001; Kurimchak & Graña, 2012; Hunt, 
2013). This participation in the regulation of the cell cycle is therefore a role fulfilled by PP2A in the 
H9c2 cell line, but not in adult heart tissue, and as such poses a potential complicating factor in the 
comparison of our H9c2 and isolated heart results. However, for these experiments, we only 
exposed near confluent H9c2 cells to a relatively brief SI intervention. Taken together, these two 
precautionary measures should have minimized the effects of the cell cycle per se on our results. 
Any possible remaining confounding effect that the cell cycle might still have was controlled for by 
the control group. We therefore believe that cell cycle progression exerted a nominal effect on our 
results. 
 
Determination of protein levels and posttranslational modification (i.e. phosphorylation and 
methylation) was done using standard Western Blotting techniques. Posttranslational modification 
was expressed both in absolute terms, as well as relative to total PP2A-C levels – since we 
considered both these values as informative. Use of an antibody specific for phosphorylated PP2A-
C indicates changes in the actual levels of phosphorylation (the absolute values), and if the 
principles of Western Blotting hold (i.e. immunology-mediated recognition of a specific protein or 
modified protein), we must accept this. Expressing it as a ratio to PP2A-C gives us an additional 
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vantage point: it allows us to ‘correct’ for any possible changes in PP2A-C and it reveals the 
relative degree of phosphorylation of the intracellular pool of PP2A-C. The dissociation between 
these two values with which we are sometimes confronted (for example a reduction in absolute 
phosphorylation with no change in the relative degree of phosphorylation) is problematic, but could 
be due to small fluctuations in the intracellular content of PP2A-C or due to the lack of precision 
associated with Western Blotting.  
 
Although the use of immunological techniques to investigate proteins is a powerful approach which 
allows for a high degree of sensitivity, laboratory experience has shown that Western Blotting lacks 
precision (i.e. repeatability). Possibly its high sensitivity makes it more prone to confounding 
influences during the experimentation process. In this sense Western blotting can be likened to 
using an ultrasensitive scale on a rickety old wooden bench in the middle of an undergraduate 
laboratory. This must be kept in mind when interpreting results, as it implies that we are looking for 
trends and not absolutely rigid data. Irrespective the reason, the lack of an observed change in 
phosphorylation relative to total levels, is indicative of a relatively small change which lacks 
robustness – yet it hints at a change in phosphorylation which cannot be ignored. I will follow this 
rationale to interpret Western Blotting data throughout this thesis. 
 
We hypothesized that as ischaemia progresses PP2A activity will remain stable, or possibly 
increase during the later periods of ischaemia in association with a global cellular reduction in ATP 
levels. Reperfusion would however reverse this by inducing a reduction in PP2A activity. Since 
methylation of PP2A-C is closely linked to its substrate specificity and subcellular distribution, we 
also expected to see changes in methylation as ischaemia progresses followed by a reversion 
back to pre-ischaemic patterns during reperfusion, although the timeframe for this possible return 
to baseline is unknown. Previous work done in our laboratory had found that kinase 
phosphorylation had returned to control levels at 30 minutes reperfusion in the isolated rat heart 
exposed to 20-35 minutes ischaemia. It is therefore very probable that PP2A would also return to 
its control-levels and distribution at this time. 
PP2A in unfractionated “complete cell” preparations 
Data from the H9c2 cell model 
The most interesting observation made in this model of ischaemia was the transient reduction in 
total PP2A-A levels at 60 minutes of SI (Figure 3.6) and again at 15 minutes reperfusion following 
120 minutes SI (Figure 3.12). This suggests that in the relatively early stages of a stress situation, 
either ischaemia or reperfusion, a shift in the balance between the synthesis and degradation of 
PP2A-A occurs. A reduction in PP2A means that either the rate of synthesis was inhibited, or the 
rate of degradation was increased. PP2A-A is a relatively stable protein with a half-life of 
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approximately 10 hours (Zhou et al., 2003). This being said, there was an increase in the levels of 
PP2A-C relative to PP2A-A at 60 minutes SI (Figure 3.6), which was also associated with a 
reduction in the methylation of PP2A-C. Taken together this could indicate a dissociation of the 
PP2A dimer or trimer, with PP2A-C being demethylated and stabilised in association with another 
molecule – possibly α4, which preferentially binds to nonmethylated PP2A-C thereby stabilizing 
and inactivating it (Chung et al., 1999; Kong et al., 2009; McConnel et al., 2010). Since assembly 
into the dimer or trimer stabilizes the different components of PP2A (Silverstein et al., 2002), the 
dissociated PP2A-A would then become unstable and be broken down - as has been shown to 
happen with PP2A-C, B and B’ in the absence of PP2A-A (Strack et al., 2004).  
 
Intriguingly a similar pattern was seen at 120 minutes SI: an increase in PP2A-C/A in association 
with a reduction in non-methylated PP2A-C levels (Figures 3.10 & 3.11). Although these shifts are 
statistically significant, their magnitude and physiological importance may be doubtful, since these 
changes were not observed at 90 minutes SI and the PP2A-C/A shift at 120 minutes SI was not 
accompanied by a reduction in PP2A-A nor was the nonmethylation signal statistically elevated 
when expressed relative to PP2A-C. Inversely, the reduction in PP2A-A at 15 minutes reperfusion 
did not lead to a change in PP2A-C/A at that time, nor was it associated with a change in 
methylation status.  
 
If the above theory is however true, then the observed reduction in PP2A-A is due to an increase in 
degradation, rather than reduced synthesis.  
 
The absolute levels of PP2A-C phosphorylation was reduced at 15 minutes reperfusion (Figure 
3.13), indicating a surprising increase in PP2A activity in early reperfusion. Although the ratio of 
phosphorylated PP2A-C to total PP2A-C did not change at 15 minutes, the observation of an 
increase in phosphorylation must not be ignored, since it indicates a slight increase in PP2A 
activity.  
 
At 30 minutes reperfusion though, all the parameters investigated seem to have returned back to 
pre-ischaemic (i.e. control) patterns (Figures 3.14 and 3.15). This means that in this model of I/R 
injury PP2A does not participate in the more long term consequences of I/R. 
Conclusion 
In the H9c2 cardiomyoblast cell line PP2A is already implicated in its stress response at 60 
minutes simulated ischaemia. After 30 minutes of reperfusion, following 2 hours of SI, PP2A levels 
and its posttranslational modifications return to control values. There are four noteworthy results / 
trends that we see in these experiments: (1.) the stability of PP2A-A levels are reduced during both 
ischaemia and reperfusion; (2.) The ratio of PP2A-C to PP2A-A levels increases during ischaemia; 
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(3.) the methylation of PP2-C is reduced during ischaemia; and (4.) phosphorylation of PP2A is 
reduced in early reperfusion. Taken together our results implicate the involvement of PP2A, 
especially during ischaemia, with regards to changes in methylation associated with changes in 
PP2A enzyme assembly. This has certain, unknown, implications for the cellular distribution and 
substrate targeting of PP2A. As proposed, ischaemia did not influence PP2A activity, although 
early reperfusion was associated with a slight reduction in PP2A phosphorylation – suggesting an 
increase in PP2A activity. 
Data from the isolated rat heart 
We were very surprised by the increase we saw in PP2A-C and PP2A-A levels at 20 minutes of GI 
in comparison to even 10 minutes GI (Figure 3.16). We therefore decided to strengthen our 
statistical analysis by increasing the n-value. Throughout this project we repeated these protocols 
in conjunction with pharmacological based studies (Chapters 4 and 5). This worked in our favour, 
because it meant that we had data collected over a period of  approximately 4 years and spanning 
3 different experiments which we could pool, thereby strengthening our results. After normalizing 
all data obtained to the common control condition, subsequent analysis showed that PP2A-C levels 
were indeed elevated at 20 minutes GI, in contrast with PP2A-A (Figure 3.18).  
 
In the original study this elevation was temporarily suppressed at 5 minutes reperfusion and then 
re-emerged at 10 minutes reperfusion – a pattern which was extremely surprising. This sudden 
reduction in total PP2A-C and PP2A-A could be explained by the wash-out of cellular content 
released from damaged and dead cells in the first minutes of reperfusion. The ensuing increase 
which was measured at 10 minutes reperfusion was however extraordinarily rapid. In light of these 
unlikely results, we therefore also followed the same rationale as for the 20 minutes GI data and 
pooled all our available reperfusion data from other experiments (Figures 3.21 and 3.22). This 
showed a much more probable normalisation of the 20 min GI elevated PP2A-C back to control 
levels at 5 minutes reperfusion (possibly accelerated by the washout of cellular content) which then 
remained stable at 10 minutes reperfusion. PP2A-A actually showed a significant, but very 
transient, dip in its levels at 5 minutes reperfusion. By 10 minutes reperfusion both PP2A-C and –A 
levels had returned to control levels and remained there at 30 minutes reperfusion. 
 
We therefore clearly found that especially ischaemia induced changes in the total levels of PP2A-C 
and PP2A-A. This was surprising taking into account the rate at which it happened, with the 
changes reaching significance within 10-20 minutes. It has been shown that PP2A-C levels are 
maintained within very narrow limits by an autoregulatory mechanism (Baharians et al., 1998) 
resisting overexpression, which make our results even more surprising. However, others have also 
shown that hypoxia or ischaemia is associated with an increase in cellular PP2A: Larsen et al. 
(2008) found that chronic exposure (14 days) to hypoxic conditions (10% oxygen) led to an 
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increase in PP2A-C mRNA levels in the left ventricles of C57Bl/6j mice; while Totzeck and 
colleagues (2008) showed that PP2A-A expression was increased by 154% in the hearts of 
minipigs exposed to 85 minutes of low flow ischaemia. Although these studies differ from our 
experiments with regards to animal species tested, as well as the nature of ischaemia / hypoxia 
applied, they both illustrate that it is conceivable for PP2A to be upregulated during exposure to 
ischaemia.   
 
How is this rapid increase in protein levels accomplished? Such an elevation must be due to either 
an increase in the synthesis or a reduction in degradation of PP2A-C. PP2A-C has been reported 
to have a half-life of 13 – 16.5 h (Lizotte et al., 2007; Baharians et al., 1998) making it a very stable 
protein, with rates of synthesis and degradation probably being quite low. The rate at which these 
changes in our experiments occurred favours a protein degradation mechanism, i.e. either 
proteasomal degradation or autophagy, where ischaemia exerts an inhibitory effect on the 
degradation of PP2A-C. As reported in Chapter 1, ischaemia has been shown to be associated 
with an increase in the occurrence of autophagy (Hamacher-Brady et al., 2006; Matsui et al., 2008; 
Nishida et al., 2009). It is therefore unlikely that autophagy is involved in the modulation of PP2A-C 
levels which we observed. Myocardial ischaemia however does induce proteasomal dysfunction, 
specifically the ubiquitin proteasome system (UPS) develops a diminished ability to process 
ubiquitinated proteins – i.e. proteins tagged for proteolysis are not degraded (Calise & Powell, 
2013). As mentioned previously, through its association with α4 and MID-1 PP2A-C can be 
ubiquitinated and possibly, though not necessarily, be broken down as a result (Trockenbacher et 
al., 2001; McConnell et al., 2010). There is however a major flaw in this theory, namely that it 
seems as if the autoregulation of PP2A under normal conditions relies more on regulation of the 
translational processing of PP2A, than the turnover thereof (Baharians & Schöntal, 1998). This 
idea was later confirmed by Wei et al. (2006) who reported that inhibition of the proteosomal 
system does not influence the levels of either total PP2A-C or PP2A-A. Lizotte et al. (2007) 
however reported that 12 hours of incubation with a proteasome inhibitor led to the accumulation of 
especially mono-ubiquitinated PP2A-C, indicating the potential relevance of the proteosomal 
system in regulating PP2A-C levels. Mono-ubiquitinated PP2A-C has a molecular weight of 44 
kDa, we however did not see such a band in our blots. In conclusion, it is therefore theoretically 
possible that the reduced UPS activity associated with ischaemia could favour an increase in PP2A 
levels, although the contribution of this to the significant increase in PP2A-C that we observed is 
unknown. 
 
By process of elimination this leaves us then with a mechanism entailing an increase in the 
synthesis of PP2A-C as ischaemia progresses. The question is however if an  increase in PP2A 
expression could occur within 20 minutes? In their study on the ability of the ob/ob mouse heart to 
be protected by postconditioning, Bouhidel and co-workers (2008) reported a PostC-mediated 
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significant increase in the levels of MKP-1 and PTEN only ten minutes  after the application of 
PostC. Lizotte and co-workers (2007) found that a significant amount of PP2A-C can be 
synthesised within 20 minutes. These studies therefore show that in principle it is possible that an 
increased expression of PP2A-C could explain the elevation observed at 20 minutes GI (Figures 
3.16 and 3.18) . This increase in synthesis must however be very transient, since we did not see a 
sustained elevation during reperfusion following 20 minutes GI (Figures 3.21, 3.22 and 3.23).  
 
In their characterization of PP2A in the heart, DeGrande and colleagues (2013) reported that both 
PP2A-C and PP2A-A were elevated 5 days after myocardial infarction in a canine model. This 
elevation was also present in human ischaemic heart failure models. Combination of our data and 
DeGrande’s results leads to the hypothesis  that ischaemia stimulates an increase in PP2A levels, 
which is then sustained during the development of heart failure. Our reperfusion results however 
contradict this model, exposing the gap in both studies – namely sufficient temporal 
characterization of PP2A. The elevation we observed is an acute response to ischaemic stress and 
damage. Their data encompasses not only I/R injury, but also the compensatory mechanisms 
involved in the development of heart failure after 5 days. However, no information is available 
concerning what happens to PP2A in the interim period between ischaemia and ischaemic heart 
failure. Our data suggest a transient reduction in PP2A. 
 
An increase in cellular PP2A-C content does not necessarily imply an increase in the activity of the 
enzyme. We found that at the end of sustained ischaemia there was an increase in the absolute 
levels of PP2A-C phosphorylation (Figures 3.17 and 3.18). This increase was however due to the 
accompanying increase in PP2A-C levels, as evident by the unchanged phosphorylated to total 
PP2A-C ratio. This means that in absolute terms there was an increase in PP2A activity as 
ischaemia progressed, coupled to the increase in PP2A-C levels. The onset of reperfusion 
however definitely inhibited PP2A activity as seen by the increase in PP2A-C phosphorylation 
relative to the total population of enzyme at 5 and 10 minutes reperfusion (Figures 3.20, 3.21 and 
3.22). This increase was however dissipated after 30 minutes of reperfusion (Figure 3.24). In 
summary, our data show that as ischaemia progresses PP2A-C levels increase, in conjunction with 
an increase in activity (dephosphorylated enzyme), which is then inhibited by early reperfusion. 
 
Although the original experiments showed a change in the methylation of PP2A-C relative to total 
PP2A-C (Figure 3.17) a much more pronounced trend was exhibited by the pooled data (Figure 
3.18). Here we see that sustained ischaemia favours demethylation of PP2A-C, as determined by 
an antibody which recognizes nonmethylated PP2A-C. This change in methylation pattern is 
indicative of changes in holoenzyme assembly, subcellular distribution and substrate specificity. In 
relation to this it is noteworthy that this increased demethylation was associated with an increase in 
the PP2A-C/A ratio, indicating a possible dissociation between PP2A-C and PP2A-A. Such a 
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dissociation might explain the slight reduction in total PP2A-A at 5 minutes reperfusion (Figure 
3.21). This same methylation pattern was observed during reperfusion, in the absence of an 
increased PP2A-C/A ratio at 10 minutes reperfusion. Fluctuations in methylation were however 
abolished at 30 minutes reperfusion. 
In conclusion 
Our data clearly implicates PP2A as a participant in the processes involved with I/R, since both the 
expression and posttranslational modification of PP2A were altered by ischaemia, as well as early 
reperfusion. At the end of 20 minutes GI both PP2A-C and PP2A-A levels were significantly 
elevated in the isolated heart model. This elevation was very specific for ischaemia, since it 
dissipated during reperfusion. The increase in PP2A levels was also associated with an almost 
matched increase in phosphorylation (i.e. reduced activity) and reduction in methylation, along with 
an increase in the ratio of PP2A-C to PP2A-A. Early reperfusion was also characterized by an 
increase in phosphorylation which implies a reduction in PP2A activity. 
 
Having summarized our results from both the H9c2 cells exposed to SI and the isolated rat heart 
undergoing 20 minutes GI, the next section will focus on the combination of these two. 
What does the combination of the H9c2 cell and isolated rat heart models 
reveal? 
Protein levels of PP2A-C and PP2A-A 
These two models showed different responses regarding protein levels during I/R. The H9c2 cells 
revealed an unstable PP2A-A subunit which tended to be present at reduced levels, while the 
isolated heart exhibited an increase in the PP2A-C subunit. Pooling of the perfusion data also 
showed a reduction in PP2A-A levels at 5 minutes reperfusion, similar to the reduction seen in the 
H9c2 cells at 15 minutes reperfusion. In both models PP2A-A returned to normal levels with 
prolonged reperfusion. Not much is known concerning the dynamics of the PP2A-A subunit in the 
heart. Penna et al. (2011) reported that PostC reduced PP2A-A levels as measured at 60 minutes 
reperfusion. Unfortunately they did not include a non-ischaemic group for comparison. Although 
their data shows a reduction at a different timepoint than ours, it does illustrate that the levels of 
the A subunit are dynamic in the heart and that its reduction during reperfusion could be beneficial. 
Possibly the reduction observed could be part of the pro-survival cascades activated in the heart 
cells in response to I/R. 
 
These observed differences between the H9c2 cells and the isolated rat heart can obviously be 
ascribed to differences between these two models – and there are outspoken differences. H9c2 
cells are very different from the beating heart in terms of susceptibility to ischaemic damage, 
metabolic requirements, exposure to inflammatory mediators, contractile characteristics and 
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proliferation. It would therefore be interesting, and possibly more informative, to also characterize 
PP2A in freshly isolated cardiomyocytes exposed to I/R. 
 
It is however fascinating that despite these differences in total protein levels a similar trend can be 
seen in both models: ischaemia is associated with an increase in the ratio of PP2A-C to PP2A-A 
(Figures 3.6, 3.10, 3.16 and 3.18), which is abolished during reperfusion in the H9c2 cells, and 
from 10 minutes reperfusion onwards in the heart tissue. In fact there is a reduction in the ratio at 
30 minutes reperfusion in the isolated organ model. This would indicate an increase in PP2A-A 
relative to PP2A-C, and at 30 minutes reperfusion might be due to a residual over-correction of 
PP2A-C levels. Since PP2A-A is unstable if not incorporated into the PP2A holoenzyme 
(Silverstein et al., 2002), it would be interesting to see if this reduction in ratio persists following a 
longer period of reperfusion.  
PP2A-C methylation 
Not only were there similarities regarding the ratio of PP2A-C to PP2A-A, but the associated 
methylation pattern was also comparable. Whenever we see an increase in the ratio of PP2A-C/A 
in both models, there is also an accompanying increase in at least absolute measured 
nonmethylation (Figures 3.11 and 3.17), if not the ratio of nonmethylated to total PP2A-C as well 
(Figures 3.7, 3.18 and 3.21). Although there are instances when the nonmethylated signal 
increased in the absence of changes in PP2A-C/A, it is very tempting to speculate that these two 
observations are linked, especially since methylation influences enzyme assembly and a shift in 
PP2A-C/A could be an indication of trimer disassembly. Disregarding the possible link between 
PP2A-C/A and methylation, our data shows that ischaemia is associated with a reduction in 
methylation (increase in nonmethylation) in both the H9c2 cells, as well as isolated heart tissue. In 
our ex vivo rat heart preparation we also found that this reduction in methylation persisted for at 
least the first 10 minutes of reperfusion. 
 
To my knowledge nothing is known regarding methylation in the heart exposed to I/R. Consistent 
with ischaemia inducing PP2A demethylation, Lee and co-workers (2013) found that an 18 hour 
exposure of a neuroblastoma cell line to a mitochondrial complex I inhibitor, MPP+ (1-methyl-4-
phenylpyridinium), led to the demethylation of PP2A. In agreement with our tissue reperfusion 
data, De la Vega and colleagues (2002) also reported reperfusion-associated demethylation of 
PP2A in an in vivo rat model of induced forebrain ischaemia and reperfusion. They also reported 
that methylation of PP2A-C was associated with the formation of the trimeric holoenzyme. As 
discussed previously, this is dependent on the type of B-subunit present. Interestingly, and 
contradictory to our data, Benziane et al. (2012) found that the activation of AMP-activated protein 
kinase (AMPK) induced the methylation of PP2A in L6 myotubes. Since AMPK activation is also a 
feature of ischaemia (Hopkins et al., 2002; Hardie, 2004), this implies that PP2A might be 
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methylated due to activated AMPK during ischaemia. However, as already discussed in Chapter 1, 
ischaemia is much more complex than just one kinase. 
PP2A-C phosphorylation 
We hypothesised that the activity of PP2A will either remain the same, or increase, as ischaemia 
progresses, followed by a reduction in activity at the onset of reperfusion. We utilized tyr307 
phosphorylation of PP2A as a readout of its activity, since it has been reported that the activity of 
PP2A is reduced in conjunction with phosphorylation of this residue (Chen et al., 1992).  
 
This expectation was met in the H9c2 cell model, where SI failed to elicit any response with 
regards to the phosphorylation of PP2A-C. Only at 15 minutes reperfusion a reduction in the 
absolute levels of phosphorylated PP2A-C was seen (Figure 3.13) which might imply an 
unexpected increase in activity during reperfusion. The physiological impact of this increase is 
uncertain, since it was not robust enough to change the level of phosphorylation relative to total 
PP2A-C. The heart tissue, on the other hand, revealed an increase in absolute phosphorylation at 
20 minutes GI (Figure 3.18), which persisted and increased in strength into early reperfusion so 
that the ratio of phosphorylated to total PP2A-C also increased (Figures 3.21 and 3.22). This 
indicates a robust reduction in PP2A activity, which is unexpected at the end of ischaemia, but 
supports the suggestion that adaptive endogenous pro-survival kinase-mediated pathways 
dominate during early reperfusion (provided ischaemia was not too lethal). 
 
A literature search on the response of PP2A to I/R, yielded controversial results. On the one hand 
it has been found that the activity of PP2A increases during ischaemia (Kunjan et al., 2013) and 
also during reperfusion (Zhao et al., 2008), while others have found that these events inhibit PP2A 
(Ho et al., 2003; Zhu et al., 2012). All these studies however focussed on I/R of the brain where a 
wide variety of protocols were followed. Kunjan and colleagues (2013) found that PP2A was 
activated in isolated rat  hippocampal synaptosomes exposed to 60 minutes of oxygen and glucose 
deprivation; similarly Zhao et al. (2008) reported peak activation of PP2A at 1 hour reperfusion 
following 10 minutes of forebrain ischaemia in a rat model. On the other hand Ho and colleagues 
(2003) reported a reduction in PP2A activity in rat brains at 30 minutes reperfusion following 8 
minutes of asphyxia; while Zhu et al. (2012) noted a reduction in PP2A levels and activity 24 hours 
after a 1 hour occlusion of the middle cerebral artery in a rat model. There is however nothing 
known in the context of the heart. Studies done in the setting of oxidative stress have also reported 
that PP2A is either activated (Pham et al., 2000; Yasuoko et al., 2004; Liu & Hofmann, 2004) or 
inhibited (Zheng et al., 2003; Jung et al., 2013). 
 
It is very interesting to note that most of the changes observed at the end of ischaemia (increased 
nonmethylation, increased PP2A-C/A ratio and increased phosphorylation) persisted into 
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reperfusion and were not reversed by alleviation of ischaemia. It is possible that these changes are 
part of a general response to cell stressors, or it could be that the temporal dynamics of 
reperfusion extend past the timepoints which we investigated. 
Connecting the dots 
Although some of the data generated in the two experimental models differed from each other, the 
following model seems to emerge from the combination of these results (Figure 3.56): Especially 
during ischaemia the ratio of PP2A-C to PP2A-A increases, indicating that in comparison to control 
conditions there is an increase in PP2A-C relative to PP2A-A. Since they associate in a 1:1 ratio in 
both the core- and holoenzyme complexes, this indicates that there must be additional PP2A-C 
present in the cells. Although it seems that PP2A-A becomes unstable, especially during the onset 
of reperfusion – indicating the possible disassembly of the enzyme complex – there are no 
indications of a reduction in PP2A-C levels. This implies that PP2A-C must be binding to a 
stabilising factor. The reduction in methylation hints at the factors which might be involved. 
Demethylation itself will require association with PME-1. PME-1 has been shown to stabilise an 
inactive form of the enzyme, however it does not compete with PP2A-A for binding to PP2A-C. It 
therefore seems more likely that PP2A-C binds to α4. As already mentioned elsewhere, α4 
preferentially binds nonmethylated and dephosphorylated PP2A-C (Chung et al., 1999; Kong et al., 
2009; McConnel et al., 2010). This implies that the phosphorylated PP2A-C which we measured 
might be an inactive form of the core- or holo-enzyme, presenting yet another potential store of 
PP2A inside the cells. 
 
But why the association with α4? It could be part of a mechanism to transiently deactivate PP2A-C 
during ischaemia and especially reperfusion (linking with our phosphorylation data) without 
reducing its actual levels in the cell. Binding to α4 is in this sense ideal, since it could theoretically 
regulate the rate of degradation of PP2A-C (linking to the increase in PP2A-C which we observed 
in the heart tissue). It could also be that α4 targets PP2A-C to specific substrates and areas within 
the cell, without necessarily inactivating the enzyme.  
 
In view of the above, we speculate that cardiomyocytes keep a potentially inactive store of PP2A 
during I/R and that the degree and duration of ischaemia will influence the utilization of this store – 
possibly as ischaemia progresses and cells become committed to apoptosis these stores of PP2A-
C can be utilized to mediate the process.  
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In our experimental model, this inhibition of PP2A-C at the end of ischaemia and the onset of 
reperfusion could be beneficial, since it will allow the activation of cellular processes which are 
usually inactivated by PP2A-C, contributing to survival. 
 
In view of the reduction in methylation of PP2A-C during I/R, it is very possible that PP2A-C 
translocates inside the cells as ischaemia and reperfusion progress. To investigate the intracellular 
dynamics of PP2A-C, we also investigated its levels and posttranslational modifications in crude 
nuclear, cytosolic and membrane fractions. 
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The cellular distribution and posttranslational modification of PP2A 
during ischaemia and reperfusion. 
For these experiments we only used tissue collected from the isolated rat heart experiments to 
prepare nuclear, cytosolic and membrane fractions, in which we measured total PP2A-C, PP2A-A, 
nonmethylated PP2A-C and phosphorylated PP2A-C. We can therefore only speculate on the 
actual holoenzyme composition and substrate targeting in these different fractions. For a helpful 
review concerning the distribution of regulatory B subunits, as well as the factors involved in 
enzyme assembly, see Janssens et al. (2008). Each fraction will be discussed with regards to 
PP2A changes throughout the latter part of ischaemia, as well as early reperfusion. 
The nuclear fraction 
This fraction proved to be the most interesting fraction (at least at 10 minutes of GI). At this 
relatively early stage of ischaemia there was an accumulation of PP2A-C in the nucleus, 
associated with an increase in PP2A-C/A (Figure 3.25), absolute phosphorylation and 
nonmethylation. However the increase in total PP2A-C was of such a magnitude that most of the 
PP2A-C present was unphosphorylated and methylated (Figure 3.26).  
 
The increase in absolute phosphorylation and nonmethylation implies that a portion of the PP2A-C 
might be associated with either α4, or PME-1. This is an attractive idea, since it explains why we 
did not measure a similar increase in PP2A-A. PME-1 has been shown to be abundant in the 
nucleus (Longin et al., 2008), while α4 has been implicated in targeting PP2A to the nucleus 
(Fielhaber et al., 2009). However, the majority of the accumulated PP2A-C seems to be methylated 
(Figure 3.26) – thereby excluding PME-1 and α4 as possible binding-partners. There are also no 
indications of an accumulation of a matching amount of PP2A-A for the formation of a canonical 
holoenzyme. This implies an association with an unknown binding-partner besides PP2A-A, α4 or 
PME-1. The endogenous inhibitors of PP2A, I1PP2A and I2PP2A can both be localised to the nucleus 
(Santa-Coloma, 2003). This means that even some of the unphosphorylated PP2A-C might be 
inactive. It has been shown that I2PP2A can also bind PP2A-C alone (Li et al., 1996). Our data 
therefore indicates an accumulation of PP2A-C in the nucleus, probably bound to several scaffolds 
(methylated to PP2A-A, nonmethylated to α4) and inhibitors (α4, PME-1, I1PP2A or I2PP2A).  
 
Concerning the portion of PP2A-C assembled with PP2A-A into a holoenzyme, the presence of 
such a large proportion of methylated PP2A-C suggests that the holoenzyme will probably also 
contain B/PR55 regulatory subunits, which can target PP2A to the nucleus. Other regulatory 
subunits which have been found in the nucleus (B’’/PR72 and B’ / B56γ and B56δ) are not as 
methyl-dependent as B/PR55. B/PR55 also preferentially binds unphosphorylated PP2A-C, 
therefore implicating it even further.  
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Such a transient accumulation must have some functional implications inside the cell. Several 
possible targets for PP2A inside the nucleus have been identified. Zhou and colleagues (2007), 
following a proteomic approach to identify some of the binding-partners of B56γ1, identified 
approximately 16 binding-partners located in the nucleus. Firulli et al. (2003) reported that PP2A 
was involved in the dephosphorylation of the transcription factor HAND1, while Ling et al. (2012) 
recently showed that PP2A can interact with and dephosphorylate histone deacetylase 4. It is 
therefore very conceivable that PP2A accumulation in the nucleus will contribute to the regulation 
of nuclear function and transcription, possibly as part of a relatively early adaptive response to 
ischaemia. 
 
At 15 minutes GI the accumulation of PP2A-C was abolished and no changes relative to control 
were measured (Figures 3.31 and 3.32). Late in ischaemia the absolute phosphorylation of PP2A-
C increased (Figure 3.39) indicating a reduction in activity which becomes more robust at 5 
minutes reperfusion (Figure 3.45). By 10 minutes reperfusion all parameters measured in the 
nucleus are comparable to control levels. 
 
In summary: In the first half of ischaemia (after 10 minutes GI) PP2A is part of a nucleus-based, 
probably transcription-related, response to ischaemia. This raises the question whether PP2A is in 
some or other way also involved in late preconditioning (SWOP) which is dependent on protein 
expression to mediate its protective effects. This initial response is however soon replaced by the 
inhibition of PP2A-C later in ischaemia and at the very early stages of reperfusion (5 minutes) – 
similar to the trend observed in the “complete cell” unfractionated preparations. 
The cytosolic fraction 
It is only at 15 minutes GI that a response to ischaemia was seen, which was in the form of an 
increase in total PP2A-C (Figure 3.33) with an associated reduction in phosphorylation (Figure 
3.34). There was no increase in the ratio of PP2A-C to PP2A-A. Taken together, this implies an 
increase in active PP2A-C in the cytosol. Almost all of the regulatory subunits have been found to 
be present in the cytosolic fraction, including B/PR55, B’’/PR72 and B’/PR61. Since we did not see 
any changes in methylation, it does not give us information regarding the identity of the specific 
regulatory subunit(s) involved. 
 
For all the other time periods investigated, no evidence for any form of posttranslational 
modification was obtained. Interestingly, despite the absence of changes in methylation, a 
consistent increase in the PP2A-C/A ratio during both ischaemia and reperfusion was observed.  
 
In summary, it seems as if the nuclear accumulation of PP2A-C at 10 minutes GI is followed by an 
increase of PP2A-C in the cytosolic fraction at 15 minutes GI. For the rest of the experimental 
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duration there is, possibly, a residual increase in the amount of PP2A-C relative to PP2A-A. This 
small portion of excess PP2A-C will necessarily have to be bound to α4. In the absence of 
changes in posttranslational modification we cannot speculate on which binding partners are 
involved. Initially most of the PP2A-C present is in an active form, although as ischaemia 
progresses and during early reperfusion the levels of phosphorylation do not differ from the control 
levels.  
The membrane fraction 
At 10 minutes GI there is a borderline reduction in PP2A-C levels (Figure 3.29), suggesting that 
some of the PP2A-C accumulated in the nucleus at this time might have originated from the 
membrane fraction. As explained in the results section, the cytosolic and membrane fractions 
contain much larger amounts of PP2A-C than the nucleus, so that small changes in these fractions 
could be associated with a major change in PP2A levels in the nucleus.  
 
The level of methylation fluctuates substantially during I/R; at 10 minutes GI there is a reduction in 
methylation, at 20 minutes GI an increase in methylation and then again a reduction at 10 minutes 
reperfusion. This suggests possible movements of PP2A-C between different regulatory subunits. 
B/PR55 is methyl-dependent and has been described in association with a membrane fraction, 
while the other membrane associated subunit, B’/PR61, has been found associated with both 
methylated and nonmethylated PP2A-C. If PP2A-C is indeed being shuttled between regulatory 
subunits, a very dynamic regulatory system must be at work here. 
 
Following the same trend as the unfractionated samples and the nuclear fraction, the 
phosphorylation of PP2A increases at 5 minutes reperfusion; suggesting the inhibition of PP2A 
during early reperfusion. 
Connecting the dots 
Our data indicate that PP2A participates in a relatively early nuclear response to sustained 
ischaemia, as evident by an accumulation of especially dephosphorylated, methylated PP2A-C in 
the nucleus. Following this accumulation, PP2A-C translocates away from the nucleus towards the 
cytosol. The cytosol is the compartment which contains the most PP2A, and it is in this 
compartment where we see an increased ratio of PP2A-C to –A from 20 minutes GI, continuing 
through 5 and 10 minutes reperfusion. This links with the increased ratio observed in the 
unfractionated preparations. Contrary to expectations, we did not observe the same associated 
changes in methylation, as was the case for the unfractionated samples. In fact, we failed to pin 
down the position of the nonmethylated PP2A-C which we found to be abundant in the “whole cell” 
preparations. At 20 minutes GI and especially 5 minutes reperfusion it seems that most of the 
phosphorylated PP2A-C is localized in the nuclear, as well as the membrane fractions. 
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Given the obvious differences in the preparation of the fractionated versus the unfractionated 
samples, the fact that each fraction contributes differently to the total pool of PP2A and the 
additional complexity due to the increase in PP2A-C levels and reduction in PP2A-A levels at 5 
minutes reperfusion in the unfractionated preparations, it is not surprising that there are differences 
between these data sets which we cannot explain. 
 
Although the membrane fraction did not participate in the translocation of PP2A-C, there seems to 
be a dynamic methylation-dependent mechanism at work, potentially targeting PP2A to different 
substrates within this fraction as ischaemia and reperfusion progresses. 
 
A summary of the model which our data suggests is given in Figure 3.57.  
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Limitations and future directions 
In my view, the major outcomes of this study are: (1.) It provides definite proof that PP2A is 
recruited into the cellular response to I/R, thereby identifying PP2A as a role-player in this setting 
which needs to be further investigated; and (2.) It forms a basic lattice-work for future studies. We 
only described the basics concerning PP2A, without investigating any of the role-players involved 
in its regulation, for example PME-1 and α4. These are all aspects which still require further 
investigation.  
 
Future directions include further experimentation to confirm our results, as well as to expand on 
what has already been done. With regards to confirmation the following can still be done: 
1.) As mentioned earlier in this text, the ongoing proliferative capacity of the H9c2 cells is a 
potential confounding factor, since PP2A has been implicated in the control of the cell 
cycle. One possible way in which to minimize this effect would be to chemically differentiate 
the cells prior to experimentation. This entails incubating the cells for a period of 4-6 days in 
medium containing low levels of serum (1% vs the normal 10% used here), combined with 
a relatively low concentration of retinoic acid (10 nM). Under these conditions H9c2 cells 
have been shown to differentiate into cells with an increased expression of cardiac specific 
proteins and a markedly reduced proliferative capacity (Ménard et al., 1999; Pagano et al., 
2004; Pereira et al., 2011; Branco et al., 2012). It would therefore be advantageous to 
repeat our SI/R experiments in such a cardiac-specific differentiated H9c2 cell model. 
2.) Investigation of the increase in total PP2A-C in unfractionated lysates at 20 minutes GI. 
This can be done by measuring both the mRNA levels of PP2A-C, as  well as determining 
the level of PP2A-C ubiquitination as ischaemia progresses. Investigating the effects of 
proteosomal inhibition during ischaemia and reperfusion will also be very insightful. 
3.) The fractionation data revealed some interesting and sometimes surprising results, 
especially the nuclear accumulation of PP2A-C at 10 minutes GI. The fractionation 
procedure should be improved to yield pure sarcolemmal, mitochondrial, sarcoplasmic 
reticulum and myofibrillar fractions. It would also add value if the intracellular distribution of 
PP2A-C is investigated in the H9c2 cell model using immunofluorescence microscopy and 
live cell imaging. 
 
In addition to the above, the following aspects should be investigated:  
1.) Identification of the substrates targeted by PP2A-C in the nucleus at 10 minutes GI. This 
could be addressed by pharmacological modulation of PP2A-C combined with phospho-
proteomic analysis of the nuclear fraction at this time point. 
2.) We only focussed on methylation and phosphorylation of PP2A-C as indications of its 
regulation. There are however several important proteins in the regulation of PP2A-C which 
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should receive attention in the context of myocardial I/R. These include PME-1, LCMT-1, 
α4, TIPRL and PTPA. 
3.) In our quest of a basic description of PP2A, we only focussed on the components of the 
core enzyme: PP2A-A and PP2A-C. The regulatory B subunits are however the 
determinants of cellular location and substrate specificity. It will be very interesting to 
determine which regulatory subunits are involved where and when in this setting. 
4.) The characterization of PP2A could also be extended beyond 10 minutes of reperfusion, 
and even beyond 30 minutes reperfusion. As mentioned before, DeGrande et al. (2013) 
and others have found that myocardial hypertrophy and failure are associated with elevated 
PP2A levels. It could be interesting to see whether PP2A is a molecular link, or simply a 
component, of the continuum between infarction and the development of post-MI heart 
failure. 
Conclusion 
Ischaemia elicits a mismatch between PP2A-C and PP2A-A, in such way that there is an increase 
in the levels of PP2A-C relative to PP2A-A. This surplus PP2A-C is especially noticeable in the 
cytosolic fraction and is probably stabilised in the cell, possibly through binding to a scaffold or 
inhibitor, such as α4. Late ischaemia and early reperfusion is associated with an increase in the 
phosphorylation of PP2A-C, which suggests its inhibition – thereby favouring the activation of 
adaptive pro-survival cellular events. This inhibition of PP2A was evident in both the nuclear and 
membrane fractions. 
 
The nucleus hosted an accumulation of dephosphorylated, methylated PP2A-C at 10 minutes 
ischaemia. The reason for this is unknown, although PP2A probably participates in a nuclear 
response to ischaemia, including aspects such as changes in protein expression, etc.  
 
The membrane fraction also revealed a dynamic situation in which the methylation of PP2A-C 
fluctuates throughout ischaemia and early reperfusion, implying dynamic changes in substrate 
specificity throughout this period. 
 
After 10 minutes of reperfusion the levels and distribution of PP2A-C seemed to be almost back to 
normal, except for the elevation of PP2A-C/A in the cytosolic fraction. Posttranslational 
modifications however persisted at 10 minutes reperfusion.  
 
We have now shown that PP2A is involved in cellular response to myocardial I/R. The next 
question however is, how important is PP2A in contributing to the outcome of an I/R episode? 
Otherwise put: could the manipulation of PP2A significantly change the outcome of I/R injury? 
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CHAPTER 4 
Pharmacological modulation of PP2A: 
Inhibition 
  
“Greebo had spent an irritating two minutes in that box. Technically, a cat locked 
in a box may be alive or it may be dead. You never know until you look. In fact, 
the mere act of opening the box will determine the state of the cat, although in 
this case there were three determinate states the cat could be in: these being 
Alive, Dead, and Bloody Furious.” 
Terry Pratchett 
Lords and Ladies 
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Chapter 4 
Pharmacological modulation of PP2A: Inhibition 
Introduction 
As discussed in Chapter 1, possibly one of the greatest benefits of the considerable research effort 
which has been directed at cardioprotection, is the delineation of the signalling cascades which are 
involved in the heart’s response to an I/R episode. We know now that cardioprotection is mediated 
by a vast network of interrelated signalling cascades communicating information regarding stress 
and adaptation from cell membrane receptors and cellular sensors to end-targets, of which the 
most important seems to be the mitochondria and the nucleus. For complete reviews concerning 
these cardioprotective signalling pathways see Yellon & Downey (2001), Hausenloy & Yellon 
(2007) and Yang et al. (2010).  
 
Although several signalling pathways are involved in the cardiac response to I/R, cardioprotection 
has become almost synonymous with the RISK pathway and MAPK signalling. We were therefore 
interested to know what the relationship, if any, is between these signalling pathways and PP2A 
within the setting of I/R. This mini-review will therefore only focus on what is currently known 
regarding these pathways within the context of I/R, as well as the interactions which have been 
described between PP2A and these pathways. 
Signalling in ischaemia/reperfusion and cardioprotection 
The Reperfusion Injury Salvage Kinases (RISK) pathway was originally coined by Hausenloy & 
Yellon in 2004 as a collective concept encompassing both the PI3-kinase – PKB/Akt and ERK 
p42/p44 pathways. They made the observation that IPC induced the activation of both PKB/Akt 
and ERK p42/p44 during the trigger phase of IPC (i.e. prior to ischaemia), as well as during the 
onset of reperfusion (Tong et al., 2000; Uchiyama et al., 2004; Fryer et al., 2007; Hausenloy et al., 
2004 & 2005). Activation of these pathways has also been implicated in the cardioprotection 
elicited by pharmacological PostC, as well as ischaemic PostC (Yang et al., 2004; Bopassa et al., 
2006; Bell et al., 2007). The importance of these pathways is underpinned even more by the work 
of Sivaraman et al. (2007) who found that PostC protection in human atrial tissue was dependent 
on the activation of the RISK pathway. 
 
It must however be noted, that the traditional components of the RISK pathway (PKB/Akt and ERK 
p42/p44 mediated signalling) are not the only signalling pathways implicated in survival and 
cardioprotection. In 2005 Lecour and colleagues identified the reperfusion associated activation of 
STAT3 as a mediator of cardioprotection independent of PKB/Akt and ERK p42/p44. STAT3 
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therefore presents an alternative cardioprotection pathway which they coined the SAFE (Survivor 
Activating Factor Enhancement) pathway (Lecour, 2009). 
 
For simplicity and specificity sake, we will however limit our focus on components of the RISK and 
MAPK pathways. 
The PI3-kinase – PKB/Akt pathway 
The phosphorylation and activation of PI3-kinase and its downstream target PKB/Akt is associated 
with I/R (Armstrong, 2004). Cardioprotective interventions, such as IPC, PostC and their 
pharmacological mimetics stimulate an even further increase in the phosphorylation of PKB/Akt. 
Most studies have found that the protection induced by these interventions is dependent on this 
increased phosphorylation and activity of PKB/Akt, so that inhibition of the PI3-kinase – PKB/Akt 
pathway abolishes protection (Yang et al., 2004; Tillack et al., 2006; Fujita et al., 2007). Several 
downstream effectors of PKB/Akt which are involved in cardioprotection have been identified and 
include signalling proteins such as endothelial nitric oxide synthase (eNOS) (Tsang et al., 2004; 
Zhu et al., 2006), mTOR (Hernández et al., 2011) and GSK-3β (Zhu et al., 2006; Tillack et al., 
2006). This PI3-kinase – PKB/Akt mediated phosphorylation of GSK-3β is especially noteworthy, 
since the phosphorylation and associated inhibition of GSK-3β is thought to mediate the 
stabilisation of the mPTP in a closed conformation (Juhaszova et al., 2004; Bopassa et al., 2006). 
As discussed in Chapter 1, the mPTP is regarded as one of the more, if not the most, important 
end-effector which mediates the balance between survival and injury following I/R. 
 
Despite all the data which has implicated PI3-kinase – PKB/Akt as a key mediator of 
cardioprotection, it must also be noted that not all studies have shown a causal link between this 
pathway and protection (Darling et al., 2005; Schwartz & Lagranha, 2006). In their isolated rabbit 
heart model, Darling and colleagues (2005) found that PostC protection was neither associated 
with an increase in PKB/Akt phosphorylation, nor alleviated by the inhibition of PI3-kinase. This 
study however confirmed the cardioprotective role of the other component of the RISK pathway: 
ERK p42/p44. 
ERK p42/p44 signalling 
The other “leg” of the RISK pathway is the MEK1/2 (MAPK/ERK kinase 1/2) – ERK p42/p44 
pathway which, as the name denotes, is a member of the larger MAPK family which also includes 
c-Jun NHP2-terminal kinase (JNK) and p38 MAPK. In the absence of a cardioprotective 
intervention, early reperfusion following ischaemia leads to an increased phosphorylation and 
activation of ERK p42/p44 (Armstrong, 2004) in a pattern that is very similar to PKB/Akt. 
Cardioprotective interventions enhance this phosphorylation and inhibitor studies targeting the 
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upstream MEK1/2 have also confirmed that ERK p42/p44 acts as a mediator of cardioprotection 
(Yang et al., 2004; Darling et al., 2005; Fujita et al., 2007; Hausenloy & Yellon, 2007). 
 
It has also been suggested that ERK p42/p44 phosphorylates GSK-3β, thereby promoting 
maintenance of the mPTP in a closed conformation (Juhaszova et al., 2004; Hausenloy & Yellon, 
2007).  
 
As is the case with PKB/Akt, there is no consensus in the literature regarding the importance of 
ERK p42/p44 in mediating protection. In this regard, Feng and co-workers (2006) reported that 
isoflurane PostC, though dependent on PI3-kinase – PKB/Akt signalling, is not associated with 
ERK p42/p44 phosphorylation. In an intriguing study by Schwartz & Lagranha (2006) a PostC 
protocol induced the phosphorylation of both PKB/Akt and ERK p42/p44, but failed to elicit an 
infarct sparing effect. 
 
A possible explanation for these disparate results is hinted at by a study done by Hausenloy et al. 
(2004) which indicated the existence of cross-talk between the PI3-kinase – PKB/Akt and MEK1/2 
– ERK p42/p44 pathways in such a way that inhibition of the one pathway was associated with an 
increase in the phosphorylation of the other pathway. Application of the principle indicated by this 
study to the myocardial context, where multiple pathways mediating protection are activated by an 
ischaemic conditioning intervention, suggests a situation where eventual protection is mediated by 
more than one pathway. The implication of this is that the inhibition of a single pathway may not 
abrogate protection, while activation of only one or two of these pathways is not necessarily 
enough to cross the threshold of protection. 
 
Despite these conflicting results, the current paradigm is that the activation of PKB/Akt and ERK 
p42/p44 is involved in mediating cardioprotection. It is also noteworthy that both these kinases 
signal on to GSK-3β, placing it as a central regulator in cardioprotection. 
 
Another member of the MAPK family which has received a large amount of attention, but with 
much less unequivocal results is p38 MAPK. 
p38 MAPK in cardioprotection 
As a member of the MAPK family it seems obvious that p38 MAPK would be a mediator of 
cardioprotection. However, its varied and intricate roles in survival and apoptosis excludes such a 
straightforward answer. 
 
In contrast to ERK p42/p44 and PKB/Akt, p38 MAPK phosphorylation already increases during 
sustained ischaemia, peaking during early reperfusion (Armstrong et al., 1998; Ma et al., 1999; 
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Armstrong, 2004). In 1997 Weinbrenner and colleagues reported that an IPC protocol applied to 
the isolated rat heart induced an increase in the ischaemic phosphorylation of p38 MAPK. 
Combined with the observations that this activation was linked to protection and the inhibition of 
p38 MAPK abolished cardioprotection, the authors concluded that p38 MAPK activation is an 
important component of IPC protection. Similarly Armstrong and co-workers (1999) reported that 
IPC increased the phosphorylation of p38 MAPK during ischaemia in conjunction with protection. 
The importance of p38 MAPK was also shown to extend beyond ischaemia, with Da Silva et al. 
(2004) reporting that IPC elicited an increase in p38 MAPK phosphorylation after 40 minutes of 
global ischaemia and 30 minutes reperfusion in an isolated rat heart model. Others have also 
implicated p38 MAPK phosphorylation during I/R as an important component of IPC (Nagy et al., 
2007; Hernández et al. 2011), as well as other cardioprotective interventions such as dietary 
supplementation with red palm oil (Engelbrecht et al., 2006) and insulin administration during 
reperfusion (Tiron et al., 2006). There are however other studies which have shown the opposite, 
namely that p38 MAPK activation and phosphorylation during sustained ischaemia and reperfusion 
are detrimental to the heart (Ma et al. 1999; Mackay & Mochly-Rosen et al., 2000; Kim et al., 2012; 
Thomas et al., 2011; Surinkaew et al., 2013). For a review about the inconsistencies concerning 
the research which has been done regarding the role of p38 MAPK in cardioprotection see 
Steenbergen (2002). 
 
So, ultimately the question remains: Is p38 MAPK activation protective or detrimental? In his 
review on the topic Steenbergen (2002) lists some of the confounding factors which could explain 
the controversy, including animal species differences, issues with the pharmacological inhibitors 
used in these studies and the question regarding the specific p38 MAPK isoforms involved. Early 
studies did not take this latter variable into account, but it is a relevant issue since the two 
prevalent isoforms in the heart (α and β) exert different effects, as exemplified in a study by Wang 
et al. (1998) which showed that p38α MAPK seems to induce apoptosis, while p38β MAPK favours 
hypertrophic remodelling. In this regard, Saurin et al. (2000) found that IPC protection is dependent 
on the inhibition of specifically p38α during sustained ischaemia. For a review concerning the 
importance of the p38 MAPK isoforms in myocardial I/R see Bassi and colleagues (2008). Another 
aspect which must be kept in mind concerns the temporal characteristics of p38 MAPK activation 
in and around cardioprotection. 
 
Research done in our laboratory placed the pro-survival aspect of p38 MAPK activation within the 
triggering phase of IPC, i.e. during the ischaemic conditioning stimulus prior to sustained 
ischaemia (Marais et al., 2001 and 2005). In this model IPC elicits an increase in the activity of p38 
MAPK during the triggering stimulus, but reduces it during subsequent sustained ischaemia and 
reperfusion. The cardioprotective importance of p38 MAPK activation during the IPC protocol itself 
has also been shown by Da Silva et al. (2004). 
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The precise role and contribution of p38 MAPK to I/R injury and cardioprotection is therefore still an 
open book, but that it is somehow involved in these processes is however unquestionable. 
The role of PP2A in intracellular signalling 
Having briefly described the current state of knowledge regarding the participation of PKB/Akt, 
ERK p42/p44, GSK-3β and p38 MAPK in cardioprotection, the focus will now shift to the interaction 
between PP2A and these signalling molecules.  Due to the limited information available concerning 
the involvement of PP2A in cellular signalling in the heart, data generated in other tissues and 
models will also be included in this mini-review. 
p38 MAPK: activator or effector of PP2A? 
In 1995 it was already reported that p38 MAPK can be dephosphorylated, and in the process 
inactivated, by PP2A in rat PC12 cells (Doza et al., 1995). This early study also found that 
activation of this kinase requires simultaneous phosphorylation of both a tyrosine and a threonine 
residue (at positions 182 and 180 respectively). PP2A was implicated in the dephosphorylation of 
the threonine residue, while protein tyrosine phosphatase-1B (PTP-1B) dephosphorylated the 
tyrosine residue. The phosphorylation of two residues are therefore of importance here, while the 
dephosphorylation of these two residues can be catalyzed by any of the three families of protein 
phosphatases.  
 
Mackay & Mochly-Rosen (2000) targeted the inhibition of the tyrosine phosphatases in a model of 
isolated rat ventricular cardiomyocytes exposed to hypoxic conditions. They found that incubation 
of the cells with the PTP inhibitor, vanadate, during hypoxia increased the phosphorylation of p38 
MAPK compared to control and in the process also augmented the release of LDH from the cells, 
implying that p38 MAPK activation is detrimental. Focussing on the PSPs, Armstrong and 
colleagues (1998 and 1999) found that the incubation of isolated rabbit cardiomyocytes with the 
PP2A and PP1 inhibitor, Calyculin A, from 10 minutes prior to ischaemia through 30 minutes 
ischaemia (induced by pelleting the cells and sealing the pellets from atmospheric oxgen with a 
layer of mineral oil) was also associated with an increase in the phosphorylation of p38 MAPK. It is 
interesting to note that the increase in p38 MAPK phosphorylation during ischaemia in this 
particular model was associated with a protective effect. Juxtaposing these studies leads to the 
speculation that the phosphorylation of tyr182 is detrimental, while thr180 is associated with 
resistance against stress. Data reported in a recent study by Omar and colleagues (2012) however 
disprove this speculation. They found that adenosine-triggered cardioprotection is mediated by a 
reduction in glycolysis and proton generation during reperfusion following 17 minutes GI in an 
isolated working rat heart model. These metabolic effects were dependent on the 
dephosphorylation of both AMPK and p38 MAPK and could be abrogated by the administration of 
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cantharidin or okadaic acid – both inhibitors of both PP1 and PP2A. This work has three intriguing 
implications: (1.) p38 MAPK activity during reperfusion is detrimental; (2.) PP1 and / or PP2A can 
mediate protection and; (3.) PP1 and / or PP2A dephosphorylate p38 MAPK in the heart. Utilization 
of small T expression (a protein of viral origin which can inhibit PP2A, see the introduction to 
Chapter 3) to modulate and inhibit the activity of PP2A also revealed an increased phosphorylation 
of p38 MAPK in a mouse fibroblast cell system (Andrabi et al., 2007). In T leukemia cells Boudreau 
and colleagues (2007) found that PP2A was involved in maintaining p38 MAPK in a 
hypophosphorylated state, potentially by directly interacting with the kinase. Intriguingly in their 
study the activity of both PP2A and p38 MAPK favoured cell survival, so that the combined 
inhibition of both these enzymes led to apoptosis. 
 
These studies therefore firmly establish PP2A as an upstream regulator of p38 MAPK. There is 
however also a large body of work which places PP2A as a downstream effector of p38 MAPK 
signalling. 
 
In one of the first demonstrations of a link between p38 MAPK and ERK p42/p44, Westermarck 
and colleagues (2001) reported that, in a fibroblast cell model, MAPK kinase 3 (MKK3) activation of 
p38α MAPK induced a reduction in the activity of the MEK1/2 – ERKp42/p44 pathway by somehow 
activating PP1 and PP2A, thereby mediating the dephosphorylation and inactivation of MEK1/2. Li 
et al. (2003) confirmed these results, with the only additions that p38β MAPK also induces MEK1/2 
inactivation and the proposal that the relevant phosphatase is probably PP2A. Following these 
studies in fibroblast and cancerous cell models, the existence of this pathway was also confirmed 
in endothelial cells (Grethe & Pörn-Ares, 2006) and isolated adult rat ventricular myocytes (Liu & 
Hofmann, 2004). In both these studies the p38 MAPK-PP2A mediated dephosphorylation of the 
MEK1/2-ERK p42/p44 pathway favoured apoptosis following exposure to either TNF-α or oxidative 
stress. These studies place PP2A as the “connector” in the cross-talk between p38 MAPK and 
ERK p42/p44, and simultaneously also at the signalling tipping point between cell survival and 
apoptosis. 
 
It is however not only ERK p42/p44 which is targeted by a p38 MAPK-PP2A mechanism. Avdi and 
colleagues (2002) demonstrated a similiar pathway in human neutrophils, but with the major 
difference that p38 MAPK activated PP2A directed against MAPK kinase 4 (MKK4), which is 
upstream of JNK. In this case however JNK dephosphorylation was associated with an abrogated 
apoptotic response to TNF-α exposure. In cardiomyocytes Zuluaga et al. (2007) also found 
evidence that p38α can induce the dephosphorylation of PKB/Akt in a PP2A dependent manner. 
Interestingly, the mechanism which they described implicates p38 MAPK in regulating the 
interaction between caveolin-1 and PP2A which is necessary for the translocation of PP2A from 
the nucleus to the sarcolemma where it can target PKB/Akt. 
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There is therefore compelling evidence identifying PP2A as both a regulator of p38 MAPK, as well 
as a downstream target of p38 MAPK. The only conclusion that can be made is that both these 
scenarios are possible, and that the type of cell as well as the stimuli affecting that cell will 
determine which of these pathways are recruited. 
ERK p42/p44: Inhibited or activated by PP2A? 
As already touched upon in the previous section, PP2A has been associated with the 
dephosphorylation and inactivation of ERK p42/p44. In fact, this link was identified many years 
ago. As decribed for p38 MAPK, full activation of ERK p42/p44 requires the phosphorylation of 
both a tyrosine, as well as a threonine residue. In 1990 Anderson and colleagues reported that 
ERK p42/p44 could be deactivated by treatment with either the tyrosine phosphatase CD45, or 
PP2A. Since then several studies have shown that PP2A is involved in the dephosphorylation of 
ERK p42/p44 (Sontag et al., 1993; Alessi et al., 1995; Quintaje et al., 1996; Nyunoya et al., 2005). 
In fact Alessi and colleagues (1993) suggested that PP2A might be the major factor involved in the 
deactivation of ERK p42/p44. It is also important to note that Quintaje et al. (1996) demonstrated 
this interaction between PP2A and ERK p42/p44 in rat neonatal cardiomyocytes, implicating PP2A 
as a negative regulator of ERK p42/p44 in the heart. This was also demonstrated by Taglieri et al. 
(2011) who showed that p21-activated kinase-1 (Pak-1) can inhibit ERK p42/p44 in the heart in a 
PP2A dependent manner. 
 
Although PP2A has been identified as the primary direct deactivator of ERK p42/p44, it seems that 
the interaction of PP2A with the broader ERK p42/p44 pathway is more complex. In the extended 
pathway, activation of Ras leads to the plasma membrane localization and activation of the kinase 
Raf-1, which in turn can phosphorylate and activate MEK1/2, which then activates ERK p42/p44. 
The activation of Raf-1 is a complex procedure which requires multiple phosphorylations, transient 
interaction with the scaffold 14-3-3 and, importantly for this discussion, dephosphorylation of the 
inhibitory phospho-residues serine 259 and 621. Work done by several researchers have revealed 
that PP2A is involved in the dephosphorylation of the inhibitory serine 259 residue, implicating 
PP2A as an activator of Raf-1 and therefore also of the MEK1/2-ERK p42/p44 pathway (Jaumot & 
Hancock, 2001; Abraham et al., 2001; Adams et al., 2005). In addition to this, Ory and colleagues 
(2003) also showed that PP2A-mediated dephosphorylation of serine 392 in the scaffold protein 
KSR1 (kinase suppressor of Ras 1) is important for the successfull KSR1 mediated interaction of 
MEK1/2-ERK p42/p44 with Raf-1 at the cell membrane. PP2A is therefore involved as a positive 
regulator at two points in the pathway in the eventual activation of ERK p42/p44. 
 
We are therefore left with two disparate conclusions regarding PP2A and ERK p42/42, namely that 
PP2A is both an activator, as well as a deactivator of ERK p42/p44. The obvious  question which 
emerges is how are these two roles reconciled in one cell? One possible answer is alluded to by 
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Adams et al. (2005) who identified the PP2A holoenzymes which target and activate Raf-1 as 
containing either Bα or Bδ. In their study Sontag et al. (1993) found that small T expression failed 
to exert an effect on Raf-1, although it inhibited the ability of PP2A to dephosphorylate MEK and 
ERK. This lack of an effect on Raf-1 makes sense though when you realize that in their model 
small T exchanged with Bα, thereby reducing the abundance of this specific PP2A holoenzyme. As 
discussed in Chapter 3, the regulatory B subunit is important in determining both the cellular 
location as well as substrate specificity of PP2A. It is therefore very probable that in this situation 
different regulatory subunits are involved in targeting PP2A to either Raf-1, RSK1 or ERK p42/p44. 
The type of B subunit involved is however probably not the only factor involved, since Van 
Kanegan et al. (2005) showed that in PC3-6 cells Bα and Bδ also directly targeted PP2A to ERK 
p42/p44, exactly the same regulary subunits as linked to the dephosphorylation of Raf-1 (Adams et 
al., 2005). No doubt other factors, such as cell type and stimulus involved, are also important in 
determining the role of PP2A in ERK p42/p44 signalling. 
 
Another twist in the interaction between ERK p42/p44 and PP2A has been revealed by Letourneux 
and colleagues (2006). They found that the protein IEX-1 (or ier3) can protect ERK p42/p44 from 
PP2A dephosphorylation by docking ERK p42/p44 and the B56γ1 containing PP2A holoenzyme in 
the same ternary complex. When associated in this complex ERK p42/p44 has an increased 
activity towards the B56 subunit. ERK p42/p44 mediated phosphorylation of B56 however triggers 
the dissociation of PP2A-C from the holo-enzyme. IEX therefore serves as a scaffold allowing for 
the ERK p42/p44  mediated inhibition of PP2A activity directed against ERK p42/p44, as well as 
PKB/Akt (Rocher et al., 2007). It must however be noted that this mechanism was identified in 
several experimental cell models and to my knowledge has not yet been identified in the heart. 
PP2A negatively regulates the PKB/Akt – GSK-3β pathway 
In contrast to the MAPKs, research has revealed a more straight-forward interaction between 
PP2A and PKB. In 1996 Andjelković and colleagues reported that both vanadate and okadaic acid 
treatment of Swiss 3T3 cells led to an increased phosphorylation of PKB/Akt. This study implicated 
both a tyrosine phosphatase as well as PP1 or PP2A in the regulation of this kinase. The link 
between PKB/Akt and tyrosine phosphatases does not however lie in the direct phosphorylation of 
PKB/Akt, but rather in the upstream tyrosine kinase receptors involved in the activation of PKB/Akt 
(Bhuiyan & Fukinago, 2009). Andjelković et al. (1996) however also reported that incubation of 
PKB/Akt with PP2A led to the dephosphorylation of the kinase, thereby confirming PP2A as a 
phosphatase directly targeting PKB/Akt. Following these observations many others have also 
found that PP2A can dephosphorylate and thereby inactivate PKB/Akt, and as a result positively 
regulate downstream GSK-3β (which is inhibited when phosphorylated) in a wide variety of tissues 
(Salinas et al., 2000; Resjö et al., 2001; Ivaska et al., 2002; Van Kanegan et al., 2005; Mott et al., 
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2008). This interaction between PP2A and PKB/Akt has also been shown in mouse neonatal 
cardiomyocytes, under the regulation of p38 MAPK (Zuluaga et al., 2006). 
 
Interestingly Andrabi et al. (2007) found that small T expression combined with growth factor 
treatment in NIH 3T3 cells led to an unbalanced phosphorylation of PKB/Akt between its two 
phospho residues (serine 473 and threonine 308) which actually favoured apoptosis. It therefore 
seems that under stimulatory conditions PP2A (or at least the specific holoenzyme affected by the 
presence of small T) only dephosphorylates threonine 308.  
 
Since the phosphorylation of GSK-3β is tightly associated with PKB/Akt activity, not many studies 
have investigated the possibility of a direct interaction between PP2A and GSK-3β. In 1994 
Sutherland & Cohen showed that phosphorylated, and therefore inactivated, GSK-3α and GSK-3β 
purified from rabbit skeletal muscle can be dephosphorylated and reactivated by the addition of 
PP2A. More recently Mitra and colleagues (2011) also showed a direct interaction between PP2A 
and GSK-3β in a melanoma cell line, where a heatshock protein, DNAJB6, can mediate the 
formation of a HSPA8 (heat-shock cognate protein, HSC70)-PP2A-GSK-3β complex. 
 
Yao et al. (2011 & 2012) made some very interesting observations regarding the effects of GSK-3β 
on PP2A. In their 2011 publication they propose a mechanism by which activated GSK-3β 
mediates the inhibition of PTP-1B, thereby favouring the inhibitory phosphorylation of PP2A-C. At 
the same time GSK-3β can also reduce the expression of PP2A-C in a CREB (cAMP-response-
element-binding protein) dependent manner. Their model therefore places GSK-3β as a negative 
regulator of PP2A, at least in human embryonic kidney-293 and mouse neuroblastoma (N2a) cells. 
Continuing with this focus, this group also reported that GSK-3β induces demethylation of PP2A-C, 
by increasing the expression of PME-1 and decreasing the levels of LCMT-1, also in human 
embryonic kidney-293 and mouse neuroblastoma cells (Yao et al., 2012).  
 
PP2A has therefore been implicated in the negative regulation of the PKB/Akt – GSK-3β pathway. 
The relatively recent work by Yao et al. (2011 and 2012) however also reveals the possibility that 
GSK-3β can modulate PP2A, at least in human embryonic kidney-293 and mouse neuroblastoma 
cells. If one keeps in mind that inhibition of PKB/Akt (possibly by PP2A) can favour the activation of 
GSK-3β (possibly also by PP2A), one can speculate that GSK-3β-mediated inhibition of PP2A 
could be a negative feedback to keep GSK-3β activity in check. The effects of PP2A on PKB/Akt – 
GSK-3β has however received vey little attention in the context of the heart. 
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Summary 
The potential interactions between PP2A and p38 MAPK, ERK p42/p44 and PKB/Akt – GSK-3β 
are shown in Figure 4.1. There is still much uncertainty concerning the interactions between PP2A 
and these signalling molecules; reflecting the complexity of these signalling pathways. 
 
Inhibition of PP2A as a tool to investigate its importance 
The pharmacological modification of PP2A activity has been a dominant approach in investigating 
the contribution of PP2A to cellular events and signalling networks. It is especially its inhibition 
which has been pursued by many researchers, possibly simply due to the fact that there are very 
few direct activators of the enzyme. 
PP2A inhibition: okadaic acid (OA) 
For this study we utilized okadaic acid (OA) as a pharmacological tool to inhibit PP2A. OA is a 
marine toxin which was first decribed in the late 1970’s and early 1980’s as the active component 
responsible for diarrhetic shellfish poisoning in humans (Dounay & Forsyth, 2002; Dawson & 
Holmes, 1999). Although it was originally isolated from the black sea sponge Halichondria okadaii, 
it is actually synthesized by dinoflagellates (unicellular marine microorganisms) which are fed upon 
by marine sponges (Cohen et al., 1990; Dounay & Forsyth, 2002). Since its isolation and 
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characterization, it has become one of the most used natural marine products in biological 
research in the world (Dounay & Forsyth, 2002). The reason for all this scientific interest in OA is 
due to its potent protein phosphatase inhibition capabilities.  
 
Numerous studies have shown that OA is an inhibitor of the phosphoprotein phosphatases (PPPs) 
PP1 and PP2A, as well as the less abundant protein phosphatases 3, 4, 5 and 6 while only 
exerting an effect on other protein phosphatases at much higher concentrations or not at all 
(Cohen et al., 1990; Honkanan et al., 1994; Herzig & Neumann, 2000; Janssens & Goris, 2001; 
Dounay & Forsyth, 2002). It is especially specific for PP2A, presenting with a 10-100 times higher 
IC50 value for PP2A than PP1. In this regard OA inhibits PP2A with an IC50 value of 0.2-1 nM, while 
the IC50 value for PP1 is in the range of 10-100 nM (Bialojan & Takai, 1988; Cohen et al., 1990; 
Dawson & Holmes, 1999; Herzig & Neumann, 2000). As reported by Honkanan et al. (1994) OA 
also exhibits  a lower IC50 value for PP3 than PP1, but still the lowest for PP2A (IC50 values (in 
nM): PP2A: 0.28; PP3: 3.91; PP1: 49.0). An explanation for this specificity for PP2A was recently 
put forward by Xing and colleagues (2006) who found that OA binds to an area located right above 
the active site of PP2A-C with a hydrophobic cage, which is absent in PP1, accomodating the 
hydrophobic end of OA.  
 
Early kinetic studies (Bialojan & Takai, 1988) showed that OA acts as a reversible, non-competitive 
or mixed inhibitor of its target phosphatases. Although its interaction with PP2A is reversible, it is 
still very tight, as demonstrated by Favre and colleagues (1997) who reported that three to four 
ethanol precipitations were required to reactivate OA inhibited PP2A, in comparison to a single 
ethanol precipitation which could induce the complete dissociation of the regulatory subunits from 
PP2A-C. 
 
OA is a hydrophobic polyether fatty acid which therefore has the ability to transverse cell 
membranes, making it a very useful tool for the study of cellular PP2A and PP1 (Cohen et al., 
1990; Dawson & Holmes, 1999; Dounay & Forsyth, 2002). That being said, OA has some crucial 
limitations which must be kept in mind. Although it can cross cell membranes, it does so with some 
difficulty (Herzig & Neumann, 2000). That, combined with the fact that PP1 and PP2A are often 
present at quite high levels in some cell types (0.1-1.0 μM) (Cohen et al., 1990) necessitate the 
use of higher concentrations of OA than the IC50 values generated under in vitro conditions. The 
consequence of this is that there could be a degree of uncertainty regarding the precise 
phosphatase (PP1 or PP2A) being inhibited by a given concentration of OA. 
 
Keeping in mind the major contribution of PP1 and PP2A to protein dephosphorylation in 
mammalian cells, it is no surprise that administration of OA can induce a major increase in cellular 
protein phosphorylation, even within minutes (Cohen et al., 1990). In isolated guinea pig ventricular 
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cardiomyocytes, Neumann et al. (1993) found that a 5 minute incubation with 1, 10 and 30 μM of 
OA induced an increase in phosphorylation of several proteins, with maximum phosphorylation 
elicited by 10 μM. This however presents with a new problem: OA treatment may elicit a 
pleiotrophic multitude of effects, making the interpretation of data even more difficult (Dawson & 
Holmes, 1999). 
 
The wide array of cellullar responses associated with OA treatment is reflected by the various 
effects which OA exerts in different tissues. OA has been associated with tumor progression, but 
has also been characterized as a tumor suppressor, it induces cytotoxicity and apoptosis, it is a 
neurotoxin and elicits a diarrhoeagenic effect (Cohen et al., 1990; Jayaraj et al., 2008; Munday, 
2013). The extent to which phosphatase inhibition contributes to some of its toxic effects is 
however debatable (Munday, 2013). 
 
In summary, OA is a work horse for the study of the protein phosphatases PP1 and PP2A. Due to 
its preferential inhibition of PP2A at considerably lower concentrations than PP1, OA can be used 
to specifically target PP2A. Its use and data generated by its administration must however be 
approached with caution, since its relatively low cell membrane permeability necessitates the use 
of OA at higher dosages than would be ideal. 
 
These limitations are however also present with other inhibitors of PP1 and PP2A and are indeed 
characteristic of the intrinsic difficulties associated with investigating the protein phosphatases.   
Motivation, hypothesis and aims 
It is notable in the literature that very little research has been done concerning the interactions 
between PP2A and p38 MAPK, ERK p42/p44 and PKB/Akt – GSK-3β in the heart, and specifically 
in the setting of I/R injury. Work in other cell systems and tissues however provide compelling 
evidence that PP2A could be a regulator of these pathways in the heart. This possibility must be 
investigated in view of the proposed importance of the protein phosphatases in regulating cellular 
signalling (Heinrich et al., 2002 & Hornberg et al., 2005) and the continuous requirement for more 
knowledge and a better understanding of the signalling events associated with myocardial I/R in 
order to advance the efficacy of cardioprotective interventions. 
 
The purpose of this part of the project was therefore to investigate the importance of PP2A in 
myocardial I/R injury and to better define the participation of PP2A within the signalling networks of 
p38 MAPK and the RISK pathways in this setting. 
 
In order to achieve this purpose we set about accomplishing the following aims: 
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1.) Determining the consequence of PP2A inhibition in conjunction with I/R in an isolated working 
rat heart model on infarct size, as well as post-ischaemic function. 
2.) Investigating the mechanism by which PP2A inhibition elicited its effects in the heart by 
focusing on the expression and phosphorylation of p38 MAPK, ERK p42/p44, PKB/Akt, GSK-
3β, as well as PP2A-A, PP2A-C and the methylation and phosphorylation of PP2A-C. 
 
As has been reported by several others (Armstrong et al., 1997; Isotani et al., 2002; Sariahmetoglu 
et al., 2012), we expect to find that PP2A inhibition will be cardioprotective due to an increased 
phosphorylation and activation of pro-survival elements – specifically ERK p42/p44 and PKB/Akt.  
 
Concerning the signalling dynamics we hypothesise that phosphorylation of p38 MAPK during 
sustained ischaemia is an upstream event from PP2A. PP2A will however probably be involved in 
the dephosphorylation of both ERK p42/p44 and PKB/Akt during ischaemia. The 
dephosphorylation of PKB/Akt will favour GSK-3β dephosphorylation and activation during 
ischaemia, a process to which PP2A might contribute directly. During initial reperfusion the 
reduction in PP2A activity (Chapter 3) will present an opportunity for the phosphorylation and 
activation of the pro-survival pathways.Materials and Methods 
Material and Methods 
Rationale 
In order to shed more light on the importance and role of PP2A in myocardial I/R injury we followed 
an approach based on the administration of pharmacological modulators of PP2A activity to hearts 
exposed to I/R whereafter infarct size, functional recovery and kinase profiles were assessed 
(Figure 4.2).  
 
This chapter will specifically focus on the effects of OA mediated inhibition of PP2A within this 
setting, while chapter 5 will focus on the effects of PP2A activation.  
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Protocols 
OA dosage and administration 
Okadaic acid was obtained from Calbiochem as okadaic acid sodium salt (# 459620). For all 
experiments we utilized OA at a concentration of 10 nM. We selected this concentration because: 
(1.) It falls safely within the IC50 value range for the OA mediated inhibition of PP2A, without 
coming close to the IC50 range for PP1. Since our focus is PP2A, it was obviously very important to 
try and inhibit only PP2A. (2.) Similar dosages have been reported in the literature. A slightly lower 
concentration of 7.5 nM has been used in our laboratory before (Fan et al., 2010). Ladilov et al. 
(2002) also found that 5 nM of OA partially enhanced the protection afforded by hypoxic 
preconditioning in an isolated rat heart model.  
 
As shown in Figure 4.2 we tested the effects of PP2A inhibition on infarct size development by 
administering OA either directly before sustained ischaemia and/or at the very onset of reperfusion. 
Which ever of these protocols elicited a significant effect on infarct size was then further 
investigated to assess its effects on functional recovery and determine the phosphorylation profiles 
of the RISK pathways as well as p38 MAPK. 
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Infarct size (IFS) 
The PP2A inhibitor OA was administered at a PP2A specific concentration of 10 nM for a period of 
10 minutes directly prior to 35 minutes of sustained regional ischaemia (RI) and/or at the onset of 
reperfusion (Figure 4.3). Reperfusion administration was accomplished by administering OA for the 
final 5 minutes of RI, as well as the first 10 minutes of reperfusion. As described in Chapter 2, 
during ischaemia hearts were monitored and the temperature maintained at 36.5 ºC. Hearts were 
reperfused for a total of 60 minutes, whereafter the left descending coronary artery was 
permanently occluded and the viable area stained with 0.5% Evans Blue dye. Hearts were then 
frozen and later stained with TTC to further delineate the necrotic infarcted zone and the area at 
risk (AAR), defined as viable tissue in the area which did not recieve perfusion during the RI 
intervention. 
 
Many workers in the field prefer to expose the hearts to longer periods of reperfusion (up to 120 or 
180 minutes) to ensure complete formation and stabilisation of the infarct before measuring its 
size. We however opted for a shorter period of time, since previous work in our laboratory has 
shown that shorter reperfusion periods do not influence the relative degree of IFS development 
between groups (Marais et al., 2005; Fan et al., 2009). 
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Functional recovery 
We found that pretreatment with OA (PreOA) was the only protocol which elicited a signifcant 
effect on IFS. We therefore focussed our attention on the PreOA protocol to determine if it could 
also influence functional recovery following 20 minutes of global ischaemia (GI) (Figure 4.4 A). 
Protein profiles 
Using standard Western blotting techniques we also sought to determine the effects of PreOA 
treatment on the expression and phosphorylation of PP2A-A, PP2A-C, phosphorylated PP2A-C 
and nonmethylated PP2A-C. In order to shed light on the mechanisms by which PreOA treatment 
elicits its effect, we also determined the expression and phosphorylation of PKB/Akt, GSK-3β, ERK 
p42/p44 and p38 MAPK. For all these experiments we utilized 20 minutes GI in order to generate 
homogenous tissue for analysis. Since OA was administered before sustained ischaemia we had 
to determine its effects both at the end of sustained ischaemia, as well as at the onset of 
reperfusion (Figure 4.4 B). As motivated elsewhere we were specifically interested in the clinically 
relevant first moments of reperfusion, we therefore collected tissue at both 5 and 10 minutes 
reperfusion. 
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Combined with these Western blotting experiments, we also performed immunoprecipitation (as 
described in Chapter 2) of PP2A-C at 5 minutes reperfusion in an attempt to confirm its association 
with the RISK and MAPK pathways under investigation. 
Statistical analysis 
Unpaired Student T-tests were utilized in all cases where only two groups were compared. For the 
analysis of more than two groups an ANOVA was performed. For data shown in the graphs all 
groups were compared with each other by applying the Bonferroni post hoc test. Whenever 
multiple experimental groups were compared with a single common control group alone, Dunnett’s 
post hoc test was additionally performed. A P-value of less than 0.05 was deemed significant. 
Results 
The effect of okadaic acid mediated PP2A inhibition on infarct size 
In order to better define the contribution of PP2A to the development of I/R injury we inhibited 
PP2A in an isolated working rat heart model exposed to 35 minutes of regional ischaemia with 
infarct size as primary endpoint. As discussed in Chapter 1, ischaemia and reperfusion, although 
linked, can be seen as two separate molecular entities. For this reason we administered OA either 
before sustained ischaemia, or during the onset of reperfusion. We limited OA administration to the 
first 10 minutes of reperfusion, since the existence of early-reperfusion interventions such as PostC 
identified early reperfusion as an important period in the development of reperfusion injury. A group 
was also included in which OA was administered both before ischaemia, as well as during early 
reperfusion (Figure 4.3). For these experiments we utilized rudimentary measurements to assess 
the quality and function of the isolated hearts at the end of the stabilisation period (table 4.1): 
coronary flow (CF) during retrograde perfusion, and during work mode aortic output (AO) and 
cardiac output (CO). There were no signifcant differences between any of the groups with regards 
to any of these parameters. 
Table 4.1. Baseline functional parameters of isolated rat hearts subsequently exposed to 35 
minutes of RI in conjunction with okadaic acid administration.  
† Coronary flow as measured during normal retrograde perfusion. 
Group Coronary flow† (ml/min) 
Aortic output 
(ml/min) 
Cardiac output 
(ml/min) 
n-value 
Control 8.25±0.29 46.56±2.50 62.81±3.02 16 
PreOA 7.69±0.21 49.00±1.96 66.25±2.82 8 
PostOA 7.79±0.59 45.53±2.20 60.53±2.97 7 
Pre+PostOA 9.08±0.52 52.50±1.54 68.58±1.89 6 
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Following OA administration and exposure to 35 minutes of RI, hearts were reperfused for a total 
of 60 minutes before staining and quantification of infarct size (Figure 4.5). Of the three OA 
administration protocols which were followed, it is only pretreatment with OA which induced a 
signifcant change in the percentage infarct size by reducing it (Control:  41.53±2.81% vs PreOA: 
26.26±5.10%, n=8-16; P<0.05). This reduction in infarct size was independent of any  changes in 
the area at risk. 
 
Midway through the reperfusion period we also assessed the functional recovery of the hearts by 
measuring AO and CO at the end of the reperfusion work mode and expressing these parameters 
as a percentage of the pre-ischaemic baseline values (table 4.2). OA treatment failed to exert any 
effect in terms of functional recovery, even the infarct sparing PreOA treatment was associated 
with very poor functional recovery (AO: Control: 27.00±4.09% vs. PreOA: 19.00±6.42%; CO: 
Control: 48.94±4.60% vs. PreOA: 36.25±5.79%).  
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Table 4.2. Functional recovery of hearts treated with OA and exposed to 35 minutes of RI. None of 
the OA treatment protocols was associated with significant changes in post-ischaemic functional 
ability. 
Group Recovery as a percentage of baseline n-value Aortic output Cardiac output 
Control 27.00±4.09 48.94±4.60 16 
PreOA 19.00±6.42 36.25±5.79 8 
PostOA 18.57±6.59 37.29±5.61 7 
Pre+PostOA 25.33±5.86 41.50±4.96 6 
 
These results identified pretreatment with OA prior to sustained ischaemia as an infarct sparing 
intervention, although it failed to improve functional recovery in this model of ischaemia. 
The effect of OA administration prior to ischaemia on functional 
recovery in a model of global ischaemia 
Having established that pretreatment with OA exerted an infarct sparing effect, we wanted to 
investigate the signalling events associated with this protection. To do this we wanted a 
homogeneous tissue sample for Western blotting analysis, in contrast to the heterogenous cardiac 
preparation generated  by regional ischaemia where per definition only a portion of the heart is 
exposed to I/R, while the rest (viable area (VA)) receives normal perfusion throughout. This left us 
with two options: either dissect the AAR from a heart exposed to RI and analyse that, or expose 
the whole heart to ischaemia (GI). Dissection of the AAR however has two drawbacks: (1.) it yields 
only a small amount of tissue for analysis; and (2.) there is the risk of accidentaly including VA in 
the sample. We therefore opted for the latter option of exposing the hearts to GI. This approach 
however had the major disadvantage that it necessitated the characterization of a new perfusion 
protocol. We therefore had to assess the effects of pretreatment with OA on functional recovery in 
this new model. 
For these experiments hearts were exposed to 20 minutes of GI followed by 30 minutes of 
reperfusion (Figure 4.4 A). Since function was the primary endpoint for these experiments we also 
measured work performance in conjunction with AO and CO (see Chapter 2). Baseline stabilisation 
values for the hearts used are shown in table 4.3. 
Table 4.3. Baseline functional parameters of hearts exposed to 20 minutes of GI in the presence or 
absence of OA administration for a period of 10 minutes prior to sustained ischaemia. *mW: 
milliWatt. 
† Coronary flow as measured during normal retrograde perfusion. 
Group Coronary flow (ml/min) † 
Aortic output 
(ml/min) 
Cardiac output 
(ml/min) 
Total work 
(mW*) 
n-value 
Control 8.33±0.26 48.00±2.51 64.44±2.53 14.44±0.47 9 
PreOA 8.78±0.29 49.89±1.69 67.22±1.96 15.12±0.75 8 
 
At the end of reperfusion, function was measured and expressed as a percentage of pre-ischaemic 
function, thereby indicating the degree of functional recovery. In contrast to the infarct sparing 
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effects observed after 35 minutes of RI, PreOA failed to staticitically increase functional recovery 
after 20 minutes GI (Figure 4.6). 
 
Pre-ischaemic treatment with OA was therefore unable to elicit an increase in functional recovery 
following 20 minutes of GI. 
Protein profiles elicited by OA treatment prior to sustained ischaemia 
followed by reperfusion 
Although the administration of OA prior to 20 minutes GI failed to exert a significant 
cardioprotective effect, in contrast to its infarct sparing effects in a model of 35 minutes RI, it could 
still be used as a model of OA treatment in the context of ischaemia and reperfusion per se. We 
therefore collected samples at the end of 20 minutes GI, as well as at 5 and 10 minutes 
reperfusion, and analysed the expression and phosphorylation of PP2A, PKB/Akt, GSK-3β, p38 
MAPK and ERK p42/p44 following pre-ischaemic treatment with OA in an attempt to shed light on 
the infarct sparing effects of PP2A inhibition (Figure 4.4 B). 
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Protein profiles after 20 minutes of GI 
Protein phosphatase 2A 
Twenty minutes of ischaemia was not associated with any changes in the expression of PP2A-C or 
PP2A-A (Figure 4.7). This is in starck contrast to our earlier characterization of PP2A. In Chapter 3 
we reported that 20 minutes of GI was associated with a significant increase in PP2A-C levels, 
combined with an upward shift in the ratio of PP2A-C to PP2A-A (Figure 3.18). This increase was 
however small and best seen with a high n-value, while for these experiments we only had four 
hearts in the control group. It must however be noted that these four controls were included in the 
analysis depicted in Figure 3.18 which confirmed the ischaemia-induced increase in PP2A-C 
levels.  
 
Stellenbosch University  http://scholar.sun.ac.za
- 164 - 
 
Interestingly, as noted in Chapter 3, the anti-bodies against nonmethylated PP2A-C and 
phosphorylated PP2A-C sometimes detected a double band (Figure 4.8). This double band could 
be indicative of the two PP2A-C isoforms (PP2A-Cα and –β). We however did not distinguish 
between them but rather combined the two bands in a single analysis.  
 
OA treatment was associated with an increase in the phosphorylation of PP2A-C in comparison to 
a non-ischaemic control (Figure 4.8: Absolute phosphorylated PP2A-C: Control: 1.00±0.08 AU vs 
PreOA: 1.47±0.11 AU, n=4-5; P<0.05, and relative to total PP2A-C: Control: 1.00±0.07 AU vs 
PreOA: 1.39±0.13 AU, n=4-5; P<0.05). The absence of a signifcant increase in PP2A-C 
phosphorylation in the ischaemic group, in contrast to the data in Figure 3.18, can also be 
attributed to limited sample size. Absolute nonmethylation was also elevated in the OA treatment 
group in comparison to a non-ischaemic control (Figure 4.8: Control: 1.00±0.04 AU vs PreOA: 
1.32±0.03 AU, n=3-5; P<0.05). The degree of demethylation of the PP2A-C population (Figure 4.8 
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D) was similar in the OA and ischaemic groups, while both were elavated compared to control 
(Control: 1.00±0.01 AU vs. 20 GI: 1.30±0.02 AU and PreOA: 1.24±0.05 AU, n=3-5; P<0.05). 
 
Pretreatment with OA therefore elicited an increase in phosphorylation and reduction in 
methylation of PP2A-C as evidenced by the differences between the OA treated group and the 
non-ischeamic control. 
Protein  kinase B (Akt) 
Sustained ischaemia was associated with a reduction in the phosphorylation of PKB/Akt at serine 
473 compared to the positive control exposed to 20 minutes GI followed by 30 minutes reperfusion. 
The administration of OA had no effect on this profile (Figure 4.9).  
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Glycogen synthase kinase-3β 
Pre-ischaemic treatment with OA was associated with an increase in the phosphorylation of GSK-
3β relative to control values (Figure 4.10: Phosphorylated GSK-3β: Control: 1.00±0.21 AU vs. 
PreOA: 3.44±0.33 AU, n=3-5; P<0.05; and Phosphorylated to total ratio: Control: 1.00±0.17 AU vs. 
PreOA: 4.04±0.28 AU, n=3-5; P<0.05). Although ischaemia per se was not associated with a 
statistical elevation in phosphorylated GSK-3β this can be ascribed to the degree of variation in the 
data, as well as as the type of statistical analysis applied. The reason for the observed variation in 
the data is unknown, although it seems to indicate that GSK-3β phosphorylation is very sensitive to 
external stimuli and experimental conditions. Direct comparison of the ischaemic group with 
control, using an ANOVA followed by Dunnett’s post hoc test, reveals a statistical difference 
(Phosphorylated to total GSK-3β ratio: Control: 1.00±0.17 AU vs. 20 GI: 3.43±0.97 AU, n=3-4; 
P<0.05 with Dunnett’s correction). 
 
Our data therefore reveals that ischaemia induces an increase in the phosphorylation of GSK-3β 
which is slighty enhanced by the administration of OA. 
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p38 Mitogen activated protein kinase 
As was observed for GSK-3β, ischaemia induced the phosphorylation of p38 MAPK. In this 
instance we therefore expressed all data relative to 20 minutes GI and not control (Phosphorylated 
to total ratio: Control: 0.10±0.06 AU vs. 20 GI: 1.00±0.21 AU, n=3-4; P<0.05). Inhibition of PP2A 
was not associated with any changes in this ischaemia-induced phosphorylation of p38 MAPK (20 
GI: 1.00±0.21 AU vs. PreOA: 1.14±0.13 AU, n=4-5) (Figure 4.11). 
 
Extracellular signal-regulated kinase p42/p44 
Ischaemia suppressed the phosphorylation of both isoforms of ERK, while OA treatment exerted 
no additional effects to this (Figure 4.12: Phosphorylated protein relative to total: ERK p42: Control: 
1.00±0.01 AU vs. 20 GI: 0.30±0.05 AU and PreOA: 0.32±0.07 AU; and ERK p44: Control: 
1.00±0.15 AU vs. 20 GI: 0.10±0.04 AU and PreOA: 0.10±0.03 AU, n=3-5; P<0.05). 
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Equal loading: β-Tubulin 
To assess loading, a randomly selected membrane was probed for β-Tubulin as a quality control 
sample for the whole series of blots. No significant differences between groups were observed 
(Figure 4.13). 
 
Protein profiles after 20 minutes of GI and 5 minutes reperfusion 
Protein phosphatase 2A 
Corresponding with the changes we observed in our initial characterization of PP2A during 
ischaemia and reperfusion (Chapter 3), the levels of PP2A-A was reduced relative to control values 
at 5 minutes reperfusion (Control: 0.98±0.05 AU vs. 5 Repf: 0.75±0.05 AU, n=4; P<0.05) (Figure 
4.14). Pre-ischaemic treatment with OA however had no effect on the levels of PP2A-C or –A. 
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Okadaic acid administration however exerted an effect on the posttranslational modification of 
PP2A-C (Figure 4.15). On the one side OA enhanced the phosphorylation of PP2A-C (Control: 
1.00±0.08 AU vs. PreOA: 2.33±0.23 AU, n=4-6; P<0.05), even to the degree that absolute 
phosphorylation was greater in the PreOA group than 5 minutes reperfusion alone (5 Repf: 
1.35±0.18 AU vs. PreOA: 2.27±0.25 AU, n=4-6; P<0.05). Direct comparison of the phosphorylated 
to total ratio at 5 minutes reperfusion alone to PreOA also showed a significant difference (5 Repf: 
1.55±0.21 AU vs. PreOA: 2.33±0.23 AU, n=4-6; T-test: P<0.05). On the other side OA reduced the 
methylation of PP2A-C relative to control (nonmethylated to total ratio: Control: 1.00±0.19 AU vs. 
PreOA: 2.27±0.19 AU, n=4-5; P<0.05). 
Stellenbosch University  http://scholar.sun.ac.za
- 171 - 
 
 
As seen at 20 minutes GI, these data do not always correspond with the data shown and 
discussed in Chapter 3 (Figure 3.21), probably because of the much smaller sample size utilized 
for these experiments. 
PP2A inhibition prior to ischaemia therefore leads to an increase in PP2A-C phosphorylation and a 
reduction in methylation at 5 minutes reperfusion. 
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Protein kinase B (Akt) 
Despite a relative degree of fluctuation in the data (Figure 4.16) OA treatment was associated with 
an increase in the phosphorylation of PKB/Akt relative to control values (Absolute phosphorylated: 
Control: 1.00±0.23 AU vs. PreOA: 2.35±0.21 AU, n=4-6; P<0.05; and phosphorylated to total ratio: 
Control: 1.00±0.29 AU vs. PreOA: 2.25±0.27 AU, n=4-6; P<0.05 with Dunnett’s correction). This 
data therefore shows that the inhibition of PP2A permits an increase in the phosphorylation of 
PKB/Akt in this setting. 
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Glycogen synthase kinase-3β 
Corroborating the effects we observed concerning the increased phosphorylation of PKB/Akt, we 
found that OA administration increased the degree of phosphorylation of GSK-3β relative to the 
total amount of protein (Figure 4.17: Control: 1.00±07 AU vs. PreOA: 4.70±1.06 AU, n=4-6; 
P<0.05). As was the case at 20 minutes GI, the lack of statistical significance in the relatively 
blatant difference between 5 minutes reperfusion and PreOA is due to the variance within the data. 
Maybe it is more accurate to consider the fact that only 50% of untreated hearts which received 
reperfusion alone were phosphorylated, while 100% of the hearts in the PreOA group were 
phosphorylated relative to control (Figure 4.17). 
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p38 Mitogen activated protein kinase 
Although visual inspection of the phosphorylated p38 MAPK blot would seem to indicate significant 
differences, at least between the control and OA treated groups, the large degree of variation in the 
data precludes statistical signifcance (Figure 4.18). 
 
Extracellular signal-regulated kinase p42/p44 
At 5 minutes reperfusion the group treated with OA prior to sustained ischaemia revealed a very 
outspoken difference from control and reperfusion alone in that it was associated with an increase 
in the absolute phosphorylation levels of ERK p42 (control: 1.00±0.15 AU and 5 Repf: 1.20±0.24 
AU vs. PreOA: 6.18±0.55 AU, n=4-5; P<0.05), as well as ERK p44 (control: 1.00±0.12 AU and 5 
Repf: 1.33±0.33 AU vs. PreOA: 3.56±0.64 AU, n=4-5; P<0.05) (Figure 4.19). Although these 
differences persisted for ERK p42 when expressed relative to total protein (control: 1.03±0.19 AU 
and 5 Repf: 1.70±0.46 AU vs. PreOA: 6.54±0.80 AU, n=4-5; P<0.05), it remained significant for 
only the comparison between control and PreOA for ERK p44 (control: 1.00±0.08 AU vs. PreOA: 
3.96±0.88 AU, n=4-5; P<0.05). This data definitely places PP2A as an important negative regulator 
of ERK p42/p44, especially p42, at the onset  of reperfusion. 
Stellenbosch University  http://scholar.sun.ac.za
- 175 - 
 
 
  
Stellenbosch University  http://scholar.sun.ac.za
- 176 - 
 
Equal loading: β-Tubulin 
To assess loading, a randomly selected membrane was probed for β-Tubulin. No significant 
differences between groups were observed (Figure 4.20). 
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Protein profiles after 20 minutes of GI and 10 minutes reperfusion 
Protein phosphatase 2A 
Although PP2A inhibition failed to induce any changes in the protein levels of PP2A-C or –A 
(Figure 4.21), we made the surprising observation that OA treatment was associated with a 
reduction in the ratio of PP2A-A to PP2A-C (Control: 1.00±0.07 AU vs. PreOA: 0.84±0.03 AU, n=3-
6; P<0.05). In view of the fact that this shift in the ratio of PP2A-C to –A was very slight, was not 
associated with significant changes in total protein levels of either and was also not part of a larger 
pattern, it seems very doubtful if this is of biological consequence despite its statistical significance.  
 
Furthermore, OA treatment also failed to elicit any changes in the phosphorylation of PP2A-C 
relative to 10 minutes reperfusion alone (Figure 4.22), although both were significantly elevated in 
comparison to control (Phosphorylated to total ratio: Control: 1.00±0.13 AU vs. 10 Repf: 1.50±0.11 
AU and PreOA: 1.54±0.05 AU, n=3-5; P<0.05). OA was however associated with a reduction in 
methylation in comparison to control (Control: 1.00±0.05 AU vs. PreOA: 1.42±0.07 AU, n=3-6; 
P<0.05). 
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Besides this effect of OA treatment to favour demethylation, PP2A inhibition exerted no further 
effect at 10 minutes reperfusion. 
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Protein kinase B (Akt) 
By 10 minutes reperfusion the level of phosphorylation of PKB/Akt was signifcantly elevated 
compared to control, with PP2A inhibition making no difference in this elevation (Figure 4.23: 
phosphorylated to total ratio: Control: 1.00±0.12 AU vs. 10 Repf: 4.03±0.27 AU and PreOA: 
3.04±0.28 AU, n=3-6; P<0.05). It is possible that the level of phosphorylation due to reperfusion 
per se had reached an optimal level and PP2A inhibition could not enhance it any further. 
 
Glycogen synthase kinase-3β 
PP2A inhibition was not associated with any statistically signifcant changes in the phosphorylation 
of GSK-3β (Figure 4.24). However a seemingly obvious increase in the phosphorylation of GSK-3β 
in the reperfusion alone group compared to control was observed. Again it is the degree of 
variability in the data which precludes statistical significance. It is however noteworthy that while 
none of the three control hearts were phosphorylated at this time, at least three of the five hearts in 
the reperfusion group and two of the six in the PreOA group were phosphorylated. Despite this, it 
seems clear that OA treatment before ischaemia did not influence the phosphorylation of GSK-3β 
at 10 minutes reperfusion. 
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p38 Mitogen activated protein kinase 
PP2A inhibition was not associated with any changes in the phosphorylation of p38 MAPK (Figure 
4.25). Ten minutes reperfusion on its own was however associated with a significant reduction in 
total p38 MAPK levels (Control: 1.00±0.09 AU vs. 10 Repf: 0.52±0.08 AU, n=3; P<0.05). This has 
not been reported before. Investigation of the membrane itself also casts doubt upon this 
observation, since it might be poor antibody binding (primary or especially secondary) which might 
explain this very unexpected result. In this regard, there are especially two bands in the 10 minutes 
reperfusion group which seems faded in comparison to the other bands in the group.  
As observed for GSK-3β, the lack of statistical significance regarding phosphorylation does not 
seem to correspond to the actual results on the membrane, where all of the hearts in the 
reperfusion group show phosphorylation compared to none of the hearts in the control group. 
Direct comparison of these two groups with a T-test reveals a significant difference (Control: 
1.00±0.03 AU vs. 10 Repf: 1.66±0.18 AU, n=3-5; P<0.05). Irrespective of this though, it is evident 
that OA treatment did not impact on the phosphorylation of p38 MAPK. 
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Extracelllular signal-regulated kinase p42/p44 
After the outspoken effect of OA treatment on ERK p42/p44 at 5 minutes reperfusion, it seems as if 
PP2A is of less importance at 10 minutes reperfusion (Figure 4.26). The phosphorylation of ERK 
p42 was significantly elevated at 10 minutes reperfusion in comparison to control, but unaffected 
by PP2A inhibition (ratio of phosphorylated to total protein: Control: 1.00±0.11 AU vs. 10 Repf: 
3.08±0.30 AU and PreOA: 2.79±0.30 AU, n=3-6; P<0.05). No statistically signifcant differences 
were observed for ERK p44.  
Stellenbosch University  http://scholar.sun.ac.za
- 182 - 
 
 
Stellenbosch University  http://scholar.sun.ac.za
- 183 - 
 
Equal loading: β-Tubulin 
To assess loading, a randomly selected membrane was probed for β-Tubulin as a representative 
test for the whole series of blots. No significant differences between groups were observed (Figure 
4.27). 
 
Co-immunoprecipitation with PP2A-C at 5 minutes reperfusion 
Western blotting of PP2A, the RISK pathway and p38 MAPK at the end of ischaemia and initial 
reperfusion, with and without pre-ischaemic treatment with OA, identified 5 minutes reperfusion as 
a period during which PP2A inhibition was associated with changes in phosphorylation of almost all 
proteins monitored: PP2A itself (Figure 4.15), PKB/Akt (Figure 4.16), GSK-3β (Figure  4.17) and 
ERK p42/p44 (Figure 4.19). Our data therefore point to 5 minutes reperfusion as a period of 
dynamic interaction between PP2A and its substrates. We wanted to determine if the elevation in 
phosphorylation of these proteins, associated with PP2A inhibition, were due to direct interactions 
with PP2A or due to PP2A involvement upstream of these kinases. To address this we 
immunoprecipitated PP2A-C from lysates prepared from the same isolated hearts which were used 
for the initial Western blotting experiments. We then probed the immunoprecipitate for our kinases 
of interest to determine if they were directly and physically associated with PP2A-C. 
We included a positive control for the Western blotting component of the experiment, which was 
simply a normal, unprecipitated lysate, exposed to 20 minutes ischaemia and 5 mintues 
reperfusion. A lysate was also exposed to the precipitation protocol, but without actual exposure to 
the anti-PP2A-C antibody used for precipitation. This sample was used as a negative control and 
served to indicate background signal. For each sample analysed we therefore had to subtract this 
negative control signal, or alternatively the lowest signal on the blot (which per implication then had 
to be representative of the background signal), from the signal measured. As described in Chapter 
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2, this corrected value was then expressed relative to the signal of the primary precipitation target, 
namely PP2A-C. 
Using the protocol described in Chapter 2 we succeeded in precipitating PP2A-C from the lysate, 
as can be judged by the strong signal for PP2A-C in the precipitate relative to even the positive 
control in Figure 4.28. No significant differences between groups were evident when probing for 
PP2A-C. 
 
The scaffold subunit for PP2A-C (PP2A-A) 
To confirm successful co-immunoprecipitation we also probed for PP2A-A (Figure 4.29), since this 
subunit has been found to almost always be associated with PP2A-C in forming the core dimer. 
Surprisingly, we found that a direct comparison of the 5 minute reperfusion group with PreOA using 
an unpaired T-test showed a significant difference between these groups (5 Repf: 0.37±0.08 AU 
vs. PreOA: 0.02±0.01 AU, n=3-4; P<0.01). It therefore seems that OA interferes with the stability of 
the core enzyme, leading to a dissociation of PP2A-A from PP2A-C. 
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Protein kinase B (Akt) 
Co-precipitation with PKB/Akt is shown in Figure 4.30. Although we found PKB/Akt associated with 
PP2A-C, this interaction was not statistically influenced by PP2A inhibition – although a strong 
trend showing reduced interaction was evident.  
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Glycogen synthase kinase-3β 
As was the case for PKB/Akt, although GSK-3β could be precipitated together with PP2A-C, OA 
administration failed to exert any effect on this interaction (Figure 4.31). 
 
p38 Mitogen activated protein kinase 
Surprisingly we found that not only was p38 MAPK associated with PP2A-C, but OA administration 
reduced this interaction compared to 5 minutes reperfusion alone (Figure 4.32: 5 minutes 
reperfusion: 0.27±0.03 AU vs. PreOA: 0.14±0.01 AU, n=3-4; P<0.01). This interaction between 
PP2A-C and p38 MAPK and the negative effect of OA administration on it was however not evident 
in the Western blotting data. This could possibly be explained by the fact that p38 MAPK could 
potentially be both upstream (as an activator) or downstream (as a substrate) of PP2A.  
 
If it is not exclusively a substrate of PP2A (as indicated by our Western blotting data), than its 
interaction with PP2A-C, which is implicated by our precipitation data, could be indicative of an 
upstream role for p38 MAPK in this setting. 
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Extracellular signal-regulated kinase p42/p44 
Data concerning the interaction between ERK p42/p44 and PP2A-C are shown in Figure 4.33. As 
expected, we could precipitate ERK p42/p44 alongside PP2A-C, confirming physical interaction 
between these two proteins. Direct comparison of Control with PreOA revealed a reduction in the 
association of ERK p42 with PP2A-C in the presence of OA (Control: 0.09±0.02 AU vs. PreOA: 
0.03±0.01 AU, n=4; unpaired T-test: P<0.05). Analysis of variance of the ERK p44 data also 
revealed a significant reduction in its association with PP2A-C in the presence of OA (Control: 
0.26±0.02 AU, and 5 minutes reperfusion: 0.22±0.04 AU vs. PreOA: 0.11±0.02 AU, n=3-4; 
P<0.05). Taken together, this implicates a physical interaction between ERK p42/p44 and PP2A-C 
at 5 minutes reperfusion. 
 
Discussion 
Having established in Chapter 3 that PP2A is recruited into the cellular response of the 
myocardium to I/R, the obvious next question pertains to the exact role of PP2A in the 
development of I/R injury. To answer this question we followed a pharmacological-based approach 
whereby we modulated the activity of PP2A within this setting. The consequences of PP2A 
activation will be addressed in Chapter 5, while in this part of the study we investigated the effects 
of PP2A inhibition. 
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Effects of PP2A inhibition on infarct size 
We used 10 nM of the marine toxin okadaic acid (OA) to inhibit PP2A. As described in “Materials 
and methods”, this concentration was chosen since it is a suitably low concentration to ensure that 
only PP2A is inhibited, and not PP1 as well (Bialojan & Takai, 1988; Cohen et al., 1990; Dawson & 
Holmes, 1999; Herzig & Neumann, 2000). Others have also used similar concentrations (Ladilov et 
al., 2002; Fan et al., 2010). As a starting point for this study we administered OA directly before 
sustained ischaemia and/or during the onset of reperfusion to assess the effects of PP2A inhibition 
on IFS. We found that of the three protocols tested, only pretreatment with OA elicited a significant 
effect: namely a reduction in IFS (Figure 4.5). The association between protein phosphatase 
inhibition and cardioprotection has been made by several researchers, although most of these 
studies failed to distinguish between the inhibition of PP2A and PP1. Studies which utilized OA are 
described in table 4.4.  
 
Our results confirm the majority of these studies, namely that pre-ischaemic treatment with OA 
confers cardioprotection. The use of other inhibitors such as fostriecin and calyculin A generated 
similar results where pretreatment and even administration during ischaemia conferred protection 
(Armstrong et al., 1997; Weinbrenner et al., 1998). Concerning specifically IFS as end-point, there 
are two noteworthy exceptions: Fenton and colleagues (2005) investigated the interplay between 
IPC mediated cardioprotection and phosphatase inhibition in aged versus young rat hearts. In their 
study it was only reperfusion treatment with 100 nM OA which reduced IFS in young hearts, and 
not pre-ischaemic treatment, while in aged hearts OA had to be administered both before and after 
ischaemia to elicit a similar effect. Recently, Fan and co-workers (2010) reported that treatment 
with 7.5 nM OA had no effect in non-preconditioned hearts on IFS. As is too often the case, there 
are several fundamental differences between these studies and ours which might explain the lack 
of consistency in results. 
 
There are especially four differences which are important: (1.) The type of ischaemia applied: 
Although Fan et al. and ourselves utilized a similar 35 minute regional ischaemic intervention, 
Fenton et al. used 30 minutes of GI. (2.) The dose of OA administered: We used 10 nM while Fan 
et al. used 7.5 nM. It is a small difference, but might explain the lack of effect in their model, since 
even 10 nM is quite a low dose compared to the concentrations used in other studies. Fenton, for 
example, used 100 nM OA. (3.) The duration of OA administration: Fenton et al. administered OA 
over a period of 25 minutes, while Fan et al. and ourselves only administered OA for a duration of 
10 minutes. Taking the latter two points into consideration, hearts in Fenton et al.’s study were 
exposed to much more OA prior to ischaemia, than those investigated in our study, as well as the 
study by Fan and co-workers. (4.) Perfusion mode: Fan et al. and ourselves utilized a combination 
of normal retrograde and work mode perfusion, while Fenton et al. only retrogradely perfused their 
hearts.   
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Table 4.4. Studies which have reported the use of OA in the setting of I/R. 
LVdevP: Left ventricular developed pressure; HR: Heart rate; RPP: Rate pressure product. 
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In view of these differences it is difficult to compare our results with those generated by Fenton and 
colleagues, as well as Fan et al. This present study is much closer to the study reported by Fan et 
al. with the only major difference being the concentration of OA used, which might explain the lack 
of an infarct sparing effect in their experiments. In this regard it is noteworthy that combination of a 
reperfusion treatment of OA with an IPC intervention increased functional recovery after 20 
minutes GI in Fan et al.’s model. This protective effect of OA in combination with IPC could imply 
that their dose of OA was indeed too low. 
 
There seems to be consensus that protein phosphatase, specifically PP2A, inhibition prior to 
sustained ischaemia is cardioprotective. This however raises the question why reperfusion 
treatment alone, or combination of pre-and reperfusion treatment could not elicit similar effects. We 
can only speculate on the reasons for this, but it seems the following two parameters must be 
taken into consideration (see also table 4.4): 
 
1.) The concentration of OA administered. This has already been referred to above. As alluded to 
in the “Materials and Methods” section, the cell membrane permeability and intracellular 
protein phosphatase content also contribute to determining an optimal dose for OA. Thus, 
even though the IC50 of OA for PP2A is in the range of 0.2-1 nM, it has been reported that 
doses even as high as 1 μM is necessary to effectively inhibit PP2A, while still not exerting an 
effect on PP1 (Favre et al., 1997 – this work was done on a cancerous cell line, and given the 
fact that PP2A is modulated in some forms of cancer (Schöntal, 2001), these observations 
must be interpreted with caution). Recently Sariahmetoglu et al. (2012) investigated the effects 
of OA administration in the isolated rat heart exposed to 20 minutes GI. They measured PP2A 
activity in hearts exposed to either 10, or 100 nM OA and found that only 100 nM statistically 
reduced the activity of PP2A and it was also the dose which exerted a cardioprotective effect. 
On the other hand, the standard error  on the data generated by 10 nM OA precluded 
statistical significance, and this dose also failed to elicit cardioprotection. 
2.) The duration of OA administration: In their characterization of OA, Favre and colleagues 
(1997) reported that OA administered in a range of 10 to 100 nM inhibited PP2A in MCF7 cells 
over a period of 12 (100% inhibition at a dose of 100 nM) to more than 48 hours (~ 80% 
inhibition with 10 nM at 48 hours incubation). Jayaraj et al. (2009) found that 100 nM of OA 
inhibited PP2A by only 50% in HeLa cells following 8 hours of incubation. In line with these 
reports which emphasise the importance of the duration of OA exposure, it is noteworthy that 
some researchers working on the isolated rat heart model administered their PP2A inhibitors 
for relatively long periods of time. Ladilov et al. (2002) administered OA over a period of 20 
minutes, while Weinbrenner and colleagues (1998) administered the PP2A inhibitor fostriecin 
for a total period of 45 minutes. 
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Applying these two variables to our study it seems clear that the dose we used, while probably not 
inhibiting PP1 and only affecting PP2A, is possibly at the lower limits of efficacy. In fact, it is 
possible that the significant reduction in IFS in the PreOA group could be attributed to the duration 
of administration: if administered 10 minutes prior to ischaemia, and assuming that the drug 
remains in the infarcted zone for the following 35 minutes of RI, the ischaemic portion of the heart 
would be exposed to OA for a total of 45 minutes. Obviously the timing of OA administration is also 
important, and our results, together with the majority of work published, imply that ischaemia itself, 
and possibly the very onset of reperfusion are important time points for the inhibition of PP2A to 
exert cardioprotection. During these time periods there must therefore be intracellular proteins 
which are normally dephosphorylated by PP2A, and which elicit pro-survival effects when 
phosphorylated. 
 
This then may explain why, in this study, the relatively low dose of OA administered prior to 
ischaemia protected the heart. If long enough exposure to OA is the key, why did the combined 
pre- and reperfusion treatment with OA fail to protect the hearts? A possible answer to this lies in 
the balance between the degree of PP2A inhibition and the specific subpopulations of PP2A which 
are inhibited. It could be argued that in our model, a fine balance exists between optimal and 
detrimental inhibition of PP2A in terms of the degree of loss of PP2A activity, as well as the 
substrates affected by this. Administration of OA both before and after sustained ischaemia might 
disrupt this balance and negate the positive effects of PP2A inhibition associated with the pre-
ischaemic administration of a PP2A inhibitor. More specifically, it could be that the loss of too much 
PP2A activity at the onset of reperfusion may be detrimental. This would then also explain why we 
did not see an infarct sparing effect when OA was administered during reperfusion alone. If this is 
the case, what could the potential mechanism be? The answer to this question lies outside the 
scope of this study and can only be speculated about. In 1993 Neumann et al. reported that OA 
can induce a positive inotropic effect in papillary muscles isolated from the guinea pig heart. They 
found that this effect was associated with an increase in Ca2+ flux through the L-type Ca2+ channel. 
Since then, PP2A has been implicated in the regulation of several Ca2+ regulator molecules such 
as PLB and the RyRs (see appropriate section in Chapter 1). It is therefore possible that the same 
mechanism involved in inducing a positive inotropic effect under baseline conditions could favour 
intracellular Ca2+ overload during reperfusion, thereby contributing to I/R injury. 
 
But why then did Fenton and colleagues report an infarct sparing effect associated with the 
reperfusion administration of 100 nM OA in an isolated rat heart model exposed to 30 minutes GI? 
There are two possible explanations: First, there are fundamental differences in the experimental 
model utilized by Fenton et al. vs. ourselves: Fenton and co-workers exposed their hearts to 
retrograde perfusion with pacing alone, while we utilized a work heart model which presents with a 
different experimental platform concerning metabolic and Ca2+ homeostasis. Second, the 
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differences in dosage OA applied: It could be argued that we simply administered OA at a too low 
dose during reperfusion to see the same effects which Fenton and co-workers reported. 
 
Despite the contradictory and challenging results in the literature, our data stands: OA treatment at 
a relatively low concentration of 10 nM prior to sustained ischaemia reduced IFS, thereby 
indicating that PP2A activity during ischaemia, and possibly the very onset of reperfusion is 
detrimental to the heart.  
Effects of PP2A inhibition on functional recovery 
In a model of 35 minutes regional ischaemia 
Although we found that pre-ischaemic treatment with OA reduced infarct size, there was no 
associated increase in the functional recovery of these same hearts despite the reduction in infarct 
size (table 4.2). This is an unexpected result, as one would expect that the reduction in IFS would 
also translate in an increase in functional recovery. Although many authors have found the 
expected association between IFS and post-ischaemic functional capacity (Jenkins et al., 1995; 
Salie et al., 2011), an uncoupling of functional ability and IFS has also been reported by several 
others as well (Cohen et al., 1999; Ford et al., 2001; Uematsu et al., 2001; Lochner et al., 2003; 
Van Vuuren et al., 2008; Huisamen et al., 2012).  
 
The most plausible explanation for the dissociation between IFS and functional recovery lies in 
what is fundamentally measured by these endpoints. The determination of IFS is dependent on the 
leakage of enzyme (dehydrogenases) from damaged cells (see Chapter 2). Thus, IFS is a 
measure of necrosis and possibly late apoptosis, since major damage to the cell membrane is a 
prerequisite for the detection of an infarcted zone. Functional recovery on the other hand is a 
composite endpoint which is affected by several factors including, cell death, stunning and 
arrhythmias. This means that even if the degree of cell death is reduced by an intervention, it will 
not necessarily translate into an increase in functional recovery. An excellent example of this is the 
phenomenon known as stunning, where an ischaemic period which is too short to induce 
meaningful necrosis still suppresses function (Braunwald & Kloner, 1982; Bolli, 1990). Stunning 
has been attributed to, amongst others, dysfunctional Ca2+ handling (Gross et al., 1999) and might 
in fact be one of the most important reasons why infarct size does not necessarily match post-
ischaemic function. In 2000 Cohen and co-workers reported that only when reperfusion time was 
extended to 3 weeks, the infarct sparing effects of an IPC protocol better matched functional 
recovery. They suggested that this could be due to the effects of stunning diminishing over time, as 
well as adaptive remodelling of the heart. 
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We therefore conclude that pre-ischaemic administration of 10 nM OA exerts a greater effect on 
PP2A-mediated dephosphoryation of proteins involved in cell survival than on other determinants 
of function such as stunning and arrhythmias. 
In a model of 20 minutes global ischaemia 
Having established that OA treatment failed to increase functional recovery in a model of RI, we 
wanted to determine what the effect of OA administration would be in a model specifically aimed at 
measuring functional recovery as primary endpoint. For these experiments we employed a model 
of global ischaemia. A major benefit of this model is the fact that it generates a relatively 
homogeneously damaged heart, thereby offering much more tissue for Western blotting analysis 
than RI. 
 
Treating hearts with 10 nM OA directly prior to 20 minutes GI however failed to elicit a significant 
increase in functional recovery (Figure 4.6). We propose three possible reasons for this: (1.) We 
saw a  large degree of variation in the data, as indicated by the large errors. Using a higher dose of 
OA (as discussed in the previous section) might have led to a more robust effect with less variation 
in the data. In this regard, Sariahmetoglu and colleagues (2012) recently reported that 10 minutes 
of OA administration at 10 times the concentration we used (100 nM) before and after a period of 
20 minutes GI exerted a cardioprotective effect in terms of functional recovery. (2.) In view of our 
hypothesis explaining the lack of an infarct sparing effect in hearts treated with OA at reperfusion 
alone or in combination with pretreatment (explained in the previous section), as well as the 
observation that the infarct limiting effects of pretreatment was not associated with functional 
recovery in the RI model, it seems probable that PP2A inhibition does not exert beneficial effects 
on the proteins involved in Ca2+ homeostasis. (3.) Studies comparing GI and RI (Lochner et al., 
2003; Bibli et al., 2012) indicate that GI is a much more rigorous and stressful intervention than RI, 
rendering it more difficult to demonstrate changes in functional recovery due to an experimental 
intervention. In this regard, Lochner and colleagues (2003) concluded that IFS following RI is an 
easier and more reliable endpoint than functional recovery. 
 
Despite the lack of functional recovery associated with OA treatment in this model, we decided to 
still use it to investigate the effects of OA treatment on the protein profiles of PP2A and other 
signalling proteins. The rationale behind this decision was that in order to assess the effects of OA 
on the cellular response to ischaemia and reperfusion a whole heart exposed to GI would be just 
as suitable as the area at risk in a heart exposed to RI, with the only difference that a GI 
intervention would generate more tissue for analysis than RI. 
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Effects of PP2A inhibition on protein profiles 
As has already been alluded to in Chapter 1, there are numerous possible substrates for PP2A 
which could be of importance in the setting of I/R, ranging from apoptotic mediators to regulators of 
Ca2+ homeostasis. We decided to focus on the contribution of PP2A to the signalling dynamics 
associated with this setting, especially in view of the potential importance of PP2A as a regulator of 
signalling and bearing in mind that very little has been done in this regard. We also selected to 
specifically investigate the well-characterized RISK pathway (encompassing ERK p42/p44, as well 
as PKB/Akt and GSK-3β), as well as the much investigated, but still controversial p38 MAPK. 
These kinases were selected because they have been identified as key role-players in the balance 
between life and death.  
 
When interpreting results generated by phosphatase inhibition, there is a simple golden principle 
which is often neglected, but should not be forgotten. This principle is simply that phosphatase 
inhibition in itself cannot stimulate or induce an increase in the phosphorylation of a substrate. It 
can only be associated with such an increased phosphorylation if the relevant opposing 
phosphorylation-stimulator (a kinase or activated receptor) is also active. In the absence of 
phosphorylating events (i.e. kinases), phosphatase inhibition is ineffectual and will have no visible 
consequences. 
 
The effects of OA pretreatment on PP2A itself will be discussed first. 
Protein phosphatase 2A-C 
The administration of OA to our isolated rat heart model prior to global ischaemia, elicited changes 
in both posttranslational modifications of PP2A-C, namely methylation and phosphorylation. 
The effect of OA administration on PP2A-C methylation 
At the end of ischaemia, before the onset of reperfusion, OA treatment was associated with a 
significant increase in the absolute nonmethylation signal relative to control alone (Figure 4.8), 
implying that it was extending the effects of ischaemia alone on PP2A-C methylation. This effect 
became more robust during reperfusion and at 5 and 10 minutes reperfusion OA treatment was 
associated with an increase in nonmethylated PP2A-C relative to the whole population of PP2A-C 
(Figures 4.15 and 4.22). OA therefore favours the demethylation of PP2A-C, irrespective of 
ischaemia and reperfusion. 
 
This is not an unexpected result, since although OA treatment is primarily associated with PP2A 
inhibition, it has been reported that OA also favours demethylation of PP2A-C (Favre et al., 1997; 
Zhou et al., 2008). In 1994 Floer and colleagues reported that OA treatment at concentrations 
which inhibit PP2A activity, favours demethylation of PP2A. Conversely, OA (40 nM) has been 
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reported to inhibit methylation of PP2A-C (Li et al., 1994). This inhibition was found to be 
dependent on the concentration of PP2A-C present in the mixture and independent of the 
concentration of methyltransferase (in retrospect probably LCMT-1); implying that OA elicits its 
inhibitory effect via a direct interaction with PP2A-C, and not LCMT-1. Recently Stanevich et al. 
(2011) also reported that OA inhibits the LCMT-1 mediated methylation of PP2A-C. 
 
Seemingly in contrast to this, in 1996 Lee et al. (1996) identified a methylesterase in bovine brain 
samples which specifically demethylates PP2A-C (in retrospect probably PME-1) and which is 
inhibited by OA at doses in the nanomolar range. Similarly, Ogris and colleagues (1999) reported 
that OA inhibited PME-1. Thus, OA can also inhibit the demethylation of PP2A-C.  
 
These studies all together seem to confirm the original hypothesis put forward by Lee et al. (1996) 
and Li et al. (1998) that OA binding to PP2A-C blocks the accessibility of PP2A-C for both PME-1 
and LCMT-1. If both enzymes are however blocked equally, one would expect no changes in the 
methylation of PP2A in the presence of OA, at least at saturation concentrations. The fact that OA 
has been found to either enhance or suppress methylation implies that differences in OA 
concentration, as well as the cellular milieu (or reaction mixture) to which the OA is added, will 
influence the eventual effect on methylation. In this regard it is interesting that Kranias et al. (2010) 
reported that in mast cells OA at lower concentrations (less than 100 nM)  favoured methylation, 
reaching a peak of methylation at 100 nM, while at higher concentrations it seemed to suppress 
sustained methylation. 
 
In our model, OA enhances the demethylation associated with ischaemia and reperfusion. As 
discussed in Chapter 3, we hypothesise that I/R is associated with an increase in the interaction 
between PME-1 and PP2A-C, thereby explaining the demethylation we observed at 20 minutes GI, 
as well as at 5 and 10 minutes reperfusion. Taking this into consideration, it seems that OA binding 
to PP2A-C in our model, for some unknown reason, blocks access to LCMT-1 specifically, thereby 
enhancing the demethylating effects of PME-1. 
 
These observations emphasise the complexities associated with OA treatment, particularly in the 
scenario of I/R. Keeping in mind that methylation determines interaction with the regulatory 
subunits, thereby contributing to the regulation of substrate specificity and subcellular localisation, 
the question arises what the implications of OA treatment are on B subunit stability, as well as on 
substrate and intracellular targeting immediately following OA dissociation from PP2A-C.  
The effect of OA administration on PP2A-C phosphorylation 
In their original description of the tyrosine 307 phosphorylation of PP2A-C, Chen and colleagues 
(1992) reported that the autodephosphorylation of PP2A-C could be inhibited by OA, thereby 
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favouring enhanced phosphorylation of the enzyme. More recently Zhou et al. (2008) also reported 
that OA treatment favours PP2A phosphorylation.  
 
Our data also confirmed these observations in that OA treatment increased the absolute level of 
phosphorylation of PP2A-C in comparison to control at 20 minutes GI (Figure 4.8) and exerted an 
even stronger effect at 5 minutes reperfusion, when OA administration increased absolute 
phosphorylation in comparison to 5 minutes reperfusion (without OA) as well, and also increased 
the degree of phosphorylation relative to total PP2A-C in comparison to control (Figure 4.15). 
Since 5 minutes reperfusion increased the phosphorylation of PP2A-C per se (Chapter 3), OA 
treatment simply enhanced this by inhibiting autodephosphorylation. It is also important to note that 
at 10 minutes reperfusion OA exerted no further effect on PP2A-C phosphorylation (Figure 4.22).  
 
Our results imply that at especially 5 minutes reperfusion, under normal conditions, there is a large 
degree of autodephosphorylation exerted by PP2A, thereby maintaining PP2A activity at this time, 
in opposition to the concurrent increase in phosphorylation of PP2A-C which we have previously 
reported (Chapter 3).  Autodephosphorylation therefore does not abolish the I/R mediated increase 
in PP2A-C phosphorylation (Chapter 3). By 10 minutes reperfusion, the effects of OA had 
dissappeared. This could be simply due to the effects of OA waning over time, although our 
methylation data would argue against this. Alternatively, the kinases involved in the 
phosphorylation of PP2A-C could be too dominant at this timepoint for our relatively small dose of 
OA to effectively/visibly influence phosphorylation/dephosphorylation. It could also be that the 
autodephosphorylating activity of PP2A is somehow downregulated at this time, possibly in 
association with the “storage” of inactive PP2A through interaction with PME-1. In all likelihood it is 
probably a combination of these three factors. 
 
In summary: 20 minutes of GI and especially 5 minutes of reperfusion is associated with 
autodephosphorylation of PP2A-C opposing the I/R induced phosphorylation of this enzyme. Thus, 
even the activity of PP2A-C is in the end the product of both phosphatase (in the form of 
autodephosphorylation) and tyrosine kinase activity. 
The effect of OA administration on PP2A holoenzyme assembly 
Immunoprecipitation of PP2A-C from lysates of hearts collected at 5 minutes reperfusion, in the 
presence and absence of a pre-ischaemic administration of OA revealed an unexpected finding in 
that OA treatment was associated with a significant reduction in the physical interaction between 
PP2A-C and PP2A-A (Figure 4.29). 
 
I am not aware of any previous work which has been done with OA which has investigated the 
effects of OA administration on dimer assembly. These results are however difficult to explain for 
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two reasons: First, Xing and colleagues (2006) managed to characterize the crystal structure of 
PP2A core enzyme bound to either OA or microcystin-LR. This implies that OA does not interfere 
with the formation of the core enzyme. Second, some authors have found that long-term treatment 
with OA is associated with an increase in the levels of PP2A-C (Favre et al., 1997; Zhou et al., 
2008). You would however not expect such an increase if PP2A-C was indeed dissociated from 
PP2A-A, since unless PP2A-C binds to another protein (such as PME-1 or α4), it will become 
unstabe and be degraded (Strack et al., 2004; Van Kanegan et al., 2005).  
 
However, this observed OA mediated disassembly of the PP2A core enzyme is an intriguing result 
which, if confirmed, warrants further investigation. 
Protein kinase B (Akt) 
At 20 minutes GI, PKB/Akt is not phosphorylated, as can be seen from the relevant blot in Figure 
4.9, in comparison to the positive control (a heart which was exposed to 20 minutes GI followed by 
30 minutes reperfusion). This has also been observed by others (Mockridge et al., 2000; Beauloye 
et al., 2001). In keeping with the golden principle stipulated at the onset of this discussion, it is 
therefore not surprising that OA inhibition exerted no effect on PKB/Akt phosphorylation at this 
stage. Reperfusion however rapidly induced an increase in the phosphorylation of PKB/Akt (Figure 
4.16). In this milieu of PKB/Akt phosporylation at 5 minutes reperfusion, PP2A inhibition was 
associated with an increase in the phosphorylation of PKB/Akt in comparison to control (Figure 
4.16), suggesting that OA enhances the reperfusion mediated phosphorylation of PKB/Akt. At 10 
minutes reperfusion phosporylated PKB/Akt is significantly elevated in both 10 minutes reperfusion 
per se and PreOA (Figure 4.23). This loss of OA specific effect could be due to either washout of 
OA at this time point, or it could be indicative of diminished importance of PP2A at this time. 
 
From the data which we have, it is clear that PP2A dephosphorylates PKB/Akt within the first 
minutes of reperfusion; an observation which fits with the PP2A-PKB/Akt interactions which have 
been noted by others (Andjelković et al., 1996; Van Kanegan et al., 2005; Zuluaga et al., 2006; 
Mott et al., 2008). Our co-immunoprecipitation experiments not only showed that PP2A is 
physically associated with PKB/Akt, but it also showed a strong trend for OA interfering with this 
association (Figure 4.30). The data is however unfortunately not definitive, although in combination 
with what is known in the literature it seems very probable that PP2A directly dephosphorylates 
PKB/Akt at 5 minutes reperfusion. 
Glycogen synthase kinase-3β 
Although GSK-3β has been reported to be downstream of PKB/Akt (Cross et al., 1997), we already 
observed a dissociation between these kinases at 20 minutes GI, since GSK-3β was 
phosphorylated at this time (Figure 4.10). Pre-ischaemic OA administration enhanced the 
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phosphorylation of GSK-3β at 20 minutes ischaemia as evidenced by the significant difference 
between PreOA and control at this time (Figure 4.10). This OA-mediated enhancement of GSK-3β 
phosphorylation became more evident at 5 minutes reperfusion (Figure 4.17), but dissipated at 10 
minutes reperfusion (Figure 4.24). 
 
Our experiments therefore implicate PP2A as a phosphatase which targets GSK-3β both at the 
end of ischaemia, as well as within the first minutes of reperfusion. Since PKB/Akt is not activated 
during ischaemia, and therefore also not influenced by the presence of OA, the OA mediated 
elevation in the phosphorylation of GSK-3β which we observed must either be due to an interaction 
between PP2A and another upstream regulator of GSK-3β which is active during ischaemia, or 
PP2A must be directly dephosphorylating GSK-3β. Unfortunately we did not investigate either of 
these possibilities. Co-immunoprecipitation experiments at 5 minutes reperfusion however 
indicated a physical association between PP2A-C and GSK-3β (Figure 4.31), which was not 
influenced by OA administration. This would favour the model that PP2A inhibition does not 
influence GSK-3β directly, but rather exerts an effect on upstream signalling. This at least seems 
to be the case at 5 minutes reperfusion, and is very conceivable given the fact that OA favoured 
the phosphorylation of PKB/Akt at this time. 
 
The question of the nature of the interaction between PP2A and GSK-3β at 20 minutes GI remains 
open. Our co-immunoprecipitation data at 5 minutes reperfusion both confirms the possibility of a 
direct interaction between GSK-3β and PP2A, but also casts some doubt on the idea since it 
actually implied that OA exerts its effects on GSK-3β at reperfusion via the activation of PKB/Akt. 
As discussed by Juhaszova and colleagues (2004) numerous pathways potentially signal on to 
GSK-3β. The main thrust of research in the field of I/R injury and cardioprotection has been aimed 
at elucidating cellular events either during or following and IPC stimulus, or during reperfusion with 
remarkably little known concerning events during ischaemia itself. It is therefore a matter of 
speculation concerning which potential kinases are activated during ischaemia and are responsible 
for the phosphorylation of GSK-3β. Potential kinases which have been implicated as upstream 
inhibitors of GSK-3β and which are also activated by ischaemia include PKC (Prasad  & Jones, 
1992) and PKA (Krause et al., 1983; Zhang et al., 2010). Of these two it is especially PKA which 
could potentially play a role during ischaemia, given the fact that sustained ischaemia is associated 
with an increase in cellular levels of cAMP (Rabinowitz et al., 1975; Krause et al., 1983; Zhang et 
al., 2010). If it is indeed PKA which is involved as an upstream inhibitor of GSK-3β during 
ischaemia, it is just as conceivable that the effects of OA are mediated through an increase in PKA 
activation, since PP2A has been implicated in the dephosphorylation of PKA as well (Liauw & 
Steinberg, 1996). 
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It must also be mentioned that there is not consensus regarding ischaemia induced 
phosphorylation of GSK-3β. In a hepatic model of I/R, Ren and colleagues (2011) found that 90 
minutes of ischaemia actually slighly reduced GSK-3β phosphorylation. Obviously, differences in 
the organ investigated may explain this contrast between their data and ours. 
 
We can therefore conclude that GSK-3β phosphorylation at the end of ischaemia and at the onset 
of reperfusion is sensitive to PP2A activity. Whether this happens through a direct interaction 
between GSK-3β and PP2A, or through the PP2A-mediated regulation of upstream GSK-3β 
kinases remains to be established. Our co-immunoprecipitation data at 5 minutes reperfusion 
favours the theory that OA exerts it effects upstream from GSK-3β. 
p38 Mitogen activated protein kinase 
As elaborated on in the introduction of this chapter, p38 MAPK is controversial, not only concerning 
its role in I/R and cardioprotection, but also with regards to the way in which it interacts with PP2A: 
either as a regulator or as a substrate. 
 
At the end of ischaemia OA administration exerted no effect on the ischaemia induced 
phosphorylation of p38 MAPK (Figure 4.11). Similarly, PP2A inhibition had no significant effect on 
p38 phosphorylation at 5 or 10 minutes reperfusion (Figures 4.18 and 25). This then implies that in 
our model p38 MAPK is not a substrate for PP2A. Given this it was quite surprising that our co-
immunoprecipitation experiments on tissue collected at 5 minutes reperfusion showed an 
association between PP2A and p38 MAPK which was mitigated by OA treatment (Figure 4.32). 
Following on the proposal discussed above, that OA binding to PP2A-C interferes with PME-1 and 
LCMT-1 binding to PP2A-C, it could be argued that OA binding to PP2A-C blocks an association 
with p38 MAPK. In this regard it has been shown that p38 MAPK can influence PP2A activity by 
physically associating with the enzyme (Grethe & Pörn-Ares, 2006). 
 
Our data therefore favours a model where, in the setting of both ischaemia and reperfusion, p38 
MAPK is upstream of PP2A and possibly contributes to its regulation by physically interacting with 
it. 
Extracellular signal-regulated kinase p42/p44 
We found that ischaemia suppressed ERK p42/p44 phosphorylation below control levels (Figure 
4.12). The fact that OA administration failed to influence this indicates that PP2A is not involved in 
this ischaemia mediated dephosphorylation of ERK p42/p44. The question therefore remains open 
as to which phosphatase is involved in this response? 
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Intriguingly, PP2A is recruited as an ERK p42/p44 phosphatase at the onset of reperfusion, as 
shown by the profound increase in phosphorylation of ERK p42/p44 in OA treated hearts at 5 
minutes reperfusion (Figure 4.19). This OA mediated effect was however lost at 10 minutes 
reperfusion (Figure 4.26). The contribution of PP2A to the dephosphorylation of ERK p42/p44 is 
further confirmed by our co-immunoprecipitation experiments which  indicated an association 
between ERK p42/p44 and PP2A-C, which was abolished by OA treatment.  
As discussed in the introduction, PP2A has been implicated as a positive regulator of the ERK 
p42/p44 pathway by contributing to activation of the upstream kinase Raf-1(Jaumot & Hancock, 
2001; Abraham et al., 2001; Adams et al., 2005). Our data is however in agreement with the body 
of work which idenifies PP2A as an ERK p42/p44 phosphatase (Sontag et al., 1993; Alessi et al., 
1995; Quintalje et al., 1996; Nyunoya et al., 2005) at the onset of reperfusion, but not at the end of 
ischaemia. 
Summary 
Having discussed the effects of PP2A inhibition on PP2A, the RISK pathway and p38 MAPK at the 
end of 20 minutes GI and the onset of reperfusion, some trends and issues have emerged which 
require further discussion: 
1.) Although OA was administered immediately prior to sustained ischaemia it did not exert an 
effect on the selected kinases during ischaemia itself. The only exception to this is GSK-3β 
which showed enhanced phosphorylation in the presence of OA. 
 
2.) Five minutes reperfusion is a very dynamic time point concerning the phosphorylation and 
dephosphorytion of the pro-survival kinases. It is at this time that PP2A shows the most 
outspoken autodephosphorylation, and that the effects of PP2A inhibition is most evident. 
 
3.) The observations referred to in the previous paragraph were made using Western blotting 
techniques. We also applied a co-immunoprecipitation approach to further confirm and 
characterize these observations. On the one hand, this seems to have worked, since we found 
that in almost all instances (except for GSK-3β) OA treatment interfered with the interaction 
between these kinases and PP2A. On the other hand it is worrisome that 5 minutes 
reperfusion in itself was never associated with the expected increase in PP2A-kinase 
interactions relative to control. One possible explanation for this pertains to the way in which 
the lysates were prepared, and is based on the idea that different cellular populations of 
kinases and phosphatases are involved in different mechanisms. In order to co-
immunoprecipitate we had to adjust our lysis buffer in order to avoid protein-protein 
dissociation. One of these adaptations involved the reduction of the concentration detergent in 
the buffer from 1% to 0.1% Triton X-100. This led to a better co-immunoprecipitation, but also 
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to less efficient extraction of proteins from the cell membranes. The implication of this is that 
by reducing the protein extraction from the membrane fraction, we inadvertently changed the 
composition of the lysate analysed, relative to the lysates used for the Western blots which 
were prepared in 1% Triton X-100. This opens the door for the possibility that, although the co-
immunoprecipitation experiments revealed the impact of OA exposure in protein interactions, it 
did not include the same population of kinases as the lysates analysed by Western blotting, 
thereby possibly missing (or at least partially missing) those kinases of which the 
phosphorylation was influenced by the presence of OA.  
 
Another adjustment that we had to make was the omission of PSP inhibitors (β-
glycerophosphate and tetrasodiumpyrophosphate) from the immunoprecipitation lysis buffer. 
We did this to avoid possible interference in the interactions between PP2A and its substrates. 
In the case of the OA treated group OA had already bound to and inhibited PP2A in the 
cardiomyocytes, thereby interfering with the interaction between PP2A and its substrates. In 
the control and 5 minutes reperfusion group though, PP2A was not inhibited by anything – not 
even phosphatase inhibitors in the lysis buffer. This opens the door for the possibility of PP2A 
interacting with any potential substrate in the lysate mixture itself, sometime between the 
making of the lysate and preparing the final boiled sample containing Laemmli buffer. This 
would then in effect “mask” any differential intracellular association between PP2A and its 
substrates in the controls and at 5 minutes reperfusion alone.  
 
These are limitations which we encountered while attempting co-immunoprecipitation with 
PP2A-C and necessitate the interpretation of this data in the context of the more conservative 
Western blotting data. 
 
4.) Although we identified 5 minutes reperfusion as a dynamic protein phosphorylation-
dephosphorylation timepoint, 10 minutes failed to show the same dynamic profile. There are 
three possible explanations for this: (1.) The one explanation which almost immediately comes 
to mind is that all the intracellular signalling processes which we measured have normalized at 
10 minutes reperfusion. This conclusion is however only valid if enough OA is still present 
inside the myocytes to effectivley inhibit PP2A, and should ideally be tested by comparing the 
PreOA group with a control group which received perfusion throughout, in conjunction with a 
comparable OA administration (in order to assess the effects of OA on non-ischaemic control 
hearts). (2.) While characterizing the phosphorylation mediated inactivation of PP2A, Chen 
and colleagues (1992) postulated that the autodephosphorylation of PP2A presents a 
mechanism controlling the transient inhibition of PP2A, thereby opening a window of 
opportunity for signalling processes to happen uninhibited by PP2A. In our experimental setup 
such a “window of PP2A inhibition” would be characterized by an increased phosphorylation of 
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the enzyme, lack of OA-mediated changes to the phosphorylation of both PP2A and its 
substrates and strong phosphorylation of the involved signalling pathways. Ten minutes 
reperfusion seem to meet all these criteria, and as such could indicate an early endogenous 
mechanism to reduce PP2A activity in order to allow pro-survival signalling to occur unabated. 
(3.) Another possible, less glamorous but probably more likely, explanation is that the low OA 
dose initially administered has been washed out of the hearts by 10 minutes reperfusion. Our 
experimental design unfortunately does not allow us to determine which of these explanations 
are valid. The 10 minute reperfusion data should therefore be interpreted with great caution.  
 
In conclusion, although PP2A shows significant phosphorylation (and therefore inhibition) at 5 
minutes reperfusion, this is balanced by an active autodephosphorylation activity of the enzyme. 
We have identified PP2A as an important direct phosphatase of both PKB/Akt and ERK p42/p44 at 
5 minutes reperfusion, but not during sustained ischaemia. PP2A also favours the activation of 
GSK-3β during sustained ischaemia and early reperfusion, although this does not seem to be 
mediated by a direct interaction but rather through the action of PP2A on signalling molecules 
upstream of GSK-3β. At no point in I/R is p38 MAPK a substrate of PP2A, although we did find 
evidence for a physical association between the two, revealing the possibility of p38 MAPK 
mediating some of its effects via PP2A. 
PP2A inhibition in the isolated rat heart exposed to I/R: limitations and 
future directions 
As discussed at length earlier in this chapter, we utilized a relatively low concentration of OA for a 
relatively short period of time. The advantage of this approach was that all effects observed could 
be ascribed with a high degree of certainty to PP2A, but not PP1 inhibition. It is however very likely 
that we would have generated more robust data, especially concerning functional recovery and 
protein profiles had we used a higher dose of OA, possibly also for a longer period of time. In this 
regard it would be interesting to repeat these experiments but with an OA dose of 100 nM, 
administered for no less than 20 minutes at a time. 
 
A caveat is warranted at this time. It has been found that at PP2A specific concentrations OA 
inhibits not only PP2A, but also the less prevalent protein phosphatases PP3, 4, 5 and 6 
(Honkanen et al., 1994; Herzig & Neumann, 2000; Janssens & Goris, 2001; Dounay & Forsyth, 
2002). The obvious implication of this is that some of the effects we have observed might be 
attributable to any of these less well described phosphatases. This is a fundamental shortcoming 
using OA, and as more research is done on these phosphatases the relative contribution of each to 
the effects associated with OA administration will hopefully become clearer. For now, we assume 
that most of the effects elicited by OA can be ascribed to PP2A. 
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It is therefore clear that a fundamental problem in this type of research is the ability to modulate 
PP2A activity. OA is a well-accepted and -characterized tool to investigate PP2A, it is however not 
the only one. It would be beneficial to compare our OA studies with other PP2A and PP1 inhibitors 
such as fostriecin and calyculin A in an attempt to better elucidate the role of PP2A (and PP1 for 
that matter) in I/R. Silencing of PP2A-C (or PP2A-A, which would eventually lead to a reduction in 
PP2A-C levels (Van Kanegan et al., 2004)) is also an approach which can be used to modify PP2A 
activity. It offers the advantage of greater specificity, although its application is limited to a cell 
based system and it will exert its effects over a longer period of time, which could complicate 
matters, especially if compensatory mechanisms come into effect (as noted by Van Kanegan et al., 
2004). The ideal study would therefore combine PP2A silencing with pharmacological inhibition to 
better describe the role of PP2A. 
 
It is also very unfortunate that we were not able to measure PP2A activity. This is a shortcoming 
which must be addressed, since it will allow quality control on whichever intervention is chosen to 
modulate PP2A activity. At the onset of this study we attempted to measure PP2A activity by 
measuring the generation of free phosphates in tissue lysates pre-cleared of phosphates, but failed 
to optimize the technique in our model (see Chapter 2). Other approaches to measure PP2A 
activity will have to be explored. Concerning this study, the low dose of OA which we used almost 
guarantees that the effects observed, can be ascribed to PP2A inhibition. 
 
We found that pre-ischaemic treatment of heart preparations with OA conferred protection. 
Although we then analysed timepoints at the end of ischaemia and early in reperfusion in order to 
investigate the mechanisms at work, it would probably be insightful to also analyse the effects of 
OA on the protein profiles immediately before the onset of ischaemia. It may also be useful to 
investigate 15 minutes reperfusion in order to better understand the sequence of events in 
reperfusion and also to assess if there are any longterm effects elicited by OA. 
 
As explained in the discussion, we utilized a model of 20 minutes GI in order to shed light on the 
mechanisms involved in the infarct sparing effect of OA administration in a model of 35 minutes RI. 
The rationale was that we were interested in the effects of OA administration on I/R tissue per se. 
We limited the duration of GI to 20 minutes in order to also assess functional recovery. If however 
the focus is purely to delineate the singalling mechanisms involved in 35 minutes RI, it would 
possibly be better to use a model of 35 minutes GI. 
 
As also mentioned in Chapter 3, our failure to investigate the regulatory B subunits was a 
conscious decision to simplify the study by first focussing on the most basic elements, namely the 
core enzyme of PP2A. Our results however necessitate further research into the specific regulatory 
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subunits which are involved in targeting PP2A to its different substrates during ischaemia and 
reperfusion.  
 
Linking with this, we chose to focus our study on the impact of PP2A inhibition on signalling events. 
The lack of effect of PP2A inhibition on functional recovery and the body of work which has 
implicated PP2A in the regulation of proteins involved in Ca2+ homeostasis, however make a good 
argument to also investigate the effects of PP2A inhibition on Ca2+ homeostasis in the setting of 
I/R. 
 
We found that p38 MAPK is possibly an upstream regulator of PP2A. Such a relationship between 
these two signalling molecules have been described by others and as such warrant investigation in 
our setting as well. To do this we will have to modulate the activity of p38 MAPK (either through 
pharmacological means, or by silencing the enzyme) and then assess the effect of this on PP2A in 
terms of activity, cellular location and substrate specificity. 
 
Finally, we utilized a co-immuprecipitation approach to assess the binding partners of PP2A-C at 
the onset of reperfusion. This approach is potentially very useful and contributes to the 
interpretation of the Western blotting results. In this study however, we can only utilize our 
immunoprecipitation data to indicate possible relationships which should be investigated in the 
future, since our results still require confirmation. Confirmation of co-immunoprecipitation results 
entails the immunoprecipitation of each of the proposed binding partners of PP2A and then probing 
for PP2A-C in order to see if it co-precipitates with these proteins. This is however a major 
undertaking which did not fall within the range of this project. Other forms of confirmation which 
could also be pursued entail the use of immunofluerescence microscopy in order to assess co-
localisation of PP2A-C with these kinases, or FRET (Fluorescence Resonance Energy Transfer) 
analysis. 
 
Despite these limitations and shortcomings, this study serves as a preliminary report on the 
contribution of PP2A to the signalling events associated with myocardial I/R. It has revealed some 
expected, and some intriguing results which set the foundation for further studies.  
PP2A inhibition in the isolated rat heart exposed to I/R: 
summary and conclusion 
The pre-ischaemic treatment of isolated rat hearts with 10 nM OA was associated with an infarct 
sparing effect, which can most likely be ascribed to the favourable elevation in phosphorylation of 
the pro-survival RISK pathways at the onset of reperfusion. PP2A is therefore involved in the 
negative regulation of these pathways during early reperfusion. Inversely to this, PP2A is a positive  
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regulator of GSK-3β during ischaemia, with PP2A inhibition favouring the inhibition of GSK-3β, 
which can potentially also have cardioprotective consequences. 
 
Our results have therefore placed PP2A as a relevant and important regulator of survival signalling 
during sustained ischaemia and especially at the onset of reperfusion. 
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CHAPTER 5 
Pharmacological modulation of PP2A: 
Activation 
 
  
“’Have you guessed the riddle yet?’ the Hatter said, turning to Alice again. 
‘No, I give it up,’ Alice replied. ‘What’s the answer?’ 
‘I haven’t the slightest idea,’ said the Hatter. 
‘Nor I,’ said the March Hare.” 
Lewis Carroll 
Alice’s adventures in wonderland 
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Chapter 5 
Pharmacological modulation of PP2A: 
Activation 
Introduction 
The fungal species Cordyceps (class Ascomycetes, family Cordycipitaceae) was already 
recognised in Chinese folk medicine to have medicinal value when ingested. This traditional belief 
motivated modern studies into the composition of these fungi which, in turn, revealed several 
interesting fungal metabolites to medical science. One of the metabolites from Isaria sinclairii, 
myriocin, was especially interesting due to its immunosuppressive characteristics. In 1994, a novel 
compound was derived from myriocin which was called FTY720, also known as fingolimod (Chun 
& Brinkmann, 2011). 
 
Although the initial interest in this drug centred on the possibility of utilizing its immunosuppressive 
abilities to combat transplanted organ rejection, it is its beneficial effects in the setting of multiple 
sclerosis (MS) which led to its eventual approval by the United States and European Union for 
clinical use as an oral treatment for MS under the commercial name Gilenya (Novartis) (Chun & 
Brinkmann, 2011; US Food and Drug Administration, accessed 2013). 
Immunosuppressive mechanism in MS 
MS is an autoimmune disease in which immune cells transverse the blood-brain barrier to attack 
the central nervous system, leading to eventual demyelination and neurodegeneration (Rubin, 
2013). There are two mechanisms by which FTY720 can suppress this autoimmune response: 
Regulating lymphocyte egress from the lymph nodes 
The movement of lymphocytes from the lymph nodes in response to an immunological challenge is 
a regulated process characterized by an almost paradoxical initial retention of lymphocytes in the 
nodes in order to increase the number of antigen-specific T cells (Brinkmann, 2009). This retention 
is associated with a down-regulation of sphingosine-1-phosphate (S1P) receptor 1 (S1P1) in the T 
cells stationed in the lymph nodes, implicating S1P stimulated signalling in the regulation of T cell 
egress (Brinkmann, 2009). It is this S1P link to lymphoid function which supplies the point of 
interaction between FTY720 and the immune response. 
 
FTY720 is a structural analogue of the sphingolipid, sphingosine, which is a structural component 
of cell membranes and of importance in cellular signalling (Hla & Brinkmann, 2011). Just like 
sphingosine, FTY720 easily crosses cellular membranes and can be phosphorylated intracellularly 
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by the enzyme sphingosine kinase 2 (SK2) (Karliner, 2009). Following its phosphorylation, 
phosphorylated FTY720 (P-FTY720) can exit the cell to act in a paracrine or autocrine fashion to 
bind to S1P receptors in the cell membrane. Of the five S1P receptors which have been identified, 
P-FTY720 can bind to S1P1, 3, 4 and 5 (Brinkmann, 2009).  
 
Although P-FTY720 therefore acts as a S1P1 receptor agonist, it elicits its immunomodulatory 
effect by paradoxically acting, as Brinkmann (2009) puts it, as a “functional antagonist” of S1P 
signalling (Chun & Brinkmann, 2011). It elicits this effect by inducing the down regulation of S1P1 
both in terms of receptor internalization, as well as promoting the proteosomal degradation of the 
receptor (Brinkmann, 2009). These antagonistic effects in the lymphoid tissue culminates in the 
suppression of especially central memory T cell egress from the lymph nodes (Hla & Brinkmann, 
2011).  
Effects of FTY720 on the central nervous system 
Additional to these effects of FTY720 on the immune system, there is also some evidence for a 
direct protective interaction between FTY720 and the central nervous system. As described for the 
immune tissue, P-FTY720 down regulates S1P1 and S1P3 receptors in astrocytes in the central 
nervous system. This is beneficial, since both S1P1 and S1P3 have been implicated in mediating 
astrogliosis; the pathological transformation of astrocytes associated with several 
neurodegenerative conditions, such as MS (Brinkmann, 2009; Chun and Brinkmann, 2011). 
 
In conclusion, FTY720 elicits its effects on MS by virtue of being a sphingosine analogue. It is 
phosphorylated to P-FTY720 which can then act as a S1P receptor agonist, but with the significant 
difference that it down-regulates the S1P receptors, thereby modulating the release of activated 
lymphocytes from the lymph nodes, as well as pathological transformation in the central nervous 
system. We were however not interested in FTY720 for its immunomodulatory effects. It is its 
potential as a tumour suppressor which is of more interest to us. 
FTY720 as a tumour suppressor 
FTY720 has also received some attention as a possible tumour suppressor, primarily through its 
effects on cell survival signalling via its modulation of the activity of the tumour suppressor PP2A. 
 
Although PP2A has been implicated as an oncogenic effector, it has also been linked to tumour 
suppression (Arnold & Sears, 2008; Perrotti & Neviani, 2013). The combination of these two 
disparate characteristics can however be reconciled if one takes into account the multitude of 
PP2A holoenzymes which could potentially target a very wide variety of substrates in the cell (see 
the introductions to especially Chapters 3 and 4). There is therefore some interest in the potential 
clinical value of drugs which can activate PP2A, of which FTY720 is one (Perrotti & Neviani, 2013). 
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One of the first studies revealing this effect of FTY720 was published in 2003 by Matsuoka and 
colleagues. They reported that 45 minutes of exposure to 8 µM FTY720 activated PP2A, or a 
PP2A-like phosphatase, in Jurkat cells. They further confirmed this effect by illustrating that 
incubation of purified PP2A with 10 µM FTY720 was associated with an outspoken increase in 
phosphatase activity (175% increase in activity of a PP2A holo-enzyme and 120% increase of the 
PP2A core dimer). These latter results imply that FTY720 exerts a direct effect on PP2A activity. 
This direct effect of FTY720 on PP2A to increase its activity in cancerous cells in which PP2A 
activity was compromised, has since been demonstrated by several workers (Neviani et al., 2007; 
Oaks et al., 2013; Saddoughi et al. 2013).  
FTY720 as an activator of PP2A 
There seems to be two probable mechanisms by which FTY720 can induce an increase in the 
activity of PP2A: either directly, or through the activation of a signalling pathway. 
Direct activation 
Recently, Saddoughi and colleagues (2013) reported that FTY720 (5-10 µM) can directly bind to 
SET, a protein which has been identified as an endogenous inhibitor of PP2A, also known as I2PP2A 
(see the introduction to Chapter 3). Through this interaction FTY720 blocks the inhibitory 
interaction between SET and PP2A, in a mechanism akin to the way in which ceramide increases 
the activity of PP2A (Mukhophadyay et al., 2009). This mechanism is dependent on the non-
phosphorylated form of FTY720, with P-FTY720 showing no interaction with SET (Saddoughi et 
al., 2013). It is also noteworthy that these authors determined phosphorylated PP2A as a measure 
of PP2A activity within this setting, where the phosphorylated form of the enzyme is inactive (see 
introduction to Chapter 3). This mechanism has two important implications concerning the cellular 
scenario within which it occurs, as well as the effects ascribed to FTY720. 
 
First, the scenario within which it functions. Neviani and co-workers (2007) already made the 
observation that in some cancerous cell lines PP2A activity is suppressed due to an 
overexpression of SET. This means that FTY720 actually reactivates PP2A in these cancer cell 
lines (Saddoughi et al., 2013), which might explain why FT720 can induce cell death in tumorigenic 
cells while not exerting any detrimental effects on normal body cells (Neviani et al., 2007; Oaks et 
al., 2013). This means that the effects of FTY720 on PP2A, at least through this mechanism, is 
limited to cells in which SET plays a substantial role in PP2A inhibition. It is however interesting 
that Matsuoka et al. (2003) showed a direct interaction between PP2A and FTY720 in a system 
containing purified PP2A, thereby implying the existence of some other SET independent 
mechanism. Confirming this possibility, Collison et al. (2013) used a nonphosphorylatable FTY720 
analogue to activate PP2A in the setting of immunology. This implies that the analogue used 
elicited a direct effect (at least a S1P receptor independent effect) in a setting in which SET-
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mediated PP2A inhibition is probably not relevant (although their work did implicate MID1 as a 
PP2A inhibitor, see the introduction to Chapter 3). 
 
Second, concerning the experimental effects attributed to FTY720 administration. As mentioned 
previously, the immunomodulatory effect of FTY720 is actually mediated by the phosphorylated 
form of the drug which can act as a S1P analogue, thereby binding to S1P receptors in the cell 
membrane. We are therefore now confronted with a drug which can exert effects both in its 
unphosphorylated and phosphorylated form, a complex situation which recently confronted Oaks 
and colleagues (2013). They found that in myeloproliferative neoplasms, unphosphorylated 
FTY720 can activate PP2A through its interaction with SET. In contrast to this, P-FTY720 acting on 
S1P1, activates a signalling pathway which phosphorylates SET, thereby increasing its inhibitory 
function of PP2A, thus leading to the inhibition of PP2A. Despite FTY720 and P-FTY720 exerting 
these opposing effects on PP2A activity, treatment with FTY720 (10 mg/kg per day) improved 
survival in leukemic mice with no signs of toxicity. These results may imply that in their animal 
model of leukaemia, FTY720 exerted a predominantly PP2A-activating effect. 
 
It however seems that P-FTY720, functioning as a S1P analogue and binding S1P receptors, does 
not necessarily always mediate a reduction in PP2A activity. 
Activation through a signalling pathway 
The family of S1P receptors are all G-coupled protein receptors which can activate a range of 
signalling kinases and cascades, including the RISK pathway, eNOS and others (Knapp, 2011; 
Igarashi & Michel, 2009). As such it is important to note that S1P and its associated signalling has 
been implicated in cardioprotection against I/R injury (Karliner, 2009; Egom et al., 2010). One of 
the potential signalling proteins which has been implicated in S1P (and therefore also P-FTY720) 
signalling is Pak-1 (Ke et al., 2012). There is however evidence that Pak-1 exerts most its effects 
via the activation of PP2A (Ke et al., 2008; 2010; and 2012). That being said, it is very difficult to 
reconcile some of the seemingly opposing effects of P-FTY720 stimulation, since it has been 
associated with the simultaneous activation of Pak-1 and PKB/Akt (Egom et al., 2010 and 2011). 
The most plausible explanation for the simultaneous activation of PP2A, as well as a probable 
substrate of PP2A (see Chapter 4), lies in the compartmentalization of signalling where PP2A and 
PKB/Akt are activated in different cellular locations. 
 
It is therefore clear that the signalling cascades linked to P-FTY720 is more complex and extensive 
than the activation of PP2A alone. 
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Effects of FTY720 on tissues other than the heart 
As already discussed, FTY720 in its phosphorylated form exerts immunomodulatory effects by 
binding to and desensitizing the S1P receptors, especially S1P1, thereby limiting the movement of 
lymphocytes from the lymph tissue into the circulation (Brinkmann, 2009; Hla & Brinkmann, 2011). 
This mechanism of immunosuppression differs from the classical immunosuppressors and allows 
FTY720 to exert very specific effects on the immune system without suppressing the 
responsiveness of the whole immune system (Chun & Brinkmann; 2011). Linking with the immuno-
modulatory abilities of FTY720, Collison et al. (2013) found that FTY720 abrogates airway 
inflammation and the allergic response in mice exposed to house dust mite infection. 
 
Its ability to activate PP2A has received special attention in cancer research, since the reactivation 
of PP2A in tumorigenic tissues in which PP2A is suppressed through overexpression of SET leads 
to a reduction in the activity of pro-survival signals such as ERK p42/p44 and PKB/Akt, thereby 
favouring apoptosis and cell death (Matsuoka et al., 2003; Neviani et al., 2007; Liu et al., 2008; 
Perroti, 2013). 
 
The fact that FTY720 in its phosphorylated state can bind to and activate the S1P receptors has 
also stimulated interest in the use of this drug in association with I/R, since S1P has been 
implicated in cardioprotection against I/R (Knapp, 2011; Somers, et al., 2012; Karliner, 2013). In 
this regard Kaudel and colleagues have reported (in two separate publications in 2007) that 
FTY720 treatment is associated with increased survival in mouse models of in vivo renal and liver 
I/R. They administered 2 doses of FTY720 to mice exposed to liver ischaemia and reperfusion, 
with the first dose administered 30 minutes prior to ischaemia and the second dose given 5 
minutes before reperfusion. Deviating slightly from this protocol they administered only one dose of 
FTY720 to mice exposed to renal ischaemia, 5 minutes prior to reperfusion. In both scenario’s 
FTY720 was associated with increased survival, probably due to its anti-inflammatory effects, 
especially the depletion of T-cells in the peripheral blood. 
 
Similarly Wei and co-workers (2010) reported that FTY720 administration reduced IFS and 
improved outcomes in a mouse model of transient middle cerebral artery occlusion. In this study 
FTY720 was also administered during ischaemia or reperfusion and exerted a neuroprotective 
effect also mediated rather by its anti-inflammatory effects than any direct effect on neuronal 
tissue. 
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Cardiovascular effects of FTY720 
FTY720 has also been investigated in the context of the vasculature, as well as the heart. 
The effects of sphingosine-1-phosphate and FTY720 on the vasculature 
It seems that FTY720 exerts most of its effects on the vasculature by binding to and activating S1P 
receptors. This short section will therefore briefly discuss the effects of S1P stimulation on the 
vasculature as well. 
 
The complexity of FTY720 action is enhanced by the different effects elicited by this drug, 
depending on which S1P receptor is stimulated, as well as which cell type is involved. Stimulation 
of the S1P2 and 3 receptors have been associated with vasoconstriction, while others have found 
S1P3 to exert a vasodilatory effect along with S1P1 (Karliner et al., 2003; Means & Brown, 2009; 
Igarashi & Michel, 2009). Since S1P2 has a very low affinity for P-FTY720 (Brinkmann, 2009), it is 
only S1P1 and 3 which are relevant with regards to the effects elicited by P-FTY720. 
 
Irrespective of whether it be S1P1 or S1P3 stimulation, in the vascular endothelium both seem to 
be able to elicit vasodilation by a PI3-kinase-PKB/Akt-eNOS pathway in conjunction with an 
increase in intracellular Ca2+ levels which alleviates the inhibitory interaction of caveolin with eNOS 
by mediating the replacement of caveolin with calmodulin. The end effect of these interrelated 
pathways is that eNOS is activated, leading to an increased production of NO which in turn 
stimulates vasodilation (Tolle et al., 2005; Igarashi & Michel, 2009).  
 
Vasoconstriction associated with S1P stimulation in vascular smooth muscle cells follows a 
classical smooth muscle contraction pathway involving an increase in intracellular Ca2+ combined 
with the stimulation of Rho-associated kinase (ROK) and specific PKC isoforms which inhibit the 
activity of myosin light chain phosphatase (MLCP). The net result is an increase in the 
phosphorylation of the myosin light chain which then leads to contraction (Brinkmann, 2007; 
Igarashi & Michel, 2009; Means & Brown, 2009). 
 
The precise effects of FTY720 on the vasculature in humans is uncertain. Westhoff and colleagues 
(2007) found that FTY720 treatment of renal transplant recipients failed to show beneficial 
vasodilatory effects. In fact, replacing FTY720 with mycophenolate mofetil (MMF) improved arterial 
stiffness as well as flow-mediated dilation. These results therefore suggest that long-term FTY720-
treatment predominantly exerts a vasoconstrictory effect in humans. 
FTY720 and the heart 
Heart tissue expresses S1P receptors 1, 2 and 3 (Brinkmann, 2007; Means & Brown, 2009; Hla & 
Brinkmann, 2011), of which only receptors 1 and 3 are relevant when considering the effects of 
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FTY720. Both these receptors are associated with a reduction in heart rate (Hla & Brinkmann, 
2011). This seems to be due to the interaction between activated S1P receptors and the inwardly 
rectifying atrial K+ channel (IKACh). Hofmann (2007) reports that activation of the S1P receptors 
activate IKACh in atrial myocytes thereby inducing an increase in the inward flux of K+, resulting in 
the hyperpolarization of the cell membranes and a reduction in membrane excitability. Interestingly, 
Hofmann (2007) speculates that prolonged exposure of the heart to S1P or FTY720 stimulation 
leads to a desensitization of the receptors, allowing normalization of the heart rate. This transient 
FTY720-mediated reduction in heart rate has also been reported in humans (Schmouder et al., 
2012). In conjunction with its effects on heart rate, S1P1 activation also exerts a negative inotropic 
effect (Means & Brown, 2009) which is probably linked to the activation of IKACh, as well as Gi 
mediated reduction in cAMP levels (Means & Brown, 2009). 
 
As already mentioned, S1P has been associated with cardioprotection against I/R injury (Knapp, 
2011; Somers et al., 2012; Karliner, 2013). It is therefore no surprise that FTY720 has also 
received attention in the context of myocardial I/R injury. Research which has been published 
concerning the potential cardioprotective abilities of FTY720 is summarized in table 5.1. The last 
column of the table highlights the controversies regarding the effects of FTY720. It seems there is 
relative consensus regarding the ability of FTY720 to mediate functional recovery after an I/R 
incident (Hofmann et al., 2009; Vessey et al., 2013). It is also evident that it exerts an important 
effect on the rhythmicity of the heart, although the exact nature of this is unknown. Egom and 
colleagues (2010) found that FTY720 reduced the occurrence of rhythmic disturbances following 
I/R. In stark contrast to this, Hofmann et al. (2010) reported that FTY720 administration at 
reperfusion increased mortality in an in vivo model due to an increased occurrence of 
dysrhythmias. Intriguingly, the administration of FTY720 both prior to ischaemia, as well as during 
reperfusion increased survival (Hofmann et al., 2010). In conjunction with this increase in survival, 
pre-treatment with FTY720 24 hours prior to ischaemia also induced a reduction in S1P1 receptor 
expression. It therefore seems that in this setting FTY720 exerted a cardioprotective effect not by 
acting as a S1P receptor agonist, but rather by acting as a functional antagonist which stimulates 
the desensitization of the S1P1 receptor. Concerning the ability of FTY720 to preserve the viability 
of tissue exposed to I/R, the results are inconclusive with two of the studies reporting an inability 
for FTY720 to reduce IFS (Hofmann et al., 2009 and 2010) while two other studies reported that 
FTY720 can protect against cell death (Egom et al., 2011; Vessey et al., 2013).  
 
Potential reasons for these contradictory results are unknown, although differences in experimental 
models probably contribute to a large degree. The study which reported on the detrimental effects 
of FTY720 treatment on reperfusion rhythmicity (Hofmann et al., 2010) was the only in vivo study, 
thereby including the systemic effects of FTY720 on inflammation and vascular tone. The rest of 
the in vitro studies differ with regards to dosage, mode of application, animal species used, type of  
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simulated ischaemia or hypoxia induced in the cellular models, etc. There is almost no common 
ground between these studies, illustrating some of the typical challenges in basic cardioprotection 
research.  
 
It is also interesting to note that all of these studies focussed on the application of FTY720 during 
ischaemia and reperfusion. None of the studies investigated the effects of FTY720 treatment 
directly prior to sustained ischaemia. Despite the probable effects of FTY720 on PP2A activation, 
none of these studies investigated this link either. In this regard it is noteworthy that Egom et al. 
(2011) reported that FTY720 treatment exerted its effects via the activation of both PKB/Akt and 
Pak-1, the latter also being implicated by others as an upstream activator of PP2A (Ke et al., 2008; 
2010; and 2012).  
 
FTY720 therefore exerts an effect on the heart in the context of I/R, although the precise nature of 
this still requires investigation. The question regarding the effects of FTY720 on the heart is of 
clinical interest for two reasons: First, since MS patients are using FTY720 it is useful to define the 
effects of FTY720, and secondly since FTY720 does not exert toxic effects (Neviani et al., 2007; 
Oaks et al., 2013), even at high doses, it is a very attractive drug for clinical use. 
Summary 
FTY720 is a sphingosine analogue, which can utilize the same cellular mechanisms as 
sphingosine to exert its effects, i.e. FTY720 can be phosphorylated and following this can bind to, 
and activate S1P receptors. Initial interest in FTY720 focussed on its immunosuppressive effects 
which were exploited for its clinical use in the management of MS. It has however also been shown 
that FTY720 exerts a cytotoxic effect on cancerous cells, mediated by the activation of PP2A. As a 
S1P analogue FTY720 also influences several aspects of cardiac function including vascular tone, 
contraction, rhythmicity, and resistance to I/R injury.  
 
We are therefore confronted by an intriguing pharmacological drug which can exert a multitude of 
effects, both in its unphosphorylated as well as phosphorylated forms. Of these effects, it is 
especially its ability to activate PP2A which elicited our interest. 
Motivation, hypothesis and aims 
FTY720 has been implicated in the activation of PP2A, both directly in its unphosphorylated form, 
as well as via activation of a signalling pathway. We therefore decided to utilize FTY720 to 
manipulate PP2A activity in conjunction with I/R to better define the contribution of PP2A to the 
myocardial response to I/R.  Comparison of inhibitor studies (Chapter 4) with activator studies 
(FTY720 mediated) will contribute greatly to delineating the role of PP2A in I/R. 
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The fact that FTY720 is already in clinical use opens up questions regarding its potential effects on 
myocardial I/R injury. Not much research has been done on this aspect of FTY720 and the work 
done thus far has delivered contradictory results (table 5.1), did not focus on PP2A per se and, 
very importantly, has not investigated the effects of FTY720 treatment directly prior to sustained 
ischaemia. 
 
We therefore decided to investigate the effects of FTY720 treatment on the outcomes of /IR in our 
isolated working rat heart model, as well as the effects of the drug on intracellular signalling in this 
setting. More specifically we aimed to determine: 
 the effects of FTY720 treatment (prior to ischaemia or during reperfusion) on IFS in a model of 
regional ischaemia, as well as functional recovery in a model of global ischaemia. 
 the effects of FTY720 treatment on signalling (specifically the RISK pathway, p38 MAPK and 
PP2A) in the context of global ischaemia and reperfusion. 
 
Due to the miscellaneous effects of FTY720 it is difficult to hypothesize on the outcomes. In view of 
the literature, we expect FTY720 to induce a degree of bradychardia as well as vasodilation (or 
constriction) in our hearts, which in turn, will probably influence the outcome of I/R injury. In its 
capacity as a S1P agonist, it is very likely that FTY720 will exert a protective effect. In Chapter 4 
we however found that PP2A is a negative regulator of the RISK pathway at reperfusion. If this is 
the case, and if FTY720 does increase PP2A activity in our model, it is also possible that FTY720 
given at reperfusion will be detrimental to hearts exposed to I/R. This activation of PP2A will induce 
a reduction in the phosphorylation of PKB/Akt, GSK-3β and ERK p42/p44. 
 
Despite the uncertainty about the outcomes, the results generated should prove interesting, novel 
and thought-provoking. 
Material and methods 
Rationale 
In Chapter 4 we described the effects of PP2A inhibition on isolated rat hearts exposed to I/R in an 
attempt to delineate the role of PP2A regarding the outcomes of I/R injury, as well as the signalling 
events associated with this. This part of the study aims to address the same question, but by 
approaching it from the opposite direction, i.e. determining the effects of PP2A activation on the 
outcomes of I/R, as well as investigating the signalling events associated with the activation of 
PP2A in this setting. We therefore utilized a similar approach as in chapter 4, as set out in Figure 
5.1. 
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Protocols 
FTY720 dosage in the isolated perfused rat heart 
FTY720 was obtained from Cayman Chemical (product number 10006292; Cayman Chemical, MI, 
USA). The drug was first dissolved in dimethyl sulfoxide (DMSO) and then added to the perfusate. 
In all studies the concentration of DMSO never exceeded 0.03% (vol/vol), i.e. 0.004 M. Since this 
concentration is well below the level of DMSO associated with changes in cardiac function (Bell et 
al., 2008)  or toxicity (Shlafer & Karow, 1975), and given that we found that up to 0.05% DMSO did 
not influence signalling in a model of RI (Van Vuuren, 2008), vehicle controls were not included in 
this study. 
 
Several different dosages of FTY720 have been reported for isolated heart studies in the literature 
(Table 5.1). Based on these reported dosages we assessed three different concentrations of 
FTY720 (0.5, 1 and 2.5 μM) in terms of their ability to activate PP2A under baseline conditions. 
Measuring PP2A activity, as alluded to before, is itself a challenging exercise. We utilized two 
different approaches: (1.) Western blotting was used to determine the degree of PP2A 
phosphorylation, where phosphorylated PP2A is inactive (Chen et al., 1992). Saddoughi and co-
workers (2013) also used the same approach. (2.) The activity of PP2A immunoprecipitates was 
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measured directly, using a commercially available kit which utilized a substrate (DiFMUP) which  is 
cleaved by protein phosphatases to generated a fluorescent product (DiFMU), as described in 
Chapter 2. Tissue samples for both these experimental approaches were prepared as shown in 
Figure 5.2. FTY720 was administered for a period of 15 minutes following a suitable time period of 
stabilisation and in the absence of any other experimental interventions. 
 
Infarct size (IFS) 
The effects of FTY720 (1 μM and 2.5 μM) administration, both immediately before sustained 
ischaemia or at the onset of reperfusion (Figure 5.3), were evaluated. These two time points were 
chosen in order to match our inhibition studies (Chapter 3); to assess the effects of PP2A 
activation during both ischaemia, as well as reperfusion; and also to address the lack of data 
concerning the effects of FTY720 administered immediately prior to ischaemia.  
 
 
In addition to these studies, the effects of FTY720 administered as a preconditioning stimulus 
(Figure 5.4) were also determined. For this we specifically utilized 1 μM FTY720. For most of our 
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ex vivo experiments we administered FTY720 for a period of 15 minutes, the exception being the 
preconditioning administration of FTY720 which we limited to 10 minutes in order for it to fit into the 
general timing of the perfusion protocols (Figures 5.2,  5.3 and 5.4). As described in Chapters 2 
and 4, 35 minutes of regional ischaemia was utilized in combination with 60 minutes of reperfusion. 
 
Functional recovery 
The effects of FT720 administration on functional recovery were studied during reperfusion 
following 20 minutes of global ischaemia. Three experimental protocols were employed in the 
setting of sustained global ischaemia (Figure 5.5). 
 
 
Stellenbosch University  http://scholar.sun.ac.za
- 220 - 
 
Protein profiles 
Since the central focus of this project was to determine the role and importance of PP2A in the 
myocardial response to I/R, we decided to focus our experimental approach at this stage on a 
single FTY720 concentration. Since we found that FTY720 at a concentration of 1 μM, 
administered for 15 minutes, was adequate to increase PP2A activity (as will be reported in the 
next section), we only investigated the effects of this dose administered either prior to ischaemia or 
at the onset of reperfusion on mediators of the RISK pathway (ERK p42/p44, PKB/Akt and GSK-
3β), p38 MAPK and PP2A. Different timepoints were investigated to assess the temporal spectrum 
of effects elicited by FTY720 on these signalling proteins (Figure 5.6). 
 
Statistical analysis 
Multiple groups were compared with each other by performing an ANOVA analysis. Unless 
otherwise specified, the Bonferroni post hoc test was applied for all graphed data. Exceptions to 
this was the comparison of only two groups with each other, for which a T-test was used, or 
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analyses where multiple experimental interventions were compared with control alone, in which 
case Dunnett’s test was applied. 
Results 
FTY720 dosage in the isolated perfused rat heart 
We utilized two different approaches to determine which concentration of FTY720 (0.5, 1 or 2.5 
μM) would increase the activity of PP2A under pre-ischaemic baseline conditions. Firstly, standard 
Western Blotting techniques were used to determine the effect of FTY720 on the phosphorylation 
of PP2A, since the phosphorylation of PP2A is associated with its inhibition (Chen et al., 1992). 
Results are shown in Figure 5.7 (A-C). FTY720 treatment did not exert an effect on the levels of 
PP2A-C relative to control. All three concentrations FTY720 reduced the absolute phosphorylation 
of PP2A  (Control: 1.00±0.11 AU vs. 0.5 FTY: 0.65±0.08 AU, 1 FTY720: 0.48±0.03 AU & 2.5 FTY: 
0.62±0.04 AU, n=2-4; P<0.05). However only 1 μM and 2.5 μM of FTY720 were associated with a 
reduction in the phosphorylation of PP2A relative to total PP2A-C (Control: 1.00±0.14 AU vs. 1 
FTY720: 0.57±0.04 AU & 2.5 FTY: 0.61±0.05 AU, n=2-4; P<0.05).  
 
Secondly, PP2A activity was measured in PP2A-C targeted immunoprecipitates incubated with a 
phosphatase substrate (DiFMuP) which generates a fluorescent product (DiFMU) when hydrolyzed 
by a phosphatase (as described in Chapter 2). Okadaic acid (10 nM) was used to distinguish 
PP2A-mediated phosphatase activity even further. For this aspect of the evaluation of FTY720, we 
assayed tissue perfused with either 1 μM or 2.5 μM FTY720. As shown in Figure 5.7 (D) both 
these concentrations slightly, yet significantly, increased the activity of PP2A (Control: 400.8±23.75 
fluorescence units vs. 1 FTY: 475.3±5.41 fluorescence units and 2.5 FTY: 489.0±20.11 
fluorescence units, n=2-4; P<0.05).  
 
Both these experimental approaches indicated that both 1 µM and 2.5 µM FTY720, when 
administered for 15 minutes, are sufficient to increase the activity of PP2A. To avoid non-PP2A 
related effects associated with FTY720 administration, we decided to use the lowest dose to 
investigate the effects of PP2A activation on the selected signalling molecules of interest. Since 
FTY720 is a clinically relevant drug, of which the effects in the setting of myocardial I/R are still 
very much uncertain, both concentrations were included in our initial study concerning the effects 
of FTY720 administration on the outcomes (IFS and functional recovery) of myocardial I/R. 
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The effect of PP2A activation by the administration of FTY720 on infarct 
size 
In Chapter 4 we utilized the pharmacological inhibition of PP2A either prior to ischaemia, or during 
the clinically relevant first moments of reperfusion in an attempt to better understand the 
contribution of PP2A to the development of I/R injury. Here we extend these experiments by 
activating PP2A activity at the same time points. Additional to these pre-ischaemic and reperfusion 
treatment based studies, we also  included a preconditioning group in which 10 minutes of FTY720 
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(1 µM) was followed by 5 minutes washout before the onset of ischaemia. This intervention was 
included to better investigate the effects of FTY720 per se on IFS. 
Baseline, pre-drug and -ischaemic functional parameters for all of these groups are shown in table 
5.2. There were no significant differences between any of these groups and control (using 
Dunnett’s correction). 
Table 5.2. Pre-ischaemic functional parameters of isolated rat hearts exposed to 35 minutes 
regional ischaemia in conjunction with different administration protocols of FTY720. 
*PC FTY1: Preconditioned with 1 µM FTY720. 
†Coronary flow measured during retrograde perfusion. 
Group Coronary flow (ml/min)† 
Aortic output 
(ml/min) 
Cardiac output 
(ml/min) n-value 
Control 9.00±0.52 48.33±3.56 62.83±4.34 6 
PreFTY1 8.92±0.45 55.50±1.63 69.08±3.98 6 
PostFTY1 10.00±0.82 44.00±4.30 58.14±5.49 7 
PC FTY1* 8.51±0.35 40.57±2.21 53.64±3.03 7 
PreFTY2.5 10.25±0.54 47.00±3.53 63.17±4.39 6 
PostFTY2.5 9.67±0.76 52.33±3.20 69.42±3.94 6 
 
For statistical comparison of IFS data we only compared different administration protocols of the 
same concentrations of FTY720.  
The effect of 1 µM FTY720 on infarct size and associated functional recovery  
The effects of the different protocols of FTY720 administration at 1 µM is shown in Figure 5.8. 
Reperfusion treatment with FTY720 reduced infarct size in comparison to control (Control: 
39.89±3.93% vs. PostFTY: 23.96±3.99%, n=6-7; P<0.05), while pretreatment with the drug actually 
increased IFS (Control: 39.89±3.93% vs. PreFTY: 51.73±2.36%, n=6; T-test: P<0.05). This was an 
unexpected effect and prompted us to also investigate the effect of FTY720 preconditioning on 
IFS. Although preconditioning with FTY720 failed to reduce IFS relative to control (Control: 
39.89±3.93% vs. PC FTY720: 35.58±4.73%, n=6; non-significant), it resulted in a lower IFS than 
pretreatment (PC FTY720: 35.58±4.73% vs. PretFTY: 51.73±2.36%, n=6-7; T-test: P<0.05). These 
data confirm the detrimental effects of FTY720 pretreatment immediately before sustained 
ischaemia, since a period of only 5 minutes washout between FTY720 administration and the 
onset of RI alleviated the FTY720-mediated increase in IFS observed with pretreatment. 
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Functional recovery of these hearts (table 5.3) deviated from the IFS data, since none of the 
interventions elicited any significant change in functional recovery, except for a lowering in CO 
associated with FTY720 preconditioning (Control: 46.56±10.25% vs. PC FTY: 21.55±4.38, n=6-7; 
P<0.05). 
Table 5.3. Percentage functional recovery following the administration of 1 μM FTY720 to isolated 
rat heart preparations. 
* P<0.05 vs. Control using Dunnett’s post test. 
Group 
Recovery as a percentage of baseline 
n-value 
Aortic output Cardiac output 
Control 27.86±13.22 46.56±10.25 6 
PreFTY 17.04±6.07 28.29±6.22 6 
PostFTY 6.72±3.77 26.59±6.84 7 
PC FTY 6.58±3.13 21.55±4.38* 7 
 
CO is a composite end-point which is determined by multiple aspects of function. We therefore 
also analysed the degree of recovery of several other functional parameters (table 5.4), in order to 
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ascertain why CO was reduced in the preconditioning group. Although all functional parameters 
measured tended to be lower in the PC FTY group, nothing was statistically reduced except the 
degree of heart rate (HR) recovery (percentage HR recovery: Control: 95.00±1.85% vs. PC FTY: 
59.39±12.35%, n=6-7; T-test: P<0.05). It therefore seems that preconditioning with FTY720 
suppressed the recovery of contractile function, specifically HR, contributing to a reduction in CO.   
Table 5.4. Analyses of different aspects involved in functional recovery of control and FTY720 
preconditioned (1 μM) hearts. 
† Coronary flow measured during work mode. 
* NS: non-significant 
Group 
Recovery as a percentage of baseline 
n-value 
Coronary 
flow† Total work Heart rate 
Systolic 
pressure 
Control 106.80±6.68 40.74±9.98 95.00±1.85 84.79±2.70 6 
PC FTY 69.41±17.17 19.83±4.04 59.39±12.35 78.81±13.17 7 
Significance NS* NS P<0.05 NS  
 
In summary, 1 µM FTY720 exerted an infarct sparing effect when administered at reperfusion, but 
unexpectedly increased IFS when administered immediately prior to ischaemia. This effect was 
abrogated when 5 minutes normal perfusion was applied between FTY720 administration and 
sustained ischaemia (a preconditioning protocol). Preconditioning with FTY720 could however not 
reduce IFS compared to control, and in fact functional recovery in these hearts were compromised 
relative to control, especially with regards to CO and HR. Functional recovery in all other groups 
were comparable to control and did not mirror the observed changes in IFS. 
The effect of 2.5 µM FTY720 on infarct size and associated functional 
recovery  
The effects of 2.5 µM FTY720 administration on I/R injury in the isolated rat heart are shown in 
Figure 5.9. Reperfusion administration of 2.5 µM FTY720 exerted a relatively small, yet significant, 
infarct sparing effect similar to what was observed with FTY720 at a concentration of 1 µM FTY720 
(Control: 39.89±3.93% vs. PostFTY: 30.45±2.1.6, n=6; P<0.05). In contrast to 1 µM FTY720, pre-
ischaemic treatment with 2.5 µM FTY720 was however associated with a significant reduction in 
IFS (Control: 39.89±3.93% vs. PostFTY: 29.97±1.03%, n=6; P<0.05). It is therefore clear that 
FTY720 elicits a dose-dependent response. Since pre-ischaemic FTY720 administration already 
exerted a cardioprotective effect, we did not include a preconditioning protocol for 2.5 µM FTY720. 
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Despite 2.5 µM FTY720 exerting an infarct sparing effect, both as a pre-ischaemic treatment as 
well as during reperfusion, functional recovery in these hearts was severely compromised as 
shown in table 5.5. Both pre-ischaemic and reperfusion administration of 2.5 µM FTY720 was 
associated with a profound reduction in functional recovery, as is evident by the fact that of the four 
hearts treated with FTY720 prior to ischaemia only one was able to produce an aortic output during 
reperfusion. Similarly, in the group treated with FTY720 at the onset of reperfusion, only one of the 
six hearts produced a measurable aortic output. Further analysis of the different components 
contributing to AO and CO reveals that although all parameters appeared suppressed (table 5.6) it 
was only coronary flow and total work which were significantly reduced in the reperfusion 
administration group (Coronary flow: Control: 106.80±6.68% vs. PostFTY: 53.96±18.27, n=6; 
P<0.05, and Total work: 40.74±9.98% vs. PostFTY: 11.84±4.59%). 
Table 5.5. Percentage functional recovery following the administration of 2.5 μM FTY720 to 
isolated rat heart preparations. 
* P<0.05 vs. Control by using Dunnett’s correction. 
Group 
Recovery as a percentage of baseline 
n-value 
Aortic output Cardiac output 
Control 27.86±13.22 46.56±10.25 6 
PreFTY 0.93±0.93 30.73±3.83 4 
PostFTY 2.08±2.08 15.02±5.38* 6 
 
Table 5.6. The effects of 2.5 µM FTY720 administration on different aspects of recovery following 
35 minutes regional ischaemia.  
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† Coronary flow measured during work mode. 
*P<0.05 vs. Control (Dunnett’s test) 
Group 
Recovery as a percentage of baseline 
n-value 
Coronary 
flow† Total work Heart rate 
Systolic 
pressure 
Control 106.80±6.68 40.74±9.98 95.00±1.85 84.79±2.69 6 
PreFTY 112.00±9.34 22.60±4.93 85.37±7.97 73.34±11.30 4 
PostFTY 53.96±18.27* 11.84±4.59* 60.73±19.46 50.96±16.58 6 
 
In summary, FTY720 at 2.5 µM exerted a paradoxical effect: on the one hand both pre-ischaemic 
and reperfusion treatment reduced IFS, while on the other hand, both these administration 
protocols significantly reduced functional ability during reperfusion. In the case of reperfusion 
administration, these reductions in functional recovery were mediated by a reduction in coronary 
flow and total work. This indicates that FTY720 has a protective effect with regards to cell death, 
but detrimental effects regarding functional recovery. 
The effect of PP2A activation by the administration of FTY720 on 
functional recovery 
Having established that both 1 µM and 2.5 μM FTY720 administered directly before sustained 
ischaemia or at the onset of reperfusion exerted dose-specific effects on IFS we decided to 
investigate these administration protocols in the context of a perfusion approach specifically aimed 
at assessing functional recovery after 20 minutes of GI. This model has the additional advantage 
that it generates a homogeneous heart preparation which is ideally suited for protein determination 
and profiling experiments using Western blotting techniques. 
 
For these experiments we followed the same approach as for the IFS determination experiments: 
FTY720 was administered either directly before sustained ischaemia, or at the onset of reperfusion 
(Figure 5.5).  
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The effect of 1 µM FTY720 on functional recovery following 20 minutes global 
ischaemia 
The baseline pre-ischaemic data for these hearts are shown in table 5.7. There were no significant 
differences between any of the FTY720 administration groups relative to control. 
Table 5.7. Pre-ischaemic functional parameters of hearts before exposure to 20 minutes of GI 
(FTY720 1 μM). 
@ Coronary flow measured during pre-ischaemic retrograde perfusion. 
Group Coronary flow (ml/min)@ 
Aortic output 
(ml/min) 
Cardiac output 
(ml/min) 
Total work 
(mW) n-value 
Control 8.45±0.75 44.20±3.41 60.55±4.10 13.17±1.22 5-10 
PreFTY 9.13±1.13 47.13±4.11 63.81±4.78 14.41±0.56 5-8 
PostFTY 6.70±0.47 51.50±1.78 66.39±2.45 14.02±0.74 9-10 
 
 
 
Functional recoveries following 20 minutes GI are shown in Figure 5.10. In agreement with 
functional recovery data from the IFS study, FTY720 administration at 1 μM failed to elicit any 
effects on functional recovery relative to control. In contrast to RI, under these conditions of GI, 
FTY720 had no effect on HR (Percentage heart rate recovery: Control: 85.00±6.12% vs. PreFTY: 
93.21±6.19% and PostFTY: 69.05±13.44%, n=8-9; non-significant). 
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The effect of 2.5 µM FTY720 on functional recovery following 20 minutes 
global ischaemia 
Baseline values for these experiments are shown in table 5.8. There were no significant 
differences between control and any of the experimental FTY720 groups, except for coronary flow 
which was lower in the PostFTY group compared to control (Control: 8.45±0.75 ml/min vs. 
PostFTY: 5.50±0.49 ml/min, n=7-10; P<0.01). All the other functional parameters in the PostFTY 
group were however comparable to control. It is therefore unlikely that the lower CF value could be 
a confounding factor in terms of the experimental outcomes. 
 
Table 5.8. Pre-ischaemic functional ability of isolated rat hearts before exposure to 20 minutes GI 
(FTY720; 2.5 μM). 
@ Coronary flow measured during pre-ischaemic retrograde perfusion. 
# P<0.01 vs. control. 
Group Coronary flow (ml/min)@ 
Aortic output 
(ml/min) 
Cardiac output 
(ml/min) 
Total work 
(mW) n-value 
Control 8.45±0.75 44.20±3.41 60.55±4.10 13.17±1.22 5-10 
PreFTY 6.50±0.52 41.00±5.21 55.25±6.48 13.98±0.41 4-6 
PostFTY 5.50±0.49# 44.29±2.88 58.93±4.81 11.54±1.09 6-7 
 
The effect of 2.5 μM FTY720 on functional recovery during reperfusion is shown in Figure 5.11. 
Pretreatment with the drug at 2.5 μM was associated with a profound reduction in aortic output 
(Control: 33.88±6.12% vs. PreFTY: 0%, n=6-10; P<0.001), cardiac output (Control: 45.94±5.57% 
vs. PreFTY: 12.20±2.68%, n=6-10; P<0.001) and total work (Control: 45.67±8.98% vs. PreFTY: 
2.79±2.79%, n=4-5; P<0.01). 
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The detrimental effects of pretreatment with FTY720 are further analysed in table 5.9.  
 
Table 5.9. The effects of 2.5 µM FTY720 administration on different aspects of recovery following 
20 minutes of GI.  
† Coronary flow measured during work mode. 
@ P<0.0001 vs. Control (Dunnett’s test) 
# P<0.05 vs. Control (Dunnett’s test) 
Group 
Recovery as a percentage of baseline 
n-value 
Coronary flow† Heart rate Systolic pressure 
Control 72.27±8.97 85.00±6.11 88.13±4.45 8-10 
PreFTY 45.19±7.25# 10.53±10.53@ 15.10±15.10@ 6 
PostFTY 104.00±5.80 92.94±3.77 87.99±3.64 7 
 
Pre-ischaemic treatment with 2.5 μM FTY720 suppressed all functional parameters during 
reperfusion. In fact, of the group of six hearts pretreated with FTY720, only one recovered 
sufficiently to record heart rate and pressure data, while the other five hearts presented with zero 
percent recovery. 
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The effects of FTY720 on coronary flow 
During our initial experiments to determine the effects of FTY720 on PP2A activity, as well as 
during the IFS study, we noticed that FTY720 exerted a potent, but transient effect on CF by 
dramatically increasing it. We therefore utilized the 20 minutes GI (functional recovery alone) study 
to monitor the effects of FTY720 on CF at different time points during the perfusion protocol and 
expressing it relative to pre-ischaemic stabilisation values.  All CF values were measured during 
retrograde perfusion episodes in the perfusion protocol. 
Pretreatment with FTY720 
Pre-ischaemic treatment with both 1 μM and 2.5 μM FTY720 elicited a potent increase in CF 
(Figure 5.12 A) as measured at the end of the FTY720 administration period (Control: 0.95±0.05 
AU vs. PreFTY1: 2.25±0.27 AU and PreFTY2.5: 2.56±0.27 AU, n=5-8; P<0.01). Unexpectedly 
pretreatment also led to a reduction in the CF over the first 15 minutes of reperfusion (Figure 5.12 
B: Control: 1.94±0.17 AU vs. PreFTY1: 1.60±0.08 AU and PreFTY2.5: 1.08±0.05 AU, n=3-5; 
P<0.05) in a dose dependent manner, since 2.5 μM FTY720 elicited a greater reduction in CF than 
1 μM (PreFTY1: 1.60±0.08 AU vs. PreFTY2.5: 1.08±0.05 AU, n=3-5; T-test: P<0.01). This effect 
was however shortlived and at the end of retrograde reperfusion (20 minutes reperfusion) there 
were no differences between any of the groups (Figure 5.12 C). Pretreatment hearts therefore had 
an increased CF relative to control at the onset of ischaemia, but lower CF at the onset of 
reperfusion. 
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Reperfusion treatment with FTY720 
As expected, FTY720 administration during reperfusion (Figure 5.13) was associated with a 
significant increase in CF (Control: 1.21±0.11 AU vs. PostFTY1: 2.59±0.18 AU and PostFTY2.5: 
2.19±0.15 AU, n=4-9; P<0.01) which still persisted 5 minutes later at the end of retrograde 
reperfusion (Control: 0.85±0.13 AU vs. PostFTY1: 1.86±0.15 AU and PostFTY2.5: 1.77±0.17 AU, 
n=7-11; P<0.001). 
 
The effects of FTY720 on CF is summarised in Figure 5.13 C. Administration of FTY720 (1 and 2.5 
μM) consistently increased coronary flow during drug administration. This effect was however 
transient and in the pretreatment groups (1 and 2.5 μM) there was in fact a reduction in coronary 
flow at initial reperfusion (the first 15 minutes of reperfusion), which stabilized at control values by 
the end of retrograde perfusion (20 minutes). Our data therefore indicate that FTY720, at both 
doses studied, exerted a potent direct vasodilatory effect in the isolated rat heart. Intriguingly, this 
vasodilatory effect was replaced by vasoconstriction with the addition of I/R to FTY720, as seen in 
the pre-ischaemic treatment groups. 
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Protein profiles associated with pre-ischaemic FTY720 treatment 
Our initial interest in the effects of FTY720 on the heart exposed to I/R had two components to it: 
Firstly, not much work has been done regarding FTY720 in this setting per se; while secondly, 
FTY720 administration has been linked to an increase in the activity of PP2A. Our initial studies 
concerning the effects of FTY720 on IFS and functional recovery addressed both these aspects, 
since we employed two different concentrations of FTY720, which revealed dose-depency with 
regards to the effects of FTY720. 
 
Concerning the effects of FTY720 on signalling protein levels and phosphorylation, the aim was to 
specifically focus on the contribution of PP2A activation. For these experiments we therefore 
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investigated a single dose of FTY720, namely 1 μM: a relatively low dose yet still capable of 
activating PP2A (see Figure 5.7). 
Pre-treatment with FTY720: Protein profiles at the onset of ischaemia 
Hearts were perfused for 15 minutes with 1 μM FTY720 and immediately freeze-clamped before 
the onset of sustained ischaemia. 
Protein phosphatase 2A 
 
Similar to initial results concerning the effect of FTY720 administration on PP2A under base-line 
conditions (Figure 5.7) we found that 15 minutes of exposure to FTY720 did not elicit any changes 
in the levels of PP2A-C, PP2A-A or the ratio between the two (Figure 5.14). FTY720 however 
reduced the level of phosphorylation of PP2A (Figure 5.15: Absolute phosphorylation: Control: 
1.00±0.05 AU vs. PreFTY: 0.86±0.18 AU, n=3-5, P<0.05; Phosphorylated relative to total PP2A-C: 
Control: 1.00±0.02 AU vs. PreFTY: 0.74±0.06 AU, n=3-5, P<0.05), indicative of an increase in the 
activity of PP2A, thereby confirming the efficacy of this dose FTY720. Interestingly, despite 
exerting an effect on the phosphorylation of PP2A-C, FTY720 failed to induce any changes in the 
degree of methylation of PP2A-C. 
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Protein kinase B (Akt) 
Despite activation of PP2A by FTY720, it was also associated with a potent increase in the 
phosphorylation, and therefore activity of PKB/Akt (Figure 5.16), both in absolute terms (Control: 
1.00±0.06 AU vs. PreFTY: 1.61±0.09 AU, n=3-5, P<0.01) as well as in relation to the total levels of 
PKB/Akt (Control: 1.00±0.06 AU vs. PreFTY: 1.99±0.18 AU, n=3-5, P<0.01). 
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Glycogen synthase kinase-3β 
Although FTY720 exerted a strong stimulatory effect on PKB/Akt phosphorylation, this was not 
associated with a similar increase in the phosphorylation of GSK-3β (Figure 5.17). FTY720 failed 
to exert any significant effect on GSK-3β. 
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p38 Mitogen activated protein kinase 
Not only did FTY720 activate both PP2A, as well as PKB/Akt, but it was also associated with a 
very potent increase in the phosphorylation of p38 MAPK (Figure 5.18), again with regards to both 
absolute phosphorylation (Control: 1.00±0.08 AU vs. PreFTY: 2.77±0.52 AU, n=3-4, P<0.05), as 
well as the degree of phosphorylation relative to the total levels of p38 MAPK (Control: 1.00±0.07 
AU vs. PreFTY: 2.89±0.53 AU, n=3-4, P<0.05).  
 
Extracellular signal-regulated kinase p42/p44 
In combination with the activation of PKB/Akt, FTY720 also induced an increase in the 
phosphorylation of the other RISK pathway signalling component, namely ERK p42/p44 (Figure 
5.19). FTY720 elicited a potent increase in the phosphorylation of both ERK p42 (Absolute 
phosphorylation: Control: 1.00±0.14 AU vs. PreFTY: 2.52±0.24 AU, n=3-5, P<0.01; 
Phosphorylated relative to total ERK p42: Control: 1.00±0.18 AU vs. PreFTY: 3.17±0.43 AU, n=2-
5, P<0.05), as well as ERK p44 (Absolute phosphorylation: Control: 1.00±0.29 AU vs. PreFTY: 
2.53±0.26 AU, n=3-5, P<0.01; Phosphorylated relative to total ERK p44: Control: 1.00±0.02 AU vs. 
PreFTY: 2.07±0.31 AU, n=3-5, P<0.05). 
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Equal loading: β-Tubulin 
In order to confirm equal loading, a representative blot for the lysates was probed for β-Tubulin 
(Figure 5.20). No differences were detected between control and the FTY720 treatment groups. 
  
Pre-treatment with FTY720: Protein profiles at the end of 20 minutes GI 
Following 15 minutes treatment with FTY720, hearts were exposed to 20 minutes GI and then 
snap frozen. 
Protein phosphatase 2A 
At the end of sustained ischaemia pretreatment with FTY720 was associated with an increase in 
the ratio of total PP2A-C to total PP2A-A (Control: 1.00±0.06 AU vs. PreFTY: 1.31±0.05 AU, n=3-5, 
P<0.01), although levels of neither of these proteins were significantly changed by FTY720 
administration (Figure 5.21). In addition to this, FTY720 induced an increase in absolute 
phosphorylation relative to control (Control: 1.00±0.03 AU vs. PreFTY: 1.62±0.12 AU, n=3-6, 
P<0.05), although when expressed relative to total PP2A-C FTY720 exerted no additional effect 
relative to 20 minutes ischaemia (Control: 1.00±0.06 AU vs. 20 GI: 1.52±0.17 AU and PreFTY: 
1.46±0.07 AU, n=3-5, P<0.05). Absolute nonmethylation was also increased in the FTY720 group 
relative to both control and 20 minutes ischaemia (Control: 1.00±0.05 AU and 20 GI: 1.15±0.04 AU 
vs. PreFTY: 1.53±0.09 AU, n=3-5; P<0.05), although when expressed relative to total PP2A-C it 
became evident that FTY720 did not elicit any effects additional to the effect already associated 
with 20 minutes GI (Control: 1.00±0.09 AU vs. 20 GI: 1.30±0.01 AU and PreFTY: 1.44±0.05 AU, 
n=3-5, P<0.05). It therefore seems that FTY720 induces the phosphorylation and demethylation of 
PP2A, although after 20 minutes GI this effect is no longer significant when expressed relative to 
the total pool of PP2A-C. 
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Protein kinase B (Akt) 
The pre-ischaemic administration of FTY720 was not associated with any changes in total PKB/Akt 
expression or phosphorylation at the end of 20 minutes GI (Figure 5.23). 
 
Glycogen synthase kinase-3β 
Twenty minutes of GI activated GSK-3β (Phosphorylated GSK-3β relative to total GSK-3β: Control: 
1.00±0.18 AU vs. 20 GI: 2.98±0.35, n=3; P<0.05), as was also noted in Chapter 4. Although 
PreFTY did not differ significantly from 20 minutes GI alone, it also did not differ significantly from 
control (Figure 5.24 B). In addition to this, an unpaired T-test directly comparing 20 minutes GI with 
PreFTY shows a bordeline significant difference between the two groups (20 GI: 2.98±0.35 AU vs. 
PreFTY720: 1.70±0.41 AU, n=3-4; P=0.073). Taken together our data suggests that FTY720 is 
associated with a reduction in the ischaemia-mediated phosphorylation of GSK-3β. It could be 
speculated that FTY720 elicits this effect through its function as an activator of PP2A. 
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p38 Mitogen activated protein kinase 
Pre-ischaemic treatment did not elicit any effect on the levels of total p38 MAPK (Figure 5.25). It 
also failed to elicit any effect regarding the ischaemia-associated increase in absolute 
phosphorylation levels of p38 MAPK (Control: 1.00±0.03 AU vs. 20 GI: 9.16±0.77 AU and PreFTY: 
6.70±1.08 AU, n=3-5; P<0.01). However expression of phosphorylation levels relative to total p38 
MAPK revealed that although both 20 minutes GI and PreFTY were still elevated above control 
levels (Control: 1.00±0.13 AU vs. 20 GI: 10.00±0.55 AU and PreFTY: 6.14±1.03 AU, n=3-5; 
P<0.05), PreFTY was associated with a lower relative degree of phosphorylation than ischaemia 
alone (20 GI: 10.00±0.55 AU vs. PreFTY: 6.14±1.03 AU, n=3-5; P<0.05). As was the case with 
GSK-3β, it therefore seems that FTY720 suppresses the ischaemia mediated phosphorylation of 
p38 MAPK, possibly through the activation of PP2A. 
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Extracellular signal-regulated kinase p42/p44 
FTY720 administered prior to sustained ischaemia failed to elicit any effect on the ischaemia-
induced dephosphorylation of ERK p42/p44 (Figure 5.26). The phosphorylation of both ERK p42 
and ERK p44 were profoundly reduced by sustained ischaemia, an effect which was unaffected by 
the administration of FTY720 (ratio of phosphorylated ERK p42 to total ERK p42: Control: 
1.00±0.26 AU vs. 20 GI: 0.08±0.01 AU and PreFTY: 0.11±0.04 AU, n=3-5; P<0.01, and ratio of 
phosphorylated ERK p44 to total ERK p44: Control: 1.00±0.29 AU vs. 20 GI: 0.05±0.02 AU and 
PreFTY: 0.06±0.02 AU, n=3-5; P<0.01). This implies that PP2A plays no role in the ischaemia-
mediated dephosphorylation of ERK p42/p44. 
Stellenbosch University  http://scholar.sun.ac.za
- 246 - 
 
 
  
Stellenbosch University  http://scholar.sun.ac.za
- 247 - 
 
Equal loading: β-Tubulin 
Blotting for β-Tubulin revealed no differences between any of the groups, thereby confirming equal 
loading (Figure 5.27). 
 
Pre-treatment with FTY720: Protein profiles at 5 minutes reperfusion 
Perfusion with FTY720 was followed by 20 minutes GI and 5 minutes reperfusion. Heart samples 
were then flash frozen and analysed using Western blotting techniques. 
Protein phosphatase 2A 
At 5 minutes reperfusion following 20 minutes GI, pre-ischaemic treatment with FTY720 failed to 
elicit any effect on the levels of PP2A-C, PP2A-A, or the ratio between the two (Figure 5.28). 
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Concerning the posttranslational modification of PP2A-C (Figure 5.29), FTY720 treatment was 
associated with an increase in absolute phosphorylation of PP2A-C relative to control (Control: 
1.00±0.12 AU vs. PreFTY720: 1.79±0.18 AU, n=3-5; P<0.05). Expression of phosphorylated 
PP2A-C relative to total PP2A-C however revealed that FTY720 did not exert much of an effect in 
addition to the reperfusion mediated increase in the degree of PP2A-C phosphorylation (Control: 
1.00±0.13 AU vs. 5 Repf: 1.75±0.09 AU and PreFTY: 1.84±0.08 AU, n=3-5; P<0.01). FTY720 also 
failed to induce any changes in the methylation of PP2A-C relative to 5 minutes reperfusion alone 
(nonmethylation relative to total PP2A-C: Control: 1.00±0.08 AU vs. 5 Repf: 1.62±0.12 AU and 
PreFTY: 1.54±0.07 AU, n=3-4; P<0.01). Pre-ischaemic treatment with FTY720 therefore failed to 
exert any effect on PP2A at 5 minutes reperfusion. 
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Protein kinase B (Akt) 
Despite the lack of FTY720 induced effects on PP2A at 5 minutes reperfusion, pretreatment with 
FTY720 exerted an intriguing effect on PKB/Akt (Figure 5.30). Since absolute phosphorylation and 
the relative degree of phosphorylation followed the same pattern, I shall only report on the ratio of 
phosphorylated PKB/Akt relative to total PKB/Akt. Five minutes reperfusion was associated with a 
pronounced increase in the phosphorylation of PKB/Akt  relative to control, irrespective of FTY720 
pretreatment (Control: 1.00±0.20 AU vs. 5 Repf: 7.51±0.44 AU and PreFTY: 3.19±0.17 AU, n=3-5; 
P<0.001). That being noted, pre-ischaemic treatment with FTY720 was associated with a reduction 
in the phosphorylation of PKB/Akt relative to 5 minutes reperfusion alone (5 Repf: 7.51±0.44 AU 
vs. PreFTY: 3.19±0.17 AU, n=3-5; P<0.001). FTY720 therefore either down-regulated upstream 
activating events in the PKB/Akt pathway or directly mediated the dephosphorylation of PKB/Akt. 
Both these scenarios could accomodate FTY720-mediated activation of PP2A as part of this signal 
modification. 
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Glycogen synthase kinase-3β 
These outspoken effects of pre-ischaemic administered FTY720 on PKB/Akt however failed to 
induce significant effects on one of the downstream effectors of PKB/Akt signalling, namely GSK-
3β (Figure 5.31). The phosphorylation of GSK-3β was increased at 5 minutes reperfusion relative 
to control, irrespective of FTY720 administration (ratio phosphorylated to total GSK-3β: Control: 
1.00±0.09 AU vs. 5 Repf: 8.37±1.81 AU and PreFTY: 5.91±0.85 AU, n=3-5; P<0.05, absolute 
phosphorylation followed the same pattern).  
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p38 Mitogen activated protein kinase 
Similar to GSK-3β, 5 minutes reperfusion was associated with a profound increase in 
phosphorylation of p38 MAPK, which was not influenced at all by the pre-ischaemic administration 
of FTY720 (Figure 5.32: ratio phosphorylated to total p38 MAPK: Control: 1.00±0.38 AU vs. 5 Repf: 
6.47±1.01 AU and PreFTY: 7.86±1.03 AU, n=3-5; P<0.05, absolute phosphorylation followed the 
same pattern). It therefore seems that at this time point p38 MAPK is unaffected by the signalling 
alterations associated with FTY720. 
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Extracellular signal-regulated kinase p42/p44 
At 5 minutes reperfusion pre-ischaemic FTY720 treatment was associated with an increase in the 
phosphorylation of ERK p42/p44 relative to total ERK p42/44 in comparison to control (Figure 5.33: 
ERK p42: Control: 1.00±0.54 AU vs. PreFTY: 8.03±1.52 AU, n=3-5; P<0.05, and ERK p44: 
Control: 1.00±0.42 AU vs. PreFTY: 5.43±0.97 AU, n=3-5; P<0.05). Surprisingly, 5 minutes 
reperfusion alone was not associated with a significant increase in the phosphorylation of ERK 
p42/44, despite an almost obvious visible increase in ERK p42/p44 phosphorylation according to 
the blot. The lack of statistical significance can be attributed to the unfortunate degree of variation 
within the data combined with low n-values for these groups (ERK p42: Control: 1.00±0.54 AU vs. 
5 Repf: 3.24±0.59 AU, n=3; NS, and ERK p44: Control: 1.00±0.42 AU vs. 5 Repf: 2.75±0.73 AU, 
n=3; NS). 
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Equal loading: β-Tubulin 
Western blotting of a representative blot for β-tubulin confirmed equal loading (Figure 5.34). 
 
Pre-treatment with FTY720: Protein profiles at 10 minutes reperfusion 
Hearts exposed to 15 minutes perfusion with 1 μM FTY720 were immediately exposed to 20 
minutes ischaemia, followed by 10 minutes reperfusion. Hearts were then freeze-clamped and the 
selected signalling proteins investigated using Western blotting. 
Protein phosphatase 2A 
Pre-ischaemic treatment with FTY720 did not lead to any changes in the levels of either PP2A-C or 
PP2A-A (Figure 5.35). 
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Interestingly, FTY720 treatment elicited an increase in the phosphorylation of PP2A-C, but only in 
comparison to control (Figure 5.36: ratio phosphorylated to total PP2A-C: Control: 1.00±0.11 AU 
vs. PreFTY: 1.57±0.09 AU, n=3-5; P<0.05) and not 10 minutes reperfusion on its own (10 Repf: 
1.55±0.16 AU vs. PreFTY: 1.57±0.09 AU, n=3-5; NS). This indicates that the increased 
phosphorylation associated with FTY720 treatment is not very strong, especially in comparison to 
10 minutes reperfusion alone, and therefore probably not important. Concerning the methylation of 
PP2A-C, pre-ischaemic FTY720 treatment also failed to induce any changes relative to 10 minutes 
reperfusion. It can therefore be concluded that, just as at 5 minutes reperfusion, FTY720 exerts no 
effects on PP2A at 10 minutes reperfusion. The FTY720 mediated activation of PP2A is therefore 
transient and does not extend beyond 20 minutes GI. 
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Protein kinase B (Akt) 
The outspoken effects of reperfusion and FTY720 treatment on PKB/Akt phosphorylation which 
was evident at 5 minutes reperfusion (Figure 5.30), was no longer present after 10 minutes 
reperfusion (Figure 5.37). An unpaired T-test comparing control with 10 minutes reperfusion 
reveals that PKB/Akt phosphorylation was still elevated at this time point (phosphorylated to total 
PKB/Akt ratio: Control: 1.00±0.04 AU vs. 10 Repf: 2.00±0.10 AU, n=3; P<0.001). Although PreFTY 
was associated with a significant increase in PKB/Akt phosphorylation relative to control (ratio 
phosphorylated to total PKB/Akt: Control: 1.00±0.04 AU vs. PreFTY: 3.03±0.52 AU, n=3-5; 
P<0.05), it did not differ significantly from the group exposed to 10 minutes reperfusion alone, 
indicating that this was not a profound increase in phosphorylation. 
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Glycogen synthase kinase-3β 
Despite the borderline stimulatory effect of FTY720 on PKB/Akt (Figure 5.37), it was definitely 
associated with an outspoken increase in the phosphorylation of GSK-3β (Figure 5.38) relative to 
both control (ratio phosphorylated to total GSK-3β: Control: 1.00±0.12 AU vs. PreFTY: 11.19±0.25 
AU, n=3-5; P<0.0001), as well as 10 minutes reperfusion (ratio phosphorylated to total GSK-3β: 10 
Repf: 5.83±0.83 AU vs. PreFTY: 11.19±0.25 AU, n=3-5; P<0.001). This increase in GSK-3β is all 
the more impressive since it is in addition to the increase in phosphorylation already induced by 
reperfusion itself (ratio phosphorylated to total GSK-3β: Control: 1.00±0.12 AU vs. 10 Repf: 
5.83±0.83 AU, n=3; P<0.001). Pre-ischaemic treatment with FTY720 therefore elicited a surprising 
and sudden increase in the phosphorylation of GSK-3β at 10 minutes reperfusion, over and above 
the change induced by 10 minutes reperfusion alone. 
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p38 Mitogen activated protein kinase 
As shown in Figure 5.39, 10 minutes reperfusion was associated with an increase in the 
phosphorylation of p38 MAPK, with pre-ischaemic FTY720 administration exerting no effect on this 
(ratio of phosphorylated to total p38 MAPK: Control: 1.00±0.34 AU vs. 10 Repf: 5.79±0.92 AU and 
PreFTY: 6.75±0.43 AU, n=3-5; P<0.01). The effects of FTY720 on p38 MAPK therefore seems to 
have dissipated by 10 minutes reperfusion. 
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Extracellular signal-regulated kinase p42/p44 
Following a similar pattern to 5 minutes reperfusion, pre-ischaemic FTY720 was associated with an 
increase in the phosphorylation of ERK p42/p44 (Figure 5.40). In the case of ERK p42 this 
increase was only relative to control (ratio of phosphorylated to total ERK p42: Control: 1.00±0.33 
AU vs. PreFTY: 2.12±0.19 AU, n=3-5; P<0.05), while for ERK p44 it was also elevated compared 
to 10 minutes reperfusion (ratio of phosphorylated to total ERK p44: Control: 1.00±0.29 AU and 10 
Repf: 1.56±0.19 AU vs. PreFTY: 4.60±0.66 AU, n=3-5; P<0.01). Although 10 minutes reperfusion 
itself was not associated with an increase in the phosphorylation of ERK p42 in comparison to 
control, a direct comparison reveals a significant increase in the phosphorylation of ERK p42 at 10 
minutes reperfusion per se (Control: 1.00±0.33 AU vs. 10 Repf: 1.99±0.09 AU, n=3; T-test: 
P<0.05). The data indicate that FTY720 enhances the phoshorylation already induced by 10 
minutes reperfusion itself. 
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Equal loading: β-Tubulin 
Western blotting of a representative blot for β-tubulin showed that there were no statistical 
differences between any of the groups (Figure 5.41). 
 
Reperfusion-treatment with FTY720: Protein profiles at 15 minutes 
reperfusion 
In these experiments hearts were exposed to 20 minutes GI, followed by FTY720 (1 μM) 
administration at the onset of reperfusion for a period of 15 minutes. At the end of this 15 minute 
period, hearts were freeze-clamped for subsequent determination of the signalling protein profiles. 
Protein phosphatase 2A 
Administration of FTY720 at the onset of reperfusion was not associated with any changes in the 
levels of total PP2A-C or PP2A-A (Figure 5.42). Interestingly, comparison of the ratio between 
PP2A-C and PP2A-A with control using a Dunnett’s post hoc test shows that this ratio was 
increased at 15 minutes reperfusion (Control: 1.00±0.09 AU vs. 15 Repf: 1.21±0.04 AU, n=3; 
P<0.05). This is a very slight increase which, although it fits the trend of an increased ratio at 5 
minutes reperfusion (Figure 3.21), is in contrast to the absence of such a difference at 10 minutes 
reperfusion (Figure 3.22). 
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Surprisingly, reperfusion treatment was not associated with any changes in the phosphorylation of 
PP2A-C (Figure 5.43). It however elicited a reduction in methylation, but only relative to control 
(ratio nonmethylated PP2A-C to total PP2A-C: Control: 1.00±0.08 AU vs. PostFTY: 1.22±0.04 AU, 
n=3-5; P<0.05). In the absence of an effect relative to 15 minutes reperfusion only (in the absence 
of the drug), this observed change probably represents a very slight reduction in PP2A-C 
methylation. Post-treatment with FTY720 therefore elicited surprisingly little effect on PP2A. 
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Protein kinase B (Akt) 
Fifteen minutes reperfusion was in itself associated with a profound increase in the 
phosphorylation of PKB/Akt (Figure 5.44). The administration of FTY720 in combination with 
reperfusion failed to elicit any effect on this increase in phosphorylation (ratio of phosphorylated to 
total PKB/Akt: Control: 1.00±0.04 AU vs. 15 Repf: 6.96±0.47 AU and PostFTY: 6.06±0.96 AU, n=3-
5; P<0.01). 
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Glycogen synthase kinase-3β 
As was seen with PKB/Akt, 15 minutes reperfusion in itself was associated with a potent increase 
in the phosphorylation of GSK-3β (Figure 5.45). Statistically FTY720 administration failed to impact 
this increase in phosphorylation (ratio of phosphorylated to total GSK-3β: Control: 1.00±0.11 AU 
vs. 15 Repf: 6.79±1.22 AU and PostFTY: 4.21±0.58 AU, n=3-5; P<0.05). However, a direct 
comparison between 15 minutes reperfusion alone and the FTY720 treatment group shows a 
bordeline significant difference between the two groups (ratio of phosphorylated to total GSK-3β: 
15 Repf: 6.79±1.22 AU vs. PostFTY: 4.21±0.58 AU, n=3-5; P=0.07). Our data therefore reveal a 
strong trend indicating that FTY720 treatment reduced the reperfusion mediated phosphorylation of 
GSK-3β. 
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p38 Mitogen activated protein kinase 
P38 MAPK fell into the same pattern as all the other kinases analysed, in the sense that 15 
minutes reperfusion itself already potently activated the kinase (Figure 5.46). As with the other 
kinases, FTY720 treatment failed to make any difference in this reperfusion-associated elevation in 
phosphorylation (ratio of phosphorylated to total p38 MAPK: Control: 1.00±0.09 AU vs. 15 Repf: 
8.78±1.38 AU and PostFTY: 7.13±10.02 AU, n=3-5; P<0.01). 
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Extracellular signal-regulated kinase p42/p44 
FTY720 administered during reperfusion failed to elicit a strong and robust effect on the 
phosphorylation of ERK p42/p44 (Figure 5.47). Reperfusion itself increased the phosphorylation of 
ERK p42 and FTY720 failed to impact this at all (ratio phosphorylated to total ERK p42: Control: 
1.00±0.22 AU vs. 15 Repf: 2.77±0.49 AU and PostFTY: 2.18±0.07 AU, n=3-5; P<0.05). 
Interestingly, the effect of reperfusion on ERK p44 was much less pronounced and FTY720 
treatment seemed to enhance it, so that FTY720 treatment was associated with a significant 
increase in phosphorylation relative to control (ratio phosphorylated to total ERK p44: Control: 
1.00±0.24 AU vs. PostFTY: 2.21±0.17 AU, n=3-5; P<0.01). This elevation was however not 
significant in comparison to reperfusion alone. Direct comparison of control with reperfusion alone 
reveals a borderline significant difference (ratio phosphorylated to total ERK p44: Control: 
1.00±0.24 AU vs. 15 Repf: 1.68±0.21 AU, n=3; T-test: P=0.0968). The absence of a statistical 
difference (P<0.05) can possibly be attributed to the low n-value. Taken together, FTY720 failed to 
elicit any outspoken effects on ERK p42/p44 activation when administered during reperfusion. 
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Equal loading: β-Tubulin 
Western blotting for β-tubulin on a representative blot failed to show any significant differences 
between any of the groups (Figure 5.48). 
 
Pre- and reperfusion treatment with FTY720: Protein profiles at 35 minutes 
reperfusion 
For these experiments hearts were exposed to 15 minutes of FTY720 (1 μM) administration either 
directly before 20 minutes GI, or for the first 15 minutes of reperfusion. Hearts were snap frozen 
after 35 minutes of reperfusion. The control group in these experiments constituted hearts which 
were also exposed to I/R, but without FTY720 administration. 
Protein phosphatase 2A 
After 35 minutes of reperfusion FTY720 administered during the first moments of reperfusion was 
associated with a significant increase in the levels of PP2A-C in comparison with pretreated hearts 
(Figure 5.49: PreFTY: 0.88±0.03 AU vs. PostFTY: 1.10±0.04 AU, n=5; P<0.05). Neither of these 
groups however differed from control (Control: 1.00±0.09 AU vs. PreFTY: 0.88±0.03 AU vs. 
PostFTY: 1.10±0.04 AU, n=4-5; NS). The levels of PP2A-C relative to PP2A-A also did not differ 
between any of the groups. The importance of this elevation in PP2A-C in the PostFTY group is 
therefore doubtful and probably simply the result of a slight downward fluctuation in PP2A-C in the 
PreFTY group in combination with a slight upward shift in the PostFTY group. 
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Interestingly, FTY720 failed to exert any effect on the phosphorylation of PP2A-C (Figure 5.50) at 
this time point. This highlights the transient nature of FTY720’s effects on PP2A. 
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At this stage of the project our stock of antibody against nonmethylated PP2A-C had become quite 
old and our attempt to probe the blots with it failed. Unfortunately, the supplier from whom we had 
obtained the antibody had in the meantime decided to take this antibody of the market. We were 
therefore unable to assess the level of PP2A-C methylation in these final experiments. 
Protein kinase B (Akt) 
At 35 minutes reperfusion FTY720 exerted no effect on total PKB/Akt levels (Figure 5.51).  
 
Reperfusion administration of FTY720 was however associated with a significant increase in the 
absolute phosphorylated levels of PKB/Akt in comparison with a I/R control (Control: 1.00±0.12 AU 
vs. PostFTY: 2.25±0.35 AU, n=3-5; P<0.05). Direct comparison of control with PreFTY also 
revealed a significant difference (Control: 1.00±0.12 AU vs. PreFTY: 1.50±0.11 AU, n=3-5; T-test: 
P<0.05). Both these differences disappeared when phosphorylation was expressed relative to total 
PP2A-C (Control: 1.00±0.27 AU vs. PreFTY: 0.93±0.09 AU and PostFTY: 1.31±0.22 AU, n=4-5; 
NS). The observed increase in phosphorylation can therefore probably be ascribed to residual 
effects of FTY720, which at this stage of the experiment had diminished considerably, thereby 
explaining the absence of any significant differences in the phosphorylation of PKBAkt relative to 
the total pool of PKB/Akt. 
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Glycogen synthase kinase-3β 
Neither pre-ischaemic or reperfusion administration of FTY720 was associated with any changes in 
the levels of total or phosphorylated GSK-3β (Figure 5.52). 
 
p38 Mitogen activated protein kinase 
Similar to PKB/Akt, reperfusion administration of FTY720 was associated with an increase in the 
absolute phosphorylation of p38 MAPK relative to control (Figure 5.53: Control: 1:00±0.15 AU vs. 
PostFTY: 2.21±0.26 AU, n=3-5; P<0.05). In contrast to the effects of FTY720 on PKB/Akt, its 
stimulatory effect on p38 MAPK was more robust, with the increase in phosphorylation still evident 
when expressed relative to total p38 MAPK (Control: 1.00±0.15 AU vs. PostFTY: 2.25±0.26 AU, 
n=3-5; Dunnett’s test: P<0.05). PreFTY did not elicit significant effects compared to control. 
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Extracellular signal-regulated kinase p42/p44 
FTY720 administration, regardless of the time of administration, failed to exert any effects on ERK 
p42/p44 at 35 minutes reperfusion (Figure 5.54). 
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Equal loading: β-Tubulin 
No significant differences were observed between any of the groups when probed for β-tubulin 
(Figure 5.55). 
 
Discussion 
The results concerning the effects of FTY720 and PP2A activation on the heart are summarized in 
Figures 5.56-58. In the introduction to this chapter we described the complexity and paradoxical 
nature of FTY720, characteristics which have become evident in our results. We defined two 
central aims for this investigation: Our primary aim was to apply FTY720 as a PP2A activator in the 
setting of myocardial I/R in order to determine the role of PP2A in this setting. In this context, this 
study is complimentary to Chapter 4 in which we inhibited PP2A. We will therefore also attempt to 
combine the results and conclusions from these two studies in Chapter 6. A secondary aim was 
however to simply make a contribution to the body of knowledge concerning the effects of FTY720 
on the heart exposed to I/R per se. We will first focus on the latter aim and then shift our attention 
to what our results reveal concerning PP2A. 
The effects of FTY720 on the outcomes of myocardial ischaemia / 
reperfusion 
In view of the cardioprotective abilities of S1P (Knapp, 2011; Karliner, 2013), it was expected that 
FTY720 would also limit myocardial I/R injury – an exciting prospect since FTY720 is already in 
clinical use as treatment for MS (Chun & Brinkmann, 2011). Previous studies on FTY720 have 
however failed to deliver an unanimous verdict concerning this (table 5.1). Our results 
unfortunately also contribute to a deepening of the controversy (Figure 5.56). 
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For these experiments we used two concentrations of FTY720: 1 μM and 2.5 μM. The 
administration of 1 μM FTY720 during reperfusion limited IFS development, while pretreatment 
actually augmented IFS (Figure 5.8). Intriguingly, this detrimental effect of FTY720 was alleviated 
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when a brief period (5 minutes) of reperfusion was allowed between drug administration and index 
ischaemia (pharmacological preconditioning). None of the administration protocols for 1 μM 
FTY720 exerted any effect on functional recovery following 35 minutes RI (tables 5.3), except for 
the preconditioning protocol which was associated with a reduction in CO, probably due to a 
reduction in heart rate when the heart was reperfused in the work mode (table 5.4). This reduction 
in heart rate could be explained as a manifestation of the bradycardiac effects of FTY720 (Hla & 
Brinkmann, 2011).  
 
At 2.5 μM, FTY720 exerted an infarct sparing effect, irrespective of the time of administration 
(Figure 5.9). This reduction in IFS was however dissociated from functional recovery, indeed 
functional recovery was compromised in both groups (tables 5.5 and 5.6). 
 
We also administered these doses to hearts exposed to 20 minutes of GI in order to specifically 
investigate the effects of FTY720 on function. At 1 μM FTY720 exerted no effect on functional 
recovery (Figure 5.10), while pretreatment with 2.5 μM actually proved detrimental in this regard 
(Figure 5.11). 
 
These results indicate the following: 
 FTY720 exerts dose-specific effects. 
 FTY720 exerts different effects on tissue viabillity and functional capacity. 
 FTY720 at a concentration of 2.5 M is detrimental to functional recovery. 
 Pretreatment with FTY720 yielded controversial outcomes. 
 
Each of these aspects will be discussed individually. 
FTY720 exerts dose-specific effects 
This is probably the most obvious observation from our data: pretreatment with 1 μM FTY720 
aggravated IFS, while 2.5 μM protected. Also, 1 μM exerted no effects on functional recovery, 
while with 2.5 μM the reduction in IFS was accompanied by a marked depression in functional 
recovery. These observations have obvious implications concerning clinical applications of the 
drug. As already mentioned, Karliner (2009) reported that low doses of sphingosine (of which 
FTY720 is an analogue) are cardioprotective, while higher dosages are cardiotoxic. Likewise, 
Vessey et al. (2009) found that in old rat hearts 0.4 μM S1P was less effective in limiting IFS 
following 40 minutes of GI in the isolated heart model, than 0.2 μM (0.2 μM: 27±11% vs. 0.4 μM: 
39±6%). It is therefore very plausible that the effects of FTY720 are very dose dependent. 
 
This however raises another question: Are we dealing with FTY720 or P-FTY720? This is a 
conundrum which was encountered by Oaks and colleagues (2013) and also highlighted by 
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Vessey et al. (2013). This question is important since FTY720 will exert direct effects on 
intracellular machinery, while P-FTY720 will activate a receptor-mediated signalling cascade. Two 
observations in our study support the idea that a large percentage of the observed effects is 
mediated by P-FTY720. 
 
Firstly, FTY720 administration was associated with a potent increase in CF (Figures 5.12 and 
5.13). This effect is not surprising since S1P has the ability to stimulate vasodilation in a NOS-
dependent manner (Igarashi & Michel, 2009). This effect is however mediated by the occupation 
and activation of S1P1 and / or S1P3 receptors (Karliner, 2009; Igarashi & Michel, 2009), implying 
that in our experimental setup FTY720 had become phosphorylated and was eliciting its effects by 
binding to the S1P receptors. Secondly, preconditioning with FTY720 reduced heart rate during 
reperfusion, as did pretreatment with 2.5 μM (although all functional parameters were reduced in 
this protocol). These effects could be due to the bradycardiac effects of S1P (Brinkmann, 2009; Hla 
& Brinkmann, 2011), and also FTY720 (Schmouder et al., 2012). This is however also dependent 
on the activation of the S1P1 and S1P3 receptors, again implying that these effects are elicited by 
P-FTY720. 
 
The phosphorylation of FTY720 is very probable in this setting. It is mediated by SK2, which is the 
predominant sphingosine kinase in the cytosolic compartment of heart tissue (Vessey et al., 2007; 
Strub et al., 2010). In addition to this, FTY720 has the ability to activate SK2 whilst inhibiting SK1 
(Vessey et al., 2007). The implication of this is that FTY administration itself will progressively 
favour the phosphorylation of more FTY720. However to what degree the FTY720 which we 
administered to the hearts became phosphorylated is unknown. It is also possible that a significant 
portion of the drug remained unphosphorylated, thereby exerting a direct effect on intracellular 
targets. 
FTY720 exerts different effects on tissue viabillity and functional capacity 
Excluding pretreatment with 1 μM FTY720, all other administration protocols were associated with 
a reduction in IFS, however none of the protocols had a beneficial effect on functional recovery, in 
fact 2.5 μM FTY720 predominantly exerted a negative effect on reperfusion function.  The 
dissociation between IFS and functional recovery data is a well-known phenomenon as was 
discussed in Chapter 4. As mentioned in the previous chapter, IFS is a measure of tissue death 
only, while functional recovery is determined by several factors including tissue death (and thus the 
remaining viable tissue), reversible stunning of tissue and cardiac rhythmicity. The fact that 2.5 μM 
FTY720 actively contributed to the deterioration of functional capacity indicates that it might not be 
a simple detachment of function from IFS, but that FTY720 per se has harmful effects on function 
during reperfusion. We will therefore focus on IFS and functional recovery separately. 
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FT720 and infarct size 
Our data indicate that especially the reperfusion-based administration of FTY720 reduces IFS, i.e. 
increases cell viability, which is in agreement with other studies on the effects of FTY720 (Egom et 
al., 2011; Vessey et al., 2013), as well as S1P (Vessey et al., 2008; Somers et al., 2012). There is 
therefore relative concensus regarding the infarct sparing effects of FTY720 when administered at 
reperfusion. However very low FTY720 concentrations (50 and 500 nM) failed to reduce IFS in an 
isolated rat heart model exposed to 30 minutes GI, although this was associated with decreased 
apoptosis (Hofmann et al., 2009).  
 
We also made the surprising observation that pretreatment with 1 μM FTY720 was associated with 
an increase in IFS (Figure 5.8). This observation is novel, since the effects of pre-ischaemic 
treatment with FTY720 has received no attention thus far. Preconditioning with S1P has been 
shown to be cardioprotective (Jin et al., 2002; Vessey et al, 2009), however we found FTY720 
preconditioning ineffective in influencing IFS. Later in this discussion we will attempt to explain 
these unexpected results (pages 281 & 292). 
FTY720 and functional recovery 
Only a few studies focussed on the effects of FTY720 on function alone. We found that 1 μM 
FTY720 failed to influence functional recovery at all, while 2.5 μM was detrimental to functional 
recovery. 
 
Our results are in contrast to studies that have reported an increase in functional recovery following 
regional ischaemia associated with the administration of FTY720 during reperfusion (Hofmann et 
al., 2009; Vessey et al., 2013). Egom and colleagues (2010) also found that FTY720 reduced 
rhythmicity disturbances following I/R. The only study that agrees with our results was done in an 
in vivo rat model (Hofmann et al., 2010), which due to systemic effects, cannot be compared to our 
study. 
 
There are two important differences between our study and the studies reported in the literature 
which might explain these discrepancies. Firstly, the experimental model used; we used the 
isolated perfused working heart (see Chapter 2) as opposed to the retrograde perfusion model 
used by others (Hofmann et al., 2009; Egom et al., 2010; Vessey et al., 2013). This mode of 
perfusion is energetically more demanding (Taegtmeyer et al., 1980) and generates more free 
radicals (Damerau et al., 1993) compared to simple retrograde perfusion and may therefore 
compromise functional recovery (Van Vuuren et al., 2008). Secondly, the dose used; we used 
higher concentrations of FTY720 compared to what was used in the other studies (see table 5.1).  
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2.5 μM FTY720 is detrimental to functional recovery 
We found that 2.5 μM FTY720 reduced functional recovery following 35 minutes of RI, irrespective 
of whether it was administered before or after sustained ischaemia. Administration of the drug prior 
to 20 minutes GI also incurred major functional depression at reperfusion. 
 
All other studies concerning FTY720 used concentrations ranging from 0.05 to 0.6 μM (table 5.1). 
Even the concentrations of S1P used in other studies were very low relative to what we used; 
ranging from 10 nM (Jin et al., 2002) to 0.4 μM (Vessey et al., 2008 and 2009; Somers et al., 
2012). We however tested higher concentrations, since our primary focus was PP2A activation 
which has been reported to be associated with higher concentrations of FTY720, ranging from 2.5 
μM (Neviani et al., 2007) to 10 μM (Saddoughi et al., 2013). Although it could be argued that high 
doses of FTY720 exert toxic effects, this seems unlikely since the initial work on FTY720 showed 
that it did not elicit any visible toxic effects, even at high doses (Neviani et al., 2007; Oaks et al., 
2013). Although Karliner (2009) noted potential cardiotoxic effects of sphingosine at 5 μM, it is a 
dose twice as high as our highest dose. Challenging these high levels, Theilmeier et al. (2006) 
even reported a cardioprotective effect with 10 μM S1P in a rat neonatal cardiomyocyte model.  
 
Alternatively our results simply reveal the ability of FTY720 and P-FTY720 to exert differential 
effects on different components of cardiovascular function during I/R, thereby limiting cell death 
while exerting detrimental effects on function. 
Pretreatment with FTY720 yielded controversial results 
As mentioned before, to our knowledge there are no studies which have investigated the effects of 
FTY720 administered prior to ischaemia on the development of I/R injury. Our results concerning 
this is novel, albeit not promising. Pretreatment with 1 μM FTY720 increased IFS, while 
pretreatment with 2.5 μM reduced functional recovery following both 35 minutes regional 
ischaemia, as well as 20 minutes global ischaemia. 
 
The potential mechanisms involved will be discussed in the next section. 
Mechanisms explaining the effects of FTY720 
This study is limited to only describing the effects of 1 and 2.5 μM FTY720 on the outcomes 
associated with myocardial I/R. We can therefore only speculate regarding the mechanisms 
involved within this setting. We will focus our explanation on the two aspects of FTY720 as 
indicated by our results: namely its effects on cardioprotection, and the possible negative effects 
on myocardial I/R injury. 
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FTY720 in cardioprotection 
The cardioprotective effects observed in conjunction with FTY720 administration pertains solely to 
its ability to limit the development of IFS following I/R. We suggest three possible mechanisms by 
which FTY720 can elicit an infarct sparing effect: 
. 
1.) Increasing the amount of S1P in the heart.  
The amount of S1P in the heart is a function of the balance between synthesis and 
degradation. Two important enzymes in this regard are sphingosine kinase (SK, both isoforms 
1 and 2), which phosphorylates sphingosine to S1P; and S1P lyase (SPL), which is involved in 
the irreversibe degradation of S1P (Knapp, 2011). Both of these enzymes have been shown to 
be important in the context of cardioprotection.  
 
Sustained ischaemia is associated with a reduction in the activity of SK, which does not 
recover rapidly during reperfusion (Karliner, 2009). This loss in SK activity is closely linked to 
myocardial function and has been shown to be a target of IPC mediated cardioprotection, with 
IPC limiting ischaemic loss of SK activity and stimulating a rapid recovery of SK function 
during reperfusion (Vessey et al., 2006). Combined with this, animal knockout models of SK2 
have been found to be more sensitive to I/R injury than control hearts and are resistant to IPC-
induced cardioprotection (Vessey et al., 2011; Gomez et al., 2011). These data identify SK2 as 
a pro-survival kinase. Much less is known regarding SPL in the setting of myocardial I/R. In 
2011 Bandhuvula and colleagues reported that sustained ischaemia was associated with an 
increase in the activity of SPL. Inhibition or knockout of SPL was associated with a reduction in 
IFS and an improvement in post-ischaemic function. 
 
FTY720 has been shown to modulate both these enzymes. Although FTY720 has been shown 
to inhibit SK1, it has the opposite effect on SK2 (Vessey et al., 2007). FTY720 has also been 
implicated in the inhibition of SPL (Bandhuvula et al., 2005; KleinJan et al., 2013; Reina et al., 
2013). This suggests that FTY720 can potentially inhibit the detrimental SPL and activate the 
cardioprotective SK2. This will eventually favour an increase in S1P levels, which is the 
mechanism which has been proposed to explain the influence of these enzymes on I/R injury 
(Vessey et al., 2006 and 2011; Bandhuvula et al., 2011). An elevation in S1P levels then 
induces a cardioprotective effect by binding to and activating the S1P receptors. In this regard 
it is noteworthy that Bandhuvula and colleagues (2005) reported that systemic administration 
of FTY720 to a mouse model led to a transient increase in S1P levels in the thymus and 
spleen.  
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2.) Pro-survival signalling  through the S1P signalling pathways.  
As discussed above, FTY720 can theoretically induce an increase in S1P levels, initiating 
cardioprotective signalling. It must however also be kept in mind that once phosphorylated, P-
FTY720 can also bind to and activate S1P receptors, thereby also contributing to the activation 
of these pro-survival pathways. In this regard S1P1 and S1P3 receptors have been implicated 
in S1P protection (Theilmeier et al., 2006; Knapp, 2011). Following the activation of these 
GCPR’s, PKB/Akt and Stat3 are recruited into the pathway, which eventually culminates in 
protection (Vessey et al., 2008; Knapp, 2012; Somers et al., 2012). 
 
3.) Direct effects on signalling (S1P independent signalling). 
In 2008 Vessey and colleagues reported that sphingosine-induced protection is mediated 
through other pathways than S1P protection, namely protein kinase G (PKG) and PKA 
activation. Interestingly, sphingosine and S1P both eventually signal through PKB/Akt. A 
couple of years later the same group reported similiar results for FTY720 (Vessey et al., 2013). 
They found that postconditioning with FTY720 conferred protection independently of S1P 
signalling but, similiar to sphingosine, it is dependent on PKG and PKA activity. These results 
demonstrate that FTY720 can induce protection separately from S1P signalling. 
 
FTY720 therefore has several potential pathways and mechanisms by which it can elicit a 
protective effect. An explanation for its detrimental effects is however far less forthcoming. 
FT720 augmenting I/R injury 
We found that pretreatment with 1 μM FTY720 increased IFS, an effect which was avoided when 
FTY720 administration was followed by a brief period of reperfusion. Combined with the negative 
effects on functional recovery which were elicited by 2.5 μM FTY720 (Figure 5.56), these 
observations reveal a harmful side to FTY720 which can, at least partially, be explained as follows. 
 
As discussed previously, high concentrations of S1P can exert cardiotoxic effects. It can therefore 
not be ruled out that the concentrations of FTY720 which we used may have been high enough to 
exert similar cardiotoxic effects. This theory is particularly attractive when taking into account the 
fact that at 2.5 μM, and not 1 μM, FTY720 elicited the most detrimental effects on function. 
However, the dosages used were not that high (see Karliner, 2009; Theilmeier et al., 2006) and 
FTY720 has been reported to exert no toxic effects, even after prolonged exposure to relatively 
high concentrations (Neviani et al., 2007; Oaks et al., 2013). In addition, it should be kept in mind 
that the harmful effects of FTY20 (2.5 M) on function become evident during reperfusion, 
suggesting that the drug exerts its harmful effects on ischaemic damaged tissue.  
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Alternatively, in view of the reduction in infarct size seen in all instances (except pretreatment and 
preconditioning with 1 μM), it might simply be that the functional suppression is due to the negative 
inotropic and bradycardiac effects associated with S1P1 and S1P3 activation (Means & Brown, 
2009; Hla & Brinkmann, 2011). This possibility is corroborated by the fact that the reduction in CO 
during reperfusion associated with FTY720 preconditioning occurred in conjunction with a 
reduction in heart rate, while the functional depression seen in conjunction with 2.5 μM FTY720 
was also associated with a reduction in total work (reperfusion administration following 35 minutes 
RI), as well as a reduction in work, systolic pressure and heart rate (administration prior to 20 
minutes GI).  
FTY720 and coronary flow 
A prominent feature of S1P is its ability to either induce vasodilation or vasoconstriction, almost 
paradoxically, in both instances by inducing an increase in intracellular Ca2+ levels, but in different 
tissues. In the case of vasodilation, increased endothelial cellular Ca2+ contributes to NOS 
activation, and generation of the vasodilator NO. In vascular smooth muscle, it however mediates 
contraction leading to constriction (Igarashi & Michel, 2009). We observed that FTY720 exerted 
both vasodilatory- and constrictive effects in our model. On the one hand, FTY720 administration 
itself was associated with an outspoken increase in CF, irrespective whether it was 1 or 2.5 μM 
FTY720 being administered, either before ischaemia (Figure 5.12 A) or at the onset of reperfusion 
(Figure 5.13 A&B). Unexpectedly, exposure of the hearts to I/R in conjunction with FTY720 (as in 
the pre-ischaemic treatment groups) reversed this effect, so that FTY720 exerted a transient 
vasconstrictive effect during the first minutes of reperfusion (Figure 5.12 B). The mechanism 
behind this is unknown. Possibly I/R adds to a FTY720-mediated increase in intracellular Ca2+ 
levels in the vascular smooth muscle, which then dominates the NO-mediated vasodilatory effects 
of FTY720 – especially if these latter effects which were present before ischaemia are fading 
during ischaemia and reperfusion. 
 
These effects of FTY720 on CF are so outspoken that it is tempting to directly link them to either 
the infarct sparing, or function depressing effects of FTY720. Keeping in mind the dose dependent 
effects of FTY720 on functional recovery and IFS (Figure 5.56) and comparing these outcomes to 
the homogenous pattern of CF effects exerted by both concentrations of FTY720 (Figure 5.13 C), it 
becomes evident that there is no clear pattern linking changes in CF, either as a causal 
mechanism or a consequence, to the outcomes exerted by FTY720.  
FTY720 in myocardial I/R injury: summary 
In our model FTY720 administration at both 1 and 2.5 μM was associated with a reduction in 
infarct size following 35 minutes of RI, except for the pre-ischaemic and preconditioning 
administration of 1 μM FTY720. This cardioprotective effect of FTY720 can be ascribed to the fact 
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that it is a sphingosine analogue which contributes to the activation of the cardioprotective 
sphingosine and S1P pathways. These infarct sparing effects however did not extend to functional 
recovery. In fact 2.5 μM FTY720 almost consistently reduced functional ability during reperfusion. 
This could be due to the bradycardiac and negative inotropic effects of FTY720. FTY720 also 
exerted profound effects on CF, although the importance of this in relation to the outcomes 
associated with FTY720 treatment is unknown. Our data indicate that FTY720 maintains tissue 
viability, while paradoxically, undermining functional capability. 
FTY720 as an activator of PP2A in the setting of myocardial I/R injury 
The primary motivation behind our investigation into the effects of FTY720 was the fact that 
FTY720 has been associated with the activation of PP2A, both directly through interaction with the 
PP2A inhibitor SET (Oaks et al., 2013; Saddoughi et al., 2013), as well as through Pak1 signalling 
(Ke et al., 2012). For this aspect of the study we specifically used 1 μM FTY720, since it 
represented a relatively low dose of FTY720 with the ability to activate PP2A (Figure 5.7). We will 
therefore now focus our attention on the effects of FTY720 as a PP2A activator on the signalling 
components involved in RISK (PKB/Akt – GSK-3β, and ERK p42/p44) and p38 MAPK signalling.  
From there we will revisit our data concerning the effects of 1 μM FTY720 on IFS and functional 
recovery in order to ascertain if some of these effects can be ascribed to PP2A activity. 
The effects of FTY720 mediated PP2A activation on pro-survival and MAPK 
signalling 
In these experiments FTY720 was administered either directly prior to sustained ischaemia or at 
the onset of reperfusion. Hearts were then collected at different time points during the perfusion 
protocol and protein profiles determined using standard Western blotting techniques. An overview 
of the results are shown in Figures 5.57 and 5.58. We will discuss the effects of FTY720 on each 
signalling component individually. 
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Protein phosphatase 2A 
As expected FTY720 administration prior to ischaemia was associated with a reduction in the 
phosphorylation of PP2A (Figure 5.15), which is indicative of an increase in PP2A activity. These 
data agree with our initial investigations into the effects of 1 μM FTY720 on PP2A (Figure 5.7). It is 
therefore surprising that reperfusion administration of FTY720 failed to elicit any effects on PP2A 
phosphorylation (Figure 5.43). It was however associated with a reduction in methylation – 
indicating a possible change in holo-enzyme assembly, although the ratio of PP2A-C to PP2A-A 
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remained unchanged. It therefore seems as if the effect of I/R per se to inhibit PP2A by increasing 
its phosphorylation (see Chapter 3) dominated the activation effects of FTY720. It is therefore 
uncertain to what degree FTY720 administered at reperfusion could activate PP2A.  
 
The effect of FTY720 on PP2A phosphorylation was also very transient. Although pretreatment 
reduced PP2A phosphorylation directly before ischaemia, this was no longer visible at 20 minutes 
GI where the standard increase in both phosphorylation and nonmethylation of PP2A (Figure 5.22) 
was observed, as previously reported in Chapter 3. These data indicate that the effects of I/R per 
se on PP2A are quite robust and overshadow the potential effects of FTY720 on PP2A. It could 
however also mean that the signalling effects of FTY720 are intrinsically short-lived. 
 
We therefore have evidence that PP2A was activated by FTY720 administration at the onset of 
ischaemia, with no indication that this also continued during ischaemia and reperfusion. That being 
said, it should be remembered that PP2A activity is much more complex than its phosphorylation 
or lack thereof. 
Protein kinase B/Akt 
Administration of FTY720 at baseline (prior to ischaemia) elicited a pronounced increase in the 
phosphorylation of PKB/Akt (Figure 5.16). This activation was however less outspoken when 
FTY720 was administered at reperfusion (Figure 5.44), possibly because PKB/Akt was already 
phosphorylated to near maximum levels due to reperfusion per se. At 35 minutes reperfusion there 
was less pronounced PKB/Akt activation in the PostFTY group (Figure 5.51), possibly a 
consequence of FTY720 administration, which is diminishing as reperfusion progressed. The 
activation of PKB/Akt due to FTY720 administration has been reported by several other studies 
and is indeed postulated to be one of the cornerstones of the cardioprotective effects which have 
been ascribed to FTY720 (Hofmann et al., 2009; Egom et al., 2010 and 2011). This is also not 
surprising, since PKB/Akt activation is also stimulated by both sphingosine and S1P signalling 
(Vessey et al., 2008; Somers et al., 2012). 
 
This activation of PKB/Akt is suppressed during ischaemia (a well established phenomenon), 
remaining reduced at 5 minutes reperfusion relative to reperfusion alone, although it is still 
elevated relative to non-I/R control (Figure 5.30). This is a very outspoken effect, which wanes 
within the next 5 minutes so that at 10 minutes reperfusion PKB/Akt phosphorylation is elevated in 
the PreFTY group relative to a non-I/R control (Figure 5.37), an effect which had disappeared by 
35 minutes reperfusion (Figure 5.51). These data indicate that PP2A activity might be increased at 
the onset of reperfusion in the PreFTY group which might be responsible for the reduction in 
PKB/Akt phosphorylation at 5 minutes reperfusion. These PP2A-mediated effects are however 
transient and rapidly replaced by the stimulatory effects of FTY720. If this interpretation of the data 
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is correct, it also implies that FTY720 administration is simultaneously activating several very 
different pathways, which are possibly even opposing each other. 
Glycogen synthase kinase 3-β 
Pre-ischaemic administration of FTY720 did not result in an increase in the phosphorylation of 
GSK-3β (Figure 5.17) during stabilisation and remained unchanged until the end of 20 min global 
ischaemia. However, the ischaemia alone group presented with an elevation in phosphorylation 
relative to non-I/R control (Figure 5.24), indicative of a suppression of GSK-3β activity (since 
phosphorylation of GSK-3β is associated with a reduction in its activity). This is a strong indication 
that FTY720 pretreatment favoured the dephosphorylation (and therefore activation) of GSK-3β 
during ischaemia. This effect however diminished during reperfusion, so that by 5 minutes 
reperfusion both PreFTY and reperfusion alone presented with increased phosphorylation relative 
to non-I/R control (Figure 5.31). Similar to PKB/Akt, the phosphorylation of GSK-3β actually 
increased in the PreFTY group during reperfusion, to such an extent that it reached statistical 
significance at 10 minutes reperfusion (Figure 5.38). When FTY720 was administered during 
reperfusion it showed a very strong trend for reducing the degree of reperfusion-induced GSK-3β 
phosphorylation (Figure 5.45). At 35 minutes reperfusion no differences are associated with any of 
the FTY720 treatment regimes. 
 
There are four important conclusions which can be made from this data. Firstly, as mentioned in 
Chapter 4, it should be kept in mind that the effects of phosphatase activity modulation is best seen 
on a background of kinase-mediated activation. This explains the lack of an effect of FTY720 in 
GSK-3β prior to ischaemia, in contrast to the effect at the end of ischaemia. Secondly, the effects 
of FTY720 concerning the dephosphorylation of GSK-3β at the end of ischaemia is probably 
PP2A-mediated, thereby identifying GSK-3β as a potential substrate for PP2A during ischaemia. 
Thirdly, as was seen with PKB/Akt activation, these dephosphorylation effects of FTY720 are soon 
replaced with increased phosphorylation relative to I/R control, thereby indicating the co-activation 
of stimulatory pathways alongside the increase in PP2A activity. Fourthly, the PP2A mediated 
effects of FTY720 are very transient. This could be due to the intrinsic nature of the interaction 
between FTY720 and PP2A, or it could simply be due to the intracellular milieu being dominated by 
I/R associated pathways. 
p38 Mitogen activated protein kinase 
As was the case for both PKB and PP2A, baseline administration of FTY720 induced an increase 
in p38 MAPK activity, as indicated by an increase in its phosphorylation (Figure 5.18). However at 
the end of sustained ischaemia, p38 MAPK phosphorylation resembled that of GSK-3β, with a 
reduction in phosphorylation at 20 minutes GI relative to the ischaemic control (Figure 5.25). It 
must however be noted that both ischaemia alone, as well as PreFTY presented with a 
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substantially higher degree of phosphorylation than the normal perfusion control. The FTY720 
mediated suppression of p38 phosphorylation however rapidly dissipated during early reperfusion 
so that both the I/R and PreFTY groups presented with a similiar degree of elevation in 
phosphorylation relative to the non-I/R control (Figures 5.32 and 5.39).  
 
Unexpectedly, given the effects of FTY720 prior to ischaemia, administration of FTY720 at 
reperfusion failed to significantly elevate p38 MAPK phosphorylation (Figure 5.46). This is however 
similar to what we observed with PKB/Akt, and can possibly be ascribed to the already elevated 
phosphorylation of p38 MAPK due to reperfusion. Reperfusion treatment with FTY720 was 
however associated with a slight increase in the phosphorylation of p38 MAPK at 35 minutes 
reperfusion (Figure 5.53); possibly a remnant of a more potent effect of FTY720 on p38 
phosphorylation earlier in reperfusion which might be more evident at a time point between 15 and 
35 minutes reperfusion. 
 
We therefore here again observe the phenomenon that FTY720 activates multiple pathways, some 
inducing an increase in p38 MAPK phosphorylation, while others oppose it. The complicating factor 
with p38 MAPK is the fact that it might be a link between these two pathways, since p38 MAPK 
activation has been shown to be upstream of PP2A activation (see introduction to Chapter 4). 
Extracellular signal-regulated kinase p42/p44 
Fitting in with the established trend, ERK p42/p44 was phosphorylated by the administration of 
FTY720 under baseline conditions (Figure 5.19). At 20 minutes GI the phosphorylation of ERK 
p42/p44 was equally supressed in both the ischaemic, as well as PreFTY groups, relative to the 
non-I/R control (Figure 5.26). Deviating from the other kinases, FTY720 showed no suppressive 
effect on the phosphorylation of ERK p42/p44, in fact quite the opposite. At both 5 and 10 minutes 
reperfusion PreFTY presented with elevated phosphorylation of ERK p42/p44 (Figures 5.33 and 
5.40). In line with these results, reperfusion treatment with FTY720 was also associated with an 
increase in ERK p42/p44 phosphorylation, although not as robust since it only involved ERK p44 
and was only evident in comparison to non-I/R controls (Figure 5.47). At 35 minutes reperfusion, 
the effects of both Pre- and PostFTY720 treatment on ERK p42/p44 phosphorylation had 
diminished and was no longer evident. 
 
ERK p42/p44 therefore followed a different pattern than the other kinases in the sense that 
FTY720 seemed to only activate it, with no hint of a co-activated dephosphorylation pathway. 
These results therefore imply that PP2A is not an important phosphatase of ERK p42/p44 in the 
context of myocardial I/R injury. It is noteworthy that our results differ from those published by 
Hofmann and colleagues (2009) who reported that FTY720 exerted no effect on ERK p42/p44 
phosphorylation in their experimental setup. Their experimental conditions differed from ours in 
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several ways: FTY720 was administered at half the dose we used (500 nM) and they exposed their 
isolated rat hearts to 30 minutes GI and 90 minutes reperfusion. It was also only at 90 minutes 
reperfusion that they collected tissue for protein analysis. Their isolated heart experiments also did 
not include work mode perfusion. These differences with regards to concentration administered, as 
well as stress that the hearts were exposed to and reperfusion time, make it very difficult to 
compare results. Interestingly they also reported that FTY720 activated PKB/Akt, similar to our 
results, thereby indicating the robustness of this particular effect. Contributing to the complexity, 
they also found that 1 μM could in fact increase ERK p42/p44 phosphorylation (but not PKB/Akt) in 
human right atrial muscle strips when exposed to 90 minutes SI followed by 120 minutes 
reperfusion.  
Summary and conclusion 
Of the two administration protocols tested, the pre-ischaemic application of FTY720 gave the most 
information. A graphic summary of the effects of FTY720 in these experiments is given in Figure 
5.59.  
 
The interpretation of the data is challenging, since FTY720 is not the only signalling modifier 
involved in our experiments, I/R per se also elicits a signalling mediated response, which according 
to our data seemed to compete with and oppose some of the effects elicited by FTY720. It must 
also be kept in mind that PP2A activity is not only determined by its phosphorylation state. Its 
cellular location and substrate specificity are also very dynamic and also influenced by I/R (see 
Chapter 3). The implication of this is that our results might be very specific for I/R, and caution 
must be taken when attempting to extrapolate our results and conclusions to other settings. 
 
All of that being said, the following picture seems to emerge (Figure 5.60). FTY720 activates 
several pathways simultaneously, probably though direct effects as well as S1P receptor mediated 
activation. This culminates in the immediate activation of ERK p42/p44, PKB/Akt, p38 MAPK and 
PP2A (as measured prior to ischaemia). At the end of sustained GI and the onset of reperfusion 
PP2A dominates the signalling pathways and dephosphorylates PKB/Akt, GSK-3β and p38 MAPK. 
This could either reflect the temporal effects of FTY720 on PP2A signalling, or it could be due to 
the fact that some FTY720 is still present in the heart at the end of ischaemia and onset of 
reperfusion. For GSK-3β this requires some form of pre-phosphorylation, induced by sustained 
ischaemia in our experimental setup. It is theoretically also possible that PKB/Akt could 
phosphorylate GSK-3β under FTY720 stimulation, although it is very unlikely given that ischaemia 
is associated with the dephosphorylation and inactivation of PKB/Akt.  
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As discussed in the introduction to this chapter, FTY720 can potentially activate PP2A either 
directly, or via the activation of signalling pathways. In this regard Pak-1 has been identified as a 
potential upstream activator of PP2A (Ke et al., 2012). Our results however also show that FTY720 
can activate p38 MAPK, which has also been implicated as a potential activator of PP2A (see the 
introduction to Chapter 4). Irrespective of the mechanism how PP2A is activated by FTY720, it is a 
very transient phenomenon. As soon as PP2A activity dissipates, the activation of PKB/Akt and 
p38 MAPK dominate again (5 and 10 minutes reperfusion, as well as 30 minutes reperfusion in the 
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PostFTY group). This increase in PKB/Akt activation might explain the increase in GSK-3β 
phosphorylation observed at this stage, or it could be that FTY720 induces the phosphorylation of 
GSK-3β via PKA, since PKA has been implicated in the signalling pathways activated by 
sphingosine (Vessey et al., 2008). In the setting which we investigated, ERK p42/p44 activation 
was unaffected by PP2A, since it remained phosphorylated during early reperfusion. 
 
If this model is true, then the final effects of FTY720 on signalling, and obviously also on the 
eventual actions elicited by these signalling pathways, are determined by the balance between 
these different pathways; as this balance shifts over time, the effects of FTY720 shifts concurrently. 
This model therefore also contributes to our understanding of how FTY720 can exert different 
effects on IFS and functional recovery and why its effects are dose dependent. 
 
The question however arises why we did not see such a robust signalling response to reperfusion 
administered FTY720, as with pre-ischaemic FTY720 treatment. There are two possible reasons 
for this, both related to the fact that reperfusion itself also phosphorylates these signalling kinases: 
(1.) It could be that PKB/Akt and p38 MAPK are already nearly maximally phosphorylated at the 
time point we investigated due to reperfusion itself; or (2.) FTY720 and reperfusion possibly 
stimulate the activation of PKB/Akt and p38 MAPK through common pathways, which become 
saturated under these conditions and therefore unable to induce further phosphorylation. 
Irrespective of the mechanism, at 15 minutes reperfusion FTY720 is unable to stimulate further 
phosphorylation of PKB/Akt and p38MAPK. Reperfusion possibly masks the stimulatory effects of 
FTY720 at this time point. 
 
Contextualizing our data with regards to PP2A in I/R, FTY720 exposed PKB/Akt, GSK-3β and p38 
MAPK as potential substrates for PP2A, especially during ischaemia and the very first minutes of 
reperfusion. 
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The signalling-based explanation for the effects of FTY720 on IFS 
Having established the kinase profiles associated with FTY720 administration, an explanation 
involving these pathways could also be put forward for the effects of FTY720 on IFS. We found 
that pre-ischaemic treatment with FTY720 (1 μM) increased IFS. This could be due to the reduced 
phosphorylation of PKB/Akt and the activation of GSK-3β at the very onset of reperfusion. As 
noted in Chapter 1, the very first minutes of reperfusion is important in determining the eventual 
outcome of I/R injury.  
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Reperfusion treatment with FTY720 exerted an infarct sparing effect. Since samples for this group 
were collected at 15 minutes reperfusion only, possible effects of FTY720 on PKB/Akt and ERK 
p42/p44 signalling in the first moments of reperfusion could have been missed. It is however 
entirely conceivable that FTY720 induced a pronounced increase in the activity of these pro-
survival kinases in the first moments of reperfusion, thereby mediating cardioprotection. 
FTY720  in the isolated rat heart exposed to I/R: limitations and future 
directions 
This study serves as a good basic and general description of the effects of FTY720 in the setting of 
myocardial I/R. There are especially three novel aspects to this study: (1.) the inclusion of a pre-
ischaemic FTY720 administration group; (2.) investigation and contextualization of the effects of 
FTY720 on PP2A; and (3.) the description of the effects of FTY720 on GSK-3β and p38 MAPK. 
The well-known pro-survival signalling kinases, ERK p42/p44 and especially PKB/Akt have already 
received much attention with regards to S1P and FTY720 signalling. 
 
We were however confronted with several unknown factors which complicated the understanding 
and interpretation of our results: 
 
1.) The actual level of PP2A activity. Although we are confident that FTY720 at the dose we used 
activates PP2A, we are not sure how long this effect persists and if it is maintained in the 
context of a cellular environment which favours the inhibition of PP2A – i.e. at the end of 
ischaemia and the onset of reperfusion (see Chapter 3). We used PP2A phosphorylation as a 
read-out of PP2A activity, although it is not the only factor which determines its activity (see 
the introduction to Chapter 3). It would therefore be worthwhile to assess PP2A activity directly 
throughout the perfusion protocol. 
2.) Following on the previous point, cancer-related research has shown that FTY720 activates 
PP2A, not necessarily by directly influencing its phosphorylation, but by interacting with one of 
its endogenous inhibitors, namely SET. To our knowledge not much is known regarding the 
contribution and importance of SET to PP2A activity in the heart. It would therefore be 
insightful to characterize SET in this setting as well, specifically with regards to its expression, 
phosphorylation and interaction with PP2A. 
3.) Since FTY720 can act as either a sphingosine or a S1P mimetic, one is not sure whether the 
effects seen are due to FTY720, or P-FTY720. Future work on this topic will benefit from better 
characterization of the actions of FTY720. This can be done by the administration of FTY720 
in conjunction with SK2 inhibition (pharmacological inhibitor, or even silencing RNA-mediated) 
in order to block the potential phosphorylation of FTY720, or administration of specifically P-
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FTY720 or an  unphosphorylatable form of FTY720 (some studies have reported the use of 
such analogues). 
4.) FTY720 was found to elicit very short term effects on signalling. It would be interesting to 
compare our results with an experimental design aimed at enhancing FTY720 activity. This 
can be achieved by either increasing the concentration of FTY720 used, or lengthening the 
duration of FTY720 administration. Due to concentration dependent effects of FTY720, the 
former option may not be desirable. Increasing the length of administration may be more 
feasible. Others have used much longer FTY720 administration periods than we have, for 
example Vessey et al. (2013) administered FTY720 for 40 minutes of reperfusion, or Egom 
and colleagues (2010) who administered FTY720 to their isolated perfused rat heart model for 
a total period of 50 minutes. 
5.) We observed surprisingly little effects of reperfusion administered FTY720 on the signalling 
kinases, despite the fact that this protocol elicited an infarct sparing effect. As already 
mentioned in the discussion this is probably because we only investigated the kinase profiles 
at the end of the FTY720 perfusion period (15 minutes), and then again at the end of the 
experiment (35 minutes). It would be informative to include more time points for kinase 
profiling; specifically at the onset of reperfusion, as well as between the administration of 
FTY720 and the end of the experiment.  
6.) As already mentioned, the precise effects of FTY720 in these signalling cascades are difficult 
to assess within the already complex setting of I/R. Although this is the scenario in which we 
are interested,  it would also be interesting to assess the activity of these kinases during, as 
well as after FTY720 administration, under normal baseline conditions. This would shed light 
on FTY720 initiated signalling per se. 
7.) The latter point can also be extended to include measuring the effects of FTY720 
administration on function under baseline conditions, by either administering FTY720 during 
work mode perfusion or administering FTY720 to a non-recirculating retrograde perfusion 
model with a balloon inserted into the left ventricle to assess function throughout. This 
approach would be of value since, although we speculate that the negative effects of FTY720 
on reperfusion function could be due to its negative inotropic and bradycardiac effects, we 
never determined the direct effects of FTY720 administration on cardiac function in our model.  
 
It is clear that much research still needs to be done on this interesting and potentially useful drug. 
FTY720  in the isolated rat heart exposed to I/R: summary and 
conclusion 
We found that FTY720 administered to the isolated rat heart exposed to I/R exerted divergent 
effects which were dependent on the dose administered. In general, FTY720 exerted an infarct 
sparing effect, which was not associated with improved functional recovery. In fact, 2.5 μM FTY720 
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suppressed functional recovery. Pretreatment with 1 μM FTY720 also augmented IFS. These 
disparate effects are probably due to the fact that FTY720 can either directly exert an effect on the 
cardiovacular tissue, or it can be phosphorylated and then signal through the S1P signalling 
machinery. Some of the possible mechanisms by which FTY720 could have exerted its beneficial 
and detrimental effects in our model include: elevation of S1P levels and S1P associated 
signalling, activation of sphingosine mediated signalling and negative inotropic and bradycardiac 
effects on the heart. Our results caution against the potential clinical application of FTY720 in the 
setting of myocardial I/R injury, since at different concentrations it can elicit a wide variety of 
effects. 
 
Concerning FTY720 as a tool to activate PP2A, we found that this activation of PP2A occurred 
within the context of simultaneous co-activation of several intracellular signalling pathways and 
proved to be very transient. This observation that FTY720 simultaneously activates kinase- and 
phosphatase mediated pathways implies that one should be cautious to relate the effects elicited 
by FTY720 with PP2A activation alone. Keeping this in mind, our data places PP2A as a 
phosphatase with the potential to dephosphorylate GSK-3β and p38 MAPK during sustained 
ischaemia, as well as PKB/Akt within the first minutes of reperfusion. Activation of PP2A at the 
onset of reperfusion could however therefore be detrimental, since the associated inactivation of 
PKB/Akt and activation of GSK-3β is associated with an increase in IFS in our model. 
 
FTY720 therefore clearly identified PP2A as a potentially important protein phosphatase at the 
junction between sustained ischaemia and early reperfusion, with the potential to target the 
PKB/Akt – GSK-3β pathway, as well as p38 MAPK. 
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